DETECTION AND ANTIMICROBIAL ACTIVITY OF IMMOBILIZED QUATERNARY AMMONIUM ANTIMICROBIAL MONOLAYERS ON POROUS AND NON-POROUS SURFACES by Lukasz Porosa

Bachelor of Science in Applied Chemistry and Biology, Ryerson University, Toronto, Canada, 2006 Master of Science in Molecular Science, Ryerson University, Toronto, Canada, 2008

A dissertation presented to Ryerson University in partial fulfillment of the requirements for the Doctorate of Philosophy in the Program of Environmental Applied Science and Management

Toronto, Ontario, Canada, 2014 ©Lukasz Porosa 2014

AUTHOR'S DECLARATION

I hereby declare that I am the sole author of this dissertation. This is a true copy of the dissertation, including any required final revisions, as accepted by my examiners.

I authorize Ryerson University to lend this dissertation to other institutions or individuals for the purpose of scholarly research

I further authorize Ryerson University to reproduce this dissertation by photocopying or by other means, in total or in part, at the request of other institutions or individuals for the purpose of scholarly research.

I understand that my dissertation may be made electronically available to the public.

ii

DETECTION AND ANTIMICROBIAL ACTIVITY OF IMMOBILIZED QUATERNARY AMMONIUM ANTIMICROBIAL MONOLAYERS ON POROUS AND NON-POROUS SURFACES PhD, Lukasz Porosa, Environmental and Applied Science, Ryerson University, 2014 ABSTRACT This research describes the development of novel, environmentally-friendly, nonreleasing contact-active thin film coatings by immobilizing the quaternary ammonium (QA) antimicrobial group on a multitude of surfaces. Various chemical anchors based on organosilanes (i.e. textiles, silica, oxide surfaces), organosulfur comprising of thiol (noble metals), organophosphorus comprising of phosphonate and phosphonic acid (i.e. stainless steel (SS), titanium (Ti)), and catechol (Ti, SS) monolayers are employed to attach the QA antimicrobial onto metal surfaces, while benzophenone photoactive crosslinkers containing QA groups are used to coat plastic surfaces (C-H surfaces, i.e. polyethylene (PE), silicone (Si), polyvinylchloride (PVC)). Surfaces treated with covalently attached antimicrobial coatings function by killing microbes on contact, preventing surface attachment, colonization and contamination without releasing the chemical into the environment. The advantages of this method of delivery of the antimicrobial include a lower cost of application, decreased antimicrobial resistance, lower toxicity and increased environmental safety. Samples prepared by an overnight immersion in an ethanolic solution of phosphorus containing quats followed by an overnight cure at 100oC showed the highest antimicrobial reduction versus electrospray application and no curing. Short chain phosphonic acid quats and the organosilane quat were inactive on titanium. Antimicrobial activity of long chain
iii

phosphonate quats prepared by dip coating and annealing on metal surfaces (Ti, SS, Al) was tested by growth enumeration in the dry state utilizing methods developed in the Wolfaardt lab. All samples showed a 100% reduction (106 cells) of viable Salmonella, Arthrobacter, S.aureus and P.aeroguinosa after 2 hrs of contact time and maintained their activity over 24 hrs versus the uncoated controls. To demonstrate the phosphonate quats were truly immobilized, Ti samples from the first trial were washed in distilled H2O, dried, and re-innoculated with 106 Anthrobacter colonies. No visible colonies of Anthrobacter remained after 2 hrs of contact time with the Ti surfaces indicating a contact killing mechanism at play.

iv

ACKNOWLEDGEMENTS First and foremost, I would like to thank my supervisors, Dr. Foucher and Dr. Gideon Wolfaardt for this research opportunity and providing me with what ever I asked for. Secondly, I would like to thank Joe Raich and Bioshield Technologies Canada Ltd. for teaming up with Ryerson University and providing the necessary funding to run this project successfully. Special recognition goes out to my committee/candidacy members Dr. Russ Viirre, Dr. Bryan Koivisto, Dr. Rob Gossage, and Dr. Donal Macartney for their insights, helpful advice and thesis corrections. I would also like to recognize Dr. Michal Bardecki for playing a key role in my acceptance to the EnSciMan program and for supporting Ryerson athletics over the years. I would also like to thank all of the undergraduate students I had the pleasure to guide and work with over the past four years including Kamlesh Mistry, Shayan Hamzehi, Khaled Hamza, Amanda Mocella, Shayan Hamzehi and Hellen Deng. They were all instrumental in work and help on the Bioshield project over the years. Specifically, I would like to acknowledge the pioneer of the dansyl work, Kamlesh Mistry who contributed along with Grace Luk to collecting UV-VIS/fluorescence spectra. Thanks to Gabriel Wolfaardt who spent countless hours inoculating various bugs on metal and plastic surfaces treated with the QAC antimicrobials in the Wolfaardt and thanks to Alexander Caschera for his assistance with formatting the appendix. As well thanks to all of the graduate students (Aman, Sofija, Shane, Khrystyna, Michelle) who had to put up with me over the years. Most importantly, I would like to thank my patient, loving and supporting parents, Irena Porosa and Miroslaw Porosa who started everything and the reason you are reading this today.

v

DEDICATION To all my friends and family, especially my parents Mirek and Irena Porosa and my sister Natalia Porosa-Paoli for all the unconditional love and support over the years.

vi

TABLE OF CONTENTS AUTHOR'S DECLARATION..................................................................................................... ii ABSTRACT .................................................................................................................................. iii ACKNOWLEDGEMENTS ......................................................................................................... v DEDICATION.............................................................................................................................. vi TABLE OF CONTENTS ........................................................................................................... vii LIST OF TABLES ...................................................................................................................... xii LIST OF FIGURES ................................................................................................................... xiv LIST OF ABBREVIATIONS ................................................................................................. xxiv 1.0 RATIONALE FOR ANTIMICROBIAL SURFACES ........................................................ 1 1.1 Examples and Preparation of Antimicrobial Surfaces ........................................................ 5 1.2 1st Generation Antimicrobial Coatings: Literature Examples of Contact Active QA Antimicrobial Surfaces ............................................................................................................... 10 1.2.1 Polyhydroxylated Surfaces (Textiles, Silica, Glass) ........................................................ 10 1.2.2 Metal Oxides .................................................................................................................... 17 1.2.3 Plastic Surfaces ................................................................................................................ 25 1.2.3.1 "QAC's as Additives" ............................................................................................... 28 1.2.3.2 Thermoset Antimicrobial Coatings: Cross Linked Networks ................................... 29 1.2.3.3 "Grafting Onto" and "Grafting From" Plastic Surfaces ............................................ 31 1.3 2nd Generation Antimicrobial Coatings: Literature Examples of Dual Action Antimicrobial Surfaces ............................................................................................................... 36 1.4 Kill Mechanisms of QAC...................................................................................................... 38 1.4.1 Mechanism of Killing in Solution .................................................................................... 39 1.5. Mechanism of Immobilized Contact Active QAC............................................................. 46 1.5.1 Polymeric Spacer Effect ................................................................................................... 47 1.5.2 Phospholipid Sponge Effect ............................................................................................. 49 1.6 Antimicrobial Testing ........................................................................................................... 51 1.6.1 Growth Based Enumeration ............................................................................................. 52
vii

1.6.1.1 Immersion Inoculation............................................................................................... 52 1.6.1.2 Direct Inoculation ...................................................................................................... 53 1.6.1.2.1 Zone of Inhibition ................................................................................................... 53 1.6.1.2.2 Textiles ................................................................................................................... 55 1.6.1.2.3 Hard Surfaces: Metals, Plastics, Glass ................................................................... 55 (a) Aerosol Inoculation .......................................................................................................... 55 (b) Industrial Standard Test Methods .................................................................................... 57 (c) Wolfaardt's Lab Modification of ISO 22196 ................................................................... 59 (d) Green's Lab Modification (SLSDSS) of ISO 22196 ....................................................... 60 1.6.2 Cell Viability Enumeration .............................................................................................. 62 1.7 CHEMISTRY OF QUATERNARY AMMONIUM GROUPS AND PHOSPHONIC ACIDS .............................................................................................................. 64 1.7.1 Menschutkin Quaternization Reaction ............................................................................. 64 1.7.2 Precursors for the Menshutkin Reaction .......................................................................... 67 1.7.3 Stability of Quaternary Ammonium Groups .................................................................... 71 1.7.4 Detection of QAC in Solution and on Surfaces ............................................................... 75 1.8 CHEMISTRY OF ORGANOPHOSPHORUS COMPOUNDS........................................ 79 1.8.1 Mono and Didealkylation of Phosphonate Esters ............................................................ 79 1.8.2 Synthesis of Phosphonic Acids ........................................................................................ 85 1.9 RESEARCH GOALS ........................................................................................................... 87 2.0 - RESULTS AND DISCUSSION ......................................................................................... 88 2.1 Synthesis................................................................................................................................. 88 2.1.1 Alkoxysilane-Functional Quaternary Ammonium Cations (SiQAC) ........................... 88 2.1.2 Organophosphorus Functional Quaternary Ammonium Cations QAC Antimicrobials (PQAC)......................................................................................................................................... 94 2.1.2.1 -Monophosphonic Acids QAC Antimicrobials (-MPQAC) ...................................... 94 2.1.2.2 -Bisphosphonic Acids QAC Antimicrobials ( -BPQ) Synthesis ............................. 104 2.1.2.3 -CH Bisphosphonic Acids QAC Antimicrobials (-CH-BPQA) Synthesis ............. 109 Method 1: Onepot Bis Addition of Dialkylphosphites to Aldehydes .................................. 110
viii

Method 2: Michael Addition to Diethylvinylphosphonate .................................................. 116 Method 3: C-P Formation .................................................................................................... 118 Method 4: Direct Alkylation................................................................................................ 120 2.1.2.4 Bisphosphonates via the 3-Component Reaction ........................................................ 130 2.1.2.5 -Aminobisphosphonic acids QAC Antimicrobials (-ABPQA) ............................... 131 2.1.2.6 -Aminobisphosphonic Acids QAC Antimicrobials (-ABPQA) .............................. 143 2.1.2.7 Tridentate Phosphonic Acid QAC Antimicrobials (TPQA) ....................................... 154 2.1.2.8 Amine Scaffolds for Tetra Phosphonic Acid QAC Antimicrobials ............................ 159 2.2 Catechol QAC...................................................................................................................... 162 2.3 Organosulfur Based QAC .................................................................................................. 164 2.4 Benzophenone QAC (Plastic Coating) .............................................................................. 167 2.5 Dansyl QAC ......................................................................................................................... 170 2.5.1 Fluorescent Antimicrobial Coating Detection................................................................ 170 2.5.2 CO2 Detection-Dansyl Amidine ..................................................................................... 177 2.5.3 Unsuccessful Dansyl Reactions ..................................................................................... 181 2.5.3 Fluorescence Properties of Dansyl QAC ....................................................................... 185 2.6 Characterization and Properties ....................................................................................... 188 2.6.1 X-ray Crystallography .................................................................................................... 188 2.6.2 Antimicrobial Detection / Coating Procedures .............................................................. 195 2.6.2.1 Plastic Surfaces ........................................................................................................ 197 2.6.2.3 Metal Surfaces ......................................................................................................... 200 2.6.3 Antimicrobial Activity ................................................................................................... 201 2.6.3.1 Solution Killing: Minimum Inhibitory Concentration's (MIC's)............................ 201 2.6.3.2 Contact Killing on Hard Surfaces ............................................................................ 205 3.0 CONCLUSION ................................................................................................................... 211 4.0 FUTURE WORK ................................................................................................................ 214 5.0 - EXPERIMENTAL PROCEDURES ............................................................................... 218 5.1 Materials and Instrumental Methods ............................................................................... 218
ix

5.2 General Procedures ............................................................................................................ 219 Method 5.2.1 Sealed Tube Reactions ...................................................................................... 219 Method 5.2.2 µW Reactions.................................................................................................... 220 5.2.3 Purification/Preparation of Common Starting Materials ............................................... 220 5.2.4 Dow Antimicrobial Synthesis ........................................................................................ 222 5.3 General Procedure for the Synthesis of ( ­MPQA's)..................................................... 222 5.3.1 Abruzov Reaction........................................................................................................... 222 5.3.2 Menschutkin Quaternization .......................................................................................... 228 5.3.3 Didealkylation of Phosphonate diesters. ........................................................................ 237 5.4 General Procedures for the Synthesis of -CH Bisphosphonic Acids QAC Antimicrobials (-CH-BPQA) ................................................................................................. 242 5.4.1 Method 1: Bis Addition of Dialkylphosphites to Aldehydes ......................................... 242 5.4.1.1 Sequential Addition ................................................................................................. 242 5.4.1.2 Synthesis of Aldehyde Precursors ........................................................................... 244 5.4.2 Method 2: Michael Addition to Diethylvinylphosphonate ............................................ 246 5.4.3 Method 3: C-P Bond Formation ..................................................................................... 247 5.4.4 Method 4: Alkylation of Methylenebisphosphonate ...................................................... 248 5.5.0 General Procedure for the 3-Component Reaction ........................................................ 257 5.6.0 General Procedure for the Bis Kabachnik Fields Reaction ............................................ 258 5.7.0 General Procedure for the Bis Michael Addition of Amines onto Vinylphosphonates . 267 5.8.0 Preparation of Tris Phosphonic Acid Derivatives .......................................................... 276 5.9.0 Preparation of Bis Amines Scaffolds for Multidentate Phosphonic Acid Synthesis ..... 280 5.10 Preparation of Catechol QAC ......................................................................................... 282 5.11 Preparation of Organosulfur QAC .................................................................................. 284 5.12 Preparation of Benzophenone QAC ................................................................................ 287 5.13 Preparation of Dansyl QAC ............................................................................................ 290 6.0 APPENDICES ..................................................................................................................... 308 List of Appendix Tables .......................................................................................................... 308
x

List of Appendix Figures......................................................................................................... 308 6.1 X-Ray Data Tables ............................................................................................................ 320 6.2 NMR Spectra ..................................................................................................................... 368 6.3 MS Spectra. ....................................................................................................................... 766 7.0 REFERENCES .................................................................................................................... 790

xi

LIST OF TABLES SECTION 1.0 Table 1.1: Measured persistence of different nosocomial pathogens on inanimate surfaces. ....... 2 Table 1.2: Measured bacterial loads CFU/cm2 in the healthcare and food related surfaces. ......... 3 Table 1.3: Summary of different surfaces immobilized with antimicrobial organosilanes. ........ 16 Table 1.4: Common medical devices vulnerable to microbial contamination. ............................ 26 Table 1.5: Polymers commonly used for food packaging materials. ........................................... 27 Table 1.6: Examples of the benzophenone group utilized to create antimicrobial surfaces. ....... 35 Table 1.7: MIC values for ADBAC and DDAC against increasing S. aureus concentrations after 48 hrs of incubation in TSA medium............................................................................................ 41 Table 1.8: MIC values of Commercial Disinfectant BAK 50 versus thiol QAC's. ..................... 44 Table 1.9: Antibacterial activity of compound 3 in solution. ...................................................... 53 Table 1.10: Relative rates of the Menschutkin quaternization in various solvents...................... 65 Table 1.11: Examples of literature Menschutkin reaction conditions. ........................................ 66 Table 1.12: Examples of the SN2 dequaternization reaction. ....................................................... 72 Table 1.13: Literature examples of the dealkylation of phosphonate esters with mineral acids. 80 Table 1.14: Literature examples of the dealkylation of phosphonate esters with BBr3. .............. 84 SECTION 2.0 Table 2.1: Literature/patent procedures describing the preparation of SiQAC 3. ....................... 89 Table 2.2: 1H NMR (CDCl3) monitoring of the formation of 3. .................................................. 91 Table 2.3: Optimization of Step 1: Abruzov reaction between trialkyl phosphites (4, 5A-B) and dibromoalkanes (6, 7 or 8) or bromoalkanes (9, 10 or 11). .......................................................... 96

xii

Table 2.4: Optimization of Step 2: Menschutkin reaction between bromoalkylphosphonates 1214 and tertiary amines 2, 21-25................................................................................................... 101 Table 2.5: Optimization of Step 4: Didealkylation of phosphonate diester quats. .................... 103 Table 2.6: Attempted Grignard addition reactions onto 68. ...................................................... 117 Table 2.7: Preparation of bisphosphonates 49, 77-78 by Method 3. ......................................... 119 Table 2.8: Synthesis of -C-H bisphosphonates by Method 4................................................... 122 Table 2.9: Optimization of the Kabachnik-Fields reaction. ....................................................... 133 Table 2.10: Optimization of the Michael addition to -aminobisphosphonates QAC 131-144. 145 Table 2.11: Didealkylation of dansyl phosphonate diesters 211 and 212. ................................. 174 Table 2.12: MIC plate counts of samples using a 10-3 (about 200000 cfu/ml) culture of S.aureus. ..................................................................................................................................................... 205 Table 2.13: Arthrobacter reduction by antimicrobial metal surfaces treated with 26 and 34A. 207 Table 2.14: P. aeroguinosa (PA01) reduction by antimicrobial metal surfaces treated with 26 and 34A. ...................................................................................................................................... 208 Table 2.15: P. aeroguinosa (PA01) reduction by antimicrobial Ti surfaces treated with 34A and retested. ....................................................................................................................................... 209 Table 2.16: Determination of initial bacterial load dried on titanium surfaces from plate counts. ..................................................................................................................................................... 210 Table 2.17: Determination of initial bacterial load dried on SS surfaces from plate counts (raw data)............................................................................................................................................. 210

xiii

LIST OF FIGURES SECTION 1.0 Figure 1.1: Representation of bacterial adhesion and biofilm formation. ..................................... 4 Figure 1.2: The role of surfaces and antimicrobial surface coatings in the epidemiology of HAI's--beating the ``nosocomial infection loop.'' ........................................................................ 5 Figure 1.3: Example of various types of antimicrobial surfaces prepared in the literature . ......... 6 Figure 1.4: Possible anchors to generate self assembled monolayers of small molecules and polymers on various substrates . ..................................................................................................... 7 Figure 1.5: Literature examples of different biocide immobilization strategies............................ 8 Figure 1.6: Initiators typically used for growing antimicrobial polymers from surfaces "grafting from." . ............................................................................................................................................ 9 Figure 1.7: Examples of antimicrobial organosilanes described in the literature. ...................... 11 Figure 1.8: Typical procedure for immobilizing SiQAC on polyhydroxy surfaces. ................... 13 Figure 1.9: Anchoring of trialkoxysilyl compounds onto polyhydroxide surfaces. .................... 14 Figure 1.10: Comparison of silanization to phosphonic acid monolayer formation on metal oxide surfaces. ........................................................................................................................................ 18 Figure 1.11: Hydrolytic loss of dansyl-cysteine from a silane based SAM vs a phosphonate based SAM. ................................................................................................................................... 19 Figure 1.12: Mechanism of organophosphorus monolayer formation on metal oxide surfaces.. 20 Figure 1.13: IR spectrum of a deposited film of octadecylphosphonic acid.. ............................. 21 Figure 1.14: Example of literature QAC phosphonic acid antimicrobials.. ................................ 22 Figure 1.15: Bactericidal QAC prepared by plasma treated stainless steel via grafting to approach. ....................................................................................................................................... 23
xiv

Figure 1.16: Example of literature QAC catechol antimicrobials. .............................................. 24 Figure 1.17: Example of a contact active plastic self-finishing coating. ..................................... 29 Figure 1.18: Monomers and quats used to prepare polymer-QAC antimicrobial plastic coatings. ....................................................................................................................................................... 31 Figure 1.19: Bactericidal QAS polymers and small molecules prepared by plasma treated polypropylene. .............................................................................................................................. 32 Figure 1.20: Example of "grafting from" immobilization of biocidal polymers employing the benzophenone surface bound initiator. ......................................................................................... 33 Figure 1.21: Examples of benzophenone used to prepare antimicrobial surfaces.. ..................... 34 Figure 1.22: Example of "grafting from" a plastic surface. Immobilization of biocidal polymers without employing a surface bound initiator. ............................................................................... 35 Figure 1.23: Example of a releasing and repelling 2nd generation dual action antimicrobial surface. .......................................................................................................................................... 37 Figure 1.24: Example of a dual action and reversible contact killing / hydrophobic antimicrobial surface. .......................................................................................................................................... 38 Figure 1.25: QAC disinfectants commercially employed. .......................................................... 40 Figure 1.26: Bacterial membrane destruction by QAC disinfectants in solution.. ...................... 40 Figure 1.27: Scanning electron micrographs of S. aureus strain ATCC 25923 indicating the effect didecyldimethylammonium chloride (DDAC) had on cell morphology. ........................... 42 Figure 1.28: The "Cut off Effect:" A hyperbolic trend observed in MIC values of surfactants as a function of the length of the hydrocarbon chain.. ...................................................................... 43 Figure 1.29: Effect of chain length on antimicrobial activity in solution .................................... 46 Figure 1.30: Example of the polymeric spacer effect with long chain QAC............................... 48
xv

Figure 1.31: Contact-killing via the polymeric spacer mechanism.. ........................................... 48 Figure 1.32: Contact-killing via the phospholipid sponge mechanism.. ..................................... 51 Figure 1.33: ASTM E2149-10 ..................................................................................................... 52 Figure 1.34: ZOI Agar diffusion method: Antimicrobial releasing plastic film surface on A. Niger. ............................................................................................................................................ 54 Figure 1.35: Standard methods for testing antimicrobials on textiles. ........................................ 55 Figure 1.36: Diagram of the aerosol inoculation method: (i) 5-50 × 106 CFU/mL (inoculum) .. 56 Figure 1.37: Results from the aerosol inoculum method with an immobilized QAS polymer onto a glass slide. .................................................................................................................................. 57 Figure 1.38: Industrial standard method for testing antimicrobials on hard surfaces by growth enumeration................................................................................................................................... 59 Figure 1.39: Modified method for testing antimicrobials on hard surfaces by growth enumeration in the dry state testing developed in the Wolfaardt lab.. .......................................... 60 Figure 1.40: A schematic diagram of the symmertric SSLDS method depicting three distinct antimicrobial agent states.............................................................................................................. 61 Figure 1.41: Direct innoculation SLDSS methods. (A) symmetric design, (B) asymmetric design. ........................................................................................................................................... 62 Figure 1.42: Diagram of a high-thoughput biofilm retention assay that measures absorbance or fluorescence from a 96-well plate. ................................................................................................ 62 Figure 1.43: Polypropylene microscopy of control ~ 50 cfu/mL (A) vinyl terminated QAC sprayed (10%) 0 cfu/mL (B). ........................................................................................................ 63 Figure 1.44: SEM images of bacteria incubated with antimicrobial silica nanoparticles............ 64 Figure 1.45: Reactivity of the Menschutkin reaction. ................................................................. 65
xvi

Figure 1.46: Preparation of Menschutkin precursors from primary amines by direct alkylation.68 Figure 1.47: Preparation of Menschutkin precursors from primary amines. ............................... 68 Figure 1.48: Mechanism of the Eschweiler-Clarke N,N-methylation. ........................................ 69 Figure 1.49: Preparation of Menschutkin precursors from alcohols. .......................................... 70 Figure 1.50: Side reactions favoured over the Menshutkin reaction. .......................................... 74 Figure 1.51: Monophasic titration with bromophenol blue. ........................................................ 76 Figure 1.52: Monophasic titration with dichlorofluorescein. ...................................................... 77 Figure 1.53: Biphasic ion pair titration based on bromophenol blue and SiQAC 3 .................... 77 Figure 1.54: Dansyl linkers previously synthesized in the Foucher lab. ..................................... 78 Figure 1.55: Examples of reagents used to dealkylate phosphonate esters. ................................ 79 Figure 1.56: Mechanism of the didealkylation of phosphonate diesters in mineral acids. .......... 81 Figure 1.57: Mechanism of the didealkylation of dialkylphosphonate esters via silylation and hydrolysis. ..................................................................................................................................... 82 Figure 1.58: Possible products resulting from the hydrolysis of bistrimethylsilyl phosphonates. ....................................................................................................................................................... 83 Figure 1.59: Mechanism of phosphonic acid dealkylation with BBr3. ........................................ 85 Figure 1.60: Literature routes describing the preparation of QA phosphonic acids. ................... 86 SECTION 2.0 Figure 2.1: 1H NMR (CDCl3) spectrum of compound 1 + 2 in at T = 0 (A), and the formation of 3 at T = 48 hrs (B). ........................................................................................................................ 92 Figure 2.2: Comparison of trimethoxysilane pricing as of May 2013 (SA: Sigma Aldrich). ..... 93 Figure 2.3: Cyclic oxaphospholane by-products formed during the Abruzov reaction............... 99

xvii

Figure 2.4:

1

H NMR (CDCl3) spectra showing successful didealkylation of the ethyl

phosphonate ester QAC 26 and isopropyl ester QAC 27 to the corresponding phosphonic acid QAC 34 (D2O). ........................................................................................................................... 104 Figure 2.5 : 1H NMR (D2O) spectrum of -BPQAC 42. ........................................................... 107 Figure 2.6: 31P NMR (CDCl3) reaction monitoring of compound 45........................................ 109 Figure 2.7: Retrosynthesis of -CH bisphosphonic acid quats. ................................................. 109 Figure 2.8: Four retrosynthetic methods for the preparation of -CH-BPQA's. ....................... 110 Figure 2.9: The Horner-Wadsworth-Emmons rearrangement of 49.......................................... 113 Figure 2.10: 1H NMR (CDCl3) spectrum of QAC aldehyde precursor 66. ............................... 115 Figure 2.11: 1H NMR (MeOD) spectrum of cyclic bisphosphonate by-product 97. ................. 125 Figure 2.12: 31P NMR (CDCl3) monitoring for compound 94 and 95 prepared by Method 4. . 125 Figure 2.13: 1H NMR (CDCl3) spectrum of -CH-QAC 93 prepared by Method 4. ................ 127 Figure 2.14: 1H NMR (CDCl3) spectrum of precursor 102. ...................................................... 129 Figure 2.15: 1H NMR (CDCl3) spectrum of the undesired product 124 isolated from the Kabachnik-Fields Kabachnik-Fields reaction. ............................................................................ 135 Figure 2.16: Possible mechanistic routes involved in the Kabachnik-Fields reaction. ............. 136 Figure 2.17: Attempted quaternization of triazine 123 with bromoctadecane (1H NMR (CDCl3)). ..................................................................................................................................................... 139 Figure 2.18: 1H NMR (CDCl3) spectrum of -ABPQA 121. .................................................... 140 Figure 2.19: 31P NMR (CDCl3) reaction monitoring of 121 cleavage with HBr and TMSBr... 141 Figure 2.20: 31P NMR (CDCl3) reaction monitoring of tetraphosphonate 127. ........................ 143 Figure 2.21: Reaction monitoring of Michael addition reactions by 31P NMR (D2O). ............. 148 Figure 2.22: Decomposition of 132 at RT by 31P NMR (CDCl3). ............................................. 149
xviii

Figure 2.23: 1H NMR (CDCl3) spectrum of -ABPQA 137. .................................................... 150 Figure 2.24: Preparation of diethylvinylphosphonate 130 (crude mixture by 31P NMR (CDCl3)). ..................................................................................................................................................... 151 Figure 2.25: 1H NMR (CDCl3) of 144 after N2H4 deprotection. ............................................... 153 Figure 2.26: Mechanism of boiling H2O BOC deprotection. .................................................... 158 Figure 2.27: 1H NMR (CDCl3) of catechol QAC 188 (upper) and 189 (lower). ....................... 163 Figure 2.28: 1H NMR (CDCl3) spectra of organosulfur QAC 192 and 199. ............................. 165 Figure 2.29: 1H, 13C NMR (CDCl3) spectra of compound 206.................................................. 169 Figure 2.30: 1H NMR spectra of 208 (CDCl3), 209 (CDCl3), and 217 (D2O). .......................... 175 Figure 2.31: 1H, 13C NMR (CDCl3) spectra of dansyl acrylamide 219. .................................... 177 Figure 2.32: 1H, 13C NMR (D2O) spectra of dansyl amine 221 (upper) and dansyl amidine 222 (lower). ........................................................................................................................................ 180 Figure 2.33: Attempted deprotection of dansyl thioacetate 218 to dansyl thiol 212. ................ 181 Figure 2.34: 1H NMR (DMSO-d6) spectrum of compound 225. ............................................... 182 Figure 2.35: ESI-TOF MS spectrum of compound 225. ........................................................... 183 Figure 2.36: 31P NMR (D2O) reaction monitoring of the formation of 226 after 3 d. at RT. .... 184 Figure 2.37: Absorption spectra of dansyl QAC's in MeOH (ex = 525 nm). ........................... 186 Figure 2.38: Absorption spectra of dansyl QAC 213 at different pH's (ex = 525 nm). ........... 186 Figure 2.39: Fluorescence spectra of dansyl QAC's in MeOH (ex = 360 nm)......................... 187 Figure 2.40: X-ray crystal structure of 34.................................................................................. 189 Figure 2.41: Crystal packing interactions of two molecules of 34. ........................................... 190 Figure 2.42: X-ray crystal structure of 66.................................................................................. 191 Figure 2.43: X-ray crystal structure of 19.................................................................................. 192
xix

Figure 2.44: X-ray crystal structure of 220................................................................................ 194 Figure 2.45: Coating procedure of QAC antimicrobials onto porous and nonporous surfaces. 196 Figure 2.46: Plastic coating experimental set-up. ...................................................................... 198 Figure 2.47: Bromophenol blue (detection of QAC antimicrobials on plastic surfaces. ........... 198 Figure 2.48: Fluorescent detection of dansyl QAC's. ............................................................... 199 Figure 2.49: Metal coating experimental set up using 20 mL glass screw cap vial open to air. 200 Figure 2.50: Experimentally determined MIC (CFU/mL) of SiQAC 3, 34A and 34B.. ........... 204 Figure 2.51: Colony forming units per mL of Salmonella and S. aureus after 3 hrs of drying on Ti surfaces. .................................................................................................................................. 206 Figure 2.52: Agar growth method showing P. aeroguinosa (PA01) reduction by antimicrobial Ti surfaces treated with 34A.. ..................................................................................................... 209

xx

LIST OF SCHEMES SECTION 2.0 Scheme 2.1: Preparation of Dow's antimicrobial 3. .................................................................... 88 Scheme 2.2: Optimized conditions for the synthesis of -monophosphonic acid QAC's. .......... 95 Scheme 2.3: Preparation of -Bisphosphonic acid 41. ............................................................... 105 Scheme 2.4: Preparation of the potassium salt of 41. ................................................................ 106 Scheme 2.5: Attempted preparation of compound 47. ............................................................... 108 Scheme 2.6: Preparation of 50 by Method 1. ............................................................................. 111 Scheme 2.7: Attempted stepwise preparation of 49. .................................................................. 112 Scheme 2.8: Synthesis of bisphosphonates 57-59 from aldehydes. ........................................... 113 Scheme 2.9: Synthesis of aldehyde precursors 47, 54-55 used for Method 1............................ 114 Scheme 2.10: Possible synthetic routes leading to aldehyde QAC 56. ...................................... 115 Scheme 2.11: Preparation of tetraethyl ethene-1,1-diylbis(phosphonate) 73. ........................... 118 Scheme 2.12: Preparation of THP protected 3-bromopropanol 9. ............................................. 118 Scheme 2.13: Preparation of bisphosphonates by direct alkylation. .......................................... 120 Scheme 2.14: Intramolecular bisphosphonate alkylation........................................................... 124 Scheme 2.15: Preparation of bisphosphonate QAC 96 via alkylation. ...................................... 126 Scheme 2.16: Attempted preparation of trisphosphonic acid 102 via alkylation of 96. ............ 128 Scheme 2.17: Preparation of halo QAC 83 and 102 precursors for Method 4. ......................... 129 Scheme 2.18: Attempted preparation of bisphosphonate 106. ................................................... 130 Scheme 2.19: Synthetic route to -aminobisphosphonate QAC 121. Optimized conditions for each step. ..................................................................................................................................... 132 Scheme 2.20: Attempted stepwise preparation of 121. .............................................................. 139
xxi

Scheme 2.21: Attempted didealkylation of -aminobisphosphonate QAC 121. ....................... 141 Scheme 2.22: Tetraphosphonate 127 by C-P alkylation of 113. ................................................ 142 Scheme 2.23: Optimized synthetic route to -aminobisphosphonate QAC 136. ....................... 144 Scheme 2.24: Attempted synthetic route to tetraphosphonate QAC 146 from -amino bisphosphonate 141. ........................................................................................................................ 152 Scheme 2.25: Preparation of amine quat 144. ............................................................................ 153 Scheme 2.26: Attempted synthesis of tris--hydroxyphosphonate QAC 161. .......................... 155 Scheme 2.27: Attempted synthesis of precursors 162 and 164 to tris--hydroxyphosphonate QAC's. ........................................................................................................................................ 156 Scheme 2.28: Attempted synthesis of tris--hydroxyphosphonate QAC 168. ........................... 157 Scheme 2.29: Preparation of mesyl 158 and tosyl phosphonate 170. ........................................ 158 Scheme 2.30: Preparation of tris-BOC 157 and deprotection in boiling H2O to tris 171. ......... 158 Scheme 2.31: Michael addition of NMe2 to tris acrylamide 173. .............................................. 159 Scheme 2.32: Attempted preparation of tetradentate -amino QAC 179. ................................. 160 Scheme 2.33: Attempted preparation of tetradentate -amino QAC 183. ................................. 161 Scheme 2.34: Attempted N,N-dimethylation of dopamine 184. ................................................ 162 Scheme 2.35: Attempted preparation of catechol QAC 190. ..................................................... 163 Scheme 2.36: Literature routes to target thiol QAC's 194 and 199. .......................................... 166 Scheme 2.37: Preparation of the benzophenone QAC's 205 and 206. ...................................... 168 Scheme 2.38: Preparation of dansyl dimethyl 208 and halo precursors 209 and 210 for quaternization.............................................................................................................................. 171 Scheme 2.39: Preparation of bifunctional dansyl anchors 211-216 for binding onto porous and non-porous surfaces. ................................................................................................................... 172
xxii

Scheme 2.40: Preparation of dansyl acrylamide QAC 219. ....................................................... 176 Scheme 2.41: Preparation of dansyl amindine switchable fluorophore 222 and 223. ............... 179 Scheme 2.42: Attempted preparation of dansyl DTC 225. ........................................................ 182 Scheme 2.43: Attempted preparation of dansyl bis ­phosphonate 226. .................................. 184 SECTION 4.0 Scheme 4.1: Catalytic Finkelstein / Menschutkin reaction in the preparation of the Dow antimicrobial 3. ........................................................................................................................... 214 Scheme 4.2: Onepot preparation of -CH-bisphosphonates from the aldehyde quat precursor, 56. ..................................................................................................................................................... 215 Scheme 4.3: Preparation of catechol QAC, 190......................................................................... 215 Scheme 4.4: Preparation of thiol QAC, 199............................................................................... 216 Scheme 4.5: Synthesis of multifunctional QAC antimicrobial polymer coating. ...................... 216 Scheme 4.6: Synthesis of multifunctional QAC antimicrobial polymer coating. ...................... 217

xxiii

LIST OF ABBREVIATIONS Ac Ar AMA APA ARI Aq. ATRP BOC Bn t-Bu Cat Cbz CDI CFU d. DCM Diox. DIPEA DMAEMA DMSO DTC EPA Eq. Et Et3N Hrs HAI HMPA Acetyl Aromatic Antimicrobial Agent Amino Phosphonic Acid Antimicrobial Resistant Infection Aqueous Atom Transfer Radical Polymerization tert-Butyloxycarbonyl Benzyl Tert butyl Catalyst Carboxybenzoyl 1,1'-Carbonyldiimidazole Colony Forming Units Days Dichloromethane Dioxane Diisopropylethylamine 2-(N,N-dimethylamino)ethyl Methacrylate Dimethylsulfoxide Dithiocarbamate Environmental Protection Agency Equation Ethyl Triethylamine Hours Hospital Acquired Infection Hexamethylphosphoramide
xxiv

HCWU HRMS IAI iAMA iPr LAH LG Mon. Me MIC MLC Mp Mol MS NMR Nu Ms ON PBS PCC PMMA PMRA QA QAC QAM QUAT QAS RBF RT

Health Care Workers Uniforms High Resolution Mass Spectrometry Implant Associated Infections Immobilized Antimicrobial Agent Isopropanol Lithium Aluminum Hydride Leaving Group Months Methyl Minimum Inhibitory Concentration Minimum Lethal Concentration Melting Point Moles Mass Spectrometry Nuclear Magnetic Resonance Nucleophile Mesyl Overnight Phosphate buffered saline Pyridinium Chlorochromate Poly Methyl Methacrylate Pest Management Regulatory Agency Quaternary Ammonium Quaternary Ammonium Compound Quaternary Ammonium Monomer Quaternary Ammonium Cation Quaternary Ammonium Salt Round Bottom Flask Room Temperature
xxv

RXN SAM Si-QAC SIP Solv. ST THF TLC TOL PG PHT TMSCl TMSBr TMSI TMTC Tos µW UTI Yr. 4-VP Wks.

Reaction Self-Assembled Monolayer 3-(trimethoxysilyl)propyldimethyl-Octadecyl Ammonium Chloride Surface Initiated Polymerization Solvent Sealed Tube Tetrahydrofuran Thin Layer Chromatrography Toluene Protecting Group Phthalimide Trimethylsilylchloride Trimethylsilylbromide Trimethylsilyliodide Too Many To Count Tosyl Microwave Urinary Track Infection Year 4-Vinylpyridine Weeks

xxvi

CHAPTER 1 - INTRODUCTION 1.0 RATIONALE FOR ANTIMICROBIAL SURFACES Common surfaces that are frequently touched are inhabited by a variety of microorganisms such as bacteria, viruses and fungi which can persist on these "touch surfaces" anywhere from a couple of hours up to six months (Table 1.1).1 If pathogenic bacteria persist in healthcare and food preparation facilities, patients and workers can readily develop and spread nosocomial infections from touch surfaces such as door handles, pens, telephones, health care workers uniforms (HCWU's), stethoscopes, IV poles, faucets, food and food preparation surfaces (Table 1.2).2,3 The healthcare and food industry are facing an ever growing microbial contamination problem. Contamination of medical devices, healthcare products, H2O purification systems, food packaging and food storage are becoming a serious threat both in terms of cost and safety.4 To date, infection control counter measures which rely on personal hygiene, hand washing, masks and the use of disinfectants on hospital equipment to prevent the spread of infections have been largely unsuccessful. According to the World Health Organization (WHO), nosocomial or hospital-acquired infection (HAI's) are becoming a national economic burden resulting in prolonged hospitalization and can lead to serious complications and even death.5 For example, hospital-acquired infection (HAI's) from contact with pathogenic microorganisms affect approximately 2 million people and result in more than 100,000 deaths each year in the US.6 Such unintended infections require 10-20 d. of additional patient hospitalization, costing the already strained US health-care system between ~$25,000-$30,000 per infection and billions of dollars per year.6 Another route for bacteria to infect patients is through hospital invasive support
1

equipment such as intravascular lines and implanted medical devices such as artificial prosthetics, cardiovascular implants and urinary catheters.6,7 Implant associated infections (IAI's) occur in more than 1 million patients and cost an estimated $3 billion in the US per year to treat.4 For example, approximately 10-50% of patients with implanted catheters run the risk of developing urinary tract infections (UTI's) translating to an average of $200,000 per infection in additional healthcare costs. The rise in the frequency and severity of (HAI's) and (IAI's) can be attributed to decreased antibiotic efficacy against drug-resistant strains of pathogens found in surface biofilms.3 Table 1.1: Measured persistence of different nosocomial pathogens on inanimate surfaces.8 Type of Bacterium
Acinetobacter spp. Bordetella pertussi, C. difficile (spores) E. coli H. influenza M. tuberculosis S. aureus (including MRSA) S. pyogenes

Duration of Persistence
3 d. to 5 mon. 3-5 d. 5 mon. 1.5 hrs to 16 mon. 12 d. 1 d. to 4 mon. 7 d. to mon. 3 d. to 6.5 mon.

Type of Virus
Adenovirus Astrovirus HIV Herpes Simplex Influenza Parvovirus Papiloma Rhino Virus

Duration of Persistence
7 d. - 3 mon. 7 - 90 d. 7 d. 4.5 hrs to 8 wks. 1 - 2 d. 1 yr. 7d. 2 hrs to 7 d.

Type of fungus
C.albicans C.parapsilosis Torulopsis glabrata

Duration of Persistence
1 - 120 d. 14 d. 102 - 150 d.

2

Table 1.2: Measured bacterial loads in the healthcare and food related surfaces (colony forming units, CFU/cm2).9 Site of Study
Food Food Food Food Food Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare

Site
Abbatoir surfaces Food contact surfaces Meat preparation surfaces Refrigerator surfaces Vegetable preparation surfaces Nurse workstation Hospital ward surfaces Hospital kitchen surfaces Hospital ward floors Hospital underward bed Stethoscope membrane

Bacterial Load Found
8 to 1.3 × 104 cfu/cm2 630 to 1.8 × 109 cfu/cm2 105 cfu/cm2 813 to 6 × 108 cfu/cm2 >105 cfu/cm2 < 9 cfu/cm2 2.5 to 40 cfu/cm2, cleaning reduced to < 2.5 cfu/cm2 2-29 cfu/cm2 < 5 cfu/cm2 < 25 cfu/cm2 In > 54% of cases > 5 cfu/cm2, in 18% of cases > 29 cfu/cm2

Surface biofilms are complex communities of bacteria that offer protection from environmental hazards (eg. biocides). Biofilm formation involves three phases beginning with the initial reversible adhesion of bacteria though polysaccarides and adhesion proteins on the bacterial membrane (phase I). After 2-3 hrs under appropriate conditions, bacteria irreversibly attach to a surface (phase II). Once formed (usually after 24 hrs) the bacterial biofilms secrete a protective peptidoglycan matrix (biofilm) capable of withstanding 1000 × the antibiotic dose of non adherent bacteria (Figure 1.1).10 As a result, once the infection occurs, it becomes difficult to
3

treat and strategies that prevent bacterial contamination or destroy adsorbed microorganisms that lead to biofilm formation are actively sought.10

Figure 1.1: Representation of bacterial adhesion and biofilm formation (Used with permission from Ref.10). Consumer demand for odor and contamination free hygienic textile products has grown remarkably. Estimates of antimicrobial textile production worldwide were 100,000 tonnes in 2000.11 With an estimated growth of 15% per year in Western Europe, antimicrobial textiles are one of the fastest growing sectors in this industry.11 In addition, managers in the health care/food industries as well as medical device makers are actively seeking to introduce antimicrobial coatings as part of an infection control strategy combined with hygiene and disinfection protocols. In this regard, introducing antimicrobial surfaces that prevent biofilm formation could help reduce the spread of pathogenic bacterial infections from surfaces and implants to patients and healthcare workers, thereby closing the "nosocomial infection loop" (See Figure 1.2).8,9

4

Contaminated surf ace
Antimicrobial coating

x

x
Hygiene (hand washing) Healthcare worker

Patient

Figure 1.2: The role of surfaces and antimicrobial surface coatings in the epidemiology of HAI's--beating the ``nosocomial infection loop.''8, 9

1.1 Examples and Preparation of Antimicrobial Surfaces

In order to prevent the formation of biofilms, strategies utilizing antimicrobial surfaces have been employed to make surfaces inhospitable to bacteria.12,13 Small molecule monolayers or polymer thin films either "grafted to" or "grown from" a surface have been widely used to prepare antimicrobial surfaces and clothing. Figure 1.3 shows examples of the different approaches that have been used to prepare antimicrobial surfaces or objects. These prior art monolayers or polymer coatings include, for example, non-biofouling coatings which are passive strategies that rely on preventing bacterial adhesion with hydrophobic or zwitterionic thin films, but do not kill the approaching bacteria. A second class of antibacterial thin films kills microbes on contact either by releasing a biocidal agent or immobilizing a biocidal agent. A third class of
5

antibacterial thin films utilize a combination strategy of including a non-biofouling and biocidal component into the coating (see Section 1.3).12,13

Figure 1.3: Example of various types of antimicrobial surfaces prepared in the literature (Used with permission.12,13 Active releasing antimicrobial coatings based on the leaching of biocides are typically prepared by impregnating biocides in a polymer matrix coating. In this way, the leachable biocide is gradually released from the coating and kills adhered microorganisms via interaction with the cell depending on the biocide mode of action.14,15 The most popular leachable biocide is silver ion (Ag+).16,17 Quaternary ammonium compounds, although used in leaching type systems, are largely immobilized onto surfaces as small molecules or polymers that provide contact killing without leaching. The advantages of the non-leaching immobilized approach include longer antimicrobial efficacy, less chance for the development of resistant bacteria and overall is more environmentally friendly.3,18,19

6

Quaternary ammonium biocides can be immobilized onto various surfaces either as small molecule monolayers with various anchors (Figure 1.4) or as polymers.20,21 Grafting of larger molecules onto surfaces such as polymers can be accomplished in one of three ways; (A) physisorption of a polymer to a surface (grafting to approach); (B) chemisorption via reaction of anchors in the polymer with complementary functional groups at the substrate surface (grafting to approach); (C) growth of polymer brushes via surface-initiated polymerization techniques such as Atom Transfer Radical Polymerization (ATRP) (grafting from approach) (Figure 1.5). Grafting from approaches use ATRP polymerization initiators such as 2-bromoisobutyryl bromide (BIBB) directly bound to a surface or immobilized through an anchor (Figure 1.6).22 Photochemical linkers have also been used to bind antimicrobials onto textiles and polymers.23-26

Figure 1.4: Possible anchors to generate self assembled monolayers of small molecules and polymers on various substrates (Adapted from Ref.27).

7

Figure 1.5: Literature examples of different biocide immobilization strategies. (A) Polymeric thin films coating are adsorbed or painted on compatible surfaces, (B) Self Assembling Polymers (SAP's) or Self Assembling Monolayers (SAM's) of small molecules with pending biocides have been employed, (C) biocidal polymers grown from a surface via a pre-immobilized Atom Transfer Radical Polymerization (ATRP) initiator, (D) self-finishing surface where the biocide is added during the polymerization process or is attached to the monomer prior to polymerization (Adapted from Ref.28).

8

O Br Br LINKER

O Br

LINKER

+

SIP INITIATOR (BIBB)

SURFACE GRAFTED INITIATOR O Cl Si O 5 O Br

Cl

Si

OH 5

HS 5

OH

HS 5

O

Br

HO

O OH

P HO

HO

O O

O Br LINKER O POLYMER

P HO

HO HO NH2

HO HO N H O

O Br

O

O OH O Br

O

O O OH

O O Br x single component system

y

without initiator

Figure 1.6: Initiators typically used for growing antimicrobial polymers from surfaces "grafting from." 29,30,31,32,33,34 The research proposed is based on developing novel, non-releasing, contact-active monolayer thin film coatings. The following sections will highlight literature examples of

9

immobilized QA antimicrobials on porous (polyhydroxylated surfaces) and non-porous (metal and plastic) surfaces. 1.2 1st Generation Antimicrobial Coatings: Literature Examples of Contact Active QA Antimicrobial Surfaces 1.2.1 Polyhydroxylated Surfaces (Textiles, Silica, Glass) Akin to the discovery of the antibiotic penicillin by Alexander Fleming, who noticed after a month long vacation that a petri dish contaminated by a fungus killed the growing bacteria, the first contact active antimicrobial surface coating was also discovered by accident. The first report describing a surface bound antimicrobial capable of killing microorganisms on contact was published in 1972 by Isquith et al., who prepared antimicrobial glass and cotton samples with octadecyldimethyl (3-trimethoxysilylpropyl)-ammonium chloride (ODDMAC or Si-QAC) (see Figure 1.7, Compound 3).35 The publication was based on Abbott's research at Dow Corning on silicone and silane based compounds for the control of algae.36 When measuring minimum inhibitory concentrations (MIC's) of silane quaternary ammonium compounds in solution, Abbott unexpectedly found that he was getting extremely low values (cfu  0).36 He attributed his observations of false positives to the adsorption of the active compounds on to the wall of his equipment.36 As a result, (3-trimethoxysilylpropyl)dimethylalkyl ammonium chlorides with alkyl chains from 6 to 22 carbons produced the highest algae reductions and were quickly patented by DOW Corning (Figure 1.7, Compounds 1-11).37

10

Cl
O O Si O N O O Si O

Cl
N

O O Si O

Cl
N

C18H37

O O Si O

Cl
N

Bu

(1)

(2) I

(3) I Bu
P

(4) Cl
O O Si O

O O Si O

OH
N

O O Si O

Bu

Bu

O O Si O

NH2 S (8) NH2

P

(5)
O O Si O

(6) I
N O O Si O

(7) Cl R
N O O Si O

I
N

R

R

O O

C10F21

(9)
O O Si O

(10) R = C2-C16 I
N O O Si O

(11)
H N H N H N H

C6H13

S

Ag

O O Si O

Cu2+

N

(12)
O HN O

n

(13)
F F F O O O Ag Ag Ag Ag F O O H N

n

N H

(14)

F F F F F F Ag O Si O O Ag Ag Ag

O Si O O

(15)

n N N Si O O O (17) O Cl N

n O

n O O O Si O O Br N

m O

N
Bu N Cl

N Cl

O Si O (18)

(16)

Figure 1.7: Examples of antimicrobial organosilanes described in the literature. (1)38, (2-11)36, (13)39, (14)40, (15)39, 41, (16)42, (17)43, (18)44.

11

After years of extensive toxicological testing, Dow Corning's antimicrobial quaternary ammonium agent 3, sold as an antimicrobial finish for textiles, was approved by the EPA in 1977 and received the Industrial Research and Development award as the best new commercialized product that year.3 SiQAC (Figure 1.7, Compound 3), is commercially prepared from 3chloropropyl trimethoxysilane (excess ~1.2 eq.) and N,N-dimethyloctadecylamine, and available as a 40-72% methanolic solution from the following companies: Aegis (AEM 5772), Piedmont (Ztrex72), Flexipel (Q-1000), and Dow Corning (Q9-6346), (Figure 1.7, Compound 3).45 In the original publication, Si-QAC (72%) was typically applied as a 0.1 wt % solution in H2O on cleaned glass or cotton followed by annealing at 70°C for 30 min in order to form strong Si-O-Si bonds with free ­OH groups on oxide surfaces, e.g glass, ceramics, cellulose, silica. However, for industrial applications the compound was limited by the ready polymerization of neighbouring silanols in H2O and precipitation of the product upon long term storage (Figure 1.8). In aqueous environments, alkoxy silanes are rapidly hydrolyzed under neutral conditions leading to condensation of neighbouring silanols, resulting in the undesired precipitation or gelling of the product (Figure 1.9). For large scale applications, methanol-based products are undesirable due to their toxicity, flammability and the highly regulated nature of methanol.46

12

Figure 1.8: Typical procedure for immobilizing SiQAC on polyhydroxy surfaces.38

13

Hydrolysis (RO)3Si(CH2)3R + H2O OH OH OH + (HO)3Si(CH2)3R
Substrate

(HO)3Si(CH2)3R + ROH
Substrate

Condensation

O O Si (CH2)3R O

R=

OH HO OH O O OH

OH O O OH OH n

OH O OH OH OH

CELLULOSE
HO O Si O O HO O Si O Si O O OH
Si

OH Si O Cl N Cl N Cl N

O

O O Si O O

SiO2
Examples of polyhydroxy surfaces

O Si O Si O Si O OH n OH OH Polymeric form of SiQAc (1)

Figure 1.9: Anchoring of trialkoxysilyl compounds onto polyhydroxide surfaces. It would take another 18 years to develop a safer and more environmentally friendly SiQAC. In 1995, Dr. Gary Allred and Dr. Lanny Liebeskind patented the Si-QAC as a 5% active stabilized product in H2O.47 The researchers from Emory University added a proprietary stabilizer that gave the organosilane an alternative to polymerization in H2O and resulted in a stabilized product. Currently the safer and more environmentally friendly Si-QAC is
14

commercially available from Pureshield as a H2O soluble solution of the active quat at 5 wt % and sold under different brand names such as AM 500, SiShield 500, BioProtect 500, or Microbe Guard in several countries. The product is currently used commercially as an antimicrobial finish on textiles such as cotton, nylon, polyester and wool.11,20 In the original publication, Isquith claimed that immobilized Si-QAC on different substrates such as siliceous surfaces, natural fibers, man-made fibers, metals and others had broad-spectrum antimicrobial activity.38 However, the publication only demonstrated antimicrobial activity of Si-QAC on glass against F. faecalis (gram-positive) and on cotton cloth against E. coli (gram-negative). The silane modified surfaces killed > 95% of the F. facealis visible colonies after 30 min measured with the Dow Corning Corporate Test Method 0923 (CTM-0923, See Section 1.6.1.1.1).38 The antibacterial treatment of Si-QAC and related organosilanes onto polyhydroxy surfaces such as textile fabrics, glass and silica nanoparticles (NP's) are well studied in the literature. Table 1.3 summarizes the historical account of various antimicrobial organosilane treated surfaces described in the literature starting from the original publication by Isquith in 1972 until 2013. Examples include different textiles surfaces: polyester fabrics (Entry ii), cotton polyester (Entry vi), microfibrillated cellulose (Entry xi), cotton gauze (Entry xiv), cotton textile (Entry xv) as well as glass (Entries i-ii, iv, xiii, xvii), titanium (Entry xii) and silica NP's (Entry xvi). These treated materials were shown to be antimicrobicidal after treatment with the antimicrobial trialkoxysilane 1. Other surfaces normally inert to silanization such as silicone rubber and metal oxides were also coated with 1 but required prior surface pre-treatment: sanding (Ti, Entry ix) and plasma treatment (silicone, Entries vii and x) necessary to activate them towards silanization. Similarly, organosilane antimicrobials based on the release of Ag+
15

(Entries xiii and xv) and polymeric QAC's (Entries xv and xvi) were developed after the original silane QAC 3. However the application of the antimicrobial varies in each study as well as the type of bacteria tested and the testing methods.

Table 1.3: Summary of different surfaces immobilized with antimicrobial organosilanes. Entry i38, 48 ii48 iii36 iv49 v50 vi51 vii52 viii53 ix54 x55 xi56 xii42,57, 58 xiii59 xiv60 xv61 xvi62 xvii63 Antimicrobial silane 1 1 2-16 1 1 1 1 1 1 1 1 16,17 12 1 1 1 1 Immobilized Surface Siliceous surfaces, man-made fibres, natural fibres, metals, leather, wood, rubber. Glass, cotton, cellulose, polyester Cellulose acetate, nylon 6,6, polyester, silica Glass Polyurethane foam Cotton-polyester fabrics Silicone rubber Polyethylene terephthalate (PET) Titanium dental implants Silicone rubber stents Microfibrillated cellulose Glass, cotton, paper Glass Cotton gauze Cotton textile SiO2 nanoparticles Glass Year 1972 1973 1982 1984 1985 1988 2002 2004 2005 2006 2007 2008 2009 2010 2011 2011 2011

16

1.2.2 Metal Oxides Basic metal oxide surfaces (e.g. Ti, SS) typically contain far fewer surface functional groups (-OH) than are necessary for grafting monolayers and often require surface pretreatment, also know as passivation, in order to increase surface ­OH groups compared to the acidic metal oxide surface representative of silica. Passivation is typically achieved by either chemical means64,
65

(dipping in Pirhana solution, sanding, or heating over 130oC in air) or physical

methods (electrochemical grafting, plasma deposition).66 A simpler way to functionalize metal oxide surfaces without the use of expensive and surface altering plasma pre-treatment involves the direct formation of phosphonates and catechol monolayers on metal oxide surfaces. Phosphonate monolayers have been shown to be advantageous over self-assembled monolayers (SAMs) of thiols and silanes in terms of durability, long-term stability and surface coverage, especially on Ti and SS.67-69 Thiol-based SAM's lack substrate specificity (mainly reserved for Au surfaces) and long-term stability needed for biomedical applications, (i.e. implants).70 Over time, thiols become oxidized to sulfonates, which lack affinity for Au and become displaced from the surface.71 In comparison to silane based SAM's on metal oxide surfaces, phosphonate based SAM's are advantageous because they resist hydrolysis under physiological conditions and higher surface coverage can be obtained without a harsh acid surface pretreatment (to increase OH content).72 The problem with silanization on the native oxide of titanium is the presence of only 15% surface hydroxyl groups (XPS data).69 Silanization consumes surface OH sites and a lack of a neighbouring OH group can promote the cross-linking of nearby silanes to siloxanes. Siloxanes are known to be hydrolytically unstable and are easily hydrolyzed under physiological
17

conditions.69 Once a phosphonic acid molecule coordinates to a metal, proton transfers between the coordinated phosphonate and the metal surface can take place which can create new ­OH groups accessible for further monolayer formation and result in bidentate or tridentate coordination (Figure 1.10).69
R O Si O O O No further OH very low surface coverage OH O O O M M M M O O O O R O Si O O O

OH O O O M M M M O O O O

O P O

R O H O 1) open up M-O-M

O P O 2) M-O-P coordination O O M

R O OH HO O O M M O O O

OH O O O M M M O O O O coordinated phosphonate can transfer H+ to surface

Figure 1.10: Comparison of silanization to phosphonic acid monolayer formation on metal oxide surfaces.69

For example, the hydrolytic stability of silane to phosphonate based SAM's was directly compared with the incorporation of a fluorescent dansyl tag.73 The silane-dansyl molecule was assembled on Ti either by (i) attaching the silane linker aminopropyl(triethoxy)silane (APTES) on Ti followed by coupling with a maleimido reagent and capped with the fluorescent tag or (ii) attachment to Ti with preformed (3-triethoxysilylpropyl)-6-N-maleimidohexanamide followed by capping with the dansyl tag (Figure 1.11, (ii)). The phosphonic acid-dansyl reporter was prepared from Ti immobilized 11-hydroxyundecylphosphonic acid followed by coupling with the maleimido reagent and capped with the dansyl cysteine (Figure 1.11, (iii)).73 Both surface
18

loadings and shear strengths of each monolayer were found to be durable enough for biomedical device surface coating. However, as expected, the Si-O-M bonds in the silane based film were completely hydrolyzed after 7 d. in pH 7 buffer, while the phosphonate film remained intact (Figure 1.11).73

O
OEt O Si OEt

NH O

N O

S O

O S O OH

N

(i) prepared from aminopropyl(triethoxy)silane (APTES) (ii) prepared from (APTES + maleimido coupling reagent) O S O OH N

O
O O P O

NH 9

N

S

O O O re rom rox are un ec iii H l h 11 d f d d y y y p osphonic acid ( )p p

Figure 1.11: Hydrolytic loss of dansyl-cysteine from a silane based SAM vs a phosphonate based SAM (Used with permission from Ref73).

19

Similar to the formation of silane monolayers on polyhydroxy surfaces, phosphonic acid monolayer formation on metal oxides requires a thermal curing step to drive off H2O resulting in a strong M-O-P bond.74 Both bidentate and tridentate phosphonate coordination modes to metal oxides are possible and depend on the metal surface and the temperature of the annealing step (Figure 1.12). For example, surface coverage of the phosphonate monolayer was enhanced 5-fold by depositing the monolayer with six cycles of spray/heat/rinse versus just one cycle (Figure 1.13 A vs. B). Six cycles of deposited phosphonate films were found to be very durable and resisted desorption by solvent rinsing or by a mechanical peeling test with tape (compared by IR peak intensities, Figure 1.13 B).72

R P O O O H H HH H H O O O O O O O O O M M M M M O O O O O - H2O R P O O H H H H O O O O O O O O O M M M M M O O O O O  - H2O O P O O  - H2O O O O M O O P O M O O O M O O O M O O M R R



OH OH O O O O O M M M M M O O O O O

Monodentate

Bidentate

Tridentate

Figure 1.12: Mechanism of organophosphorus monolayer formation on metal oxide surfaces.7577

20

Figure 1.13: IR spectrum of a deposited film of octadecylphosphonic acid. (A) no heat, control, before (lower trace) and after solvent wash (upper trace), (B) monolayer after six cycles of deposition, with heat treatment (lower trace), compared with one cycle (upper trace), after both solvent wash and tape peel tests.72 Both active and passive strategies to prevent biofilm formation have been described with mono- or bisphosphonate monolayers and polymer thin films (Figure 1.14). Examples of active surfaces include contact killing monolayers employing immobilized quaternary ammonium salts (Figure 1.14, 19-21, 23, 24), and the antibiotics daptomycin and vanomycin (Figure 1.14, 25, 28). Active surface coatings releasing biocidal NO and Ag+ ions have been patented (Figure 1.14, 20, 22).74 Passive strategies were described employing hydrophobic perfluorinated bisphosphonates on stainless steel, silicon, and titanium oxide surfaces for anticorrosion applications.74

21

Br N S

Ag I N I

N r N B H3N

O O N N HN

N

OH P O O O (19) P P O O O O O O (20) P O O O (21) P O O O (22) OH O P O O P O O O (23)

Daptomycin
HN

O O N NH S O O HN OH H2N HO O

H2N O NH

O NH2 O

HN O

N

O Br O N

O O P O O

O O P O O O (28)

N O m O O Br P O O O (24) N Bu HN O P O O (25) P O O O n O S

O O

n

n

O O O O

P O O O (26)

P O O O (27)

Figure 1.14: Example of literature QAC phosphonic acid antimicrobials. (19-21)78-80, (22)79,81, (23)82,83, (24)84, (25)85, (26)86, (27)87.
22

Another example describes an antimicrobial stainless steel (SS) surface with immobilized QAC's via plasma activation. To prepare the surface, an ethylenediamine low pressure plasma was used to functionalize the SS surface with primary amines. Quats were formed by reacting the plasma-deposited amines with hexyl bromide to generate secondary and tertiary C16 amines which were later quaternized with MeI (Figure 1.15). These QAC modified SS surfaces showed excellent bactericidal properties by killing more than 98% and 99.9% of K.pneumoniae and S.aureus respectively.66
I NH2 Plasma NH2 2. MeI NH2 (SS) 1. BrC6H13 N I N I N

Figure 1.15: Bactericidal QAC prepared by plasma treated stainless steel via grafting to approach (Adapted from Ref.66). Another linker strategy for immobilizing polymer thin films either by "graft to" or "graft from" methods onto a variety of metal oxide surfaces was introduced by the Messersmith group. Inspired by mussel adhesive proteins which contain the catechol group, the Messersmith group functionalized various polymers with this anchor and used it to create both passive and active antimicrobial surfaces for the purposes of biofilm prevention and control.88 Since the introduction of the catechol as a versatile linker, other groups created antibacterial metal surfaces by immobilizing polyethylene (PE) based polymers with microbe repelling capabilities (compound 28), and various biocidal moieties such as antibiotics, antimicrobial peptides and quaternary QAS polymers via catechol groups (Figure 1.16, compounds 18-33).
23

O O

H N O 28 ( ) O

Br n O O m

O O N Br

H N

O

O

Vanomycin n

(29)

O O

H N O (30) O

Br n O O m O Lysozyme

O O O

H N O O O C12H25 N Br O

(31)

n
O

O O O

H N

O (32)

H N n

Magainin 1

I NH2 O O O OH OH O O Polydopamine (PD) adlayer + O O N (2) MeI Quaternize (1) SIP from PD Br n O O CNT ( ) surface PD immobilized QAC (Graft from) N I PD HN O + S PD H N O O N H
N

C10H21 PD immobilized QAC (Graft to)

I NH2 H N O O N H
N

C10H21

(33)

(DP)

Figure 1.16: Example of literature QAC catechol antimicrobials. (28)88, 89, (29)90, (30)91, (31)92, (32)93, (33).94

24

1.2.3 Plastic Surfaces Common plastic or polymers surfaces widely used in the medical and food industries as medical devices and food packaging materials respectively (Tables 1.4, 1.5) are also very susceptible to biofilm colonization.95,96 Unlike polyhydroxy and metal oxide surfaces, plastic surfaces with functional C-H bonds such as polyethylene, polypropylene, and polystyrene or COR bonds in the case of polyesters are inert to direct silanization using the anchor chemistries previously described for -OH bearing surfaces / metal oxides, and thus require a different strategy to immobilize an antimicrobial group. The literature contains a limited number of examples of covalently immobilized antimicrobials as a finishing coating on plastics, however many examples are prevalent where the antimicrobial is introduced as an additive or polymerized into the plastic during the manufacturing process. Antimicrobials incorporated into plastics where the active species migrates to the surface during the polymerization process are termed "self-finishing" coatings.18

25

Table 1.4: Common medical devices vulnerable to microbial contamination.29 Medical Device Breast implants Catheters Contact lenses Dental implants Heart valves Hip and knee prostheses Intraocular lens Polymeric Materials Silicones Silicones, PVC, urethanes, fluoropolymers Methacrylates, silicones Silicones Polyester, polyoxymethylene, UHMWPE, PMMA Methacrylates, silicones

Left ventricular assist device Urethanes, carbonates Pacemakers Renal dialyzers Urethane Polyacrylonitrile

26

Table 1.5: Polymers commonly used for food packaging materials.95, 97
Polymer Ethylene vinyl acetate (EVA) Formula
m n O O

Ethylene methyl acetate (EMA) Ethylene acrylic acid (EAA)

m O O m O OH

n

n

Ethylene methacrylic acid (EMAA)

m O OH

n

Ionomer

m O

n O Na

Nylon

O N 6 H n

Polyvinylidene chloride (PVDC) Polyvinyl chloride copolymer (PVC)

H

Cl m n HO Cl

H

Cl m Cl H H H H H H n H n n n Cl

Ethylene vinyl alcohol (EVOH)

Polyethylene copolymer (PE)

Polystyrene (PS)

27

1.2.3.1 "QAC's as Additives" Wynne prepared polyurethane-QAC antimicrobial coatings by blending a long chain quat with oxyethylene groups into polyurethane.98 By increasing the length of the hydrophobic alkyl chain to octyl and decreasing the length of the oxyethylene groups from n = 4 to n = 2, allowed for increased migration of the QAC to the surface of the polyurethane resin (measured by X-ray photoelectron spectroscopy (XPS)) resulting in a 7-log reduction of S. aureus and E. coli (Figure 1.17).98 Furthermore, the antimicrobial plastics with the highest surface concentration (n = 8, m = 2) maintained their activity after immersion in H2O for 7 d., demonstrating they were truly surface bound. HPLC and antimicrobial analysis of the H2O phase further confirmed that the plastic sample was non-leaching and contact killing. This suggests that the QAC additives are initially mobile and able to surface-concentrate in the uncured polyurethane but become "locked" in place once the resin has cured. Thus, diffusion of the antimicrobial agents out of the film is prevented despite the inherent H2O solubility of the quat.98 The Foucher group successfully incorporated SiQAc into polypropylene (PP) during the injection molding process at 5wt % and obtained significant reduction in biofilm growth, the treated surface stained blue with bromophenol blue indicating prescence of the antimicrobial at the surface.99

28

Br O n N m

increasing m increasing n

Figure 1.17: Example of a contact active plastic self-finishing coating.98

1.2.3.2 Thermoset Antimicrobial Coatings: Cross Linked Networks Non-leaching antimicrobial-QAC thermoset plastic coatings are prepared by crosslinking the antimicrobial agent with polymerizable functional groups such as siloxanes, polyurethanes, epoxides and acrylates into polymerizable networks (Figure 1.18). Clarkson first prepared SiQAC-(SE) plastics by incorporating the antimicrobial agent, SiQAC, into silicone elastomer (SE) polymers via crosslinking with the hydroxy groups present in the poly(dimethylsiloxane) polymer. The coating was toxic to the algae, Amphora

coffeaeformis for up to 20 weeks, but lost activity after 23 weeks in sea H2O. The toxicity of the SiQAC-SE surfaces was attributed to a slow leaching of residual uncrosslinked SiQAC from the coating. Once all excess uncrosslinked SiQAC was removed by boiling solvent Soxlet extraction, the polymer lost its anti-algal activity.100 Structures of crosslinked siloxanes,101 polyurethanes102, epoxides103 and acrylates crosslinked by UV light104 with the antimicrobial QAC as part of the polymer are shown in Figure 1.18. For example, the polyurethane QAC 35 prepared by a covalently bonded hydroxyl terminated QAC bearing a long perfluorinated tail with a

29

polyisocyanate cross linker showed a 5 log reduction of S. aureus and E. coli at low concentrations (0.5 wt %, 0.007 mmol/g) with ISO 22196 and JIS Z 2801 protocols.102
1. Siloxane-QAC Cl
O O Si O N

Cl HO Si O C18H37 R Cl
N O Si O O

H + n

O O Si O

N

R

+

HO Si

OAc OAc

(3)

O

O O Si O O
O O Si O Si O O O O O Si O O O Si N

Cl R

= HO Si O

H n

R N Cl (34)

O Si O O O

Si O O O

2. Polyurethane-QAC

I C10H21 N

C18H37

I N 4O O O 0.14 = O O

O

O

0.86

NH C6H12 N O O N C6H12 NCO O (35) 3. Epoxide-QAC Cl C10H21 O N C6H12 NCO O C O C

N H

N H

O

(CH2)4

O

O C

N H

N H

O C

O

(36)

O Cl O

O Cl O

O

N O C10H21 (37) O

N O C14H29 (38) O

O C10H21 N C10H21 C10H21 (39)

O

30

4. Acrylate-QAC

Continued.....

O OR1 R1O Si O O R1O Si R1O Si O O O R1 = O O O Si O O

O Br
N

OR2 Si OR2

Br N

O N (41)

Br N N H

O

C18H37

OR1

(40) R2 = H or SiQAC

OR1

O

O O O OH OH 2,2-BIS[4-(2-HYDROXY-3-METHACRYLOXYPROPOXY) PHENYL]PROPANE

Figure 1.18: Monomers and quats used to prepare polymer-QAC antimicrobial plastic coatings. (34)101, (35-36)102, (37-39)103, (40-41).104

1.2.3.3 "Grafting Onto" and "Grafting From" Plastic Surfaces Covalently attached biocides such as QAS onto plastics can be achieved by involving either (i) plasma activation in order to functionalize the C-H surface with reactive groups such as OH or NH2 onto which biocidal polymers can be grafted to or from (ii) or UV light activation of functional groups known to directly react with inert C-H groups present on the polymer backbone such as benzophenones, vinyls, propargyls. In 2002, Gotenboss described the 1st antimicrobial QA plastic surfaces on an OH terminated silicone rubber after plasma treatement with SiQAC. In 2003, a patent described the plasma activation of polypropylene to either (A)

31

generate radicals from which QAC monomers were "grafted from" or (B) introduce functional groups onto which QAC polymers were "grafted to" (Figure 1.19).52

Figure 1.19: Bactericidal QAS polymers and small molecules prepared by plasma treated polypropylene (A) "grafting from" and (B) "grafting to" (Adapted from Ref.32).

An alternative way to effectively attach polymeric or monomeric antimicrobials to plastics surfaces is with photochemically active groups such as the benzophenone cross-linker. When irradiated with UV light (345-365 nm), the benzophenone group abstracts a hydrogen atom from a polymer (C-H) surface, forming a strong C-C bond (Figure 1.20).24 This linker has recently been used to attach thin polymer films to metal oxide and polyhydroxy surfaces via a phosphonic acid or silane group (Figure 1.20, 42, 45). Other examples include "grafting to" of antimicrobial QAC molecules and polymers with benzophenone groups to plastic surfaces with C-H groups under UV light (Figure 1.21, 43, 44, 46, 47). Dhende was first to covalently attach a quaternized polyethyleneimine (PEI) polymer onto various plastic surfaces25 (Figure 1.21, Table
32

1.6, compound 43) while the Foucher group experienced success with a benzophenone terminated C18 quat on PVC and silicone grade medical tubing105 (Figure 1.21, Table 1.6, compound 44). The coating was visualized with bromophenol blue and found to be stable up to 3 rinse cycles after destaining with anionic detergents and restaining. Lastly, Yang et al., used benzophenone as a surface initiator and grew polymers from PP surfaces that were later either quaternized or first quaternized and crosslinked (Figures 1.21 and 1.22, Table 1.6, Compound 47).106 With the unquaternized surfaces, a surface charge density of ~3.50 mol cm-2 was enough to kill both E. coli and S. aureus cells after 5 min. However, once the polymers were cross-linked, the surface lost its antimicrobial activity which was attributed to the loss of mobility of the immobilized polymeric cations.106
O UV light (345-365 nm) O H n polypropylene n OH

Figure 1.20: Example of "grafting from" immobilization of biocidal polymers employing the benzophenone surface bound initiator.24

33

I I N m C H n 6 12 C12H25 O N OH X

C18H36 N

n

O

O OH OH

PH O O O (42) (43)
- (44) X = Cl , Br , I n = 1, 2, 3

Br N Br

O O

n

I N OH O O O O OH O O

m

O Si O O (45) (46) (47)

Figure 1.21: Examples of benzophenone used to prepare antimicrobial surfaces. (42) 105 108 32 106 25 , (44) , (45) , (46) , (47) .

23,107 ,

(43)

34

Table 1.6: Examples of the benzophenone group utilized to create antimicrobial surfaces. Antimicrobial Surface Compound Tested 4223,27 4325 Ti, Al PP, PVC, PE Immobilization type Contact killing (%)

Bifunctional-PO3H2 SAM on metal with N/A benzophenone polymer cap Benzophenone grafting onto (1.5% sprayed, 99% E. coli acetone), UV light (365 nm, 180 mW/cm2) and S.aureus for 15 min for > 35 nm thickness coating Benzophenone grafting onto (1-5% sprayed, 99% E. coli EtOH), UV light (365 nm, 180 mW/cm2) for reduction on 5 min Silicone Bifunctional-silane SAM on glass and N/A benzophenone to antimicrobial polymer cap Benzophenone to BIBB SIP initiator ester 95% S.aureus coupling followed by ATRP graft with DMAEMA, quaternized with EtBr Benzophenone adlayer to "grafting from" 95% S.aureus with acrylate monomers then quaternizing

44105

PP, PVC, Silicone Si Wafer PP

45108 4632

47106

PP

Monomer

(A)

(B)

(C) Graft From (D)

(E) Photochemical Linker

Figure 1.22: Example of "grafting from" a plastic surface. Immobilization of biocidal polymers without employing a surface bound initiator (Adapted from Ref.106).
35

1.3 2nd Generation Antimicrobial Coatings: Literature Examples of Dual Action Antimicrobial Surfaces Since the advent and popularity of contact active QAC antimicrobials, current research has shifted towards combining both passive and active antimicrobial coating strategies on a single surface, giving rise to 2nd generation antimicrobials.109 These surfaces were designed to improve on the drawbacks of the 1st generation coatings which provide only one level of protection, either a microbe killing or microbe repelling role. 2nd generation coatings provide dual protection against invading bacteria by combining contact-killing with repelling capabilities so dead bacteria are swept or released from the surface after being killed.109 In theory, these ideal surface coatings are difficult and costly to prepare, with few literature examples (mainly on Au surfaces) known. One example of a dual killing surface with contact killing and biocide releasing (killing) capabilities was prepared by growing cationic chains from Au surfaces followed by impregnation with Ag+ ions (Figure 1.23).109 One apparent problem with solely killing surfaces is the build up and attachment of dead cells or debris that can deactivate the surface if not reactivated by a cleaning step. One solution to this problem was realized with a polymeric coating on Au surfaces that can be hydrolyzed from the quaternary ammonium (killing) to the zwitterionic form (repelling) reversibly (Figure 1.24).110 However, this surface required a manual hydrolysis similar to a cleaning step, otherwise the surface won't automatically switch after a build up of cells is sensed (Figure 1.24). The Foucher group is also interested in biocidal and self-cleaning surface coatings. Synthesis of an azo-benzene QAC with inherent self-cleaning capabilities switching from the cis and trans configuration under UV light is currently under study.99

36

The 3rd generation of antimicrobial coatings is foreseen to be capable of responding to stimuli so the surface can switch from a killing to a repelling one and vice-versa when necessary and target pathogenic bacteria exclusively. No literature reports of such stimuli responsive "switchable," "smart," futuristic surfaces are yet available.

Figure 1.23: Example of a releasing and repelling 2nd generation dual action antimicrobial surface.109

37

Resist Kill Release

O r NB O O O O Hydrolysis PBS (1 hr shaken) Regeneration O O N

O

OH

Dry surface (Au)

HAc (40 hrs) or TFA (20 min)

Wet surface (Au)

Figure 1.24: Example of a dual action and reversible contact killing / hydrophobic antimicrobial surface.110

1.4 Kill Mechanisms of QAC The kill mechanism of QAC's in solution or immobilized onto a surface is dependent on a host of factors that influence the compound's antimicrobial activity. Some of the factors include: (i) solution testing vs. surface testing, (ii) concentration/surface coverage, (iii) size (molecular weight), (iv) structural backbone, (v) type of counter ion, (vi) number of positive charges, and (vii) hydrophobicity of n-alkyl chains in the backbone of the QAC molecule or polymer.13,97,111,112 The bacterial cytoplasmic membrane is commonly targeted by different types of cationic QAC's that eventually result in cell death and is discussed below along with the

38

structural factors influencing QAC's antimicrobial activity both in solution and on hard surfaces.13 1.4.1 Mechanism of Killing in Solution In solution, long chain monocationic QAC's such as those employed commercially as disinfectants (Figure 1.25) destroy the bacterial cell wall and or cytoplasmic membranes by a two step process (Figure 1.26).113,114 First, the positively charged QAC's are inititally attracted to the negatively charged bacterial cell after which the QAC's diffuse and firmly bind to the inner cytoplasmic membrane. QAC's form ion-pairs with the head groups of acidic-phospholipids namely phosphatidylethanolamine (70% membrane composition) and in the process displace the Mg2+ and Ca2+ cations used to stabilize the lipid bilayer (Figure 1.26 b).76 Membrane function is further disrupted by the hydrophobic portion of the molecule by denaturing structural membrane proteins and inserting itself into the cytoplasmic membrane (Figure 1.26 c,d). With the QAC concentration approaching the minimum inhibitory concentration (MIC), the membrane begins to lose vital physiological functions such as osmoregularity and begins to leak K+ ions and protons.76 Eventually, physiologically relevant membrane protein function is inhibited and the cell loses the ability to respire, transport solutes, and resynthesize the cell wall.113 At high concentrations, the disinfectants form micelluar aggregates that completely solubilize membrane phospholipids and proteins causing leakage of the intracellular material, cell lysis and eventually cell death (Figure 1.26 e, f).113,115

39

Benzylalkonium chloride (ADBAC) Cl R1 N R2

Dialkyldimethylammonium chloride (DDAC) Cl N R1 R2 R1 = C8, R2 = C10 (50%) R1 = C10, R2 = C10 (25%) R1 = C8, R2 = C8 (25%)

R1 = H, R2 = C14 (50%), C12 (40%), C16 (10%) R1 = Et, R2 = C14 (68%), C12 (32%)

Figure 1.25: QAC disinfectants commercially employed.116

Figure 1.26: Bacterial membrane destruction by QAC disinfectants in solution. (Used with permission from Ref. 113).
40

For example, Iannou et al., found that the adherence of alkyldimethylbenzylammonium chloride (ADBAC, Figure 1.25) (a blend of C12, C14 and C16 alkyl homologues) and didecyldimethylammonium chloride (DDAC, Figure 1.25) to S. aureus cells occurred through slightly different mechanisms.117 ADBAC formed single monolayer coverage around the S. aureus outer membrane, while the DDAC formed a double layer. Both disinfectants eventually caused cell leakage and a total release of the intracellular K+ and 260 nm-absorbing proteins. Autolysis concentrations were similar regardless of the monolayers formed at 9 ug/mL (for both disinfectants), along with the depletion of approximately 30% of the internal K+ pool.117 The authors attributed the lethality of ADBAC and DDAC to the autolysis of S. aureus, however, it was concluded that mechanical lysis also seemed to be involved because cell autolytic enzymes became inhibited at the disinfectant concentrations employed (Table 1.7).117 Table 1.7: MIC values for ADBAC and DDAC against increasing S. aureus concentrations after 48 hrs of incubation in TSA medium.117 Biocide MIC (µg/mL) for inoculum test conc. (CFU/mL) Biocide ADBAC DDAC 105 0.6 0.4 106 0.6 0.4 107 0.7 0.4 108 1.0 0.6 109 1.8 1.6

In another example, electron microscopy was used to study the interaction and effects of QAC's on the S. aureus membrane. The micrographs (Figure 1.27) clearly showed the different stages of insertion of the QAC into S. aureus strain ATCC 25923. On the right, the arrows indicate tiny holes showing nodule formation (ND), indicating the beginning of cellular material leaking out of the cell. Cell deformity and cell leakage (CL) was also evident. Interestingly, after performing elemental analysis on QAS treated and untreated cells, the authors were unable to
41

detect the QAC chlorine counterion after it was taken up by the cells. It was theorized that the chlorine was pumped out of the cell on its own or together with the QAC from the cell prior to cell lysis.114 Another possibility could be that upon binding to the membrane, the chlorine counterion was diplaced from the QAC forming MgCl2 with structural cations within the microbial membrane.

Figure 1.27: Scanning electron micrographs of S. aureus strain ATCC 25923 indicating the effect didecyldimethylammonium chloride (DDAC) had on cell morphology, (a) control S. aureus cells containing no DDAC displayed normal spherical shapes, (b) cells treated with 20 g/L DDAC for 10 min. The arrows indicated where cell leakage (CL) and nodule formation (ND) was observed when the S. aureus cells were incubated with DDAC. (Used with permission from Ref .114).

The antimicrobial activity of the disinfectants discussed thus far are dependent on the length of the hydrophobic chain which follows a parabolic trend of MIC values (Figure 1.28). This phenomenon is called the ``cut-off effect'' where QAC's with C12 - C14 alkyl chain lengths show the highest activity against gram-positive bacteria and yeast, while those with longer alkyl chains (C14 - C16) show the highest activity against gram-negative bacteria. Compounds with short alkyl chains (n < 4) or very long alkyl chains (n > 18) showed the lowest activity.113 QAC's
42

with the highest antimicrobial activity and lowest MIC values are observed when the total alkyl chain length is (n > 10). In solution, QAC's with the optimum alkyl chain length (n > 10), exist as dimers because the attractive forces of neighbouring hydrophobic tails overcome the repulsive positive charges of neighbouring cations and thus show the highest kill activity. Dimeric-QAC's interact and solubilize bacterial membranes more freely in comparison to the monomeric QAC's. As a result the most effective QAC disinfectants are sold as a mixture of different chain lengths in order to ensure broad spectrum activity against different types of bacteria.116

Figure 1.28: The "Cut off Effect:" A hyperbolic trend observed in MIC values of surfactants as a function of the length of the hydrocarbon chain. (Used with permission from Ref.118). When QAC disinfectants are used at concentrations above bacterial MIC's, developing resistance is unlikely, however, when bacteria are exposed to sub-MIC concentrations various resistant genes are acquired.119,120 In fact, gram-negative bacteria such as E. coli121 and P. aeruginosa122 have acquired QAC efflux pumps capable of removing quats out of the cell. P.aeroguinosa also contain enzymes capable of metabolizing QAC's as a source of carbon and nitrogen, therefore, the MIC's are much higher (upto 10 ×) for this bacterium (Table 1.8). Further adaptive resistance to QAC's exists in bacteria capable of forming a biofilm, where the biofilm secreted lipopolysacharide layer can protect the bacteria from coming into contact with the
43

biocide. Single strain bacterial biofilms resistant to QAC's studied include those of P.aeroguinosa and Salmonella Enterica Serovar Enteritidis ATCC 4931.123 Lastly, grampositive bacterial membranes are less resistant to QAC's due to the loosely packed peptidoglycan outer layer allowing easier access to their inner cytoplasmic membrane and typically show lower MIC values (Table 1.8, S. aureus). Meanwhile, gram-negative bacterial membranes are inherently more resistant because a QAC must first cross the outer membrane with a bilayer phospholipid structure before it can gain access to the inner cytoplasmic membrane. Table 1.8: MIC values of Commercial Disinfectant BAK 50 versus thiol QAC's.118 Compound
HS Cl R 10 N

MIC (µmol/L) S.aureus P.aeruginosa C.albicans A.niger

BAK 50 R = CH2C6H5 R = CH3 R = C10H21 R = C12H25 R = C14H29

3.2 56.6 681.6 11.6 34.7 1306.3

93 556.9 1055.9 308.9 326.2 1121.5

8.36 1124.8 471.6 31.6 39.5 1524.6

4.74 56.6 351.0 31.6 67.2 90.0

When dealing with polymeric QAC's in solution, factors such as polymer size, type of counter ion, the length of the hydrophobic backbone and location of the positive charge along the backbone all have an affect on the antimicrobial activity. Typically, polymeric biocides are designed with the QAC's spread throughout the backbone as repeat units and such polymer
44

systems show a dependence on molecular weight where a 1.4 - 9.4 × 104 Da range shows maximum activity. Polymers exceeding the cut-off range are inactive because they are too large to adhere to or enter the bacterial cytoplasm.97 QAC-polymers with loosely bound counter anions foster increased antimicrobial activity because the weaker ion pair readily dissociates from the quat, which leads to ion-pair formation with the negatively charged bacterial membrane. On the other hand, strong ion-pair counterion associations with the polymer show decreased antimicrobial activity because the tightly held counter ion will prevent the polymeric quats from associating with the bacteria.124 The spacer length or alkyl chain length refers to the length of the carbon chain that composes the polymer backbone. The length of this chain has been investigated to see if it affects the antimicrobial activity of the polymer. Results have generally shown that longer alkyl chains result in higher antimicrobial activity. There are two primary explanations for this effect. Firstly, longer chains have more active sites available for adsorption with the bacteria cell wall and cytoplasmic membrane. Secondly, longer chains aggregate differently than shorter chains, which again may provide a better means for adsorption.124 Lastly, with polymeric QAC's, changing the hydrophobic portions can have a drastic effect on the efficacy of the antimicrobial in solution. Tiller's group synthesized a C12 mono quaternary oxazoline polymer with a terminal hydrophobic end group with either 10 or 16 hydrocarbons in length.125 Only the hexadecyl polymer demonstrated antimicrobial activity, while the shorter decyl chain prevented the polymer from refolding into the right orientation necessary to lyse the bacterial membrane (Figure 1.29).125

45

(A)

Near the bacterial membrane the polymer refolds and the hydrophobic tails lyses the phospholipid membrane. NOTE: only hexadecyl endgoup is active

(B)

Br N O biocidal group dodecyl (DDA) N n

hexadecyl

satellite end group polymeric spacer poly(2-methyl-1,3-oxazoline) (controls micelle formation) Br N O decyl N n

Figure 1.29: Effect of chain length on antimicrobial activity in solution (Adapted from Ref.125).

1.5. Mechanism of Immobilized Contact Active QAC Some authors suggest that surfaces immobilized with QAC compounds kill microbes on contact by disruption of the microbial membranes based on observations with structurally different polycationic polymers. Two contact killing hypotheses were proposed and are based on
46

disruption of the microbial membranes either by (i) physical means, e.g. membrane penetration/disruption or (ii) electrostatic/ionic interactions with oppositely charged bacterial phospholipids and the polycationic molecules/polymers. Both mechanisms are described below. 1.5.1 Polymeric Spacer Effect The first contact killing hypothesis was proposed in 2001 by Klibanov et al., after showing that long chain cationic polymers of poly(4-vinyl-N-hexyl)pyridinium bromide "grafted-from" or N-alkyl PEI adsorbed onto glass slides were highly antimicrobial (Figure 1.30).126-128 Glass surfaces modified with large cationic polymers ranging from 25 kD to 750 kD resulted in instant killing, meanwhile the shorter chain polymers (2 kD) were inactive towards airborne S. aureus cells sprayed onto these surfaces (Section 1.6.1.2.3 (a)). Similarly, glass slides immobilized with these antimicrobial polymers were capable of reducing both gram-positive and gram-negative bacteria by a factor of 109 cells after immersing these surfaces into bacterial solutions according to live/dead staining. Since bacterial cell walls typically range from 16 to 80 nm, the surface grafted cationic polymer coatings needed to be long and flexible enough to be able to penetrate the cell wall and disrupt the negatively charged inner bacterial membranes, e.g. a polymeric spacer of 50 nm would be required to destroy the E. coli cytoplasmic membrane which are ~ 46 nm thick (Figure 1.31).126

47

Figure 1.30: Example of the polymeric spacer effect with long chain QAC. PEI: polyethyleneimine, PVP: polyvinylpyridine. (Adapted from Ref.129).

Figure 1.31: Contact-killing via the polymeric spacer mechanism. (Used with permission from Ref.12,13).
48

1.5.2 Phospholipid Sponge Effect

A second membrane disrupting, contact-killing mechanism was proposed after observations that the short chain Si-QAC 3 and other shorter polymer brushes grown from surfaces (less than 10 nm) were also highly antimicrobial. Instead of being long enough to penetrate the cell wall, these surface immobilized shorter chain polycationic antimicrobials were hypothesized to disrupt membranes via ion-exchange between the polycationic biocides and structurally important mobile cations (Ca2+ and Mg2+) within the bacterial cytoplasmic membrane (Figure 1.32).130 Based on observations with short chain polycationic polymers `grafted onto' glass slides via silane linkers, surfaces with a charge density of QA cations (1012 1016 N+ positive charges per cm2) were required for killing after 10 min contact time depending on the type of bacterium. Approximately ~ 1 × 1010 QA or 0.015 pmol N+ was calculated to be necessary to kill one bacterium, thus a surface with 3.2 × 1014 N+ / cm2 would roughly kill ~ 0.3 × 105 bacteria/cm2. In all cases, surfaces grafted with more charges/cm2 of short chain QAC's caused faster release of counterions and resulted in higher and faster killing.42,131 In addition, Tiller proposed that highly charged surfaces without polymeric spacers need a certain degree of hydrophobicity around the quat in order to effectively kill microbes on contact. Based on observations with quaternized N-butyl or N-dodecyl-N,N-

dimethyldeoxyammonium cellulose polymer surfaces prepared from tosyl cellulose, polymers with only 50% of the tosyl groups (hydrophobic residues) substituted with the non-biocidal short chain (N-butyl-quat) were found to be biocidal whereas polymers with the same amount of N+ charges but with a low degree of substitution of the biocidal longer chain (N-dodecyl-quat) were

49

not biocidal. However, tosyl celluloses fully quaternized with the C12 tail were highly biocidal while the same polymers substituted with the C4 chain had no antimicrobial activity.132, 133 To further prove that a contact active mechanism was involved, the C12 fully substituted cellulose coatings were deactivated with sodium dodecyl sulfate (SDS, 1g/L, 1 min) and an oppositely charged phospholipid (liposomes with 10% phosphatidylglycerol). As expected, antimicrobial activity against S. aureus was lost as these anionic molecules completely blocked the cationic sites on the antimicrobial surface, preventing the removal of bacterial phospholipids. In contrast, the same coating but with a polyethyloxazoline spacer (~100 polymeric units) between the C12 quat and the cellulose backbone was unaffected by the same oppositely charged deactivating treatment and killed all S. aureus cell in support of the polymeric spacer mechanism. The authors proposed that in the phospholipid sponge mechanism, the H2Oinsoluble bacterial phospholipids are removed from the bacterial membrane and transverse through small holes in the bacterial cell-wall as micelles in order to reach the oppositely charged antimicrobial coating (Figure 1.32). A hydrophobic portion surrounding the positive charge may be required to further stabilize the newly formed ion-pair, utilizing van der Waals interactions with the hydrophobic tail of the removed lipids.

50

Figure 1.32: Contact-killing via the phospholipid sponge mechanism. (Used with permission from Ref.13,133). 1.6 Antimicrobial Testing A variety of methods are available for testing non-leaching (immobilized) antimicrobial products or surfaces based on either (i) growth enumeration of recovered bacterial colonies or (ii) cell viability enumeration after coming into contact with the active surface. With growth based methods, each method was tailored to a specific type of surface (textiles, metals, plastics) and differ in the way the bacterial inoculum is applied. Some methods require immersion of a test substrate with innoculum, while others apply the innoclum directly via (i) aerosol spraying and/ or (ii) placing a drop of inoculum and allowing it to dry on the surface prior to enumeration. Cell viability enumeration is typically based on fluorescence staining combined with real time
51

microscopy or assayed with various molecular biology techniques. Both growth and cell viability enumeration methods are discussed below along with their drawbacks and limitations. 1.6.1 Growth Based Enumeration 1.6.1.1 Immersion Inoculation 1.6.1.1.1 ASTM E2149-10 Originally developed by Isquith et al., the Dow Corning Corporate Test Method 0923 (CTM-0923)35 became known as the ASTM E2149-01,18 the standard test method for determining the antimicrobial activity of immobilized antimicrobial agents under dynamic contact and was later superseded by ASTM E2149-10.134Active surfaces are tested by immersion with inoculum following shaking and removal of samples at different times. Cells are serially diluted and colonies are enumerated on agar plates (Figure 1.33).

T1 antimicrobial solid sample T2 iv i ii iii v vi

Figure 1.33: ASTM E2149-10: (i) 1.5-3.0 × 105 CFU/mL (inoculum), (ii) treated surface cut into smaller pieces, (iii) treated surface mixed with 50 mL inoculum, (iv) place on mechanical shaker, (v) periodically remove 1.0 mL samples (T1-T4), (vi) dilute serially + growth on agar, (vii) compare to controls and calculate percent or log 10 reduction of viable cells.18 Even though the ASTM E2149 method has become the industrial benchmark for testing non-leaching (immobilized) antimicrobial products or surfaces, it has been debated whether it
52

could clearly distinguish between a contact killing surface and a biocide releasing one.63 The growth based enumeration test method assumes that an overall reduction of living cells (CFU's, colony forming units) is due to contact killing without taking into account that some of the killing could be due to slow leaching of the immobilized antimicrobial over time.63 Since the minimum inhibitory concentration (MIC) and minimum lethal concentrations (MLC) of Si-QAC in solution are very low, it is possible to observe bacterial kill from surface leaching of the active over time. For example, White et al., reported a very low MIC for gram-positive bacteria (MIC = 10 ug/mL, S. aureus) and a much higher concentration for gram-negative bacteria (MIC = 100 µg/mL, E. coli) and (MIC = 1000 µg/mL, A. niger).27 Le Song also reported a similar result (MLC = 84 µg/mL, E. coli). negligible (see Table 1.9).24 Table 1.9: Antibacterial activity of compound 3 in solution.24 Test medium Deionized H2O Artificial sea H2O Compound 3 3 MLC (µg/mL) < 84 8000
24

However, in saline solution, the activity of compound 3 was

1.6.1.2 Direct Inoculation 1.6.1.2.1 Zone of Inhibition In the agar diffusion test, or the Kirby-Bauer disk-diffusion method, the zone of inhibition is often used to determine if an antimicrobial surface releases biocides or if it kills on contact.13 An agar plate with a visible zone of dead bacteria around the antimicrobial surface is attributed to the release of the active biocide that exceeds the MIC, meanwhile an uncolonized surface with no such zone is typically considered to kill on contact (Figure 1.34). The size of the
53

zone depends on factors such as the diffusion kinetics through the nutrient media and the original concentration of the active chemical present. With this test, however, it is difficult to prove if the immobilized surface is truly contact killing solely by the absence of a zone of inhibition. For example, monolayers of immobilized biocides typically contain a very small amount of the active molecule and thus the absence of a zone of inhibition could be mistaken for a nonreleasing surface when in fact the concentration of the antimicrobial agent is above the MIC.13 On the other hand, interferences such as charged proteins and other growth media nutrients that can deactivate cationic immobilized antimicrobials on the test surface would raise the MIC and result in a smaller or no zone in an eluting surface.13

Figure 1.34: ZOI Agar diffusion method: Antimicrobial releasing plastic film surface on A. niger. (Used with permission from Ref.95)

54

1.6.1.2.2 Textiles The AATCC 100-2004 test method or the "padding test" is very similar to the Dow suspension test except only textile samples are tested and no shaking takes place. Circular texile samples are inoculated, incubated and colonies are counted after serial dilutions (Figure 1.35).18

i

ii

iii

iv

v

vi

Figure 1.35: Standard methods for testing antimicrobials on textiles. (i) 1-2 × 105 CFU/mL (inoculum), (ii) place textile in petri dish, (iii) 1 mL inncolum is added (iv) transfer to jar to prevent evaporation, (v) incubate, (vi) add neutralizer solution, (vii) serial dilutions, incubate and agar plating, (viii) compare to controls and calculate percent of log 10 reduction.18 1.6.1.2.3 Hard Surfaces: Metals, Plastics, Glass (a) Aerosol Inoculation This method, designed to mimic airborne deposition of microorganisms on surfaces, utilizes a readily available TLC sprayer to deposit a bacterial inoculum as a mist on hard surfaces followed by air drying, agar incubation and viable colony counts (Figure 1.36). Simple in design, the drawback of this method is reproducibility in the delivery of the inoculum which makes it difficult to compare to non-aerosol methods.18 Also the aerosol method does not distinguish
55

between contact killing or release killing from the surface.63 A literature example described by Klibanov shows the results of the aerosol method of a glass slide with covalently attached cationic antimicrobial PVP polymer (Figure 1.37).127

treated untreated

i

ii

iii

iv

v

Figure 1.36: Diagram of the aerosol inoculation method: (i) 5-50 × 106 CFU/mL (inoculum), (ii) inoculum sprayed onto treated and control surfaces and allowed to air dry for 2 min, (iii) cover with agar and incubate 37°C ON, (iv) compare to controls and calculate percent or log 10 reduction.18

56

Figure 1.37: Results from the aerosol inoculum method with an immobilized QAS polymer onto a glass slide. Left (control), right (polymer modified slide). (Used with permission from Ref.127) (b) Industrial Standard Test Methods A variety of standard test methods designed to quantitatively test microbial inhibition via direct innoculation on solid surfaces include the (i) JIS Z 2801, the Japanese standard, developed in 2006 and superseded by (ii) ISO 22196, the international standard method. Other similar standard methods for hard surfaces include (iii) EN ISO 846, plastics-evaluation of the action of microorganisms, (iv) ASTM G21-90, standard practice for determining resistance of synthetic polymeric materials to fungi, and (v) ASTM G22-76, standard practice for determining resistance of synthetic polymeric materials to bacteria.18,95 As with the immersion inoculation method, the test microorganism is cultured, usually by growth in a liquid culture medium. The suspension of test microorganism is standardized by
57

dilution in a nutritive broth (this affords microorganisms the potential to grow during the test).95 Control and test surfaces are inoculated with microorganisms in triplicate, and then the microbial inoculum is covered with a thin, sterile film. Covering the inoculum spreads it, prevents it from evaporating, and ensures close contact with the antimicrobial surface. Microbial concentrations are determined at "time zero" by elution followed by dilution and plating. A control is run to verify that the neutralization/elution method effectively neutralizes the antimicrobial agent in the antimicrobial surface being tested.95 Inoculated covered control and antimicrobial test surfaces are allowed to incubate undisturbed in a humid environment for 24 hrs.95 After incubation, microbial concentrations on surfaces are determined. The reduction of microorganisms relative to initial concentrations and the control surface is then calculated (Figure 1.38). The drawback of the ISO 22196 method is that it is not representative of the actual antimicrobial surface contamination scenario. Typically upon landing, microbial contaminants dry very quickly on surfaces, whereas with this method, the use of a cover slip keeps the contact between bacteria and the surface in a wet state typically overnight. In reality, bacteria rarely spend that long of an interaction with the surface in the wet state.135 As well, cells adhered to the cover slip are not typically taken into account, inflating log reduction values (LRV's).136 This method has recently been modified by the Wolfaardt lab, by forgoing the glass cover slip and allowing the inoculum to dry on the surface prior to analysis and by the Green lab, by using a polypropylene spacer in between the substrate surface and the coverslip in order to distinguish release killing vs. contact killing (discussed below).63

58

Polyethylene film inoculum Sample

ii

iii i

iv

v

vi

Figure 1.38: Industrial standard method for testing antimicrobials on hard surfaces by growth enumeration, (i) 1 × 106 CFU/mL (inoculum), (ii) 400 µL inoculum added to each 50 mm × 50 mm sample, (iii) cover incoluum with 40 mm × 40 mm sterile polypropylene coverslip, (iv) incubate for 24 hrs, (v) transfer to individual containers with 10 mL neutralizer (vi) serial dilutions, incubate and agar plating, (vii) compare to controls and calculate percent of log 10 reduction.18 (c) Wolfaardt's Lab Modification of ISO 22196 The Wofaardt method differs from the ISO 22196 method by foregoing the coverslip altogether and allowing a droplet of inoculum to dry in direct contact on the treated surface. Once dried, the surface is shaken with saline to remove unbound cells followed by serial dilution and enumeration on agar as with the other methods (Figure 1.39).137

59

Figure 1.39: Modified method for testing antimicrobials on hard surfaces by growth enumeration in the dry state testing developed in the Wolfaardt lab. (i) 1 × 1010 CFU/mL (inoculum), (ii) 1 mL inoculum added to 1 cm × 1 cm solid sample and left to dry for appropriate time 2-24 hrs, (iii) sample is added to 0.9% saline solution, (iv) vortex saline solution to remove attached cells, (v) serial dilutions and agar plating, (vi) compare to controls and calculate percent of log 10 reduction.

(d) Green's Lab Modification (SLSDSS) of ISO 22196 Recently Green et al., reported an improved microbiological test method that differentiates between contact killing and release killing from immobilized antimicrobial surfaces. The new method, known as the semi-quantitative surface-separated live­dead staining (SSLDS) technique, is a modification of the traditional live-dead staining technique based on fluorescence microscopy.63 By utilizing 50 mm polystyrene spacers between the treated surface and a control surface, the method can distinguish three outcomes: (A) live or dead cells on the control surface, (B) live or dead cells on the treated surface, (C) live or dead cells leaching (Figure 1.40). Thus in the first outcome (A) the immobilized agent is ineffective and no bacteria are killed (cells stained green), (B) the treated surface agent if firmly immobilized and only kills bacteria at the treated surface (cells are stained red) while cells on the coverslip survive (stain green) (C) the antimicrobial leaches from the treated surface via the spacer and kill cells throughout, all cells are stained red or dead (Figure 1.40).63
60

Figure 1.40: A schematic diagram of the symmertric SSLDS method depicting three distinct antimicrobial agent states: (A) no kill, all cells are stained live (green), (B) on cell that come into contact with immobilized antimicrobial are killed (bottom), (C) all cells are killed because of antimicrobial leaching.63

The Green lab modified their SSLDS method further by incorporating an asymmetric direct inoculation design in comparison to their standard symmetric design. The difference between the two designs being in the asymmetric design with both treated active glass surfaces are separated by a spacer, meanwhile the symmetric design uses an untreated control glass (coverslip) on top and an active treated slide with the immobilized antimicrobial agent on the bottom (Figure 1.41). In this way, false positives resulting from non-adherent cells or interaction of the fluorescent dyes with the antimicrobial substrate found in the symmetric SSLDS are minimized. For example, if the bacterial strains fail to adhere to the active surface and after being killed detach to the coverslip, then false conclusions can be drawn that the surface was eluting.136

61

Figure 1.41: Direct innoculation SLDSS methods. (A) symmetric design, (B) asymmetric design.136 1.6.2 Cell Viability Enumeration Cell viability on the surface can be quantified with fluorescence based on live dead staining combined with real time microscopy or assayed with various molecular biology techniques that measure (i) cellular ATP with bioluminescence, or (ii) CO2 respiration with flow cells or with (iii) redox active indicator dye (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2Htetrazolium-5-carboxanilide) (XTT) measured spectrophotometrically (Figure 1.42).

Figure 1.42: Diagram of a high-thoughput biofilm retention assay that measures absorbance or fluorescence from a 96-well plate.18
62

Microscopy techniques can be employed as tools to test antimicrobial activity on a surface. The Foucher group in collaboration with the Wolfaardt group tested QAC immobilized PP surfaces for bacterial growth. SEM microscopy showed considerable bacterial colonization on the control (left) and virtually no growth on the treated surface indicative of a contact killing surface (Figure 1.43).138

(A)

(B)

Figure 1.43: Polypropylene microscopy of control ~ 50 cfu/mL (A) vinyl terminated QAC sprayed (10%) 0 cfu/mL (B).138

Other groups captured the disruption of gram-positive and gram-negative bacterial membranes with SEM images after incubation with QAC-silica nanoparticles. Both the untreated and non quat treated nanoparticles (NP) showed normal cell morphology, meanwhile the QAS treated NP's showed cell lysis and cell death. (Figure 1.44).

63

Figure 1.44: SEM images of bacteria incubated with antimicrobial silica nanoparticles. OdS = silica with C18 chain lacking a quat, QAS = SiQAC 3. (Used with permission from Ref. 62).

1.7 CHEMISTRY OF PHOSPHONIC ACIDS

QUATERNARY

AMMONIUM

GROUPS

AND

1.7.1 Menschutkin Quaternization Reaction Discovered in 1890 by Nicoli Menschutkin, the quaternization or quat formation reaction is widely used industrially for the synthesis of antimicrobials, phase transfer catalysis, pesticides, ionic liquids and natural products.139 A typical quaternization reaction involves the reaction between two neutral molecules, a tertiary amine with an alkylhalide or sulfonate. Upon nucleophilic attack, the amine substitutes the alkylhalide or sulfonate leaving group in an SN2 fashion producing a positively charged quaternary amine with four bonds and a negatively charged counter ion, thus forming an ion pair. In accordance with an SN2 mechanism, the reaction is accelerated by more nucleophilic amines, increased leaving group ability, increased pressure and elevated temperature (Figure 1.45).140 Polar solvents also speed up the reaction by stabilizing the charged transition state (Table 1.10).141 With alkyltosyl or mesylates the reaction
64

is favored at lower temperatures and polar protic solvents in order to avoid the competing elimination reaction.142
R1 N RT-150°C + R2 X R4 R1 X R3 N R4 R2

2 min - 24 hrs solvent or solventless ____________________________________________________________ Order of reactivity X = OMs > I > Br > Cl H2O ~ DMF > ACN > ROH > TOL

R3

Increasing electrophilicity > X > X > X Alk

X

N

Alk

>

N

OEt P OEt O

>

N

>

N

Increasing nucleophilicity

Figure 1.45: Reactivity of the Menschutkin reaction. Table 1.10: Relative rates of the Menschutkin quaternization in various solvents (Adapted from Ref.143). Solvent CH3(CH2)4CH3 Et2O C6H6 n-BuOH CHCl3 EtOAc Relative Rate (s-1) 1 4 38 70 100 125 Solvent EtOH MeOH (CH3)2CO ACN CH3NO2 DMF Relative Rate (s-1) 200 285 340 375 500 900

65

In accordance with the aims of this thesis, the synthesis of quaternary ammonium antimicrobials for surface immobilization will be conducted through the Menshutkin quaternization reaction. Typically, the reaction goes to completion by employing refluxing temperatures in polar solvents from which QAS products crystallize or can be precipitated with the addition of Et2O or hexanes. Selected literature quaternization examples showing reaction conditions used to prepare surface bound antimicrobials are presented in Table 1.11. Table 1.11: Examples of literature Menschutkin reaction conditions.
R1 N RT-150°C + R2 X R4 2 min - 24 hrs solvent or solventless R1 X R3 N R4 R2

R3

Entry

Starting Materials

Product

Solvent Temp (°C) Time (hrs) Yields (%)
i Pr:MeOH i Pr:MeOH 80 80 0.5 12 na na

ia

HO

N

Br C11H23

HO

N

n

n

C11H23

iib

O O Si O

Cl

N C18H37

O O Si O

N

C18H37

neat

110

48

nah

iii

c

O O Si O

C6H13 N

MeI

O HO Si O

N

THF C6H13

RT

24

76

ivc

EtO

O Br

P EtO

N

EtO

O N H2O 82 48 nai

P EtO

Continued....

66

Entry

Starting Materials
Br

Product
I

Solvent Temp (°C) Time (hrs) Yields (%)
1.1 t -amylOH 1.2 t -amylOH 95 60 96 24 na 46

vf

N H

C6H12 n O

Br C12H25 K2CO3 I

N

N O

m C12H15

n

C6H12

1.1

O 1.2 MeI O

N

vig

n

1.1 N C4H9

1.2
O O Si O

n

1.1 THF 1.2 EtOH

50 50

6 12

naj na

N Cl

N Cl

N N Cl

N Cl N Bu

MeO

Si e MeO OM

(i),102 (ii),38 (iii),59 (iv)144, (v),25 (vi),42; b (diluted directly to 50 wt% in MeOH) c (used directly following hydrolysis with HCl, not shown), f-g (used directly in step 1.2, final yield not reported). 1.7.2 Precursors for the Menshutkin Reaction Unless commercially available, the precursor amine and alkylhalide or sulfonate often require synthesis. The most direct method for the preparation of N-alkyl secondary or tertiary amines is alkylation of a primary amine with an alkylhalide (or sulfonate) known as the "Hoffman alkylation."145 Although the method seems simple at first glance, it lacks control due to the possibility of overalkylation (Figure 1.46).145,146 When starting with unactivated primary amines the higher substituted N-alkyl amine products formed can react with the alkyl halide giving a mixture of primary, secondary, tertiary and QAS that are impossible to separate. In practice, completion only to the secondary amine stage can be achieved by using a large excess (10-100 ×) of the primary amine (Figure 1.46). However the drawbacks are the price of the starting amine used in excess and the extra purification steps required (normally distillation) to
67

remove the excess amine. The cost of the starting amine limit the scope of the reaction because only inexpensive simple primary amines such as methyl and benzyl amines could realistically be used.145 Recent developments showed that by adding a small amount of an additive (silica147, CsOH148) one can selectively stop the N-alkylation reaction at the secondary or tertiary amine without QAS formation. Stopping at the tertiary amine is also possible with microwave (µW) radiation under aqueous conditions (NaOH/H2O149,150 or NaHCO3/H2O151). Additionally, with activated substrates such as allylhalide or CH3I, a primary amine can be driven to the quaternary amine as the sole product with the addition of a base (Figure 1.46, further discussion below).
R1 R NH2 X R N H R1 R1 X R N R1 R1 R1 X R R1 N R1 X R1

Base

Base

Figure 1.46: Preparation of Menschutkin precursors from primary amines by direct alkylation. If more control is needed, two alternative reactions can be used to give N,N-methylated tertiary amines as the sole products (Figure 1.47).

R

NH2

n tki u ch ns e Me as B / I Me

R

I

N

De
H

me th y la ti o n
R N

CH2CO/HCOOH Eschweiler-Clarke

Figure 1.47: Preparation of Menschutkin precursors from primary amines. N,N-dimethyltertiaryamines are most commonly synthesized by the classic Eschweiler Clarke (EC) reaction from primary or secondary amines using formaldehyde as the source of the methyl groups and formic acid as the reducing agent generating H2O and CO2 in the mechanism
68

(Figure 1.48).152 NaBH(OAc)3,154,155

Alternative reducing agents include the borohydrides, NaBH4,153 NaCNBH4,156 and zinc reagents, ZnCl2/NaBH4/DCM157 and

Zn/AcOH/H2O.158 The advantage of the EC reductive methylation over amine methylations with MeI is that the reaction halts at the tertiary amine without producing quaternary ammonium salt because tertiary amines are inert to further imine formation with formaldehyde. However, the intermediate imine formed in the reaction can sometimes isomerize, and upon hydrolysis, yield the carbonyl derivative of the starting amine plus methylamine.152,159 As a result of by-product formation, the EC reaction can give poor yields and can be difficult to purify if mixtures of mono- and dimethylated products are formed. An alternative synthetic strategy to N,N-dimethyl tertiary amines can be considered.
O

R

N

H

H

R

O +

NH2

by-products

O R NH2 H O

H R H N H

O OH R H N

- CO2

O O R N basic work up R NH H OH

H

-H

O

H

R

N

- CO2

Figure 1.48: Mechanism of the Eschweiler-Clarke N,N-methylation. Combination of the Menshutkin quaternization with demethylation is another route towards N,N-dimethyl tertiary amines which avoids epimerization like the EC reaction. For
69

example the reaction has to be performed sequentially when the demethylating nucleophilc hydride is LAH.159 The first step performed in MeOH/bicarbonate gives N,N,N-trimethylalkyl amines which are isolated and demethylated in THF/LAH (Figure 1.47). A one-pot synthesis of N,N-dimethylalkyl amines is achieved by tandem quaternization/demethylation when NaBH4 was used as the nucleophile.160 A onepot procedure involved quaternization of either primary, secondary or tertiary amines with MeI in a polar aprotic solvent (DMF, DMSO, ACN) utilizing a sterically hindered organic base143 of greater basicity than the starting amine such as 2,6 lutidine (pKa ~ 6.77), tri-n-butylamine (pKa ~ 10.89), 1,2,2,6,6-pentamethylpiperidine or PMP (pKa ~ 11.2), to mop up the HI formed in the reaction. This sequence is followed by demethylation with the addition of NaBH4 to the reaction without isolation of the trimethylalkylquaternary ammonium salt.160 Alternatively, alcohols can be used as starting materials to prepare halo and N,N-dimethylamine functional groups either directly with the Appel reaction (CBr4/PPh3)161 or indirectly by substitution of an activated alcohol either by mesylation (MsCl/NMe3HCl, LiBr)162, or silylation (TMSCl/LiBr)163 (Figure 1.49).
R OMs on S a ti l N2 sy e e s M a L iB r /B Cl Ms r or NBS CB 4/PPh3 or TMSCl/LiBr

R

OH

R

Br

Mesylation
R OH MsCl/Base R OMs

SN2 NHMe2 R N

Figure 1.49: Preparation of Menschutkin precursors from alcohols.

70

1.7.3 Stability of Quaternary Ammonium Groups Quaternary ammonium salts undergo dequaternization or dealkylation (debenzylation, deallylation, demethylation, dealkylation) by various nucleophiles in an SN2 fashion producing tertiary amines and transalkylated by-products bound to the nucleophile. By varying the nucleophile and the alkyl leaving groups the substitution can be selective, giving the desired tertiary amine or can occur randomly, providing a mixture of products (Table 1.12).164 Selective dequaternization of QAS is an effective method used to prepare tertiary amines having different alkyl substituents.146,165 Selective dequaternization is only possible when one of the alkyl groups is a better leaving group compared to the other three groups on the quaternary nitrogen. Two examples demonstrate the utility of this discriminating method for the preferential dealkylation. In the first approach, heating a QAC bearing a 2-hydroxyethyl group with hydroxide ion allows for its preferential and clean cleavage. This is because upon heating, only the 2-hydroxyethyl group leaves as ethylene oxide whereas other alkyl groups remain untouched by hydroxide (Table 1.12, Entry i).146 In the second approach, a QAC attached through a benzyl group to a solid support resin (Merrifield resin) and bearing three different substituents can be preferentially removed from the resin by selective debenzylation over demethylation. This is possible because the alkyl leaving group ability from QAS increases with resonance stabilization and the loss of a benzyl group and allyl group is preferred over the loss of a methyl group which itself is favored over the loss of longer alkyl groups (Table 1.12, Entry iii).165 Other nucleophiles capable of selective QAC demethylation to the desired tertiary amines include the hydrides; LAH,159 NaBH4 (HMPA, DMSO, sulfone)160, LiBH(Et3)3,159 LiBH(S-Bu)3,159 and also Na/NH3,166 OH(CH2)2NH2,167 LiI,167 PhS-Na+,168 CH3(CH2)2S-Li+,169 and piperidine170 (Table 1.12, Entry iii).
71

Table 1.12: Examples of the SN2 dequaternization reaction.

R1 X R3 N R4 R2 Order of reactivity R4 = O

+

Nu

SN2 Solvent

R1 R3 N R2 > Nu Me >

+

R4 Nu

>

Nu Nu

>

Nu

Nu

Alk

Entry

Starting Material
OH

Products

Temp (°C)

Time (hrs)

Yield (%)

n-C12H23 i
a

N O 120e 1 95

n-C12H23

N

OH

N iib N OH OH

HO

n/a

35

N Merrifield resin iiic I Bn HN N 100f N R 10

65

85f

N R

Bn N N N Cl 86g 18 92

Cl ivd

N

N N

N vd n-C12H23 N N Cl n-C12H23 N Cl

N N 150h 3 68

a146,b171,c165,d170,e (no solvent), f (R = n-Bu (85%), Et (83%)), Me (83%)165, (no solvent), g (EtOH), h (EtOH = no reaction, DMF).
72

Otherwise, when a non-selective nucleophile such as OH- is reacted with a QAC possesing benzyl and methyl substitutents, a mixture of products is possible (Table 1.12, Entry ii). For example, heating benzyltrimethylammonium hydroxide gives a mixture of benzyldimethyl amine and MeOH (35%) resulting from an SN2 attack on one of the methyl groups, while attack on the benzyl carbon results in benzyl alcohol and Et3N (65%). Elimination products (alkenes and tertiary amines) are not possible in this case because this substrate lacks hydrogens necessary for elimination to take place. Of course E2 elimination, favoured by sterically hindered bases can occur only on QAC substrates with -hydrogens and the leaving group in the trans configuration.172 On the otherhand, the E1 mechanism is possible only on QAC substrates with sterically hindered  and -carbons atoms.172 Lastly, depending on the nature of the alkyl halide and the basicity of the amine, competing side reactions may take place in favor of the Menschutkin reaction. For example when an electron withdrawing group (eg. ethyl ester) is located two carbons away from the halide atom, the elimination reaction dominates and the thermodynamically favoured ethyl acrylate is formed as the sole product over the quat (Figure 1.50 a). Similarly the prescence of acidic functional groups with a lower pKa than the amine result in protonation of the nucleophilic amine instead of the SN2 quaternization (Figure 1.50 b). In order to prepare such carboxylic acid quats, the tertiary amine are quaternized with propriolactone followed by acidic work up (Figure 1.50 c).173

73

Br Alk O N O O Br Alk N H + O O O

(a) Alk

N

+

Br

ethyl acrylate thermodynamically favoured

Br Alk O N O OH H O O Br OH

(b)

Alk

N

+

Br

Alk

N

acid/base rxn favoured

(c) Alk

N

+

O O HCl Alk

Cl N

O OH

Figure 1.50: Side reactions favoured over the Menshutkin reaction.

74

1.7.4 Detection of QAC in Solution and on Surfaces A variety of titration methods employing organic dyes were developed to quantify the amount of quaternary ammonium salts widely employed as antimicrobials in consumer products and pesticides in waste H2O.174,175 The most popular methods employ bromophenol blue and dichlorofluorescein as dyes capable of binding to the quaternary ammonium through an ion pair interaction. Biphasic titrations employed bromphenol blue (Figure 1.51, 1.53) whereas

dichlorofluorescein was used in a monophasic titration to determine QAS directly (Figure 1.52).176 The biphasic titration176 involves an ion pair complex formation between the active ingredient quaternary ammonium cation and the indicator bromophenol blue anion which is readily soluble in DCM (blue bottom organic phase, Figure 1.53 b). Upon addition of [BPh4]-Na+ the bromophenol blue anion was displaced from the complex and migrated up into the top aqueous layer turning the organic bottom layer clear at the end point of the titration (Figure 1.53, c).

75

(A) Start of biphasic titration with bromophenol blue Br Cl O O Br Si O N
15

O S O O Br Br O N O
15

O S O O Br Br O

HO Br O O Si

HO Br

SiQAC (3) (B) End point O S O O

Bromophenol blue dye [BPB]-

Bromophenol blue ion pair + [BPB] [R4N] formation with SiQAC (3) (blue complex, organic layer)

Br HO Br O O Si O Br

B Br + O N
15

Na B O Si O O N
15

Bromophenol blue ion pair + [BPB] [R4N] formation with SiQAC (3)

Sodium tetraphenylborate + [BPh4] Na titrant

Titrant ion pair [R4N]+ [BPh4]with SiQAC (3) or ( ganic layer, clear) O S O O Br Br

Br HO Br

O Na a ueous a er l , y blue) ( q

Figure 1.51: Monophasic titration with bromophenol blue.

76

Cl O Cl Cl O O Si O N
15

OH

OH

O O

O

O O O O Si O Cl OH N
15

SiQAC (3)

Cl O c oro uoresce Di hl in ion pair fl DCF [ ]

Dichlorofluorescein ion pair + DCF [ ] [R4N] formation with SiQAC (3) (pink complex)

Figure 1.52: Monophasic titration with dichlorofluorescein.

(a)

(b)

(c)

Figure 1.53: Biphasic ion pair titration based on bromophenol blue and SiQAC 3, (a) prior to addition of indicator (b) start of titration, (c) past end point. The amount of QAS in the test sample employing the titration methods mentioned above is calculated using the following equation: % QUAT = (Vtit × Ntit × MQAS) / WtQAS. where Vtit is the volume of titrant, STPB added to the test solution to reach the end-point (in mL), Ntit is the normality of titrant (in mol/L), MQAS is the equivalent molecular weight of the QAS, WtQAS is the gross weight of the QAS (in grams). The bromophenol blue dye has also been used to directly visualize quaternary ammonium compounds coated on fabric surfaces (porous surfaces). This H2O soluble anionic dye complexes
77

surface bound quaternary ammonium compounds forming an ion pair which stains the surface a blue colour.2 However, the bromophenol blue dye once complexed to the fabric stains the surface, potentially damaging the test material for future use. The same dyes may be utilized to indirectly detect the prescence of surface bound quats on non-porous surfaces such as glass, and plastic. A simple alternative to bromophenol blue for the detection of QAC surface coverage and coating uniformity is fluorescent detection. Thus, treated surfaces would glow fluorescent under exposure to a low power UV lamp, identifying areas of poor adhesion as well as missed areas during application. Additionally, it can also act as a unique product identifier and security feature for treated surfaces when added in trace amounts to functional antimicrobial solutions. Previously in the Foucher group, dansyl tags with organosilane,177 phosphonate,177 benzophenone105 and vinyl138 linkers were synthesized (Figure 1.54).

N O HN S O Br O HN S O Br

N O HN S O Cl O HN S O Br

N

N

N

N

N

O

N

O Si O O

EtO P O OEt

O Ph

Figure 1.54: Dansyl linkers previously synthesized in the Foucher lab.105,138,177

78

1.8 CHEMISTRY OF ORGANOPHOSPHORUS COMPOUNDS 1.8.1 Mono and Didealkylation of Phosphonate Esters Dialkyl phosphonates undergo selective dealkylation with heteroatom nucleophiles such as KOH, NH4OH, LiI or can be directly didealkylated with mineral acids, silicone or boron reagents (Figure 1.55)
O P OR OH

R1

O P OR OR2 2

m to les a o r hi te he c leo p nu

R1

HX o

rT MS X
R1 O P OH OH

HX or TMSX or BBr3 X = Cl, Br, I

Figure 1.55: Examples of reagents used to dealkylate phosphonate esters.

Mineral acids used to completely dealkylate phosphonate esters include both HCl and HBr, which are added in excess (10-100 ×) and typically require long refluxing conditions (12-24 hrs) especially with the less reactive HCl. Under µW radiation the reaction times are shortened to 30 min with a stoichiometric amount of HCl.178,179 Selected literature examples of the dealkylation of phosphonate esters with mineral acids is shown in Table 1.13 and the mechanism of this transformation is shown in Figure 1.56. Since the formation of the carbocation intermediate is the rate determining step, the more stable iPr carbocations and more reactive Brions generally give shorter reaction times (Table 1.13).

79

Table 1.13: Literature examples of the dealkylation of phosphonate esters with mineral acids.
R1 O P R O 2 O R2 100°C 8-24 hrs + 2H X or µW 130-140°C,10-30 min X = I > Br < Cl R2 = i Pr > nBu > Et < Me R1 O OH P OH + X R2

Order of reactivity

Entry
ia

Starting Material
Cl N n

Products
Cl

HX (# eq.) Temp (°C) Time (hrs) Yields (%) HCl (20 eq.) 100 HBr (93 eq.) 100 n/ad 93e

OEt P OEt O O P OEt OEt N

N

OH P n O OH

24 48

iib

N N

N N

N N

O P OH OH

HBr/AcOH

25

20

94

O Ot Bu N O Ot Bu

iiic Cl

O OEt P OEt

Cl

O OH P OH

HCl (3 eq.)

100

0.25

79f

ivc Cl

O Oi Pr P Oi Pr

Cl

O OH P OH

HCl (3 eq.)

100

0.1

84f

vc N

NH2 N O N N O P OEt OEt N

NH2 N O N N O P OH OH HCl (2 eq.) 140 0.3 78f

vic N

NH2 N O N N O P Oi Pr Oi Pr N

NH2 N O N N O P OH OH HCl (2 eq.) 130 0.1 78f

a,178, 179 b,180 c,181 d, (n = 1), (no yield reported), e, (n = 5,9,13), f, (µW reactions)
80

R1

O P R O 2 O R2

H R1

H O O P R2 O R2

R1

H O O + P O R2

X R2

X

R1

H O O + R2 P O R2 carbocation

H

R1

H O O P O R2 H

R1

H O O P O R2 H

+

R2

carbocation

X H O O P O H

R1

Figure 1.56: Mechanism of the didealkylation of phosphonate diesters in mineral acids. On the other hand, dealkylation of phosphonate esters with TMSX (X = Cl-, Br-, I-) occurs via a different mechanism whereby the halide ion acts as both the leaving group and the nucleophile in the reaction (Figure 1.57).182-184 In the first step of the mechanism the acidic phosphoryl sp3 oxygen reversibly attacks the electrophilic silicon of the silylhalide forming a charged phosphonium intermediate while displacing the halide. Irreversible substitution with the nucleophilic halide only occurs with the attack on the phosphonate alkyl group producing one equivalent of an alkyl halide and a mixed trimethylsilylated ester. With TMSI bearing the more nucleophilic iodide ion, the reaction proceeds at a faster rate than TMSBr and occurs predictably
81

the slowest with TMSCl due to the weakly nucleophilic chloride (typically d. at refluxing temperatures). Another cycle of the mechanism produces dealkylated bis(trimethylsilyl) phosphonate which at this point can be distilled or hydrolysed with H2O or lower alcohols to the free phosphonic acid.184 Aqueous hydrolysis always leads to the free phosphonic acids while the use of higher chain alcohols (decanol and above) can result in a mixture of products depending if the nucleophilic attack site is either silicon or phosphorus (Figure 1.58).
O P R O 2 O R2 X Si 1. RT 3-24 hrs or µW, 10 min, 40-100°C 2. H2O/EtOH X = I > Br > Cl R2 = Me > Et > nBu > i Pr Decreasing Steric Hindrance

R1

+

2

R1

O OH P + OH

X R2

Order of reactivity

R1

O P R O 2 O R2

X Si

Si R1

O P

X R2 O R2 O - X R2

Si R1

O P

O O R2

X Si

R1

H O O P O H

2 H2O - Si O Si

Si R1

O P

Si O O

X - X R2

Si R1

O P

O

Si

O R2

Figure 1.57: Mechanism of the didealkylation of dialkylphosphonate esters via silylation and hydrolysis.

82

O OH P R OH + Si O Si + H2O

Attack on P

Attack on P

O OR + HO Si P R OR O OR P R OH O OH + RO Si P R OH

Mixed attack

H2O

Si O O P R O Si

ROH

Mixed attack

Attack on Si

Attack on Si

Figure 1.58: Possible products resulting from the hydrolysis of bistrimethylsilyl phosphonates.

Similarly, nucleophilic displacement of alkyl groups from phosphonate esters goes to completion with lithium trialkylborohydrides via a SN2 meachanism (Table 1.14, Figure 1.59).185 The advantages of using silicone and boron reagents include milder reaction conditions (RT) and greater function group sensitivity. Additionally, these reagents are compatible with aryl phosphonate esters, carboxylic ester, ethers, halo alkyl, alkyne and alkene functional groups.186,
187

83

Table 1.14: Literature examples of the dealkylation of phosphonate esters with BBr3.
R2 O P O O R2 R1 + 0.9 Br Br B 1. TOL / Hexanes - 30°C-->70°C (6hrs) Br 2. MeOH, RT HO O R1 + Br R2 + O P HO O B

O

Entry

Starting Material
RO O

Products
HO O

Yield (%)

i

P RO

P HO

90a,95b,89c,84d

ii

EtO

O (CH2)8CH3

P EtO

HO

O (CH2)8CH3

P HO

82

ii

MeO

O

P MeO

HO

O

P HO

92

iv

EtO

O

P EtO

HO

O

P HO

77

v

EtO

O Br

P EtO O

HO

O Br

P HO O

80

vi

EtO

P EtO O

HO N

P HO O

80 N

vii

MeO

O N O

P MeO

HO

O N O

P HO

89

(Redrawn from Ref.186) a, (R = Me), b, (R = Et), c, (R = iPr), d, (R = t-Bu)

84

R1

O P R O 2 O R2

Br

Br B

Br

Br Br B Br O P O R1 O R2 R2 - r R2 HB

MeOH

R1

O P R O 2 O R2

+ O

O B

O

Br

Br B

MeOH O P O O R2 R1

R1

O P OH O R2

+ O

O B

O

- r R2 HB

O O O P O B n R2

MeOH

R1

O P OH OH

+ O

O B

O

Figure 1.59: Mechanism of phosphonic acid dealkylation with BBr3.188,189

1.8.2 Synthesis of Phosphonic Acids The synthesis of -monophosphonic acid QAC's with hydrophobic tails typically from 12 to 18 carbons long are known in the literature. Two syntheses describe the preparation of a C18 monophosphonic acid QAC (Figure 1.60), one starting with the bromophosphonate (Route a) while the other with the bromoQAC (Route b), and both are obtained from an Abruzov reaction. Quaternary ammonium phosphonate compounds prepared by Route b were patented in 1955 for use as synthetic detergents.190,191 In the reported synthesis, the final product could only be isolated as Na salt of the phosphobetaine after hydrolysis of the phosphonate ester with HCl followed by treatment with NaHCO3 (Figure 1.60, a). Route b was used by Germanaud who
85

isolated the quats as betaines after purification on an anion exchange resin (Figure 1.60,b).192 The products synthesized by this method were not spectroscopically characterized in the patents and were used as is, while Germanaud's purification is costly and doesn't isolate the product as a phosphonic acid.192 The free phosphonic acid with a C18 was never reported (Figure 1.60, d), however the preparation of the C12 analog by method c starting from 3-bromophosphonic acid is known.193 Purification called for extraction of the H2O soluble C12 betaine into CHCl3, and no mention of emulsions was reported.193
Monodealkylated Na salt of phosphonic acid Br R N 3 R R2 4 O EtO P O Br R N 3 R4 R2

Route Br (a) R1 O P O R1 O

1

Br

Route Br (b)

2

 4-24 hrs, reflux R1

R1

R1 (a) O 24 hrs, reflux P O acetone R1 O (b)

Na n = 3; R2,R3 = Me; R4 = C18H37 Na salt of phosphonic acid O Br HO P R N 3 O 2 R R2 4 Na n = 3; R2,R3 = Me; R4 = C18H37 Free phosphonic acid

R2 O P R1 O O R1 Br 1

N R4

R3 O P R1 O O R1 Br 2 R N 3 R R2 4

100°C, 12 hrs n=3

(d)

O HO P HO

R2 O Route P HO (c) HO Br Na

N R4

R3

Br R N 3 R 2 R2 4

n

O Na O O 80°C, 8 hrs n=2

Phosphonic acid internal salt O P R HO N 3 O n R4 R2 n = 2; R2,R3 = Me; R4 = C16H33

Figure 1.60: Literature routes describing the preparation of QA phosphonic acids.189-192

86

1.9 RESEARCH GOALS

The initial aims of this research were to prepare the EPA approved Dow antimicrobial (3(trimethoxysilyl)-propyldimethyloctadecyl ammonium chloride)37 or (SiQAC, 3) and to improve on the original synthesis by altering the reaction parameters and by employing µW heating. The primary research goals were to synthesize cost-effective and commercialy viable QAC antimicrobials capable of adhering to surfaces other than porous ones (i.e. Ti, SS, plastics) for use in the health care and food handling facilities to help curb the spread of nonsomical infection spread by direct contact with "touch surfaces" colonized by pathogenic bacteria. These new antimicrobials are expected to (i) possess broad spectrum antimicrobial activity, (ii) maintain activity / stability on the treated surface over extended periods of time (months) and (iii) kill microbes on contact without leaching of the chemical into the environment (prevent development of bacterial resistance). It was hypothesized that the replacement of the trimethoxysilane (SiOMe3) anchor present in Dow's commercial antimicrobial with a phosphonate (PO3R2), phosphonic acid (PO3H2), catechol or thiol end group would dramatically improve adhesion to non-porous surfaces, specifically metals, while retaining the broad spectrum antimicrobial activity of the quaternary ammonium compound. Therefore, a variety of novel and synthetically unknown compounds were targeted comprising of either a mono- (34-37), bis-(42, 47, 96, 126, 141), tris(161, 168) or tetra-multidentate phosphonic acids (146, 179, 183), catechol (190) or thiol (194 and 199) end group connected to a long chain quaternary ammonium group. Additionally, the synthesis of a new photoactive benzophenone-silane QAC 206 for coating onto non-porous surfaces, specifically plastic surfaces (C-H surfaces, i.e. polyethylene, silicones) is described.
87

Following synthesis, antimicrobial properties in solution and of monophosphonates 26 and 34A on metal surfaces (SS, Ti, Al) as well as their detection with dansyl QAC fluorophores and or bromophenol blue was investigated. 2.0 - RESULTS AND DISCUSSION 2.1 Synthesis 2.1.1 Alkoxysilane-Functional Quaternary Ammonium Cations (SiQAC) The Dow antimicrobial (SiQAC, 3), synthesized according to published procedures37 suffers from poor purity and a lower than anticipated level of the active antimicrobial in the concentrate formula (< 72 wt %). Commercially, compound 3 is prepared from 3-chloropropyl trimethoxysilane 1 (excess ~1.2 eq.) and N,N-dimethyloctadecylamine 2 (Scheme 2.1) as a concentrate in methanol by the following companies: Aegis (AEM 5772); Piedmont (Ztrex72); Flexipel (Q-1000), and Dow Corning (Q9-6346).45 Industrially, the final concentrate is used "as is" without a purification step to remove any unreacted starting materials, and as a result, a varying amount of active quat is often produced (Table 2.1, Entry i). The composition of the concentrate on average ranges from ~ 72 wt % for the the active quat 3, ~ 15 wt % of unreacted 1, 1-5 wt % of 2, and ~ 13 wt % MeOH (Table 2.1, Entry i).
C18H37

O O Si O (1)

(2) Cl

N

O O Si O Cl (3)

N

C18H37

MeOH, Reflux, (> 48 hrs)

Scheme 2.1: Preparation of Dow's antimicrobial 3. Literature (Table 2.2, Entries ii, iii, and v) and patent procedures (Table 2.2, Entries i and iv) describe the preparation of 3 with typically long reaction times (> 24 hrs) but fail to provide
88

any spectral (NMR) characterization data for the product. Klaus observed complete conversion of starting materials to 3 only after 3 to 4 d. in MeOH without reporting any spectral data (Table 2, Entry ii).194 Similarly, Chisholm performed the reaction under solventless conditions at 110°C for 48 hrs in a sealed tube and directly prepared a 50 wt % MeOH solution without initial characterization (Table 2.1, Entry iii).195 In a recent patent, Ludwig reacted 1 with a variety of commercially available products containing alkyl amine mixtures with varying carbon chain lengths (C10, C12, C14, C16, C18 in different ratios) under neat conditions and reported a 100% conversion at 90°C after 48 hrs with a commercial starting material consisting mostly of 2 (Table 2.1, Entry iv).45 Instead of NMR, completion of the reaction was determined by diluting aliquots of the reaction mixture first in propylene glycol (1:1, 2 g total) followed by H2O (1000 mL of pH 3, 500 ppm final dilution) at different time intervals and titrating for the Cl- ion content (CHEMetrics, Inc., Calverton, Va).45 Lastly, Huang reported the synthesis of 3 using µW radiation in a 89% yield at 150°C for 1.5 hrs in MeOH (Table 2.1, Entry v).196 Table 2.1: Literature/patent procedures describing the preparation of SiQAC 3. Composition of reaction (rxn) mixture (%) Entry i37 ii197 iii195 iv45 v196 Solvent MeOH MeOH* Neat Neat MeOH Time (hrs) n/a 72-96 48 48 1.5 Temp (oC) n/a 110 110 90 150 Ratio (1):(2) 1.2:1 1:1 1:0.95 1:1 1 15 n/a n/a 0 2 1-5 n/a n/a 0 3 72 n/a n/a 100 89 MeOH 13 n/a 50 Neat -

* = 5 bar pressure, - = not reported.

89

Due to the added costs and difficulties associated with distillation197 and column chromagraphy necessary to purifying the final product, driving the reaction to completion employing solventless conditions and or µW heating would (i) save on energy costs, (ii) avoid the shipment of the concentrate with flammable organic solvents and (iii) reduce the environmental impact of the toxic unreacted impurities (1, 2) in the concentrate and (iv) potentially require less stabilizer. Microwave (µW) heating was investigated in the synthesis of 3 according to Scheme 2.1 in order to improve the yield (72 %, commercially) by altering the reaction time, temperature and solvent choice. Results from both sealed tube (ST) and µW reactions employing solvent and neat conditions are summarized in Table 2.2. Complete conversion to 3 employing a 1:1 or a 1:0.95 ratio of 1:2 was never observed even after 48 hrs reflux in MeOH (Table 2.2, Entry v) or 72 hrs at 110oC under neat conditions (Table 2.2, Entry iii). These results clearly contrast those reported by Ludwig (Table 2.1, Entry ii), where complete conversion was observed at 90oC after 3 d. Monitoring the reaction by 1H NMR is advantageous over the titration method for free Clcontent used by Ludwig and clearly shows that the reaction never achieves completion. At best, a 76-80% yield is obtained only after prolongued heating times (> 48 hrs). Additional µW reactions (4 mmol scale) were attempted in hopes of obtaining a further conversion to quat 3 by employing higher temperatures and shorter reaction times. Performing the reaction neat in the µW (Table 2.2, Entry vi) resulted in only a 10% conversion after 45 min at 150oC whereas under similar reaction conditions, but with MeOH, the reaction reached 58% conversion (Table 2.2, Entry vii). These results support those obtained by Huang who observed an 89% conversion after 90 min at 150oC in MeOH under µW heating (Table 2.1, Entry v).196 Another µW experiment employing the higher boiling iPrOH instead of MeOH, at 165oC for 60
90

min (Table 2.2, Entry xiii), also failed to drive the quaternization to completion with product conversion reaching only 64%. Table 2.2: 1H NMR (CDCl3) monitoring of the formation of 3. (%) Conversion (limiting reagent) by 1H NMR (CDCl3) Entry i ii iii iv v vi vii viii n/a : not attempted. Solvent Neat Neat Neat MeOH MeOH Neat MeOH iPrOH Time (hrs) 24 48 72 24 48 0.45 0.45 0.6 Temp (oC) 110 110 110 Reflux Reflux 150 µW 150 µW 165 µW Ratio (1):(2) 1:0.95 1:0.95 1:0.95 1:1 1:1 1:1 1:1 1:0.95 PRD. (3 %) ~ 30 ~ 53 ~ 80 ~ 45 ~ 76 ~ 10 ~ 58 64

Progress of the formation of 3 was monitored with 1H NMR (CDCl3) by observing the disappearance of the overlapping dimethylamino and amino ­CH2 protons [-CH2-N(CH3)2] at ~ 2.2 ppm from the limiting starting amine 2 and the appearance of two new upfield resonance at ~ 3.5 ppm [-CH2-N+ (CH3)2] and ~ 3.3 ppm [(-N+-(CH3)2] resulting from the quaternized product (Figure 2.1).101 Percent conversion was calculated from 1H NMR (CDCl3) integrations of the N,N-dimethyl peaks from the limiting starting amine 2 and the quat dimethyl peak in the product 3 according to the following formula: % Conversion = (x/6)/((x/6) + (y/8))

91

where y = the disappearance of the (-N(CH3)2) SM. 2 peak ~ 2.3 ppm, and x = the formation of [(-N+-(CH3)2] PRD. 3 peak at ~ 3.3 ppm (See, Figure 2.1 A and B, Appendix 1.2, Figure A18, A19). For example, % conversion (2.48/6)/[(2.48/6) + (2.97/8)] = 53% (Table 2.2, Entry ii).

92

Figure 2.1: 1H NMR (CDCl3) spectra of compound 1 + 2 in at T = 0 (A), and the formation of 3 at T = 48 hrs (B). Another option to save on energy during manufacturing is replacing the cheap but unreactive 1 with more reactive silanes (Figure 2.2). Employing other trimethoxysilanes like the bromo or iodo derivative would significantly speed up the Menshutkin reaction, however due to their high costs (> 100 × more expensive) versus the chloro derivative, this option is commercially unrealistic (Figure 2.2).
O Si O O O Si O O O Si O O O Si O O

Cl

Br

I

N

$0.25 / 1 mL SA $0.05 / 1 mL Gelest

$61.4 / 1 mL SA $5.7 / 1 mL Gelest

$5.38 / 1 mL SA $2.16 / 1 mL Gelest

$6.86 / 1 mL SA $3.58 / 1 mL Gelest

Figure 2.2: Comparison of trimethoxysilane pricing as of May 2013 (SA: Sigma Aldrich).

93

2.1.2 Organophosphorus Functional Quaternary Ammonium Cations QAC Antimicrobials (PQAC) 2.1.2.1 -Monophosphonic Acids QAC Antimicrobials (-MPQAC) A series of ­monophosphonic acid QAC's (­MPQAC) derivatives 34-37 for binding onto Ti, SS and Al were prepared in three steps (Scheme 2.2). First, the Abruzov reaction between trialkyl phosphites (4, 5A-B) and dibromoalkanes 6-16 or haloalkanes 18-19 produced the phosphonate esters 12-19 in 50-93 % yield (Tables 2.3, Entries i-xix). Compounds 12-14 were quaternized with various tertiary amines 2-24 by the Menshutkin reaction to produced QAC phosphonate esters 26-32, while compounds 12-13 were alkylated with HNMe2 and NaN3 to give precursors 32 and 33 for use in Section 2.1.3.2, Method 3. Didealkylation of 26-30 with either HX (X = Cl or Br) or TMSBr afforded the desired antimicrobial phosphonic acid derivatives 3437. All three steps were optimized with µW heating which resulted in shorter reaction times at higher temperatures and improved yields (Tables 2.3 - 2.5, Scheme 2.2).

94

Step 1 - Abruzov Reaction R1 O P O R1 O Br (4) R = Me (5A) R = Et (5B) R = i Pr Reflux, 4 hrs or W 170°C µ , , 5 min Br OH O P O O R1

R1

R1

R n 2

R2 n

Br or Br

(6) n = 1, R2 = Br (7) n = 2, R2 = Br (8) n = 3, R2 = Br (9) n = 2, R2 = OTHP (10) n = 3, R2 = PHT (11) C5H9Br3O

(12) n = 2, R1 = Et, R2 = Br (13) n = 2, R1 = i Pr, R2 = Br (14) n = 3, R1 = Et, R2 = Br (15) n = 1, R1 = Et, R2 = Br (16) n = 1, R1 = i Pr, R2 = Br (17) n = 1, R1 = Me, R2 = Br (18) n = 2, R1 = Et, R2 = OTHP (19) n = 3, R1 = Et, R2 = PHT

Step 2 - Alkylation, Quaternary Amine Formation (Menschutkin Reaction) Neat, 100°C, 35 min or ACN, µW, 150°C, 2 min (12-14) R3 N R5 R4 or N or NaN3 O P R1 O O R1 O R1 P O or O R1

R3 n N R5

R4 Br

n

N R4

R3

(2) R3, R4 = Me, R5 = C18H37 (20) R3, R4, R5 = Me (21) Pyridine (22) R3, R4 = Me, R5 = C12H25 (23) R3 = Me, R4 = H , R5 = C18H37 (24) R3, R4 = Me, R5 = H (25) NaN3

(26) n = 2, R1 = Et, R3, R4 = Me, R5 = C18H37 (27) n = 2, R1 = i Pr, R3, R4 = Me, R5 = C18H37 (28) n = 2, R1 = i Pr, R3, R4, R5 = Me (29) n = 2, R1 = TMS, R3, R4, R5 = pyridinium (30) n = 2, R1 = Et, R3, R4 = Me, R5 = C12H25 (31) n = 2, R1 = Et, R3, R4 = Me, R5 = C18H37 (32) n = 3, R3, R4 = Me (33) n = 2, R3, R4, R5 = N3

Step 3 - Phosphonate Ester Didealkylation A) TMSBr, DCM, RT, ON or ACN, µW, 60oC, 10 min (26-30) EtOH/H2O or MeOH B) 1-6 M HX, 100°C, 1-8 hrs or µW, 140°C, 4-10 min O HO P HO R3 n N R5

R4 Br

(34A) n = 2, R3, R4 = Me, R5 = C18H37 + (34B) n = 2, R3, R4 = Me, R5 = C18H37 (Na salt) (35) n = 2, R3, R4, R5 = Me (36) n = 2, R3, R4, R5 = pyridinium (37) n = 2, R3, R4 = Me, R5 = C12H25

Scheme 2.2: Optimized conditions for the synthesis of -monophosphonic acid QAC's.
95

Short chain n-bromoalkylphosphonates are commercially available although rather expensive (~ $101.50/5 mL, for compound 12 (S-A, 95%)). As mentioned above, their preparation is achieved through the classic Abruzov reaction and involves heating the two reactants (4, 5A-B) with 6, 7 or 8) neat under conventional heating (at reflux) or under µW radiation followed by distillation to isolate the target products 12-17. Table 2.3 summarizes the optimization experiments to obtain products 12-17 and details the major by-products that codistilled together with attempted purification.
R1 O P O R1 O Br Br R1

n 6 8 ( )

R1

31 ( P)  = ~140-137 ppm (4 A-C)

(a) conventional heating or (b) µW heating - BrR1

O P O O R1

Br n

31 ( P)  = 25-28 ppm (12-17) O O O R1 P R1 P O + O O n R1

R1 O O R1 n P O

31 ( P)  = ~ 50-60 ppm by-product (A)

31 ( P)  = 29-35 ppm by-product (B)

Table 2.3: Optimization of Step 1: Abruzov reaction between trialkyl phosphites (4, 5A-B) and dibromoalkanes (6, 7 or 8) or bromoalkanes (9, 10 or 11).

Rxn. Comp. (%) by (1H, 31P, CDCl3) NMR Entry Compound Time Temp. (oC) Reflux Reflux Reflux Ratio of reactants (5A+ 7) / 1:5 (5A+ 7) / 1:4 (5A+ 7) / 1:4 PRD. BYPRD. A % 4D 7D n/d BYPRD. B % 0 0.1D n/d

i
Br

ii iii
(12)

O P OEt OEt

20 hrs 20 hrs 6 hrs

52D 89.9D 79D

96

Entry

Compound

Time
3 hrs

Temp. (oC) Reflux Reflux 170 170 Reflux 190 170 170 Reflux Reflux 110TOL

Ratio of reactants (5B + 7) / 1:4 (5B + 7) / 1:4 (5B + 7) / 1:1.2 (5B + 7) / 1:1.2 (5A + 8) / 1:4 (5A + 8) / 1:2 (5A + 8) / 1:1.2 (5A + 8) / 1:2 (5A + 6) / 1:4 (5A + 6) / 1:4 (5A + 6) / 1:4

PRD.

BYPRD. A % 21 14 17 10D 15 10D 19 2 15.4 15.4 14

BYPRD. B % 0 0 0 0 35 0 0 10 0 0 0

iv v
Br O P Oi Pr Oi Pr

79 80 48 74D 50 72D 70.4 74 67 71.6 54

3.4 hrs 2 min 5 min 20 hrs

vi
(13)

vii
viii xi
Br O P OEt OEt

5 min 5 min 5 min

x (14) xi xii xiii xiv
Br

O P OEt OEt

2.2 hrs 4.3 hrs 36 hrs

(15)
O P Oi Pr Oi Pr

xv

Br

12 hrs

Reflux

(5B + 6) / 1:4

81

10

0

(16)
O P OMe OMe

xvi

Br

12 hrs

Reflux

(4 + 6) / 1:2

65

0

0

(17)
O O OEt P OEt

xvii

O

6 hrs

Reflux

(5B + 9) / 3:1

90D

n/a

n/a

(18)

97

Entry

Compound
O OEt P OEt

Time

Temp. (oC)

Ratio of reactants

PRD.

BYPRD. A %

BYPRD. B %

O N

xviii
O

20 hrs

Reflux

(5B + 10) / 3:1

90RC

n/d

n/d

(19)
EtO OEt O O P EtO P OH EtO O P OEt OEt
160 µW

xx

0.2 hrs

(5B + 11) / 6:1

0

n/a

n/a

xxi

24 hrs

Reflux

(5B + 11) / 6:1

0

n/a

n/a

(20)

Unless indicated, the crude reaction composition was checked by 1H and 31P NMR (CDCl3) after the time indicated. D = distilled product, RC = recrystallized product. By-product (A) is a result of dialkylation, by-product (B) is a result of intramolecular alkylation.

Compounds 12-16 were formed in ~70 % yield on average, with the rest of the mass corresponding to phosphorus by-products identified by 1H and
31

P NMR (CDCl3) including the

higher boiling 5- and 6-membered cyclized oxaphospholanes (Table 2.3, by-product A) as well as the corresponding bisphosphonates (Table 2.3, by-product B). The thermodynamically

favourable cyclic 5- and 6-membered by-products (Table 2.3, Entries i-x) were a likely result of intramolecular attack by oxygen of the phosphoryl group of the electrophilic C3 and C4 carbon atoms, respectively. The driving force is likely to be the energy gain in the formation of 5- and 6membered rings (Figure 2.3).198

98

O R P O O R

Br

, Br - RBr

O P O

O

Br

- Br

R

O

O O P

R

5-membered ring

Br O R P O O R , Br Br - RBr O R P O O - Br R O

O O P

6-membered ring

Figure 2.3: Cyclic oxaphospholane by-products formed during the Abruzov reaction.

Most of the lower boiling by-products which include ethyl or isopropyl bromides, and triethyl or triisopropyl phosphates were removed by distillation from the mixture while traces of the corresponding bisphosphonates (by-product B) co-distilled with the product (Table 2.3, Entries i, ii, vi, viii). With compound 14, a new 31P NMR (CDCl3) resonance was observed at 24 ppm and was attributed to the cyclic by-product, A, due to intramolecular cyclization. Compound 14 was also difficult to separate with distillation as it codistilled with the by-product upon purification. Both by-products (A and B) were readily removed in the subsequent Menschutkin reaction either by an aqueous extraction of the short chain phosphonate QAC's 28-29 or after precipitation of the longer chain phosphonates QAC's 26-27. Compounds 15-17 were prepared as precursors for dialkyl vinylphosphonates (Section 2.1.2.6). Compound 15 was used directly after distillation without characterization by NMR. Compounds 18 and 19 (Table 2.3, Entries xvi, xvii, xviii) were prepared in high yield employing an excess of P(OEt)3 (3 eq.), (Section 2.1.2.3, Method 3). A crystal structure of compound 19 was obtained after distillation to remove excess P(OEt)3 and re-crystallization from EtOAc (Section 2.6.1).
99

Preparation of compound 20 was attempted under µW heating followed by distillation which resulted in thermal decomposition of the reactants and products that led to the formation of multiple peaks observed by
31

P NMR. Another attempt to prepare compound 20 was

performed under reflux conditions with purification on column chromatography. After 24 hrs of reflux, the 31P NMR spectrum (CDCl3) of the crude reaction mixture revealed mainly unreacted P(OEt)3, likely as a result of steric hindrance. Chromatography on a short pad of silica eluted mostly P(OEt)3 which was subsequently converted to HP(OEt)2 on the column (Table 2.3, Entries xx and xxi). The second step involving the Meshchutkin reaction was optimized (Table 2.4, Compounds 12-14). With the bromo leaving group, the Menshutkin reaction was more rapid compared to the chloro derivative (48-72 hrs, reflux, compound 3, Figure 1.45). Employing a sealed screw cap glass vial in refluxing ACN, the reaction was complete in 3-4 hrs (Table 2.4, Entries ii, iv, ix) while under µW heating at 150oC the reaction was complete in 2-10 min (Table 2.4, Entries iii, v, vi, vii, viii). Compound 28 was prepared from NMe3HCl by neutralizing the amine in ethanol/NaOH followed by the Abruzov reaction with 13 directly in the µW without filtering off NaCl. Compound 29 was reacted for 10 min to ensure complete conversion of the weaker nucleophilic pyridine and then dealkylated directly in the same vial with either TMSBr/ACN or HBr/H2O (Table 2.4). ACN was the preferred solvent for the quaternization by enhancing the rate and in most cases the products solidified directly from the reaction mixture or with the addition of Et2O. Compounds 32 and 38 were prepared by nucleophilic substitution of 14 by NHMe2 and 12 by NaN3 for use in Section 2.1.3.2, Method 3.

100

Neat, 100°C, 35 min or ACN, µW, 150°C, 2 min (12-14) R3 N R5 R4 or N or NaN3

O R1 P O O R1

R3 N n R5

R4 Br

R1 or

O P O O R1

N n R4

R3

(26-33)

Table 2.4: Optimization of Step 2: Menschutkin reaction between bromoalkylphosphonates 1214 and tertiary amines 2, 21-25.
Rxn. Comp. (%) by 1H 31P NMR (CDCl3) Entry i ii iii µW iv
C18H37
C18H37 N Br

Compound
O P OEt OEt

Solvent Neat ACN ACN
O P OiPr OiPr

Time 30 hrs 2 hrs 2 min 2 hrs

Temp (oC) 100 Reflu x 150 Reflu x

Ratio of reactants (12 + 2) / 1:1 (12 + 2) / 1:1 (12 + 2) / 1:1 (13 + 2) / 1:1

SM. % n/d 10 4 10

PRD. % 67RC 90 96 90

(26)
N Br

ACN

v µW (27) vi µW
N Br O P OiPr OiPr

ACN

2 min

150

(13 + 2) / 1:1

3

97 68RC

EtOH

2 min

150

(13 + 20) / 1:1.1

n/d

vii µW

EtOH (28)

3 min

150

(13 + 20) / 1:1.4

6

94

N

viii

µW

Br

O P OTMS OTMS

ACN

10 min

150

(13 + 21) / 1:1

Ester not isolated (one-pot reaction see 4-3)

(29)
N Br O P OiPr OiPr

C12H25

ix

ACN

4 hrs

Reflu x

(13 + 22) / 1:1.2

Excess

95*

(30) 101

Entry

Compound
O P OEt OEt

Solvent

Time

Temp (oC)

Ratio of reactants

SM. %

PRD. %

x

C18H37

N

ACN

24 hrs

60

(12 + 23) / 1:1.1

n/a

90

(31)
N O P OEt OEt

xi µW (32)
N3

EtOH

5 min

110

(13 + 24) / 1:2

0

100

xii (33)

O P OEt OEt

Acetone

12 hrs

Reflu x

(13 + 22) / 1:1.2

0

100

Didealkylation of compound 26-29 was first explored with TMSBr and then optimized with HCl and HBr (Table 2.5, Entries i-xi). With anhydrous TMSBr the reaction was performed in DCM overnight and complete conversion was observed, however in situ generation of the reagent from TMSCl/NaI in ACN failed to give the dealkylated product (Table 2.5, Entry ii). This can be attributed to poor solubility of quat 26 in ACN vs DCM. Next, the phosphonate quats were successfully dealkylated in H2O with a two fold excess of HCl or HBr. Since the formation of the carbocation intermediate is the rate determining step in the mineral acid didealkylation of phosphonate esters (see Figure 1.53), the more stable iPr carbocations and the more reactive Br- ions proceeded faster compared to Et esters (Table 2.5, Entry iv vs Entry v and Entry vi vs Entry vii) and HBr was faster than HCl (Table 2.5, Entry iv vs Entry vi and Entry v vs Entry vii). µW heating was also optimized with compounds 27 and 28 with complete conversion observed within 6-10 min at 140-150oC (Table 2.5, Entries ix and xi).
102

O R1 P O O R1

R2 R N 4 R3 Br (26-30)

A) TMSBr, DCM, RT, ON or ACN, µW, 60oC, 10 min EtOH/H2O or MeOH B) 1-6 M HX, 100°C, 1-8 hrs or uW, 140°C, 4-10 min

HO

O

P HO

R2 R4 N R3 Br (34-37)

Table 2.5: Optimization of Step 4: Didealkylation of phosphonate diester quats.
Rxn. Comp. (%) by 31P NMR (CDCl3) Ratio of Entry Compound Reagent (R) TMSBr TMSCl/ NaI
C18H37 N Br O P OH OH

Time

Temp (oC) RT RT Reflux Reflux Reflux Reflux Reflux 140 µW

Reagent (R) : SM (R + 26) / 3:1 (R + 26) / 4:1 (R + 26) / 4:1 (R + 26) / 4:1 (R + 27) / 4:1 (R + 26) / 4:1 (R + 27) / 4:1 (R + 28) / 4:1

SM % 0 n/a 60 0 0 0 0 20

PRD % 100 n/a 40 100 100 100 100 80

i ii iii iv v vi vii viii
N Br O P OH OH

24 hrs 24 hrs 6 hrs 20 hrs 2 hrs 3 hrs 1 hr 3 min

HCl HCl HCl HBr HBr HBr

(34)

ix x*
N Br

(35)
O P OH OH

HBr TMSBr

6 min 10 min

140 µW 60 µW

(R + 28) / 4:1 (R + 29) / 2.5:1

0 0

100 100

xi*

HBr (36)

10 min

150 µW

(R + 29) / 4:1

0

100

xii

C12H25

N Br

O P OH n/a OH

n/a

n/a

(R + 30) / 4:1

n/a

n/a

(37)

* One pot rxn.
103

The long chain C18 phosphonic acid quat, 34, previously only isolated as the Na salt of the phosphobetaine or as an internal salt after purification on an expensive anion exchange resin (see Figure 1.57) was successfully recrystallized from EtOAc:EtOH and X-ray quality crystals were obtained (Figure 2.4, and Figure 2.40).

Figure 2.4: 1H NMR (CDCl3) spectra showing successful didealkylation of the ethyl phosphonate ester QAC 26 and isopropyl ester QAC 27 to the corresponding phosphonic acid QAC 34 (D2O). 2.1.2.2 -Bisphosphonic Acids QAC Antimicrobials ( -BPQ) Synthesis Bisalkylation of the commercially available octadecylamine 38 with 13 employing Hunig's base afforded the desired iPr-bisphosphonate 39 in good yield with conventional
104

(solventless) or µW heating (ACN). Trialkylbromophosphonates (where alkyl = Me, Et, iPr) may be used interchangeably in this reaction, however 13 was used instead of 12 due to easier cleavage with HBr during the last step of the synthesis. Any trace amounts of unreacted starting materials in the crude sample of 39 had no effect on the quaternization reaction with MeI (1.2 eq.), resulting in quantitative conversion to 40. These by-products may be purified at any stage in the preparation of 41 (Scheme 2.3). The last dealkylation step to obtain 41 proved to be a challenge due to insolubility of the bisphosphonic acid product.

O

O Br (13) DIPEA O O P O O O P O N C18H37 (39) 96% ) (

P O

H2N

C18H37 (38)

Neat, ST, 110°C, 3 hrs or ACN, µW, 150°C, 40 min

MeI, EtOH ST, 60°C, 100 min or µW, 110°C, 5 min

OH HO P O O HO P OH I N C18H37 (41)

1) 3N HBr, µW, 150°C, 9 min, or 1) TMSBr, DCM, RT, 24 hrs 2) H2O/EtOH, RT, 24 hrs

O O P O O O P O I N C18H37 (40) 100% ) (

Scheme 2.3: Preparation of -Bisphosphonic acid 41.

Initially the reaction was attempted with µW heating, however it was difficult to monitor due to solidification of the product in the NMR tube (D2O). Other deuturated solvents such as
105

CDCl3 or DMSO also failed to show any

31

P signals of the crude reaction mixture. After

evaporation of the crude product to an orange paste, the residue was treated with DCM/TMSBr at RT overnight in an attempt to isolate a crystalline compound after TMS ester hydrolysis. Once again, after extensive solubility analysis, the residue remained practically insoluble in every solvent including the NMR solvents mentioned above. Compound 41 is insoluble in H2O due the presence of two phosphonic acid groups and the hydrophobic C18 tail and the quat contributes to its insolubility in most polar solvents. Only after treatment with 2 eq. KOH to make the potassium salt of the bisphosphonic acid, 42, was it possible to solubilize the compound in D2O and obtain a clean NMR (Scheme 2.4, Figure 2.5).
K

OH HO P O O HO P (41) OH (0.5 mmol) I N C18H37

2 eq. KOH (1 mmol), H2O (5 mL)

O HO P O O HO P O K

I N C18H37 (42)

Scheme 2.4: Preparation of the potassium salt of 41.

106

Figure 2.5 : 1H NMR (D2O) spectrum of -BPQAC 42. An alternative (-BPQ) synthesis was attempted starting with N1,N1-bis(2-

aminoethyl)ethane-1,2-diamine scaffold based on Yoshimura's work with a tridodecyl quaternized star-shaped precursor 44 (Scheme 2.5).199 Precursor 44 was prepared by a modified procedure starting with paraformaldehyde instead of formalin and heated in ACN, employing anhydrous HCl and NaOEt instead of HCl(aq) and NaOH to obtain the free base amine (see Experimental, Section 5.3.3). Attempted synthesis of 45 by quaternizing with 0.33 eq. bromooctadecane followed by 0.66 eq. of 13 or vice-versa failed to give the desired quaternized product peak (31P NMR  ~ 29 ppm, Scheme 2.5, Figure 2.6). Instead, an unidentified upfield peak from the starting material 13 was observed (31P NMR  ~ 30 ppm, Figure 2.6), in a 1:1 ratio with unreacted 13 (Figure 2.6). Since the reaction was performed without filtering off NaCl after
107

44 was freebased with NaOEt prior to adding 13, any excess base could have reacted with 13. No further experimentation was attempted with this scaffold.

NH2 6 eq. H2N N (43) NH2

O (s) 6 eq.

O OH N

N

1) ACN, Reflux, 3 hrs 2) HCl anhydrous, Filter 3) EtOH, NaOEt - NaCl Br (13)

N (44)

N

O P O O 0.66 eq.

µW, 10 min, 150°C

O O P O C18H37 Br N Br N Br N

O O P O

N 0.33 eq. Br C18H37 (46)

N

N

N

Br

µW, 150°C, 3 min

N

Br

O P O O (47)

O P O O (45)

Scheme 2.5: Attempted preparation of compound 47.

108

30.12

?

1.00
50 45 40 35 30

1.05

28.92

25 f1 (ppm)

20

15

10

5

0

Figure 2.6: 31P NMR (CDCl3) reaction monitoring of compound 45. 2.1.2.3 -CH Bisphosphonic Acids QAC Antimicrobials (-CH-BPQA) Synthesis -CH Bisphosphonic acid quats envisioned coming from alkylated methylenebis

(phosphonate) (Figure 2.7) were also patentable synthetic targets of various small molecule multidentate phosphonic acid antimicrobials.
Br N C18H37 X-C18H37 + Z X = Br, NMe2 Z = Cl, Br, NMe2 R = Me, Et, i Pr O OR P OR O P OR OR

RO

O

P RO RO P O OR

Figure 2.7: Retrosynthesis of -CH bisphosphonic acid quats.
109

Four methods were identified in the literature for the preparation of halo or N,N-dimethyl substituted methylene bisphosphonate precursors for the Menshutkin reaction. Surprisingly, none of these have been used to make QAC's (Figure 2.8). The following starting materials can be used to prepared alkylated methylene bisphosphonates: (i) aldehydes, (ii) monophosphonates, (iii) dialkylvinylphosphonate (iv) methylene bisphosphonates. Each of the four methods are individually discussed in the following sections.
Method 1 Method 2 O OR P OR O P OR OR R O OR P n OR O P OR OR Y = X, NMe2 O OR P OR O OR P OR O P OR OR Method 4 R = Et R = i Pr

O Y

Y

n

Method 3

Figure 2.8: Four retrosynthetic methods for the preparation of -CH-BPQA's.

Method 1: Onepot Bis Addition of Dialkylphosphites to Aldehydes The most cost effective reaction to prepare the -CH bisphosphonate scaffold involves the one pot addition reaction of 1 eq. of HP(OEt)2 to an aldehyde followed by mesylation of the in situ formed -hydroxyl phosphonate and subsequent substitution by another equivalent of
110

nucleophilic diethylphosphite (Scheme 2.6). The only drawback here is the extra step required to prepare the commercially unavailable aldehydes.
O N O (48) O 1) HPO3R2, TOL, RT, 30 min 2) MsCl, Et3N, Reflux, 2 hrs O N O (49) O OEt P OEt O P OEt OEt

(49)

1) H2N-NH2, EtOH, Reflux, 2 hrs 2) CHO, CH3CHO, Zn 3) C18-Br, 100oC, 1 hr C18H37

O OEt P N OEt O P OEt OEt (50)

Br

Scheme 2.6: Preparation of 50 by Method 1.

Using Method 1, bisphosphonic quat 50 was targeted from the phthalimide protected aldehyde 48 after hydrazine deprotection of 49 followed by N,N-methylation and quaternization (Scheme 2.6). However, the first reaction in the sequence failed to give the desired product (31P NMR ~ 24 ppm) by the one-pot method. Instead, the one pot reaction was performed

sequentially isolating each intermediate according to Scheme 2.7.

111

O N O (48) O

O P EtO H OEt O K O O K

O N O (51)

O O P O OH

ACN, 60°C, 10 min O 1) 0 C N (51) 2) Dropwise, 10 min RT O S Cl O
O N O (49)
°

H

Cl

N

N O (52)

O O P O O O S O

O N O (52)

O OEt P OEt O O S O

O P EtO H OEt Base, Solvent, Temp, Time

O OEt P OEt O P OEt OEt

Scheme 2.7: Attempted stepwise preparation of 49.

Synthesis of the bisphosphonate 49 from 52 was unsuccessful, leading to a mixture of products (31P NMR, CDCl3). All base/solvent combinations including K2CO3/EtOH, Cs2CO3/ACN, Cs2CO3/ACN, pyridine/TOL also failed to give the desired
31

P resonance at  ~

23-24 ppm, with unidentified peaks at 17.7 ppm and 0.7 ppm always observed. A closer investigation of the literature revealed that the phthalimide protecting group is incompatible with Method 1, leading instead to heterocyclic products.200 Deprotonation of the newly formed bisphosphonate by the one pot reaction creates a nucleophilic carbanion that undergoes an intramolecular Horner-Wadsworth-Emmons reaction between the formed imide and the -functionalized phosphonate (Figure 2.9).

112

O O N O O OEt P OEt O P OEt OEt (49) O Deprotonation - H2 (EtO)2P O N O P(OEt)2 Na

Horner-Wadsworth-Emmons reaction

O (EtO)2P O - (EtO)2P(O)O N O Heterocyclic product O (EtO)2P O N O P(OEt)2

Figure 2.9: The Horner-Wadsworth-Emmons rearrangement of 49.200 Due to the rearrangement observed with precursor 49, it was hypothesized that switching to a different aldehyde would allow the one pot reaction to proceed without heterocycle formation. Synthesis of various halo substituted 54 and 55 and the quat aldehyde 56 was attempted, but were problematic to isolate by recrystallization (Scheme 2.8).
O OR P OR O P OR OR (57) R = Cl (58) R = Br - + (59) R = Br N Me2C18H37

R

O

1) HPO3Et2, TOL, RT, 30 min 2) MsCl, Et3N, Reflux, 2 hrs

R

(54) R = Cl (55) R = Br - + (56) R = Br N Me2C18H37

Scheme 2.8: Synthesis of bisphosphonates 57-59 from aldehydes.

113

Synthesis of QAC aldehyde 56 was first attempted by quaternizing the commercially available acetal 65 with 2. The desired product was obtained along with an unidentified inseparable impurity by 1H NMR (CDCl3) after numerous attempts at recrystallization. No further reaction with this compound was pursued. The second way to obtain 56 is the oxidation of the quat alcohols 66 or 67 prepared in high yield (98%) and purity (Figure 2.10, Section 2.6.1, see crystal structure). Compounds 66 and 67 remain to be oxidized with pyridinium chlorochromate (PCC) as shown in Scheme 2.10. Preparation of the chloro and bromo aldehydes precursors 54 and 55 was attempted by employing refluxing HCl or TFA/DCM with loss of the volatile product aldehydes upon distillation (Scheme 2.10). Additionally, a potential problem with Method 1 is the possibility of the unwanted substitution of the halo group with nucleophilic HP(OEt)2. Instead, Methods 2-4 were explored in order to prepare -CH-BPQA's.
O O (61) O Et3N, TOL, Reflux, 3 hrs Dean-Stark -H2O O N O (62) O (62) or OEt EtO (63) X = Cl (64) X = Br X 2N HCl, THF or TFA/DCM X O N O (47) O OEt OEt

OEt EtO (60) NH2

(54) X = Cl (55) X = Br

Scheme 2.9: Synthesis of aldehyde precursors 47, 54-55 used for Method 1.

114

OEt EtO (65) Cl

1)

N

C18H37 O Cl N (56) PCC, DCM C18H37 TEMPO HO Cl n (66) n = 1 (67) n = 2 N C18H37

Neat, 100°C, 24 hrs 2) HCl

Scheme 2.10: Possible synthetic routes leading to aldehyde QAC 56.

Figure 2.10: 1H NMR (CDCl3) spectrum of QAC aldehyde precursor 66.

115

Method 2: Michael Addition to Diethylvinylphosphonate THP protected bisphosphonate intermediate 71 and 72 are known literature compounds prepared by Method 2 (see Experimental, Section 5.4.2). However numerous attempts to obtain these compounds via the Michael addition of the Grignard to 68 failed to give the desired product according to Table 2.6. In all cases, the reaction did not proceed (Table 2.6, Entries i and ii) or resulted in a mixture of products by 31P NMR (CDCl3) after EtOAc extraction (Table 2.6, Entry iii). The failure of Method 2 can be attributed to an incomplete conversion of the alkyl halide to the Grignard nucleophile or its decomposition after it was prepared. A variety of ways to prepare the Grignard reagent were investigated. First, overnight sonication of Mg metal in Et2O was tested, however, the next day incomplete consumption of the metal remained (Table 2.6, Entry i). Activation of Mg by refluxing for 2 hrs followed by stirring at RT ON resulted in consumption of Mg and a cloudy solution was obtained (Table 2.6, Entry ii). In another trial, Mg was stirred at RT ON before adding it to 68 (Table 2.6, Entry iii). In all cases, no Michael addition products were detected by 31P NMR (CDCl3).

116

OO OEt 3) EtO P P EtO OEt (68)

1) Mg, RT, sonicate ON 2) Et2O, RT, Dropwise R (69-70) Br

EtO

P EtO

OO OEt P OEt R

(71) R = (CH2)3Cl (72) R = (CH2)3OTHP

Table 2.6: Attempted Grignard addition reactions onto 68. Rxn. Comp. (%) by (31P) NMR (CDCl3) Entry Prdt. No.
OEt O P OEt O P EtO OEt

Solvent Time (0.5M) (hrs)

Temp. (oC)

PRD %

SM %

Other %

i

Cl

Et2O

24

0-RT

64

0

36

(71) ii
OEt O P OEt O P EtO OEt

THF
OTHP

1

-10

100

0

0

iii (72)

THF

2

0-RT

0.07

13

86.9

Precursors for the Michael addition were prepared by literature procedures (see Experimental, Section 5.4.2). Compound 68 was prepared from the commercially available tetraethyl methyl bisphosphonate 73 and purified by distillation according to Scheme 2.11, while 74 was protected with tetrahydropyran and purified by column chromatography (Scheme 2.12). After performing the THP protection numerous times it was found that the reaction was complete after 1hr without added catalyst.

117

EtO

OO OEt P P EtO OEt

1) (CH2O)n, Et2NH, MeOH Reflux, 18-24 hrs 2) O OH S O H O H

EtO O P OEt O P EtO OEt (68)

(73)

TOL, Reflux, 18 hrs, Dean-Stark

Scheme 2.11: Preparation of tetraethyl ethene-1,1-diylbisphosphonate 73.
O DCM, RT, 1 hr HO (74) Br O OH S O H O H O O (9) Br

Scheme 2.12: Preparation of THP protected 3-bromopropanol 9.

Method 3: C-P Formation Method 3 was attempted in order to prepare the amine protected 49 and 77-78 according to Table 2.7. Compound 77 was only successfully prepared on a small scale (< 1 g) when LDA was made in situ from n-BuLi/diisopropylamine (Table 2.7, Entry iii) in ~ 60% yield and purified by column chromatography. Unfortunately LDA failed to deprotonate the phthalimide protected monophosphonate 19 at -78 oC due to solubility issues (Table 2.7, Entry iv). When the same reaction was performed at -10oC, a mixture of two unknown products by 31P NMR (CDCl3) were observed at  = 31.43 ppm (30%) and  = -13.13 ppm (70%) respectively, but not the desired bisphosphonate 49 (expected ~ 24 ppm) (Table 2.7, Entry v). Lastly the N,N-dimethyl phosphonate 32 also could not be deprotonated due to insolubility in THF (Table 2.7, Entry vi). For large scale preparation of 77, Method 4 was investigated and is discussed below.
118

R

O OEt P OEt

1) LDA (75), -78°C, Dropwise R O P O O Cl 2) RT, 1-2 hrs (76)

OEt O P OEt O P EtO OEt (49) R = PTH (77) R = OTHP (78) R = NMe2

(18) R = OTHP (19) R = PHT (32) R = CH2NMe2

Table 2.7: Preparation of bisphosphonates 49, 77-78 by Method 3. Rxn. Comp. (%) by 1H, 31P NMR (CDCl3) Entry Reactant Base Time (hrs)
2 2 2

Temp. (oC)
-78 -78 -78

PRD. %
0 10 60

P NMR (ppm)
n/a 24.14 23.78

31

i
O O

ii iii

O OEt P OEt O P OEt OEt

NaHMDS LDA n-BuLi / DIA LDA

(77)
O

iv
N O

v

O OEt P OEt O P OEt OEt

2

-78

0

n/a

LDA

2

-10

0*

n/a

(49)
N O OEt P OEt O P OEt OEt

vi

n/a (SM (32) insoluble in THF)

(78)

Precursors 18 and 19 were prepared by the Abruzov reaction in one step while 32 was prepared in two steps utilizing the Abruzov reaction followed by alkylation with dimethylamine (see Table 2.3, Section 2.1.2.1). A pure sample of 32, a new compound, was isolated by column chromatography (note: compound turns dark on storage at RT).
119

Method 4: Direct Alkylation In contrast to Methods 1-3, all of the starting materials used in Method 4 are commercially available and were employed to prepare the bisphosphonate QAC 93 on a large scale after a lengthy optimization of the first alkylation step according to Scheme 2.13.
OR1 O P OR1 O P n R1O OR1

R1O

P R1O

OO OR1 P OR1 R2

1) NaH, DMSO, 0 C, RT, 30 min 2) RT, 48 hrs R3 n (7-10) R4

°

R3

(72) R1 = Et, R2 = H (79) R1 = i Pr, R2 = H

(80) n = 4, R3, R4 = Br (81) n = 1, R3 = Cl, R4 = Br (82) n = 1, R3 = Cl, R4 = I - + (83) n = 1, R3 = Br, R4 = Br N Me2C18H37 (84) n = 1, R3 = Br, R4 = NMe2

(85) n = 1, R1 = Et, R3 = Br (86) n = 1, R1 = i Pr, R3 = Br (87) n = 2, R1 = i Pr, R3 = Br (88) n = 2, R1 = Et, R3 = Br (89) n = 4, R1 = i Pr, R3 = Br (90) n = 4, R1 = i Pr, R3 = Br (91) n = 1, R1 = i Pr, R3 = Cl (92) n = 1, R1 = i Pr, R3 = (CH2)3PHT - + (93) n = 1, R1 = i Pr, R3 = Br N Me2C18H37 (94) n = 1, R1 = Et, R3 = (CH2)3OTHP (95) n = 1, R1 = i Pr, R3 = (CH2)3OTHP (96) n = 1, R3 = NMe2 C18H37

N

100°C, 35 min or µW, 150°C, 2 min 1) TMSBr, DCM, RT, ON or µW, 40-80°C, 10 min 2) MeOH/H2O or 1M HCl (3 eq.) µW, 150°C, 30 min

OH Br O P OH O N P C18H37 HO OH (96)

OR1 Br O P OR1 O N P C18H37 R1O OR1 (93) R1 = i Pr

Scheme 2.13: Preparation of bisphosphonates by direct alkylation. The direct alkylation of 72 or 79 to 85-96 was explored with different alkyl halides employing different solvents and bases (Table 2.8). Reaction progress was monitored by
120
31

P

NMR (CDCl3) by observing the consumption of 72 OEt ( = 19.27 ppm), and 79 OiPr ( = 18.06 ppm, Table 2.8). In all cases, the alkylation was incomplete and resulted in a mixture containing the desired product along with unreacted starting material, often requiring a difficult column chromatography purification (Table 2.8, Entries xiv, xv, xvi). The choice of alkylhalide proved to be the most critical step in the reaction. Alkylation with the bromopropyl QAC (Table 2.8, Entry xviii) that could directly lead to the desired product in one step, failed to react (31P NMR) while the N,N-dimethyl 84 intermediate, also failed to alkylate. Next, dihalo precursors of various chain lengths C3-C6 were employed (Table 2.8, 7 (C3), 8 (C4), 80 (C6)) resulting in low yields. When NaH/DMSO (Table 2.8, Entries iii, xviii, xix, xxii) was employed with the dihalo compounds, higher yields were obtained versus THF while the n-BuLi/THF reaction resulted in a complicated mixture of products (Table 2.8, Entry iv). When an excess of NaH in DMSO was used, compound 88 was unexpectedly dialkylated due to an intramolecular reaction (Scheme 2.14, Table 2.8, Entry xvii, Figure 2.11). As a result, a protective group strategy employing compound 10 was used as the alkyl halide to prepare 93 on a large scale (Figure 2.12). Compound 95, a known compound, was previously synthesized in the literature by Method 4 with NaH/THF in low yield (30%). As a result both NaH/THF and NaH/DMSO combinations were tested in an attempt to improve the yield. Even though the NaH/DMSO conditions were higher yielding (Table 2.8, Entry xxvi), it was difficult to remove the solvent fully during extraction or distillation. Instead, when THF was dried (4°A MS) ON (Table 2.8, Entry xxiii) a 60% yield was obtained and the unreacted starting material 79 was carried throughout a lengthy deprotection/mesylation/substitution procedure to convert the alcohol to either a bromo 87 or N,N-dimethyl group 96 (Scheme 2.16).
121

RO

P RO

OO OR P OR (72) R = Et (79) R = i Pr

Base, Solvent R X (80-84)

RO

P RO

OO OR P OR R (85-96)

Table 2.8: Synthesis of -C-H bisphosphonates by Method 4.
Entry i ii iii iv* v vi (85-86) vii* viii ix x
RO O P RO RO P O OR Br 3

R-X

Base NaH NaH

Solv. THF DMF DMSO THF THF ACN ACN DMF THF DMSO

Time (hrs) 48 12 24 24 24 0.1 0.1 24 24 48

T (oC) RT RT RT RT RT 150 150 RT 60 RT

Ratio of reactants (72 + 7)/1:4 (72 + 7)/1:4 (72 + 7)/1:4 (72 + 7)/1:4 (79 + 7)/1:4 (72 + 7)/1:4 (72 + 7)/1:4 (72 + 7)/1:4 (72 + 7)/1:4 (79 + 8)/1:1.1

PRD % 3 1 22 0 0 5 n/a 20 31 68

31

PRD. P ppm (CDCl3) 25.63 25.67 25.69 n/a n/a 26.01 n/a 25.80 25.64 26.73

RO

O Br 2

NaH BuLi BuLi Cs2CO3 Cs2CO3 NaHMDS NaHMDS NaH

P RO RO P O OR

xi (87-88)
RO O P RO RO P O OR Br 5

NaH

DMSO

48

RT

(79 + 8)/1:1.1

54

26.79

xii

NaH

THF

48

RT

(79 + 80)/1:4

52

20.46

(89-90)

122

Entry

R-X
O P RO RO P O OR

Base

Solv.

Time (hrs) 24

T (oC) 60

Ratio of reactants (79 + 81)/1:4

PRD % 0

31

PRD. P ppm (CDCl3) n/a

xiii

RO

Cl 2

NaH

THF

xiv

NaH

Diox.

24

60

(79 + 81)/1:4

0

n/a

(91) xv*
O

NaH

THF

24

70

(79 + 82)/1:1.1

n/a

n/a

xvi

RO

O N 2 O

NaH

DMSO

48

RT

(79 + 10)/1:1.1

0

n/a

xvii

P RO RO P O OR

NaH
Br

Diox.

24

80

(79 + 10)/1:1.1

8

24.98

(92)
O P RO RO P O OR

RO

N 2

C18H37

xviii

NaH

DMSO

24

80

(79 + 83)/1:1.1

24

21.07

(93)
O EtO P EtO O OEt P OEt Br

xix

NaH

DMSO

24

RT

(72 + 7) / 1:1.5

99

28.50

(88a)
RO O P RO RO P O OR N 2

xx

NaH

DMSO

24

70

(72 + 84) / 1:1

0

n/a

(96)

* multiple peaks ,** PCT (phase transfer catalyst).

123

Rxn. Comp. (%) by 31P NMR (CDCl3) Entry R-X Base Solv. Time (hrs) 48 72 T o ( C) 60 RT Ratio of reactants (79 + 9)/1:1 (72 + 9)/1:1.1 PRD % 47 n/a
31

PRD. P ppm (CDCl3) 23.94 n/a

xxi xxii

NaH NaH

THF THF

xxiii xxiv *

RO

O P RO RO P O OR

NaH
OTHP 2

THF ACN

48 48

70 90

(79 + 9)/1:1 (79 + 9)/1:2

60 23

n/a 23.78

Cs2CO3 Cs2CO3 NaH NaHeq

xxv xxvi

(94-95)

ACN DMS O DMS O

72 RT

90 24

(79 + 9)/1:1 (79 + 9)/1:5

44 62

23.75 23.71

xxvii

RT

96

(79 + 9)/1:1

92

23.66

* multiple peaks ,** PCT (phase transfer catalyst).

O (RO)2P

O P(OR)2 Br

NaH, THF, 60°C, ON Intramolecular Reaction

O RO P ( )2

O P(OR)2

(88b) R = i Pr

(97) R = i Pr Isolated Product

Scheme 2.14: Intramolecular bisphosphonate alkylation.

124

Figure 2.11: 1H NMR (MeOD) spectrum of cyclic bisphosphonate by-product 97.

Figure 2.12: 31P NMR (CDCl3) monitoring for compound 94 and 95 prepared by Method 4.
125

O O (RO)2P O P(OR)2 Br (10) NaH, THF 60°C, ON O

O (RO)2P

O P(OR)2 O

TsOH, MeOH 60°C, 1 hr

O (RO)2P (98) MsCl, Et3N RT, 1 hr

O P(OR)2 OH

(79) R = i Pr

(95)

O

O (RO)2P (93)

O P(OR)2 Br N C18

NMe2C18 100°C, 30 min

O (RO)2P

O P(OR)2 Br

LiBr, ACN Reflux, 1 hr

O (RO)2P (99)

O P(OR)2 OMs

(87)

`

Scheme 2.15: Preparation of bisphosphonate QAC 96 via alkylation. Quaternization of 87 (Scheme 2.15) gave the desired bisphosphonate quat 93 (Figure 2.13), however, dealkylation with HBr (µW, 8 min) could not be monitored due to precipitation of the product 97 in the NMR tube (D2O) as well as several other deuturated solvents (CDCl3, DMSO), failing to show any 31P NMR signals of the crude reaction mixture.

126

Figure 2.13: 1H NMR (CDCl3) spectrum of -CH-QAC 93 prepared by Method 4. The rest of compound 87 was used to make the dimethyl derivative 96 in order to prepare trisphosphonate 101 via alkylation with NaHMDS/DECP (Scheme 2.16).

127

OEt O P OEt O P EtO OEt (96)

1) N 2)

Si

a N N Si Cl P

0°C, 30 min, Stir THF distilled

O P EtO ( )2 (EtO)2P

O P(OEt)2

0°C, 30 min, Stir O

O

O (100)

N

3) H2O2 Dropwise, 0°C, 30 min, Stir H N EtOH, Reflux, 1 hr 1) BrC18H37, Neat, 100°C 2) TMSBr, DCM, RT

OEt O P OEt O P EtO OEt (87)

O (HO)2P Br (HO)2P O 101 ( )

O P(OH)2 Br N C18H37

Scheme 2.16: Attempted preparation of trisphosphonic acid 101 via alkylation of 96.201

Halo QAC's 83 (bromo) and 102 (chloro) were synthesized by the Menschutkin reaction as precursors for alkylation of 79 in order to directly obtain the target bisphosphonate QAC 93 in one step with Method 4 (Scheme 2.17 and Scheme 2.13). Alkylation with bromo precursor 83 resulted in only a 24 % conversion by NMR spectroscopy (1H,
31

P, CDCl3) (Table 2.8, Entry

xviii). Purifying the product from the quat mixture was never attempted. The less reactive chloro precursor was made and characterized by NMR spectroscopy (1H,
31

P, CDCl3, Figure 2.14) but

never employed in the alkylation reaction with 79 due the low product conversion with the bromo precursor.

128

N R (7), (82) Br

C18H37 Br R N C18H37

ACN, Reflux, 4 hrs

(83) R = Br (102) R = Cl

Scheme 2.17: Preparation of halo QAC 83 and 102 precursors for Method 4.

Figure 2.14: 1H NMR (CDCl3) spectrum of precursor 102.

129

2.1.2.4 Bisphosphonates via the 3-Component Reaction A 3-component reaction was used to prepare precursor 105 in 75% yield (Experimental, Section 5.5.0) according to known procedures and quaternized with bromooctadecane (Scheme 2.18).202 No useful NMR data was obtained for compound 106 due to difficulties with purification. It remains doubtful whether 105, a weak and hindered nucleophile due to the presence of two electron withdrawing phosphonate ester groups could be quaternized.

Cl Cl H O Cl O (103) (104) O Cl O N 1. Et2O, 0°C, RT, 1 hr N 2. RT, 1 hr O P O O P O C O O O O (105) O Br C18H37 ACN, Reflux, 24 hrs + O C 2 Cl N

O P

O P O O Br

N C18H37 (106)

O P O O

Scheme 2.18: Attempted preparation of bisphosphonate 106.

130

2.1.2.5 -Aminobisphosphonic acids QAC Antimicrobials (-ABPQA) -Aminobisphosphonic acid QAC's were synthesized either directly via the three component Kabachnik-Fields reactions between formaldehyde, a primary amine and dialkyl phosphite (Scheme 2.19) or sequentially by isolating the imine intermediate (Scheme 2.20). The synthesis required a three step process starting with the Kabachnik-Fields reaction to generate novel bifunctional molecules with the -bisphosphonates anchored at one end and either a N,Ndimethylamino 113 or halo 114-117, 120 end group required for the quaternization reaction. The third and final step required didealkylation of the QAC bisphosphonate 121 to the free phosphonic acid 126 (Scheme 2.21). Initially N1,N1-dimethylpropane-1,3-diamine 108 seemed like the most logical choice of starting material for the Kabachnik-Fields reaction in order to obtain compound 113. Compound 108 is an inexpensive commercially available liquid and required no additional steps to free the primary amine as was the case with the halo precursors 109, 110 and sold as the HCl and HBr salts, respectively.

131

Br X NH2 (107A) Y = Cl (107B) Y = Br 6N NaOH Step 1: KF reaction O O R1O PH or (CH2O)n OR1 1) RT, 30 min, 2) 100°C, 1 hr or µW, 130°C, 5 min (112A) R1 = OMe (112B) R1 = OEt O OR1 P OR1 N R1O P O OR1 (113) X = NMe2 , R1 = Me (114) X = Cl, R1 = Et (115) X = Br R1 = Me (116) X = Br, R1 = Et (117) X = OH, R1 = Et Step 2: Quaternization or NaI, Acetone

X

X

NH2 (108) X = NMe2 (109) X = Cl (110) X = Br (111) X = OH

1) MsCl or TsCl, NMe3-HCl Et3N, DCM H RT, 1 hr N

N C18H37

2) EtOH, 100°C, 30 min or µW, 110°C, 5 min

100°C, 1 hr or µW, 150°C, 2 min

R1O

O N R

P R1O

Step 2: Quaternization Br C18H37 or N C18H37

O

O Br N N C18H37

P O

O P OR1 OR1 (113) R1 = Et, R2 = NMe2 (118) R1 = Et, R2 = OMs (119) R1 = Et, R2 = OTos (120) R1 = Et, R2 = I

100°C, 1 hr or µW, 150°C, 2 min

O P O O (121)

Scheme 2.19: Synthetic route to -aminobisphosphonate QAC 121. Optimized conditions for each step. As a result, optimization of the Kabachnik-Fields reaction was first explored with 108 (Table 2.10, Entries i-iv) as well as with the triazine intermediate 123 (Table 2.10, Entry v). In
132

all cases, the expected -bisphosphonate 113 product peak at  ~ 26-24 ppm (31P NMR, CDCl3) was observed while monitoring the reaction, however it was incorrectly assigned as compound 113. After minimal mass was recovered in the organic layer after extraction, the reaction was directly purified by column chromatography and the peak at ~ 26 ppm was attributed to compound 124 after a further 1H NMR (CDCl3) analysis (Figure 2.15).
O R1O PH OR1 O OR1 P OR1 N + R1O P O OR1 (113-117)

X

NH2 (108-111)

,

O or (CH2O)n X

HO

O OMe P OMe (124)

A) THF, Reflux, 12 hrs B) 0°C --> RT, 30 min; 100°C, 1 hr C) uW, 130°C, 5 min D) ST, 110°C, 20 min X (112A) R1 = OMe (112B) R1 = OEt X N 3 N 3 N X 3

(undesired product)

(122) X = OH (123) X = NMe2

Table 2.9: Optimization of the Kabachnik-Fields reaction.
Rxn. Comp. (%) by (31P) ppm NMR (CDCl3) Entry i
EtO O N N

Reactant

SM 112A + 108

Base n/a n/a n/a n/a n/a

Temp. (oC) RT RT 80 80 Reflux

Time 24 hrs 5 min 4 hrs 20 hrs 3 hrs

Solv. H2O THF THF THF ACN

PRD % 70 36 66 76 50

31

PRD P ppm

26.85 26.42 26.61 26.61 25.01

ii iii iv

P EtO

112A + 108 112A + 108 112A + 108 112A + 108

O P OEt OEt

(113) v

133

Table 2.9 continued Temp. (oC)

Rxn. Comp. (%) by (31P) ppm NMR (CDCl3) Base Time Solv. PRD .% PRD 31 P ppm

Entry

Reactant
O

SM

EtO

vi

P EtO

112B + 108
N N

NMe2

Reflux

30 min

EtOH

62

24.89

vii

O P OEt OEt

112B + 108

NMe2

110

5 min

EtOH

65

24.52

(113) viii ix x xi xii µW
EtO EtO O N Br

P EtO

112A + 110 112B + 110 112B + 110 112B + 110 112B + 110

Et3N NaOH NaOH NaOH NaOH

70 100 100 100 130

20 hrs 1 hr 1 hr 1 hr 5 min

THF H20 H20 H20 Neat

94 1 21 53 40

8.32 n/a 24.69 24.69 24.68

O P OEt OEt

(115-116)
O

xiii

P EtO

112B + 109
N Cl

NaOH

100

1 hr

H20

46

24.65

xiv

O P OEt OEt

112B + 109

KOH

100

1 hr

H20

48

24.40

(114)
EtO O P EtO

xv

112B + 111
N OH

n/a

80

4 hrs

THF

63

27.42

O P OEt OEt

xvi (117)

112B + 111

n/a

80

20 hrs

THF

85

26.60

134

Table 2.9 continued Temp. (oC)

Rxn. Comp. (%) by (31P) ppm NMR (CDCl3) Base Time Solv. PRD % PRD 31 P ppm

Entry

Reactant

SM

xvii*
EtO O N OH P EtO

112B + 111

n/a

Reflux

20 hrs

ACN

80

25.00

xviii
µW

112B + 111

n/a

130

5 min

Neat

73

24.83

O P OEt OEt

(117) 19 112B + 111 n/a 110 0.5 hr Neat 85 24.84

Figure 2.15: 1H NMR (CDCl3) spectrum of the undesired product 124 isolated from the Kabachnik-Fields reaction.
135

Based on the Kabachnik-Fields mechanism (Figure 2.16), the basic N,N-dimethylamine appears to play a catalytic role in driving the Abramov addition of dialkylphosphite to C=O bond forming -hydroxy phosphonate (Route B) over the Pudovik addition of dialkylphosphite to the imine (Figure 2.16, Route A). In fact, the literature preparation of 124 requires a catalytic amount of base (see Section 2.1.2.7). In contrast, when starting materials without a basic group such as the halo or OH derivatives were used, the Kabachnik-Fields reaction mechanism is favoured (Figure 2.16, Route A) and the bisphosphonates, 114-117 were obtained when 2 eq. of the dialkylphosphite was employed.
R1 O R2 + R3-NH2 R1 R2 R1 NR3 - H2O R2 OR4 + H P O OR4

Route A

OH NHR3

OR4 Route B + H P O OR4

OR4 H P O OR4

OR4 R1 H O P R OR4 1

+ R3-NH2 - H2O

OR4 R1 NHR3 O P R OR4 2

Figure 2.16: Possible mechanistic routes involved in the Kabachnik-Fields reaction.203 Next, the halo starting materials 107A and 107B (Scheme 2.19) were investigated in the Kabachnik-Fields reaction. As mentioned earlier, both the bromo 107A and chloro 107B sold as the HCl and HBr salts respectively, required an extra step to free base the amine salt prior to addition of formaldehyde and dialkylphosphonate. When Et3N or NaOH (1 eq.) were stirred with 107A for 20 min prior to the addition of formaldehyde and dialkylphosphonate in the same pot, the desired bisphosphonate was never observed (Table 2.9, Entries viii and ix). Instead of the desired bisphosphonate product with a 31P NMR (D2O) peak at ~ 24 ppm, a major downfield 31P
136

NMR peak at  ~ 8 ppm was observed with complete consumption of HPO(OMe)2 (31P,  = 14.7 ppm). In order for the reaction to proceed, 109 and 110 required a tedious extraction from 6N NaOH or KOH with isolation of the separated free bases as yellow oils that had to be used directly otherwise self-polymerization took place (Table 2.9, Entries x-xiv). No solvent was added during the extraction because when DCM, CHCl3, or EtOAc were employed for the free based halo derivatives, which prefered the aqueous phase over the organic phase (~ 5% extraction efficiency by weight). As a result, the oily extracts of the free based compounds were contaminated with ~ 40% H2O (1H NMR), resulting in only ~ 50% overall extraction yield starting from the amine salts (Table 2.9, Entries xx-xiv, note low product yields, 21-53%). Lastly, Et3N/ACN was employed in order to deprotonate the starting materials in situ without the need to extract and thus improve the yield, however the resulting triethylamine salt failed to precipitate from the solution and could not be removed prior to the Kabachnik-Fields reaction. Due to problems with starting materials 108-110 in the Kabachnik-Fields reaction described above, the reaction was screened with the amino alcohol 111 used in the literature to make 117 in refluxing THF (Experimental, Section 5.6.0). Under reflux conditions, the aminoalcohol 111 (Table 2.9, Entries xv and xvi, THF) or the triazine 122 (Table 2.9, Entry xv, ACN) worked well in the Kabachnik-Fields reaction with solid paraformaldehyde, resulting in yields over 70% by 31P NMR (CDCl3). Similarly, µW heating under neat conditions gave a 74% yield when reaction parameters were optimized to 5 min at 130oC (Table 2.9, Entry xxviii). This is the first µW synthesis of 117, while synthesis of -bisphosphonates with only alkyl chains (starting with 3-aminopropanol), has been previously reported with the Kabachnik-Fields reaction under µW heating (60 min, 100oC).204,205 After success under solventless conditions in the µW, a sealed tube experiment was thus perfomed with the alcohol starting material under
137

neat conditions for 30 min at 110oC which resulted in a 85% yield after column chromatography (Table 2.9, Entry xix). With the successful preparation of 117, the conversion to either a bromo, iodo (Experimental, Section 5.6.0) or NMe2 (Table 2.9, Entries vi and vii) required two extra steps, activation via mesyl or TsCl followed by the SN2 reaction. All sulfonyl chloride reactions resulted in higher yields and faster conversion times when the catalyst NMe3HCl162 was employed (30 min vs 24 hrs for non-catalyzed reaction). When the amine starting materials 108 or 111 were reacted solely with formaldehyde without addition of HP(OEt)2, the corresponding imines were formed respectively. However at RT, the imine compounds were in equilibrium with the trimer compounds 122 and 123 as observed by 1H NMR (CDCl3, Scheme 2.20).206 Trimer 123 was purified by an aqueous wash and subjected to quaternization with bromooctadecane. However, purification of the final product failed to give clean samples for characterization by 1H NMR spectroscopy (Figure 2.17). Instead, compound 121 was prepared from 115 and quaternized with bromooctadecane. Compound 115 was prepared via a longer route by activating the alcohol 111 via the mesyl 118 or tosyl 119 group refluxing in excess HNMe2 (Scheme 2.19, Step 1-2). Pure 121 was finally obtained after column chromatography eluting with EtOH(NaBrsat):ACN (1:3) (Figure 2.18).

138

N

Br

N

C18H37

N N N N N C18H37Br 100°C, 3 hrs

N Br C18H37 N N N Br N C18H37

(123)

(125) (crude) HPO3Et2

EtO O 3

O Br N N C18H37

P EtO

O P OEt OEt (121)

Scheme 2.20: Attempted stepwise preparation of 121.

Figure 2.17: Attempted quaternization of triazine 123 with bromoctadecane (1H NMR (CDCl3)).
139

Figure 2.18: 1H NMR (CDCl3) spectrum of -ABPQA 121. Dealkylation of ester 121 to the desired -bisphosphonic acid 126 was unsuccessful with both HBr and TMSBr (Scheme 2.21, Figure 2.19, a and b) and resulted in a mixture of products by
31

P NMR (D2O). The TMSBr reaction seemed promising at first by

31

P NMR with a major

peak at ~ 10 ppm attributed to the TMS ester (Figure 2.19, b). However, after hydrolysis with H2O and evaporation of volatiles, the product was insoluble in both D2O and CDCl3. After treatment of 126 with 1 eq. of NaOH to make the sodium salt, decomposition was observed with three unidentified 31P NMR (D2O) signals at  ~ 21, 16 and 6.5 ppm resulting in an inseparable mixture of products (Figure 2.19, c). According to Guerrero, instead of the phosphonic acid, phosphonate esters may also bind to metal oxide surfaces with the loss of an ethyl group.207
140

O

O Br N N C18H37

P O

1) TMSBr (3 eq.), DCM, RT, ON 2) MeOH/H2O 3) NH4OH or 6 N HBr, Reflux, 3 hrs

HO

O Br N N C18H37

P HO

O P O O (121)

O P OH OH

(126)

Scheme 2.21: Attempted didealkylation of -aminobisphosphonate QAC 121.

Figure 2.19: 31P NMR (CDCl3) reaction monitoring of 121 cleavage with HBr and TMSBr.

141

Synthesis of tetraphosphonate 127 was attempted from -bisphosphonate 113 after deprotonation with a strong base (LDA or NaH) and substitution with ClP(OEt)2 (Scheme 2.22). Monitoring the reaction with LDA as base at -10°C after 10 min by
31

P NMR spectroscopy

(CDCl3) showed no product 127 formation (Figure 2.20 a). Employing the same conditions as above but allowing the reaction to stir for 60 min at RT and extracting into EtOAc recovered mainly unreacted SM 113. Switching to NaH made no difference and no reaction took place (Figure 2.20 c). Allowing the deprotonation to occur at -78°C with LDA prior to the addition of ClP(OEt)2 seemed promising with consumption of 113 by 31P NMR spectroscopy (Figure 2.20 e), however after extraction into EtOAc and column chromatography of the reaction mixture no product corresponding to 127 was eluted.
EtO O N N 1) LDA or NaH / THF 2) ClP(OEt)2 EtO O O OEt P EtO P OEt O EtO P N N EtO O P OEt OEt (127)

P EtO

O P OEt OEt (113)

Scheme 2.22: Tetraphosphonate 127 by C-P alkylation of 113.

142

Figure 2.20: 31P NMR (CDCl3) reaction monitoring of tetraphosphonate 127.

2.1.2.6 -Aminobisphosphonic Acids QAC Antimicrobials (-ABPQA) Inspired by Matveeva's work208 on the H2O based synthesis of -aminobisphosphonates, the reaction was explored with various bi-functional amines in order to prepare precursor halo or dimethylamino substituted -aminobisphosphonates necessary for quaternization (Scheme 2.23, Table 2.10). Similarly to -aminobisphosphonates (Section 2.1.2.5), the most direct way to prepare N,N-dimethyl or halo -aminobisphosphonates is the addition of vinyl phosphonate to amines 108-110. The reaction progress was monitored by NMR (31P, D2O) and reaction
143

completeness was ascertained with the consumption of dialkylphosphite 129 ( = 19.97 to 23.71 ppm) and 130 ( = 18.10 ppm to 20.85 ppm, Table 2.10).
O OR P OR X NH2 O RO P OR + H2O OR P OR O = = e X R NM 131 OEt ( ) 2, = = R X 132 Cl, OEt ( ) (133) X = Br, R = OMe (134) X = Br, R = OEt (135) X = OH, R = OMe (136) X = OH, R = OEt - + (137) X = Br N Me2C18H37 , R = OMe X N

(108) X = NMe2 (109) X = Cl (110) X = Br (111) X = OH - + (128) X = Br N Me2C18H37 (135), (136) MsCl, Et3N, DCM, RT, 1 hr O RO RO P RO RO P O

RT, 24 hrs (129) R = Me (130) R = Et

O RO RO P HNMe2, EtOH N OMs ST, 90°C, 20 min RO RO P O N (139) R = Et C18Br, neat 100°C, 1-4 hrs O RO RO P C18H37 1) TMSBr/ DCM, RT, ON 2) H2O/EtOH RO RO P O N (140) R = Et Br N C18H37 N

(137) R = Me (138) R = Et

OH O P OH Br N HO P HO (141) O N

Scheme 2.23: Optimized synthetic route to -aminobisphosphonate QAC 141.

144

O OR P OR X NH2 R O O P O R + H2O X N OR + P OR X H N OR P OR O

(108) X = NMe2 (109) X = Cl (110) X = Br (111) X = OH - + (128) X = Br N Me2C18H37

RT, 24 hrs (129) R = Me (130) R = Et

(mono) O (131) X = NMe2, R = OEt (142) X = Cl, R = OEt (132) X = Cl, R = OEt (143) X = Br, R = OMe (133) X = Br, R = OMe (144) X = Br, R = OEt = r = R B X 134 OEt , ( ) (135) X = OH, R = OMe (136) X = OH, R = OEt - + (137) X = Br N Me2C18H37 , R = OMe

Table 2.10: Optimization of the Michael addition to -aminobisphosphonates QAC 131-144.
Rxn. Comp. (%) by (31P NMR, D2O) Entry Reactant
O RO RO P RO RO P O N N

SM 129 + 108 129 + 108 129 + 108 129 + 110

Base n/a n/a n/a NaOH NaOH NaOH

Time (hrs) 3 24 48 3 24 24

Temp . (oC) 100 RT RT RT RT RT

SM (%/ppm) 0 36/23.52 30/23.47 40/23.56 20*/23.51 23.51

PRD. (%/ppm) n/a 55/36.18 59/36.14 5/36.16 10/36.16 n/a

i ii iii iv v vi*

(131)
O RO RO P RO RO P O N Br

129 + 110 130 + 110

(133-134)
O RO RO P RO RO P O N

vii

130 + 109
Cl

DIPEA

64

RT

21*/20.85

31/33.36

viii

130 + 109 (132)

NaOMe

48

RT

17/20.85

50/33.40

145

Table 2.10 continued Entry Reactant
O EtO EtO P

Rxn. Comp. (%) by (31P NMR, D2O) Base Time (hrs) Temp . (oC) SM (%/ppm) PRD. (%/ppm)

SM

Br N N

ix

EtO EtO P O

130 + 128
C18H3

n/a

48

RT

51/23.68

49/35.41

(140) x**
O RO RO P RO RO P O N

129 + 111

n/a

24

RT

1/23.71

100/36.39

xi**

OH

129 + 111

n/a

24

RT

1/24.54

100/36.50

xii**

(135-136)

130 + 111

n/a

24

RT

10/20.82

90/30.00

* excess NaOH used (1.2 eq.), ** excess 129-130 was used. n/a: multiple peaks were observed and none of which corresponded to the product. In most cases the addition to amines 108-110 and the quat amine 128 resulted in a mixture containing the product with unreacted starting material (Table 2.10, Entries i-ix) or in the case of the halo amines with a mixture of mono- and bis--aminophosphonates identified by
31

P NMR (Figure 2.21 and Table 2.10, Entries iv, v, vii, viii). The added base used (Table 2.10,

Entries iv-viii) to freebase the amine salts 107A, 107B hindered the bis Michael addition to vinylphosphonate. Even when the based/amine salt was added in a 0.9/1 ratio, the reaction still resulted in an inseparable mixture of mono and bisphosphonates along with unreacted SM in the following ratios: (Figure 2.21 and Table 2.10, Entry v (1.0:0.12:0.32), Entry vii (1.0:0.65:0.43), Entry viii (0.66:1.0:0.34). Surprisingly, the quat amine 128 having no basic functionalities gave a low yield of product 140 with considerable unreacted starting material (~1:1 ratio) and was left unpurified (Figure 2.21 and Table 2.10, Entry ix). As a result bis -aminobisphosphonates were
146

successfully prepared by employing a longer indirect method that involving 3-amino-1-propanol 111. When the reaction was performed with 111 and either dimethyl- or diethylvinylphosphonate (Table 2.10, Entries x-xii) a clean reaction was observed with complete consumption of the starting material. Excess vinylphosphonate was removed by column chromatography to give pure 135 or 136 (Figure 2.21 and Table 2.10, Entries x-xii). Further functional group transformations were necessary to activate the alcohol 111 into a better leaving group through mesylation followed by substitution with excess dimethylamine and quaternization to give 140 (Scheme 2.23). The mesyl chloride 137 intermediate decomposed over time at RT and was reacted directly (Figure 2.22). Finally, quaternization with bromooctadecane gave quat 140 that was isolated after column chromatography along with 10% of impurities (27.6 and 26.8 ppm by
31

P NMR, CDCl3), (Figure 2.23, Experimental, Section

5.7.0). No dealkylation of 140 to the phosphonic acid 141 was attempted at this time.

147

Figure 2.21: Reaction monitoring of Michael addition reactions by 31P NMR (D2O).

148

Figure 2.22: Decomposition of 132 at RT by 31P NMR (CDCl3).

149

Figure 2.23: 1H NMR (CDCl3) spectrum of -ABPQA 140.

The commercially available starting material vinyl phosphonates 129-130 were quite expensive to purchase (~ $213/5mL, 95% for R1 = Et, S-A) and as a result, all of the optimization reactions were performed on a very small scale (~ 1 mmol). Preparation of 130 was attempted from 15 and KOH in EtOH following literature procedures (Section 2.1.2.1).209 However, the major product was difficult to purify by distillation from unreacted 15 and the byproduct, diethyl (2-hydroxyethyl)phosphonate, resulting from the competing elimination reaction (Figure 2.24).

150

Figure 2.24: Preparation of diethylvinylphosphonate 130 (crude mixture by 31P NMR (CDCl3)).

Preparation of tetraphosphonates starting from -aminobisphosphonate 141 according to (Scheme 2.24) was also targeted but abandoned. It was difficult to isolate the THP protected 145 intermediate even after employing an excess of p-TosOH catalyst. As a result no further reactions leading to 146 were possible.

151

HO (111)

NH2

O O P (129) O

O O P O + H O 2 HO RT, 24 hrs N (141) O P O O

p-TosOH, DCM, ON, RT 1) LDA, ClP(OEt)2 OH HO P O OH P OH N O HO P HO OH P OH OO 2) Amberslyt H-15/MeOH, 45°C, 1 hr 3) MsCl, Et3N, DCM, RT, 1 hr 4) C18Br, Neat, 100°C 5) TMSBr/ DCM, RT O O P O (THP)O (145) N O P O O

Br C18H37 N

(146)

Scheme 2.24: Attempted synthetic route to tetraphosphonate QAC 146 from -amino bisphosphonate 141.

The amine QAC precusor 144 utilized in the Michael addition was prepared via the Menshutkin reaction from amine protected alkylhalides 147-151 and N,N-dimethylocteadecyl amine in good yields. However, only the CBz 156 and PHT 152 protecting groups were successfully deprotected to the free quat amine 144 with H2/PdC and excess hydrazine hydrate respectively (Scheme 2.25). There is only one literature report describing the preparation of 144 from the amide 153 after basic hydrolysis. However in our hands, extraction of 144 into CHCl3 upon purification was problematic and led to to inseparable emulsions and low product recovery. Figure 2.25 shows the 1H NMR spectrum (D2O) of 144 prepared from hydrazine cleavage of 152.

152

N R Br

C18H37 R N Br (152) R = PHT (153) R = Ac (154) R = CN (155) R = Boc (156) R = CBz C18H37

ACN, Reflux, 4 hrs (147) R = PHT (148) R = Ac (149) R = CN (150) R = Boc (151) R = CBz O N Br O (152) N C18H37 H2N NH2 EtOH, Reflux, 1.5 hrs H2N

N Br

C18H37

(144)

Scheme 2.25: Preparation of amine quat 144.

Figure 2.25: 1H NMR (CDCl3) spectrum of 144 after N2H4 deprotection (* unidentified impurity).

153

2.1.2.7 Tridentate Phosphonic Acid QAC Antimicrobials (TPQA) Synthesis of novel multidentate tris--hydroxy phosphonic acid, tris--hydroxy phosphonic acid and or tris--hydroxy phosphonic acid QAC was explored with the inexpensive and commercially available polyhydroxy 2-amino-2-hydroxymethyl-propane-1,3-diol (tris) scaffold. Prior to installing the phosphonate group from the hydroxyl groups, the primary amine from tris was BOC protected as 157 and used to prepare tris--hydroxy phosphonic acid (Scheme 2.26), tris--hydroxy phosphonic acid (Scheme 2.27 a) and tris--hydroxy phosphonic acid QAC (Scheme 2.28). Meanwhile, the tris-N,N-dimethylacrylamide 163 was also tried in an attempt to prepare tris--hydroxy phosphonic acid but was unsuccessful (Scheme 2.27 b). First, in the preparation of tris--hydroxy phosphonic acid 161, the hydroxyl groups from tris-BOC were subjected to nucleophilic substitution with mesylphosphonate 158 according to the first step in Scheme 2.26. Unfortunately, the first step failed and none of the three nucleophilic OH's substituted the mesylphosphonate 158 with the following solvent/base combinations: NaH/DMF, KOt-Bu/DMF, KOt-Bu/t-BuOH. It is possible that steric hindrance along with the prescence of multiple nucleophiles and insolubility of tris-BOC in t-BuOH played a negative role on the reaction outcome.

154

HO HO HO N H (157) O O

Base, Solvent, 80°C, ON O O P O

O O O P O

O P O O

O O N H

O O (159)

OMs

(158)

O P O O

1) HCl, EtOH, RT, 1 hr 2) Acroyl Chloride, DCM, Et3N, RT, 3 hrs 3) NHMe2, EtOH, RT, 10 min

HO P OH O O HO P O OH O O P OH OH O O N H N r (161) B C18H37

1) NMe2C18H37, Neat, 100°C 2) TMSBr/DCM, RT, ON 3) H2O/EtOH O O P O

O

O P O O

O O N H

O N (160)

O P O O

Scheme 2.26: Proposed synthesis of tris--hydroxyphosphonate QAC 161.

Next, tris--hydroxyphosphonate QAC's 162 and 164 were targeted via the oxa-Michael addition of the three hydroxy groups from both tris-BOC 157 and tris N,N-dimethylacrylamide 163 onto dimethylvinyl phosphonate according to Scheme 2.27. As was the case with tri-hydroxyphosphonate QAC, both starting materials were inert in this reaction and no addition products were observed by TLC and NMR (31P, 1H, D2O). Once again insolubility and steric factors were likely the result of the failed addition reaction. In order to increase solubility and decrease the steric strain of the three hydroxyl groups in close proximity to each other the
155

synthesis of tri--hydroxyphosphonate QAC was explored in DMF and a longer carbon spacer (C3) was used between the phosphonate and oxygen atoms.
O O P O O O O P O O O P O O N H (162) O O O

HO

(a) HO
HO N H

O O

(129)

O

O

P O

(157)

Cs2CO3, i PrOH RT, 24 hrs

HO

(b) HO
HO N H

O N

(129)

O

O O O O P O O O P O O

O O P O

P O

O O N H (164) N

(163)

Cs2CO3, i PrOH RT, 24 hrs

Scheme 2.27: Attempted synthesis of precursors 162 and 164 to tris--hydroxyphosphonate QAC's.

The conversion of BOC protected trivinyl derivative 165 and tris-BOC 157 to tri-hydroxyphosphonate was attempted according to Scheme 2.28. However, like the case with the preparation of tri--hydroxyphosphonate and tri--hydroxyphosphonate QAC's, the first step of the reaction also failed to add the desired phosphonate groups onto these starting materials. As a result, no further reactions with these starting materials was pursued.

156

O O O N H O O (165)

AIBN

O O P 112) H O (

O

O P O

120°C, 2 hrs O OR O O P O

O O N H O O (166) O O

HO HO HO N H O O (157)

NaH, DMF, 80°C, ON O O O P O (12) Br

P

1. HCl, EtOH, RT, 1 hr 2. Acroyl Chloride, DCM, Et3N, RT, 3 hrs 3.NHMe2, EtOH, 10 min, RT

HO P O HO 1) NMe2C18, Neat, 100°C O O HO HO P O N H O Br (168) P HO O OH O N C18 3) H2O/EtOH O O P O 2) TMSBr/DCM, RT, ON O

O

O P O

O O N H O (167) P O O O N

Scheme 2.28: Attempted synthesis of tris--hydroxyphosphonate QAC 168. Commercially unavailable mesyl phosphonate 158 utilized in the proposed synthesis of tris--hydroxyphosphonate QAC's 161 and 168 (Scheme 2.26) was prepared in > 90% yield in two steps via the addition of dialkylphosphite to paraformaldehyde forming -hydroxy phosphonate 158 followed by sulfonation with catalytic Me3N.HCl (Scheme 2.29). The tosyl
157

phosphonate 170 was also prepared in an analogous fashion, but never utilized in any of the reactions involving the tris scaffold.
O EtO O P H EtO (112) K O O O K EtO P EtO (169) 1. OH 0°C, DCM, Me3N-HCl, Et3N

O

EtO

EtOH, Reflux, 1 hr

2. MsCl or TsCl Dropwise

O P OR EtO 158 ( ) R = Ms (170) R = Tos

Scheme 2.29: Preparation of mesyl 158 and tosyl phosphonate 170. BOC protection of the commercially available tris 171 followed by recrystallization from EtOAc gave precursor 157 in good yield (Scheme 2.30). A neutral BOC deprotection procedure that could be applied to any of the envisioned tris-BOC phosphonate intermediates 159, 162, 166 was identified using boiling H2O that was successfully used in deprotecting 157 to the free amine (Scheme 2.30). According to Wang et al., at elevated temperatures H2O plays the role of a dual acid/base catalyst resulting in the free neutral amine whereas the BOC group breaks down to the easily removable by products, t-BuOH and CO2 (Figure 2.26).210
O O HO HO NH2 HO (171) O

O O 172 ) ( HO HO

HO O N H O (157)

MeOH, RT, 16 hrs H2O, Reflux, 4 hrs

Scheme 2.30: Preparation of tris-BOC 157 and deprotection in boiling H2O to tris 171.
HO HO HO N H (157) O O + H3O - H3O HO HO HO N H OH OH O HO (171) HO NH2 HO + CO2 + t -BuOH

Figure 2.26: Mechanism of boiling H2O BOC deprotection.210
158

Lastly, precursor 163, a new compound was prepared from the commercially available tris acrylamine 173, and was synthesized via the rapid Michael addition with dimethyl amine (5 min by TLC) according to Scheme 2.31. Quaternization of 163 was attempted with BrC18H37 in DMF, but no clean NMR could be obtained at this time.
HO N H HO (173) RT, 5 min HO 5.6M in EtOH, H2O HO HO N H (163) O N

O

H N

HO

Scheme 2.31: Michael addition of HNMe2 to tris acrylamide 173.211

2.1.2.8 Amine Scaffolds for Tetra Phosphonic Acid QAC Antimicrobials Synthesis of tetradentate -amino phosphonate QAC 179 and 183 were targeted via the Michael addition of two free primary amines onto 129 after selective BOC protection of commercially available triamine building blocks 174 and 180 according to Schemes 2.32 and 2.33. Compound 177 decomposed upon BOC deprotection, meanwhile compound 181 was insoluble in H2O. Since the Phospha-Micheal reaction requires H2O to work, the addition of 50% EtOH to dissolve the starting material hampered the reaction and only SM was recovered after 72 hrs at RT by 31P NMR. No further reactions were carried out with these polyamine scaffolds.

159

1) KOH, TOL, 60°C, 3 hrs O N H2N H N (174) N NH2 N N
°

(175) COBHN

H N (176)

NHBOC

2) BOC2O, 60 C, 3 hrs

HO

Br (74)

DIPEA, ACN, Reflux, ON O O O P O N 2) NaOMe/MeOH neutralize O O N N (178) O P O O 1) MsCl, Et3N, DCM, RT, 1 hr 2) NMe2C18H37, Neat, 100°C 3) TMSBr/DCM, RT, ON 4) H2O/EtOH HO OH P O N HO OH N N (179) O P OH OH N Br C18H37 O OH P OH OH 3) O O P (129) O RT, 24 hrs + H2O COBHN P O N (177)

O

P O

1) 2M HCl (IPA,EtOAc), RT, 1 hr NHBOC

OH

P O

Scheme 2.32: Attempted preparation of tetradentate -amino QAC 179.
160

NH2 N (180)

(172) O O O O O Dropwise, 1 hr NH2 MeOH, RT, 16 hrs H2N

NH2 O N (181) N H O

H2N

O O P O (130)

H2O RT, ON

HO

OH

P O N

O OH P OH 1) H2O, 100oC, 4 hrs 2) CHO, CH3CHO N C18H37 3) BrC18H37

EtO

OEt

P O N

O OEt P OEt

HO

OH N N (183) O P OH OH

Br

EtO

OEt N N NHBOC

P O

P O

O P OEt OEt

(182)

Scheme 2.33: Attempted preparation of tetradentate -amino QAC 183.

161

2.2 Catechol QAC Research efforts have also focused on trying to design new types of quats from amino acids (AA) with functional linkers for attachment onto metal oxide surfaces. Since AA's are readily available in bulk at low cost and very biodegradable, QAC's based on AA's and their derivatives were envisioned as cheaper and more environmentally friendly source of antimicrobials in addition to the phosphonate QAC's. The target AA-QAC was anticipated from the dopamine amino acid analogue (L-DOPA) for binding to Ti and SS according to Scheme 2.34. Dopamine derivative 184 was the target starting material, but after problems with N,Ndimethylation of the primary amine resulting in only the tetrahydroisoquinolinone product 185 due to intramolecular cyclization (Scheme 2.34)211, it was decided to start from the commercially available OH derivative 187 and convert it to an alkyl halide 188 via the Appel reaction (Scheme 2.35). Thus, the bromo derivative 188 was quaternized with bromooctadecane but failed to crystallize as pure 189 and was analyzed as a mixture by NMR spectroscopy (1H,
31

P NMR

(CDCl3), Figure 2.27). No attempt at this time was made at removing the benzyl ethers groups to the target surface active catechol QAC 190.
O O (184) NH2 Reflux, 3-24 hrs or µW, 110 oC, 5 min O O not produced N (186) (CH2O)n or O , O OH O

O NH only product (185)

Scheme 2.34: Attempted N,N-dimethylation of dopamine 184.212

162

O CBr4/PPh3, DCM O (187) OH RT, ON - PPh3O, HCCl3 NMe2C18H37 (188) Reflux, 3 hrs

O O (188) O O (189) HO Br N (190) C18H37 Br

Br N C18H37

(189)

BBr3, DCM RT, 3 hrs - MeBr, HBr, B(OH)3 HO

Scheme 2.35: Attempted preparation of catechol QAC 190.

Figure 2.27: 1H NMR (CDCl3) spectrum of catechol QAC 189.
163

2.3 Organosulfur Based QAC The thiol group represents another functional group suitable for anchoring antimicrobials onto metals. Replacement of the methoxysilane (SiOMe3) of the commercially available Dow silane antimicrobial with a thiol (S-H) group anchors this QAC to select metal surfaces. The thiol quat forms self-assembled monolayers specifically on Au, Ag, Cu and other suitable metal surfaces while retaining the antimicrobial activity of the quaternary ammonium compound. The possible synthetic routes identified in the literature for the preparation of the thiolQAC largely involve commercially unavailable starting precursors (Scheme 2.36, Route iii) or require multiple preparative steps (Scheme 2.36, Route ia, ii). All of the routes feature a common nucleophilic substitution reaction between an alkylhalide (R-X) and a nitrogen nucleophile. Due to commercial availability of 3-chloropropyl thioacetate 191 and the disulfide 197 routes ib and iv were chosen to prepare the target thiol QAC's 194 and 199. In the thioacetate route, 3-chloropropylthioacetate was quaternized with 2 in high yield (90%) followed by cleavage with KOH/MeOH to give 194 in a 83% yield (Scheme 2.36, Route ia, Figure 2.28). Numerous attempts at obtaining a crystal structure of 194 were unsuccessful.

164

Figure 2.28: 1H NMR (CDCl3) spectra of organosulfur QAC 192 (upper) and 199 (lower). Alternatively, the C2 thiol quat 199 was prepared from the commercially available disulfide. Deprotonation of 197 with NaOMe in EtOH and the subsequent filtering of NaCl yields the free base which was then quaternized in situ with 2 eq. bromooctadecane to 198 in a 80% yield. Cleavage of the disulfide bond was attempted with HCl/Zn and NaBH4/EtOH, but the final product could not be spectroscopically characterized due to difficulties with purification and reformation of the disulfide in open air. The use of triphenyl phosphine to cleave the disulfide 198 was planned, but not pursued at this time (Scheme 2.36, Route iv).

165

(ia) O S
3

O N R S RT, 24 hrs Cl O HN S RT, 24 hrs (193) (192)
3

Br N R MeOH/HCl, 2 hrs

(ib)

(191) 3-Chloropropyl thiolacetate $4.3/g

Br Reflux, 24 hrs N
3

HS [C18H37]Br

3

N

R

R = C18H37 (194)

(ii)

N R Br
n

Br Br
n

Br RT, 24 hrs

N

R

NaSH, MeOH

(7) n = 3

(83) n = 3

(iiia)
n

Br

+

N H

n

SH

1) NaOMe/iPr Reflux, 5 hrs 2) MeI HS
3

Br N R

(46)

(195)

(iiib)

(194) R = C18H37 Br
n

+

N

n

SH

RT, 24 hrs MeOH

(46) Cl (iv) H N S

(196)

S

N

H

1. EtOH, NaOEt 2. BrC18H37, Reflux, ON

Br C18H37 N S S N Br

C18H37

(197)

Cl

(198)

(198)

PPh3/H2O -Ph3PO 2 HS

Br N (199) C18H37

Scheme 2.36: Literature routes to target thiol QAC's 194213 and 198214.

166

Previous literature describing the first thiol QAC's SAM failed to prepare a stable coating. An ethanolic solution of the thiol was coated onto Au. However, no surface antimicrobial data was reported, only MIC's in solution were reported.118,215 Further work with thiol SAM's was discontinued with greater effort focused on the preparation of organophosphonate QAC's (Section 2.1.2.1-2.1.2.6). 2.4 Benzophenone QAC (Plastic Coating) Based on previous work in our lab on benzophenone QAC 205105, the reaction conditions were optimized under µW heating by shortening the reaction time to 2 min at 150oC compared to 24 hrs reflux (Scheme 2.37). Dansyl benzophenone 214 was also synthesized for fluorescence testing onto plastics. In addition a novel benzophenone QAC with a silane linker 206 was synthesized and tested on polypropylene and nylon (Section 2.6.2.1). Post quaternization, compound 206 showed the characteristic upfield 1H resonances ( = 3.47 ppm, CDCl3) due to the two methyl groups on the quaternary amine and the characteristic silane resonance ( = 3.59 ppm) due to the silane methyl groups ­SiOMe3 (Figure 2.29).
13

C NMR spectrum reveled that compound 206 was

contaminated with a trace of unreacted SM that was difficult to separate from the mixture.

167

O Br (205) O 2 N 15

(7) n = 1 (8) n = 2 Br r n B

N C18H37 (2) O

ACN, µW, 150oC, 2 min

ACN, K2CO3, Reflux, 20 hrs O (202) n = 1 (203) n = 2 OH Cl (201)

O

n

Br

(216)

(200)

H N

O Cl O (204) N

ACN, KOH, Reflux, 20 hrs

(1) MeO Si MeO OMe

Cl

MeOH, Reflux, 48 hrs

O Cl (206) O N OMe Si e MeO OM

Scheme 2.37: Preparation of the benzophenone QAC's 205 and 206.

168

Figure 2.29: 1H (upper), 13C (lower) NMR (CDCl3) spectra of compound 206.
169

2.5 Dansyl QAC 2.5.1 Fluorescent Antimicrobial Coating Detection Fluorescence detection of antimicrobial QAC is advantageous over traditional dye based methods (i.e. bromophenol blue) because it allows for easy detection of the Si-QAC once applied by simply irradiating the treated surface with a UV lamp without destructive or permanent binding type testing. Accordingly, three fluorescent dansyl QAC derivatives were synthesized from previously developed procedures in our lab and used in product testing onto different surfaces (see Section 2.7.2).105,177 The compounds, dansylphosphonate 211-212 (metals), dansylsilane 213 (non-porous surfaces), dansyl benzophenone 216 (plastic surfaces) previously synthesized in our lab were prepared on a larger scale via the Menschutkin reaction between dansyl dimethyl obtained from dansyl chloride (Scheme 2.38) and the appropriate alkyl halide (Scheme 2.39). New dansyl derivatives reported herein were prepared in the same fashion and include dansyl isopropyl phosphonate 212, dansyl thioacetate 214 and dansyl -bisphosphonate 215 (Scheme 2.39). All dansyl compounds 211-216, 217 and 219 comprising of a dansyl group and a quaternary amine salt, represent a novel class of H2O soluble fluorescent reporters.

170

N 1) (1.5 eq.) Et3N, DCM, RT 2) (1.5 eq.), RT, 30 min H2N N N (108) O S O HN (208) N

N O S O Cl (207) 1) (3 eq.), Et3N, DCM 2) (3 eq.), RT, 30 min X NH3 (109) X = Cl X (110) X = Br O S O HN X

X = Cl (209), Br (210)

Scheme 2.38: Preparation of dansyl dimethyl 208 and halo precursors 209 and 210 for quaternization.

171

(12) R = Et, (13) R = i Pr O Br P OR (1.5 eq.) RO ACN, Reflux, 48 hrs

N

O S O HN (1) Cl O Si O (1.5 eq.) O N

Br N

O P OR OR

(211) R = Et (212) R = i Pr

ACN, Reflux, 48 hrs O S O HN N (187) Cl O S O HN (208) O OEt P 120 ( ) OEt N EtO P O . (1 1 eq.) OEt ACN, Reflux, 7 hrs O S O HN (202) Br O N (1.07 eq.) O O S O HN N N S (1.5 eq.) O S O HN O N

Cl N (213) OMe Si OMe OMe

ACN, Reflux, 28 hrs

Cl N (214) S O

I

Cl N (215) N

O OEt P OEt OEt P OEt O

ACN, Reflux, 20 hrs

Br N (216) O O

Scheme 2.39: Preparation of bifunctional dansyl anchors 211-216 for binding onto porous and non-porous surfaces.

172

Didealkylation of dansyl QAC diethyl and diisopropyl phosphonate esters 211 and 212 respectively was accomplished in the absence of previous literature describing the dealkylation of such compounds. Herein are presented optimized dealkylation conditions with the appropriate reagents according to Table 2.11. Both TMSBr in DCM (Table 2.11, Entry i) and HX (aq) reagents (Table 2.11, Entries iv-viii) were successful at generating the free phosphonic acid in quantitative yield while leaving the quat group intact. However, in situ generation of TMSBr from TMSCl/LiBr was incompatible with these compounds due to poor solubility of the quat group in ACN (Table 2.11, Entry ii). Of the mineral acids employed under both (ST) (Table 2.11, Entries iv-v and vii-viii) and µW heating (Table 2.11, Entry vi), it was necessary to use aqueous HBr as anhydrous HBr (20% in EtOH) tested intitially with these compounds was significantly slower at cleaving the phosphonate ethyl ester and never reached completion even after prolonged heating (Table 2.11, Entry iii). In aqueous HBr (Table 2.11, Entry iv), the reaction was complete after 2 hrs whereas after 24 hrs of heating in ethanolic HBr (Table 2.11, Entry iii) the reaction was only 71% completed. HBr (aq) (Table 2.11, Entries iv and vii) as expected resulted in faster dealkylation compared to HCl (Table 2.11, Entries vi-vii) and the iPr leaving group (Table 2.11, Entries vii and viii) also resulted in faster dealkylation versus the Et group (Table 2.11, Entries iv and v). Both the HBr and the iPr leaving groups produced more stable intermediates during the course of the reaction and these are supported by the observations in Table 2.11. Compound 217 is the first example of a fluorescent dansyl QA phosphonic acid compound connected through a quaternary ammonium group with excellent solubility in aqueous solution (Figure 2.30).
173

N 1) (3 eq.) TMSBr, DCM, RT, ON 2) MeOH/H2O 3) NH4+OHO P OR OR or 6 N HBr, Reflux, 3 hrs

N

O S O HN

Br N

O S O HN

Br N (217)

O P OH OH

(211) R = Et (212) R = i Pr

Table 2.11: Didealkylation of dansyl phosphonate diesters 211 and 212.
Rxn. Comp. (%) by 31P NMR (D2O) Entry i ii iii iv* v vi vii* viii R Et Et Et Et Et Et iPr iPr Reagent TMSBr TMSCl/LiBr 20% HBr HBr HCl HCl HBr HCl Solvent DCM ACN EtOH H2O H2O H2O H2O H2O Time (hrs) 24 24 24 2 12 0.3 1 2 Temp. (oC) RT RT Reflux Reflux Reflux 150 Reflux Reflux SM 0 n/a 29 0 0 0 0 0 PRD. 100 n/a 71 100 100 100 100 100

174

Figure 2.30: 1H NMR spectra of 208 (CDCl3), 209 (CDCl3), and 217 (D2O).

The thioacetate protected dansyl derivative 214 for binding onto noble metals was also successfully prepared from 208 and the commercially available 3-chloropropylthioacetate. NMR analysis (1H, 13C, CDCl3) spectrum for 214 revealed characteristic hydrogen (1H,  = 2.28 ppm) and carbon resonances (13C,  = 195.80 and  = 30.77 ppm) typical for the thioacetate group. Dansyl acrylamide, 219, was prepared in an analogous fashion to compounds 209-214 by the Menshutkin reaction except by employing the dansyl bromo precusor 210 instead of dansyl
175

dimethyl 208 and quaternized with the commercially available N,N-dimethylacrylamide derivative 218 (Scheme 2.40). Compound 219 was characterized by (1H, 13C) NMR spectroscopy and showed typical proton resonances corresponding to the acrylamide protons at   6.38 and 6.20 ppm. The 13C NMR spectrum revealed the expected ketone carbon resonance at   166.5 ppm and two new resonances   130.3 and 126.1 ppm due to the vinyl carbons (Figure 2.31). Compound 219 may find use as a solid fluorescent marker additive during the injection molding of plastics.
O N (218) N (1.1 eq.) N H N

O S O HN (210)

ACN, Reflux, 1.5 hrs Br

O S O HN

Br N (219) H N O

Scheme 2.40: Preparation of dansyl acrylamide QAC 219.

176

Scheme 2.24 Continued.....

Figure 2.31: 1H (upper), 13C (lower) NMR (CDCl3) spectra of dansyl acrylamide 219.

2.5.2 CO2 Detection-Dansyl Amidine Synthesis of amidine containing dansyl fluorophore 222 was achieved from dansyl amine 221 which was synthesized via the Menschutkin reaction similarly to dansyl QAC's 209-214 described above (Scheme 2.41). The amidine group in 222 was attached according to a procedure from Jessup et al., by employing EtOH instead of THF.216 In a typical amidine synthesis, the condensation of a primary amine with N,N-dimethylacetamide dimethyl acetal yields a mixture of acetamidine and imidate ester depending on the temperature, solvent, and structure of the primary amine. It was possible to suppress the formation of the imidate ester by performing the reaction in the presence of excess dimethyl amine, yielding acetamidine as the exclusive product. The synthesized primary amine 221 (obtained from hydrazine deprotection of 220) was used to
177

prepare amidine 222 in good yield after high vacuum purification. NMR analysis (1H,

13

C,

CDCl3) spectrum for 222 revealed characteristic amidine hydrogen (1H,  = 2.47,  = 1.83 ppm) and carbon resonances (13C,  = 174.11,  = 50.29 and  = 22.05 ppm, Figure 2.32). In the prescence of CO2, fluorophore 222 underwent a reversible phase change to 223 that could act as a fluorescence reporter for bacterial respiration. It was thought the reversible phase change to 223 would cause fluorescence quenching that would be directly proportional to the rate of CO2 produced by bacterial biofilms. However, no such change was observed with UV-light after 60 min of CO2 bubbling at RT. A H2O soluble fluorophore capable of reporting biofilm CO2 production remains a challenge at this point.

178

N O Br O S O HN (208) H2N NH2 EtOH, Reflux, 3 hrs (220) O O N O O N N NH2 NH2 N (10) N O

N

O S O HN

Br N (220)

O N O

ST, ACN, Reflux, 16 hrs

N

O S O HN

Br N (221) NH2

5.6 M EtOH H N (221)

N

Dropwise Br EtOH, RT, Dark, 18 hrs High vac, 80oC, 8 hrs O S O HN N (222) N H2O (222) RT, 1 hr, Bubble CO2 O S O HN Br N (223) O H N O OH N N N

Scheme 2.41: Preparation of dansyl amindine switchable fluorophore 222 and 223.

179

Figure 2.32: 1H NMR (D2O) spectra of dansyl amine 221 (upper) and dansyl amidine 222 (lower).
180

2.5.3 Unsuccessful Dansyl Reactions Attempted deprotection of dansyl thiolacetate 214 to the free thiol 224 with KOH was unsuccessful and the reaction turned from a light yellow to green and finally to a deep purple colour after stirring at RT for 60 min (Figure 2.33). 1H NMR (D2O) analysis of the crude mixture showed a complicated spectrum due to decomposition of the free thiol and disulfide formation. No further attempts to make the free thiol derivative were carried out.
N KOH / MeOH RT, ON S O O S O HN Cl N (224) SH N

O S O HN

Cl N (214)

Figure 2.33: Attempted deprotection of dansyl thioacetate 218 to dansyl thiol 212. In addition to thiol fluorophore QAC 224, a dithiocarbamate (DTC) anchored QAC was also targeted as an improved anchor for binding onto metals such as Au, Ag and Cu. The DTC N-C-S2 group forms a resonance structure that allows bidentate coordination to noble metals versus only monodentate coordination for thiol groups. Thus the DTC binding group forms a stronger and more stable monolayer on Au versus the thiol anchor. To the best of my knowledge, no QAC's dithiocarbamate exist in the literature. The synthesis of fluorophore 225 was attempted via the dropwise addition of CS2 to a stirred solution of 221 in methanolic KOH. A precipitate was observed after a few minutes and spectroscopically characterized (Experimental, Section 5.13). From the NMR evidence it was inconclusive whether 225 exists as the bis salt or the internal salt (Figure 2.34, Scheme 2.42).

181

Additionally characterization of 225 by HRMS spectrometry (ESI-TOF) accounted for a mass of (m/z: 469.1760, C21H33N4O2S3) indicative of the internal salt (Figure 2.35).
N

Br 1. MeOH, KOH, RT (221) 2. Dropwise, RT S C S or N (225) O S O HN N H N S S Na

S O S O HN NH S N

Scheme 2.42: Attempted preparation of dansyl DTC 225.

Figure 2.34: 1H NMR (DMSO-d6) spectrum of compound 225.
182

Figure 2.35: ESI-TOF MS spectrum of compound 225.

Lastly, the synthesis of bis -amino phosphonate fluorophore 226 was undertaken from the amine quat 221 (Scheme 2.43), however the reaction resulted in a mixture of unreacted starting material, the monophosphonate, and the desired product in a (0.51:0.71:1.0) ratio by 31P NMR spectroscopy (CDCl3) after 3 d. Purification of the crude reaction mixture of quats was unsuccessful by column chromatography (Figure 2.36).

183

1)

O O P O (129)

H2O RT, 64 hrs

N

(221) 2) TMSBr, DCM, RT, ON 3) H2O/EtOH N

Br O S O HN N (226) N

PO3Me2 PO3Me2

O S O HN

Br N (227) H N PO3Me2

Scheme 2.43: Attempted preparation of dansyl bis ­phosphonate 226.

Figure 2.36: 31P NMR (D2O) reaction monitoring of the formation of 226 after 3 d. at RT.

184

2.5.3 Fluorescence Properties of Dansyl QAC As expected, all dansyl QAC derivatives analyzed in MeOH exhibited similar fluorescence emission (emission = 525 nm) and absorption spectra (absorption = 340 nm) characteristic of the green-yellow dansyl tag (emission = 525 nm, absorption = 360 nm). Only compound 216 exhibited a different major absorption wavelength at ~300 nm due to the benzophenone group (Figure 2.37). However, in aqeous environments at low pH (0.1 N HCl) fluorescence quenching of the dansyl fluorophore 213 was observed due to protonation of the aromatic N,N-dimethylamine (Figure 2.38). At pH 7 (phosphate buffer) no deviation from the characteristic dansyl fluorescence spectra occured, only as slight decrease in intensity was observed at the same concentration versus analysis in MeOH. At high pH (0.1 N NaOH) absorption was shifted to ~ 310 nm which produced a lower intensity emission at 325 nm when excited at 340 nm (Figure 2.39). Noticable fluorescence quenching was also observed with derivative 220 likely due to  stacking interactions of the phthalimide group and the aromatic amine from the dansyl group (Figure 2.39).

185

Figure 2.37: Absorption spectra of dansyl QAC's (~ 1 x 10-3 M) in MeOH (ex = 330 nm).

Figure 2.38: Absorption spectra of dansyl QAC 213 (~ 1 x 10-3 M) at different pH's (ex = 330 nm).

186

Figure 2.39: Fluorescence spectra of dansyl QAC's (~ 1 x 10-3 M) in MeOH (ex = 525 nm).

187

2.6 Characterization and Properties 2.6.1 X-ray Crystallography Four novel crystal structures of 34, 19, 66 and 220 were obtained during the course of this research and are depicted in Figures 2.24, 2.25, 2.26, 2.27. The phosphonic acid quat 34 was re-crystallized using a 80% EtOH/EtOAc mixture, resulting in the isolation of long crystals growing vertically from the solution, representative of the long C18 chain (Figure 2.40). A hydrogen donor and acceptor group found at the end of both 34 and 66 was necessary in the formation of X-ray quality crystals of these long chain molecules (Figure 2.41). Structures with C18 tails are difficult to crystallize and are rare in the literature. In addition to 34, a crystal structure of the C18 QAC intermediate 66 was obtained with a hydroxyl terminal end group instead of a phosphonic acid (Figure 2.42). This compound was recrystallized from ACN by slow evaporation of the solvent at RT, resulting in the isolation of fine, white, prismatic crystals. Compound 66 had been previously reported in the literature, but a crystal structure of this long chain QAC was unknown. Crystals of both 34 and 66 exhibited average carbon-nitrogen bond lengths typical for an ammonium salt (1.499 Å).217 From the data obtained (see supplementary information) the bond lengths for N(1)-C(23), N(1)-C(22), N(1)-C(4), and N(1)-C(3) were 1.486(8) Å, 1.505(7) Å, 1.522(8) Å, and 1.523(8) Å respectively. These bond lengths agree with the above mentioned C-NQAC average bond lengths and along with other characterization data (Section 6.0, Appendix 1.1) support the identity of 34 and 66.

188

Figure 2.40: X-ray crystal structure of 34.

189

Figure 2.41: Crystal packing interactions of two molecules of 34.

190

Figure 2.42: X-ray crystal structure of 66.

191

Figure 2.43: X-ray crystal structure of 19. Two intermediate compounds 19 and 220 containing phthalimide protecting groups were crystallized and X-ray structures were obtained. The diethylphosphonate intermediate, 19, was
192

crystallized from EtOAc at -20oC, forming square, clear crystals (Figure 2.43). The dansyl phthalimide QAC intermediate 220 was crystallized inside an NMR tube from D2O at RT, forming star shaped, clear crystals. From the crystal structure, a close interaction of the phthalimide group near the dansyl group can be observed (Figure 2.44). This interaction supports the fluorescence quenching data for this compound due to - stacking of the two aromatic rings. The bond lengths and bond angles for all of these compounds are provided (Section 6.0, Appendix 1.1).

193

Figure 2.44: X-ray crystal structure of 220.

194

2.6.2 Antimicrobial Detection / Coating Procedures

Both non-fluorescent and fluorescent dansyl quats were attached to porous (cotton, SiO2) and non-porous (metals, plastics) by dip coating a given surface in the appropriate compound according to Figure 2.45. The dansyl QAC compounds were visualized under UV light while non-fluorescent QAC's were visualized with bromophenol blue. Coating procedures with examples on plastics and metals are described below.

195

N O HN S O O HN S O

N O HN S O

N

N Br

N

Cl

N O

Br

O Si O n O Substrate (211)

HO

Ph (214)

P O O O (217) Fluorescent Surface

(1) Dip Coat (1-10 min)

(2) Curing/Drying (2-24 hrs) or UV Light (5 min) Antimicrobial Surface (3) Rinsing 15 1-0.001 % in H2O 15 N n N N 2 O Br O O Si O Si O n OH Cl 15 N Br

Cl

O Si O n O (3)

O HO Ph (205) HO Ph

P O O O (34)

(3) + (205)

Figure 2.45: Coating procedure of QAC antimicrobials onto porous and nonporous surfaces.
196

2.6.2.1 Plastic Surfaces Grafting of non-fluorescent benzophenone compounds 205 and 3 + 205 onto polypropylene (PP) and silicone was performed as follows: plastic samples were cut into rectangles (3.5 × 2.5 cm), rinsed with H2O and MeOH and air dried prior to their use. The clean substrates were dipped into a 0.01% (w/v) solution of 214 and irradiated with UV (5 min) and any unbound material was rinsed from the substrates using H2O prior to visualization with bromophenol blue (Figure 2.46). Both PP and silicone surfaces stained a deep blue colour indicating the presence of quats on these plastic surfaces, while the controls remained unstained (Figure 2.47). Dansyl fluorescent compounds were successfully visualized without the bromophenol blue dye. Medical grade silicone tubing coated with 214, silica NP's treated with 211, PP coated with 214, and SS coated with 217 all fluoresced green, indicating their prescence on these surfaces when imaged under UV light (Figure 2.48).

197

Figure 2.46: Plastic coating experimental set-up.

Figure 2.47: Bromophenol blue (0.01 M) detection of QAC antimicrobials on plastic surfaces.
198

Figure 2.48: Fluorescent detection of dansyl QAC's. (a) Medical grade silicone tubing coated with control (left) and with 214 (right), imaged under UV light, (b) silica NP's treated with 211, PP plastic coated (c) control and (d) 214, (e) SS coated with control (upper) and 217 (lower) imaged under ambient light, (f) same image as (e) but imaged in the dark under UV light (TLC lamp).

199

2.6.2.3 Metal Surfaces Preparation of self-assembled monolayers of compound 211 on cotton and silica NP's were prepared by dip coating the samples in 0.01% (w/v) H2O or MeOH solution of 211 ON or until the solvent evaporated, followed by heating (100 oC, 24 hrs) and drying (Figure 2.49). Note a faster procedure was developed by placing the vials into an oven (100 oC) and letting the solvent evaporate (~ 30-60 min) followed by a rinsing step (MeOH) and a short oven cure (100
o

C, 1 hr). Samples prepared in both ways were found to possess the same antimicrobial activity

while uncured samples were inactive.

Figure 2.49: Metal coating experimental set up using 20 mL glass screw cap vial open to air.
200

2.6.3 Antimicrobial Activity

2.6.3.1 Solution Killing: Minimum Inhibitory Concentration's (MIC's) Minimum inhibitory concentration (MIC) experiments were performed according to standard procedures218 with both gram-positive and gram-negative bacterial strains: S. aureus, Listeria, Salmonella, and E. coli. Solutions of long chain QAC antimicrobials (0.01g/mL or 1%) were dissolved in H2O, inoculated with the test organism and serially diluted from 10-1-10-3, representing a dilution range from (0.01g/mL to 0.00001g/mL), followed by plate counts to determine the MIC values (Figure 2.50). Samples 1-3 were prepared with (1%) solutions of the C18 phosphonic acid QAC 34A obtained from hydrolysis of the phosphonate ester 26 or 27. Sample 1 is compound 34A obtained by TMSBr dealkylation of the ethyl ester (Et, TMSBr), sample 2 is the sodium salt 34B (Na salt) which is freely soluble in H2O and sample 3 is compound 34A obtained by HCl dealkylation of the iPr ester 27 (i-Pr, HCl). Sample 4 which was initially a (1%) solution of 34A used for ON dip coating experiments with Ti metal, is the residual liquid (unknown concentration) after the metal coupon was removed for antimicrobial analysis. Samples 1-3 prepared with 1% starting solutions of 34A exhibited similar MIC values but demonstrated 100 × higher efficacy with Listeria and Salmonella and 10 × higher efficacy against E. coli compared to the silane QAC 3 (sample 5 and 6) (Figure 2.50). All compounds were inhibitory towards the gram-positive S.aureus bacterium, susceptible to QAC compounds in solution (Figure 2.34). The phosphonate ester 26 (1% in H2O) was also tested for inhibition

201

against S. aureus and was found to be highly inhibitory even at 100 µg/mL concentrations (Table 2.12). As expected, sample 4, the retested aqueous phase containing residual 34A performed poorly with Listeria, Salmonella, and E. coli and no inhibition was observed at the starting concentration. This can be explained by the fact the phosphonic acid molecules in solution formed monolayers on the surface to Ti metal thereby decreasing the concentration 10-100 fold. So in fact the starting concentration was closer to a 0.001 ­ 0.0001 g/mL which after further dilution was no longer inhibitory (Figure 2.50). A stock solution (1%) of the silane quat 3 prepared from the 5% stabilized solution in H2O (SiQAC 3 (stabilized)) or prepared from the 72% concentrate in MeOH and diluted to 1% in H2O (SiQAC 3 (no stabilizer)) worked extremely well (Figure 2.50). All bacterial strains tested with these samples were inhibited at concentrations up 100 µg/mL which is in close agreement agreement with literature MIC values (84 µg/mL).61

202

203

Figure 2.50: Experimentally determined MIC (CFU/mL) of SiQAC 3, 34A and 34B. MIC plate counts of samples were perfomed using a 10-3 (about 200000 cfu/ml) culture of S. aureus (A), Listeria (B), Salmonella (C), E. coli (D). Solutions of QAC samples were prepared in H2O starting at 1mg/mL or 1% and diluted up 103.

204

Table 2.12: MIC plate counts of samples using a 10-3 (about 200000 cfu/mL) culture of S.aureus.
QAC (26) 0.01 g/mL No Growth 0.001g/mL No Growth 0.0001g/mL 0.00001g/mL No Growth No Growth

2.6.3.2 Contact Killing on Hard Surfaces Antimicrobial activity of phosphonate QAC coatings and the silane QAC 3 for comparison purposes were prepared on metal surfaces (Ti, SS, Al) and tested by growth enumeration in the dry state testing method developed in the Wolfaardt lab against various strains of bacteria. Intially, 1% solutions of compound 34A were electrosprayed in triplicate onto (Ti, SS, Al) and cured overnight at 120oC. However, no significant bacterial reduction was observed and the electrosprayed metal coupons were indistinguishable to the unsprayed controls (results not shown). Ti samples prepared by an overnight immersion in an aqueous or ethanolic solution of compound 34A followed by an overnight cure at 100oC showed promising results versus uncured samples. Ti samples were coated with compound 34A obtained by either TMSBr dealkylation of the ethyl ester (Et, TMSBr) or of the iPr ester by the HCl method (iPr, HCl). In both cases the 31P NMR spectrum were identical, however, 34A prepared by the TMSBr method was only slightly soluble in H2O and was tested in ethanol, while 34A prepared by the HCl method was tested in H2O at 10 mg/mL. S. aureus and Salmonella inoculated antimicrobial Ti surfaces were sampled after 3 hrs of drying and showed 99-100% reduction in viable bacteria versus the controls and uncured surfaces (Figure 2.51).

205

Figure 2.51: Colony forming units per mL of Salmonella and S. aureus after 3 hrs of drying on Ti surfaces. O/N is the initial concentration (105 cells/ml). 300 is the maximum cfu/mL. Blue rectangles = control untreated Ti, Red rectangles = compound 34A coated Ti ( obtained from dealkylation of the iPr ester with HCl), Green = compound 34A coated Ti (obtained from dealkylation of the ethyl ester with TMSBr)

After success with compound 34A on Ti, other organophosphorus QAC's including the ester 26, trimethylammnoium 35, pyridinium 36 as well as the silane quat SiQAC 3 on Ti were evaluated against a strain of P.aeroguinosa (PAO1) known for its robust survival on dry surfaces. Only compounds 26 and 34A showed a significant reduction of bacterial colonies after 4 hrs of sampling while the shorter chain phosphonic acid QAC's 35, 36 and the silane QAC 3 were indistinguishable from control samples (results not shown). As a result, no further sampling was performed on these surfaces. Instead the active compounds 26 and 34A were used to coat other metals SS, Al along with Ti and these surfaces were tested with other bacterial strains. Contact killing was observed immediately with compounds 26 and 34A on all surfaces tested (Ti, SS, Al). After 2 hrs these antimicrobial coatings had killed all of the cells initially dried on each surface (106 bacterial cells, Table 2.13 for Arthrobacter, Table 2.14 for PAO1).
206

Control samples without such coatings showed some bacterial reduction but only after extended periods of time. Typically, 24 hrs were required to reduce the bacterial surface population from 106 cells to 105-103 depending on the surface of the controls (Table 2.13). Aluminum control surfaces showed the largest reduction of PAO1 by a factor of 103 after 24 hrs while their survival was highest on SS with 105 cells remaining after 24 hrs. Such reductions are typical over time on surfaces with limited nutrients necessary for bacterial survival and reproduction. From these observations, the phospholipid sponge mechanism is believed to be responsible for the rapid contact killing with the longer chain QAC's. These monolayer forming organophosphorus antimicrobials required both a quat and a long hydrophobic tail to effectively remove bacterial phospholipids when in close proximity to the cells whereas QAC's without a long hydrophobic chain such as 35 and 36 were completely inactive even though they contained the same number of ammonium (N+) charges on the surface. Table 2.13: Arthrobacter reduction by antimicrobial metal surfaces treated with 26 and 34A. Arthrobacter (CFU/mL) Entry Sample 0 hrs I Ti (Ctr) 106 Ii Ti (26) 106 Iii Ti (34A) 106 Iv SS (Ctr) 106 V SS (26) 106 Vi SS (34A) 106

2 hrs 104 0 0 104 0 0

4 hrs 102 0 0 102 0 0

24 hrs 102 0 0 102 0 0

207

Table 2.14: P. aeroguinosa (PA01) reduction by antimicrobial metal surfaces treated with 26 and 34A. P.aeroguinosa PA01 (CFU/mL) Entry Sample 0 hrs 2 hrs 6 I Ti (Ctr) 10 106 Ii Ti (26) 106 0 6 Iii Ti (34A) 10 0 Iv Ti (34A) 106 0 6 V SS (Ctr) 10 106 Vi SS (26) 106 0 6 Vii SS (34A) 10 0 6 Viii Al (Ctr) 10 106 6 Ix Al (26) 10 0 6 X Al (34A) 10 0

4 hrs 105 0 0 0 105 0 0 104 0 0

24 hrs 104 0 0 0 105 0 0 103 0 0

Surfaces treated with compound 34A (Table 2.13, Entries i-iii) were further tested to determine if antimicrobial activity was retained. Samples stored in saline for 24 hrs from the first antimicrobial trial were removed, dried, washed in distilled H2O, dried, re-innoculated and then retested. All samples from the second trial showed similar Anthrobacter colony reductions (106 to 0) indicating the molecule was truly immobilized (Table 2.15). The effectiveness of the antimicrobial Ti treated with 34A to withstand Anthrobacter colonization was also demonsrated on agar. The control samples were fully colonized by the bacterium, while the antimicrobial treated Ti sample, effectively killed Anthrobacter on contact and no colonies were observed around the metal coupons (Figure 2.52).

208

Table 2.15: P. aeroguinosa (PA01) reduction by antimicrobial Ti surfaces treated with 34A and retested. P. aeroguinosa (PA01) (CFU/mL) Entry Sample 0 hrs 2 hrs 6 i Ti (Ctr) 10 104 ii Ti (34A) 106 0 6 iii Ti (34A) 10 0 iv Ti (34A) 106 0

4 hrs 102 0 0 0

Figure 2.52: Agar growth method showing P. aeroguinosa (PA01) reduction by antimicrobial Ti surfaces treated with 34A. (Cont = control, 1, 2, 3 = compound 34A).

The amount of bacteria intitially dried on the metal surfaces tested was determined by serial dilutions and agar plate counts until a countable amount of colonies was observed. For example after six dilutions of the original stock of bacteria applied to Ti and SS, 58 colonies were counted at the beginning of sampling (T = 0) which corresponds to a concentration of ~ 106 cells (Table 2.16, 2.17).
209

Table 2.16: Determination of initial bacterial load dried on titanium surfaces from plate counts (raw data). Tmtc = too many to count. Arthrobacter (Titanium) (CFU/mL) Control 100 10-1 10-2 0 hrs tmtc tmtc tmtc 4 hrs tmtc 285 24 24 hrs tmtc tmtc 35 10-3 tmtc 0 3 10-4 tmtc 0 0 10-5 tmtc 0 0 10-6 58 0 0 10-7 5 0 0

Table 2.17: Determination of initial bacterial load dried on SS surfaces from plate counts (raw data). Arthrobacter (Stainless Steel) (CFU/mL) Control 100 10-1 10-2 10-3 0 hrs Tmtc tmtc tmtc tmtc 4 hrs Tmtc tmtc 32 5 24 hrs Tmtc tmtc 34 4 10-4 tmtc 0 0 10-5 tmtc 0 0 10-6 40 0 0 10-7 2 0 0

210

3.0 CONCLUSION Water soluble quats with anchors specific for forming monolayers onto porous (([C18H37NH-(CH2)3-NMe2-R+][Cl-] (3; anchor = -Si(OMe)3) and non-porous metal oxide (Ti, SS, Al) (([C18H37-NH-(CH2)3-NMe2-R+][Cl-] (26; anchor = -PO(OEt)2, 34; -PO(OH)2) and plastic surfaces (silicones, PP) (([C18H37-NH-(CH2)4-NMe2-R+][Br-] (205; anchor = -benzophenone), ([benzophenone-NH-(CH2)3-NMe2-R+][X-] (206; R = -Si(OMe)3, X- = Cl-) were synthesized by the Menschutkin reaction and used to prepare antimicrobial coating on these surfaces. New compounds were successfully characterized by NMR spectroscopy (1H, 13C, 29Si, and 31P where required), HRMS spectroscopy and in a few instances by X-ray crystallography (34, 66, 19, 220). Improvements in the synthesis of the organosilane chloride 3, QA antimicrobial by the

dimethyloctadecyl[3-(trimethoxysilyl)propyl]ammonium

approved

Environmental Protection Agency (EPA) and the Pest Management Regulatory Agency (PMRA) was performed both under solventless (72 hrs, 100oC, 80%) and solvent (MeOH, 48 hrs, 76%) conditions in a sealed tube (ST), as well as with µW radiation in MeOH (45 min, 150oC, 58%). In all cases, the reaction never reached full conversion even after prolonged heating. Various monodentate organophosphorus phosphonates and phosphonic acid QAC's 3437 with short and long chains were successfully synthesized and used to prepare antimicrobial surfaces on Ti, SS and Al. The didealkylation of phosphoate QAC's was explored for the first time under µW heating and proved to be extremely effective and rapid with the following reagents; TMSBr (ACN, 10 min, 60°C) , HCl (3 M, 30 min, 150°C) or HBr (3 N, 10 min, 150°C). Three bisphosphonate QAC's 93, 121 and 140 were also prepared but their dealkylation to the corresponding phosphonic acids 96, 126, 141 was unsuccessful using either HBr or
211

TMSBr due to insolubility of the formed products in H2O and organic solvents. Other multidentate phosphonic acid quats were targeted (161, 168, 179, 183) but their synthesis was unsuccessful based on the synthetic schemes attempted. Novel thiol and catechol QAC's 194 and 189 were synthesized, both of which require further testing on metal surfaces. Various new quaternary ammonium dansyl containing compounds with both alkoxysilane 213, phosphonate 211-212, 217, thiolacetate 214, acrylamide 219, were similarly prepared and evaluated as potential fluorescent probes in antimicrobial coatings. Physical attachment of dansyl silane 213 to SiO2 nanoparticles (NP's) and cotton surfaces after immersion in solutions containing the fluorescent dye was verified by exposure to UV light and by complexation with bromophenol blue that rendered the surfaces visibly blue in colour. Plastic surfaces (PP, silicon medical tubing) were UV cured with dansyl benzophenone 216 and resulted in the physical attachment of the dye visualized by UV light. Dansyl phosphonic acid, 217, was attached to a stainless steel surface by exposure to an aqueous solution containing this dye, followed by a thermal cure (100°C, ON) resulting in the formation of a self-assembled fluorescent monolayer. Synthesis of a C18 benzophenone QAC 205 was improved with µW heating by lowering the reaction time to 2 min vs. an ON reflux in ACN. A new benzophenone QAC with a silane linker 206 was made and successfully visualized with bromophenol blue on PP and silicone surfaces with bromophenol blue. Antimicrobial activity of 205 and 206 on plastic surfaces remains to be tested. A dansyl amidine probe 222 prepared from dansyl amine 221 was expected to find use in the detection of microbial respiration CO2, however, no change in fluorescence was observed after exposure to CO2. Presence of non-fluorescent antimicrobial QAC coatings on surfaces was successfully detected using the bromophenol blue test. Antimicrobial activity was tested in solution by MIC
212

determinations and in the solid state (metal surfaces only, Ti, SS, Al) by growth enumeration in the dry state. SiQAC 3 was found to be the most biocidal in solution with an MIC of ~ 100 µg/g which is in close agreement to the literature value of 80 µg/g. Compounds 26 and 34 on the other hand were more biocidal on metal oxide surfaces and were capable of reducing initial concentrations of Salmonella, Arthrobacter, S. aureus and P. aeroguinosa by a factor of 106 (100%) after a contact time of 2 hrs and maintained their activity after 24 hrs. Re-testing the same active antimicrobial Ti surfaces after 3 weeks with another challenge of bacteria was performed and was also successful. Identical reductions in Arthrobacter colonies after a contact time of 2 hrs were observed 106 cells  0 cells (100%). These antimicrobial surfaces are believed to kill bacteria on contact because their MIC's are higher in solution compared to compound 3 and the monolayer concentrations of 26 and 34 are too small to effectively kill 106 cells if these surfaces released the antimicrobial upon testing.

213

4.0 FUTURE WORK Another possibility to improving the commercial synthesis of the Dow antimicrobial (SiQAC, 3) which utilizes the unreactive chlorosilane 1 (see Section 2.1.1), would entail the addition of a catalytic or stoichiometric amount of NaI or LiBr for a onepot Finkelstein / Menschutkin reaction. This would lead the the in situ formation of the more reactive iodo or bromosilane and would allow for shorter reaction times and complete conversion to the quat, previously impossible with the chlorosilane (Scheme 4.1 A). Alternatively the

Finkelstein/Menschutkin reaction could be performed sequentially with isolation of the iodosilane and the quaternization with dimethyloctadecylamine (Scheme 4.1 B).
(A) One Pot O O Si O (1) NaI or LiBr, NMe2C18H37 Cl MeOH or ACN, mW, 150°C, 20 min O O Si O Cl (3)

N

C18H37

(B) Sequential O O Si O (1) 1. NaI, Acetone, µW, 130°C, 20 min 2. NMe2C18H37, µW, 130°C, 10 min O O Si O Cl

Cl

N

C18H37

(3)

Scheme 4.1: Catalytic Finkelstein / Menschutkin reaction in the preparation of the Dow antimicrobial 3. The onepot bis addition of dialkylphosphites to aldehydes (see Section 2.1.2.3) needs to be further explored with the aldehyde quat precursor, 56, obtained by oxidation of the quat

214

alcohol with PCC/DCM (see Section 2.1.2.3). Precursor 56 would be an ideal starting material in preparing the target bisphosphonate, 59, in high yielding single pot reaction (Scheme 4.2).
O OEt P OEt O P OEt OEt - + (59) R = Br N Me2C18H37

R

O

1) HPO3Et, TOL, RT, 30 min 2) MsCl, Et3N, Reflux, 2 hrs

R

- + (56) R = Br N Me2C18H37

Scheme 4.2 .Onepot preparation of -CH-bisphosphonates from the aldehyde quat precursor, 56. The syntheses of catechol and disulfide QAC's 190 and 199 respectively remains to be finished (see Section 2.3 and 2.4). The final deprotection of catechol QAC 189 remains to be attempted with either BBr3/DMC or HBr under microwave irradiation (Scheme 4.3). Likewise the final cleavage of the disulfide QAC with PPh3/H2O remains to be performed to obtain the target thiol QAC 199 (Scheme 4.4).
O CBr4/PPh3, DCM O (187) OH O µW, 80°C, 20 min (188) O (188) NMe2C18H37, ACN O µW, 150°C, 5 min HO (189) BBr3, DCM HO µW, 80°C, 10 min (190) Br N C18H37 (189) Br O

Br N C18H37

Scheme 4.3: Preparation of catechol QAC, 190.

215

Br N S S N Br C18H37 PPh3/H2O -Ph3PO 2 HS

Br N (199) C18H37

C18H37

(198)

Scheme 4.4: Preparation of thiol QAC, 199.

The next generation of QA antimicrobials would be capable of binding to every possible surface (eg. both porous and non-porous: metal and plastic surfaces). Synthesis of a universal surface antimicrobial with multiple functional anchors is attractive with the commercially available polymer (Scheme 4.5). Different anchor groups including: silane, phosphonate, catechol and benzophenone groups could potentially be quaternized onto the polymer backbone. Dual cleavage of the catechol, and phosphonate groups may be achieved with BBr3 if desired. Alternatively, a series of diallyl monomers with different anchors can be co-polymerized to create multifunctional polymer coatings (Scheme 4.6).

n

1.1

N C4H9 N Cl N

n

N Cl

N Cl 1.2
N R

N R

N Bu Cl

Any anchor: R= Silane, benzophenone, phosphonate, phosphonic acid, catechol

Scheme 4.5: Synthesis of multifunctional QAC antimicrobial polymer coating.

216

Br

+

R

quaternize NH Alk R

Br N Alk

polymerize

N R Any anchor: R = Silane, benzophenone, phosphonate, phosphonic acid, catechol

Br Alk R

N

n Br Alk

Scheme 4.6: Synthesis of multifunctional QAC antimicrobial polymer coating.

217

5.0 - EXPERIMENTAL PROCEDURES 5.1 Materials and Instrumental Methods The majority of reagents and solvents were obtained from Sigma-Aldrich (S-A) or Alfa Aesar (A-A) and used as received. Reagents that were purified by vaccum distillation prior to use and include N,N-dimethyloctadecylamine (89%), octadecylamine, triethyl and triisopropyl phosphites. Bromooctadecane was purified by column chromatorgarphy eluting with 10% acetone/hexanes. The following anhydrous solvents, ACN (99.8%), 1,4-dioxane, DMF, DMSO, TOL and non-anhydrous solvents, MeOH, EtOH (95%), iPrOH, EtOAc and hexanes were purchased from Aldrich and used as received. Anhydrous DCM and THF were obtained from a mBraun solvent purification system by passage of the wet solvent through a bed of activated molecular sieves under an atmosphere of dry nitrogen. Nuclear magnetic resonance (NMR) experiments were recorded on a 400 MHz Bruker Avance II Spectrometer (Ryerson University) using deuterated chloroform (CDCl3) as the solvent unless otherwise indicated. 1H and
13

C NMR spectra were referenced to the residual

CDCl3 (7.26 ppm and 77.0 ppm) solvent signal while 31P spectrum were referenced externally to H3PO4 (0 ppm). Proton chemical shift assignments are given in  (ppm) and were interpreted with the aid of 2-D COSY spectra (Section 6, Appendix 1.2), while carbon chemical shift assignments are given in  (ppm) and were interpreted with the aid of 2-D HSQC spectra (Section 6, Appendix 1.2). µW reactions were performed in sealed glass reaction tubes utilizing the Biotage® Initiator µW Synthesizer (2.45 GHz) at the Ryerson University Analytical Centre (RUAC). UV218

VIS and fluorescence measurements were recorded on a Perkin Elmer Spectrophotometer (Lambda 20) at the Ryerson University Analytical Centre (RUAC). High resolution mass spectra (HRMS) were recorded by direct analysis in real time by DART-TOF or by electrospray time-of-flight (ESI-TOF) at the Advanced Instrumentation for Molecular Structure (AIMS) laboratory at the University of Toronto. X-ray crystal structure analysis was performed with a Bruker-Nonius Kappa-CCD diffractometer at the University of Toronto X-ray facilities. Thin Layer Chromatography (TLC) was carried out on Silica gel 60 aluminum backed plates and visualized with a UV lamp or staining with (KMnO4 or ninhydrin). Melting points were measured using a Fischer Scientific melting point apparatus. All prepared intermediates and compounds were stored in glass vials at RT while the dansyl derivatives were stored in the dark at RT. 5.2 General Procedures Method 5.2.1 Sealed Tube Reactions The appropriate reactants were placed, along with a magnetic stirring bar, into a 20 mL glass scintillation vial and sealed with a screw cap. The reaction mixture was heated using an oil or sand bath at the indicated time and temperature. The reaction was transferred to a round bottom flask, and volatiles removed on a rotary evaporator and the crude material purified either by distillation, Dry Column Vacuum Chromatography (DCVC) on silica gel or crystallization as indicated. In the case of dansyl derivatives, Et2O was added directly to the reaction mixture followed by decanting (repeat Et2O wash × 2) and drying under high vaccum.
219

Method 5.2.2 µW Reactions The appropriate reactants were placed, along with a magnetic stirring bar, into the appropriate size glass reaction tube (5 mL or 20 mL supplied from Biotage) and sealed with a septum/aluminum cap. The reaction mixture was heated in the Biotage® Initiator µW Synthesizer at the indicated time and temperature. Reaction mixtures were transferred to a round bottom flask and removed on a rotary evaporator and the crude material purified either by distillation, crystallization or Dry Column Vacuum Chromatography (DCVC) on silica gel as indicated. 5.2.3 Purification/Preparation of Common Starting Materials
N
4 5 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1

1

H

N
8 9

4 3

5 6

6 6

6 6

6 6

6 6

6 6

2 7

1

13

C

N,N-dimethyloctadecan-1-amine (2): This amine was purified by vacuum distillation (150oC, 0.5 mmHg) using a shortpath distillation head attached to a Schlenk line utilizing a silicon oil bath (200°C) and isolated as a clear, colourless liquid that solidified at RT. 1H NMR (400 MHz, CDCl3, ): 2.24-2.14 (m, 8H, (H4, H5 overlap)), 1.45-1.36 (m, 2H, H3) 1.22 (brs, 30H, H2 overlap), 0.84 (t, J = 7.1 Hz, 3H, H1) ppm; 13C NMR (100 MHz, CDCl3, ): 60.0 (C9), 45.5 (C8), 31.9 (C7), 29.7-29.6 (C6 overlap), 29.3 (C5), 27.8 (C4), 27.5 (C3), 22.7 (C2), 14.1 (C1) ppm.
Br
5 4 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1

1

H

220

Br
12

11 3

4 5

6 7

8 9

9 9

9 9

9 9

10 2

1

13

C

1-Bromooctadecane (46): This starting material from Aldrich (brown solid, 97%) was packed onto silica (20g / (~ 20 mL SM ) and purified by dry column chromatography (4.5 cm × 5.0 cm frit, 50 g silica) eluting with 10% acetone/hexanes (150 mL) to afford ~ 9 g of a clear oil that solidified at RT. (Note: the brown coloured impurities remained on column under these conditions but will elute in 50% acetone/hexanes). 1H NMR (400 MHz, CDCl3, ): 2.21-2.14 (m, 2H, H5), 1.88-1.81 (m, 2H, H4), 1.46-1.38 (m, 2H, H3), 1.24 (brs, 28H, H2), 0.86 (t, J = 7.0 Hz, 3H, H1) ppm;
13

C NMR

(100 MHz, CDCl3, ): 33.9 (C12), 32.8 (C11), 31.9 (C10), 29.7-29.6 (C8, C9 overlap), 29.5 (C7), 29.4 (C6), 29.3 (C5), 28.7 (C4), 28.2 (C3), 22.7 (C2), 14.1 (C1) ppm.
3 5 2 2 2 2 2 2 2 2 2

N
4

1

N
1

4 9 3

5 6

6 6

6 6

7 2

1

H

8

13

C

N,N-dimethyldodecan-1-amine (22):193 This compound was prepared by Method 5.2.2 with the EC reaction. 1H NMR (400 MHz, CDCl3, ): 2.21-2.14 (m, 8H, (H4 + H5 overlap)), 1.44-1.36 (m, 2H, H3) 1.21 (brs, 30H, H2 overlap), 0.84 (t, J = 7.0 Hz, 3H, H1) ppm;
13

C NMR (100 MHz, CDCl3, ): 60.0 (C9), 45.5

(C8), 31.9 (C7), 29.7-29.6 (C6 overlap), 29.3 (C5), 27.8 (C4), 27.5 (C3), 22.7 (C2), 14.1 (C1) ppm. (Agrees well with literature NMR values).193

221

5.2.4 Dow Antimicrobial Synthesis
O O Si O
6 4 1 7

9

N
8

5 3

3 3

3 3

3 3

3 3

3 3

3 3

3 3

2

Cl

15

O O Si O

12 3 1 14

N
13

4 5

6 7

8 9

10 10

10 10

10 10

10 10

10 11

2

Cl

N,N-dimethyl-N-(3-(trimethoxysilyl)propyl)nonadecan-1-ammonium chloride (3):194, 219 See (Table 2.2, Entry iii). This compound was synthesized according to Method 5.2.1 by heating 3-chloropropyltrimethoxysilane 1 (0.814 g, 4.1 mmol, 1.05 eq.) and N,N-dimethyloctadecyl-1amine (DMOA) 2 (1.190 g, 4 mmol, 1.0 eq.) neat for 72 hrs at 110oC. Crude yield: ~ 80% by 1H NMR spectroscopy (Section 6, Appendix 1.2, Figure A19). 1H NMR (400 MHz, CDCl3, ): 3.33 (s, 9H, H9), 3.32-3.08 (m, 10H, (H8 + H7 + H6 overlap)), 1.67-1.41 (m, 4H, (H5 + H4 overlap)), 1.01 (s, 30H, H3), 0.63 (t, J = 7.0 Hz, 2H, H2), 0.44 (t, J = 7.4 Hz, 2H, H1) ppm;
13

C NMR

(100 MHz, CDCl3, ): 65.56 (C15), 64.14 (C14), 50.61 (C13), 31.69 (C11), 29.5-29.35 (C10 overlap), 29.26 (C9), 29.18 (C8), 29.12 (C7), 29.03 (C6), 22.44 (C5), 16.26 (C4), 15.02 (C3), 13.85 (C2), 5.40 (C1) ppm. (No NMR values reported in the literature). 5.3 General Procedure for the Synthesis of ( ­MPQA's) 5.3.1 Abruzov Reaction According to general procedures220,221 for the Abruzov reaction, to a flame dried round bottom flask equipped with a reflux condenser connected to an inert atmosphere manifold, were added the appropriate reagents according to (Table 2.3). The flask was evacuated (2 min), backfilled
222

with N2 (g) and the reaction mixture refluxed for the appropriate time according to (Table 2.3) using an oil bath (175°C). The solution was then cooled to RT and excess dibromoalkane, trialkylphosphite and lower boiling by-products were removed by vacuum distillation (100°C, 1×10-2 mm Hg) using a shortpath distillation head attached to a Schlenk line. Compounds (2-12-7) were vacuum distilled as clear, colourless liquids, while compound 2-8 was recrystallized from EtOAc as a brittle crystalline solid. This reaction was also performed under µW radiation according to Method 5.2.2 and Table 2.3.
O P O O

5 1

2 3 4

Br

Diethyl (3-bromopropyl)phosphonate (12):220 See (Table 2.3, Entry iii). This compound was synthesized according to Method 5.2.1 by refluxing 1,3-dibromopropane (40 mL, 394 mmol, 4.0 eq.) and P(OEt)3 (13 mL, 75.8 mmol, 1.0 eq.) for 6 hrs. Yield: 79% (15.54 g). TLC (10% MeOH:EtOAc, KMnO4 stain), Rf = 0.65; 1H NMR (400 MHz, CDCl3, ): 4.12-4.00 (m, 4H, H5), 3.43 (t, 2H, J = 4.3 Hz, H4), 2.16-2.05 (m, 2H, H3), 1.90-1.81 (m, 2H, H2), 1.28 (t, J = 7.0 Hz, 6H, H1) ppm; 13C NMR (100 MHz, CDCl3, ): 61.6 (d, 2J C-P = 6.5 Hz, (C5)), 33.71 (d, 3J C-P = 18.6 Hz, (C4)), 25.92 (d, 2J C-P = 4.4 Hz, (C2)), 23.64 (d, 1J C-P = 142.5 Hz, (C3)), 16.4 (d, 2J C-P = 6.2 Hz, (C1)) ppm; 31P NMR (121.45 MHz, CDCl3, ): 30.2 ppm. (Agrees well with literature NMR values).220
O P O O

5 1

2 3 4

Br

223

Diisopropyl (3-bromopropyl)phosphonate (13):222 See (Table 2.3, Entry vii). This compound was synthesized according to Method 5.2.2 by µW heating 1,3-dibromopropane (5.48 mL, 53.9 mmol, 1.1 eq.) and P(OiPr)3 (11.16 mL, 49 mmol, 1.0 eq.) for 5 min at 170oC. The title compound 13 was isolated as a mixture after distillation with tetraisopropyl propane-1,3-diylbis(phosphonate) by-product A and 131

isopropoxyphospholane 1-oxide by-product B in a 0.05:0.05:1 mass ratio determined by

P

NMR spectroscopy. Of the 10.45 g isolated, approximately (5%, 0.522 g) was the bisphosphonate and the other (5%, 0.522 g) was the cyclic 5-membered ring oxaphospholane. Yield: 64% (9.45 g). TLC (10% MeOH, EtOAc, KMnO4 stain), Rf = 0.7; 1H NMR (400 MHz, CDCl3, ): 4.70-4.61 (m, 2H, H5), 3.42 (t, 2H, J = 6.5 Hz, H4), 2.15-2.04 (m, 2H, H3), 1.85-1.75 (m, 2H, H2), 1.27 (d, J = 7.21 Hz, 12H, H1) ppm; 13C NMR (100 MHz, CDCl3, ): 70.12 (d, 2J
C-P 2

= 6.51 Hz, (C5)), 33.70 (d, 3J C-P = 20.38 Hz, (C4)), 26.19 (d, 1J C-P = 4.32 Hz, (C2)), 25.76 (d,

J C-P = 25.76 Hz, (C3)), 24.01 (t, 2J C-P = 3.44 Hz, (C1)) ppm; 31P NMR (121.45 MHz, CDCl3,

): 28.34 ppm. (Agrees well with literature NMR values).222
O P O O

6 1

2 3 4

5

Br

Diethyl (4-bromobutyl)phosphonate (14):223 See (Table 2.3, Entry ix). This compound was synthesized according to Method 5.2.2 by µW heating 1,4-dibromobutane (0.88 mL, 8.69 mmol, 1.1 eq.) and P(OEt)3 (1.32 mL, 7.9 mmol, 1.0 eq.) for 5 min at 190oC. Isolated as a mixture with the bisphosphonate tetraethyl butane-1,4diylbis(phosphonate) and P(OEt)3 in a 0.1:0.29:1 mass ratio determined by 31P NMR. Of the 1.32
224

g isolated, approximately (~ 10%, 0.132 g) was the bisphosphonate by-product B and (~ 29%, 0.27 g) was by-product A. Yield: 63% (0.95 g). TLC (10% MeOH:EtOAc, KMnO4 stain), Rf = 0.65; 1H NMR (400 MHz, CDCl3, ): 4.10-3.93 (m, 4H, H6), 3.38-3.29 (m, 2H, H5), 1.91-1.80 (m, 2H, H4), 1.75-1.60 (m, 4H, (H2, H3)), 1.30-1.20 (m, 6H, H1) ppm; 31P NMR (121.45 MHz, CDCl3, ): 31.23 ppm. (Agrees well with literature NMR values).223
O P O O

4 1

2 3

Br

Diethyl (2-bromoethyl)phosphonate (15):221 See (Table 2.3, Entry xiii). This compound was synthesized according to Method 5.2.1 by refluxing 1,2-dibromoethane (40 mL, 394 mmol, 4.0 eq.) and P(OEt)3 (13 mL, 75.8 mmol, 1.0 eq.) for 4.3 hrs. The title compound 15 was purified by distillation and used directly without 1H and 13C NMR characterization in the synthesis of diethyl vinyl phosphonate 130.
O P O O

4 1

2 3

Br

Diisopropyl (2-bromoethyl)phosphonate (16):224 See (Table 2.3, Entry xv). This compound was synthesized according to Method 5.2.1 by refluxing 1,2-dibromoethane (49.6 mL, 576 mmol, 4.0 eq.) and P(OiPr)3 (32.8 mL, 144 mmol, 1.0 eq.) for 12 hrs. The title compound was isolated as a mixture after distillation with tetraisopropyl ethane-1,2-diylbis(phosphonate) by-product B and by-product A in a 0.09:0.1:1 mass ratio determined by 31P NMR spectroscopy. Of the 24.82 g isolated, approximately (~ 10%,
225

2.36 g) was identified as bisphosphonate and the other (~ 10%, 2.36 g) was the by-product A. Yield: 64% (20.10 g). TLC (10% MeOH, EtOAc, KMnO4 stain), Rf = 0.7; 1H NMR (400 MHz, CDCl3, ): 4.68-4.58 (m, 2H, H4), 3.43 (q, J = 8.8 Hz, 2H, H3), 3.31-2.20 (m, 2H, H2), 1.24 (d, J = 6.2 Hz, 12H, H1) ppm;
13

C NMR (100 MHz, CDCl3, ): 70.61 (d, 2J C-P = 6.70 Hz, (C4)),

32.05 (d, 2J C-P = 134.80 Hz, (C2)), 24.10 (s, C3), 23.90 (t, 2J C-P = 3.0 Hz, (C1)) ppm; 31P NMR (121.45 MHz, CDCl3, ): 28.34 ppm. (Agrees well with literature NMR values).224
O P O O

3

1 2

Br

Dimethyl (2-bromoethyl)phosphonate (17):225 See (Table 2.3, Entry xvi). This compound was synthesized according to Method 5.2.1 by refluxing 1,2-dibromoethane (24.12 mL, 280 mmol, 4.0 eq.) and P(OMe)3 (11.05 mL, 70 mmol, 1.0 eq.) for 12 hrs. Yield: 65% (10 g). TLC (10% MeOH, EtOAc, KMnO4 stain), Rf = 0.7; 1H NMR (400 MHz, CDCl3, ): 3.60-3.46 (m, 6H, H3), 1.30-1.26 (m, 2H, H2), 1.25-1.21 (m, 2H, H1), ppm; ppm;
31 13

C NMR (100 MHz, CDCl3, ): 51.9 (d, 2J C-P = 6.6 Hz, (C3)), 10.2 (C1), 8.8 (C2)

P NMR (121.45 MHz, CDCl3, ): 33.10 ppm. (Agrees well with literature NMR

values).225
4 4 6 4 8 5 3 2

O

O

O O P O

1 7

Diethyl (3-((tetrahydro-2H-pyran-2-yl)oxy)propyl)phosphonate (18):226

226

To a 20 mL conical round bottom flask was added the THP protected bromopropylalcohol 10 (4.55 g, ~ 20 mmol) followed by excess P(OEt)3 (10.0 mL, 60.0 mmol, 3.0 eq.). The reaction was heated at reflux (175°C) overnight. Excess P(OEt)3 was vacuum distilled at reduced pressure providing the pure product as a clear, viscous oil. Yield 89% (5.0 g). 1H NMR (400 MHz, CDCl3, ): 4.57 (t, J = 3.54 Hz, 1H, H8), 4.17-4.04 (m, 4H, H7), 3.86-3.72 (m, 2H, H6), 3.523.40 (m, 2H, H5), 1.93-1.77 (m, 4H, H3 + H4), 1.73-1.67 (m, 4H, H2), 1.31 (t, J = 7.04 Hz, 6H, H1) ppm;
13

C NMR (100 MHz, CDCl3, ): 98.90 (C8), 67.50 (d, 3J C-P = 6.5 Hz, (C5)), 62.3

(C6), 61.45 (d, 2J C-P = 3.7 Hz, (C7)), 32.90 (C4), 30.65 (d, 3J C-P = 9.9 Hz, (C5)), 25.43 (C4), 23.15 (d, 2J C-P = 3.7 Hz, (C3)), 19.45 (d, 2J C-P = 2.3 Hz, (C2)) 16.45 (d, 3J C-P = 5.9 Hz, (C1)) ppm;
31

P NMR (121.45 MHz, CDCl3, ): 32.32 ppm. (Agrees well with literature NMR

values).226
1 6

O
10 9 7 8

2

4 3

N O

O O P O 5

Diethyl (4-(1,3-dioxoisoindolin-2-yl)butyl) phosphonate (19):227 To a flame dried 50 mL round bottom flask equipped with a reflux condenser was added N-(4bromobutyl)-phthalimide (5g, 17.7 mmol, 1.0 eq.) followed by P(OEt)3 (18.24 mL, 106.3 mmol, 6 eq.) and the mixture was refluxed overnight (175C) using a sand bath. The reaction was then cooled to RT and excess P(OEt)3 was vacuum distilled using a shortpath distillation head attached to a Schlenk line. Once all of the excess P(OEt)3 was removed, the title compound was placed under high vacuum (~ 30 min) until it solidified. Further recrystallization from EtOAc (5
227

mL) at ­ 20°C provided pure product. Colourless crystals. Yield: 90% (5.43 g). TLC (5% MeOH: EtOAc), Rf = 0.90, Mp = 80-81 °C; 1H NMR (400 MHz, CDCl3, ): 7.82- 7.77 (m, 2H, H8), 7.70-7.66 (m, 2H, H7), 4.11-3.98 (m, 4H, H6), 3.66 (m, J = 7.0 Hz, 2H, H5), 1.81-1.71 (m, 4H, (H4, H3)), 1.67-1.56 (m, 2H, H2), 1.27 (t, J = 7.1 Hz, H1) ppm;
13

C NMR (100 MHz,

CDCl3, ): 168.29 (C10), 133.91 (C9), 132.06 (C7), 123.18 (C8), 61.48 (d, 2J C-P = 6.5 Hz, (C6)), 37.23 (d,1J C-P = 1.33 Hz, (C5)), 29.25 (d,2J C-P = 16.77 Hz (C4)), 24.44 (C2), 19.81 (d, 3J C-P = 5.01 Hz, (C3)), 16.42 (d, 3J C-P = 6.01 Hz, (C1)) ppm; 31P NMR (121.45 MHz, CDCl3, ): 31.48 ppm. HRMS-DART (m/z): [M+] calculated for C16H23NO5P, 340.1308; found, 340.1317. (Agrees well with literature NMR values).227 5.3.2 Menschutkin Quaternization General Procedure for the Menschutkin Quaternization. The appropriate tertiary amine and alkyl halide (1-2 eq.) were mixed with ACN or EtOH (0.5 M) employing Method 5.2.1 or Method 5.2.2 and heated for the appropriate length of time (Table 2.4) until
31

P NMR

spectroscopy showed the consumption of the starting phosphonates. The vial was allowed to cool to RT and the crude product was purified either by extraction (aq. phase isolated after washing with Et2O for H2O soluble compound only), centrifugation with a non-polar solvent, recrystallization, or dry packed onto silica and purified via dry column chromatography (4.5 cm × 5.0 cm frit, 40 g silica), eluting with 6% NaBr in MeOH/ACN (20:80). This method was also successfully used to make compounds 26-33, 40 (Scheme 2.2).

228

3 10

Br O 6 P O O
9 5 7 8 2 4 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1

N

1

H

3 16

Br O 4 P O O
17 6 15 18 6 5 7 8 9 10 11 12 13 13 13 13 13 13 14 2 1

N

13

C

N-(3-diethoxyphosphorylpropyl)-N,N-dimethyloctadecan-1-ammonium bromide (26):192,228 This compound was prepared by the Menshutkin reaction using Method 5.2.1, dimethyl (3bromopropyl)phosphonate 12 (1.264g, 4.88 mmol) and N,N-dimethyloctadecylamine (DMOA) (1.71 g, 5.1 mmol, 1.1 eq.) were reacted neat for 35 min at 100°C until the mixture solidified. The mixture was then cooled to RT, centrifuged from hexanes (15 mL), and recrystallized from 20 mL EtOAc / hexanes (1:5) to afford 26. Yield: 67% (1.82 g). Mp = 54-55 °C; 1H NMR (400 MHz, CDCl3, ): 4.09-4.01 (m, 2H, H10), 3.66-3.22 (m, 2H, H9) 3.43-3.38 (m, 2H, H8), 3.31 (s, 6H, H7), 2.03 (brs, 2H, H6), 1.84-1.80 (m, 2H, H5), 1.67 (brs, 2H, H4), 1.33-1.25 (m, 6H, H3), 1.19 (brs, 30H, H2), 0.83-0.79 (m, 3H, H1) ppm; 13C NMR (100 MHz, CDCl3, ): 64.25 (C18), 63.09 (d, 3JC-P = 6.54 Hz, (C17)), 62.14 (d, 2JC-P = 6.54 Hz, (C16)), 51.25 (C15), 31.86 (C14), 29.66-29.58 (C13 overlap), 29.55 (C12), 29.44 (C11), 29.38 (C10), 29.29 (C9), 29.19 (C8), 26.25 (C7), 22.69 (C6), 22.62 (C5), 16.49 (C4), 16.45 (C3), 16.39 (C2), 14.05 (C1) ppm;
31

P

NMR (121.45 MHz, CDCl3, ): 29.54 ppm. HRMS-DART (m/z): [M+] - Br- calculated for C27H59NO3P, 476.4227; found, 476.4240. (Agrees well with literature NMR values).192,228

229

3

O 6 10 P O O

Br
9 5 7 8 2 4 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1

N

1

H

3

Br O 4 15 P O O
13 5 12 14 7 6 8 9 10 10 10 10 10 10 10 10 10 10 11 2 1

N

13

C

N-(3-(diisopropoxyphosphoryl)propyl)-N,N-dimethyloctadecan-1-ammonium bromide (27): See (Table 2.4, entry iv). This compound was prepared by the Menshutkin reaction using Method 5.2.1. Diisopropylyl (3-bromopropyl)phosphonate 13 (0.964g, 3.36 mmol) and DMOA (1g, 3.36 mmol, 1.0 eq.) were refluxed in ACN for 3 hrs. The mixture was then cooled to RT, poured into 20 mL of Et2O, and placed into a freezer (-20oC) for 60 min to precipitate 27 as a white waxy solid. Yield: 89% (2.53 g). Mp = 54-55°C; 1H NMR (400 MHz, CDCl3, ): 4.684.60 (m, 2H, H10), 3.78-3.67 (m, 2H, H9) 3.50-3.42 (m, 2H, H8), 3.39 (s, 6H, H7), 2.05-1.92 (m, 2H, H5), 1.83-1.62 (m, 4H, H4 + H6), 1.28 (d, 2J = 6.20 Hz , 12H, H3) 1.21 (brs, 30H, H2), 0.84 (t, J = 7.03 Hz, 3H, H1) ppm; 13C NMR (100 MHz, CDCl3, ): 70.65 (d, 2J C-P = 6.54 Hz, (C15)), 64.09 (C14), 62.85 (d, 3J C-P = 6.54 Hz, (C13)), 51.55 (C12), 31.84 (C11), 29.66-29.55 (C10 overlap), 29.40 (C9), 29.29 (C8), 29.18 (C7), 22.41 (d, 2J C-P = Hz, (C6)), 23.95 (d, 1J C-P = Hz, (C5)), 22.61 (C4), 22.42 (C3), 16.70 (C2), 14.06 (C1) ppm; 31P NMR (121.45 MHz, CDCl3, ): 27.08 ppm. HRMS-DART (m/z): [M+] - Br- calculated for C29H63NO3P, 504.4540; found, 504.4546.

230

1

6

O

O
2

Br
3 5

4

P O

N

3-(diisopropoxyphosphoryl)-N,N,N-trimethylpropan-1-ammonium bromide (28): See (Table 2.4, Entry vi). NMe3HCl (0.5g, 1.5 eq., 5.2 mmol) and NaOH (0.196 g, 1.4 eq., 4.9 mmol) were placed, with a magnetic stirring bar, into a 20 mL glass reaction tube and sealed. EtOH (18 mL) was injected via a syringe and the mixture was stirred for 2 min at RT to free base the NMe3HCl. Next diisopropyl (3-bromopropyl)phosphonate 13 (1.0 g, 3.48 mmol) was introduced via syringe and the reaction mixture was heated in the µW at 150 °C (3 min). Volatiles were removed on a rotary evaporator and the crude material purified by dissolving the mixture in CHCl3 (30 mL), filtering off salts through a short pad of Celite and extracting the title compound into 30 mL of H2O. H2O was co-evaporated from ACN (100 mL), and the final product was further dried under high vaccum (~ 1 hr). Compound 28 was isolated as a clear, colourless oil. Yield: 80% (0.96 g). 1H NMR (400 MHz, CDCl3, ): 4.69-4.53 (m, 2H, H6), 3.83-3.70 (m, 2H, H5) 3.51-3.36 (brs, 9H, H4), 2.10-1.93 (m, 2H, H3), 1.83-1.67 (m, 2H, H2), 1.36-1.20 (m,12H, H1) ppm; 31P NMR (121.45 MHz, CDCl3, ): 26.77 ppm.
Me3Si O Br N

O

P Me3Si O

Bis(trimethylsilyl)-3-propylphosphonatepyridin-1-ium bromide (29): See (Table 2.4, Entry viii). This compound was prepared in a one pot reaction on a 1.74 mmol scale by reacting pyridine (0.137g, 1.74 mmol) with diisopropyl (3-bromopropyl)phosphonate 13
231

(0.5 g, 1.74 mmol) in ACN (1.5 mL) under µW heating (150oC, 10 min). Next TMSBr (0.6 mL, ~2.5 eq.) was syringed into the same vial and heated in the µW (60 oC, 10 min) to obtain a complete conversion of the TMS ester.
31

P NMR (121.45 MHz, CDCl3, ): 10.60 ppm. This

reactive intermediate was hydrolyzed directly with H2O to compound 36 (Table 2.5, Entry ix).
Br O 6 10 P O O
9 5 7 8 2 4 2 2 2 2 2 2 2 2 1

3

N

1

H

2

Br O 3 15 P O O
13 4 12 14 6 5 7 8 9 10 10 10 10 11 1

N

13

C

N-(3-(diisopropoxyphosphoryl)propyl)-N,N-dimethyldodecan-1-ammonium bromide (30): See (Table 2.4, Entry ix). This compound was prepared by the Menshutkin reaction using Method 5.2.1: diisopropylyl (3-bromopropyl)phosphonate 13 (1.13 g, 4.11 mmol, 1.15 eq.) and dimethyldodecylamine DMDA 22 (0.665 g, 3.58 mmol, 1.0 eq.) were refluxed in ACN for 4 hrs. The mixture was then cooled to RT, poured into 20 mL of Et2O, and placed into a freezer (-20oC) for 24 hrs. No precipitation of the title compound was observed so volatiles were evaporated and the crude mixture containing 28% excess diisopropylyl (3-bromopropyl)phosphonate 13 ( = 28.31 ppm, 31P NMR) was partitioned between 30 mL of H2O and 30 mL DCM and left to settle overnight. In the absence of a clear separation, the volatiles were evaporated and the crude material was chromatographed eluting with acetone / MeOH (9:1) resulting in a mixed fraction and as a result 30 was analyzed impure with left over starting material 13. Purification by further column chromatography was unsuccessful. Crude yield: 95% (1.70 g). 1H NMR (400 MHz,
232

CDCl3, ): 4.72-4.61 (m, 2H, H10), 3.79-3.73 (m, 2H, H9) 3.52-3.36 (m, 2H, H8), 3.40 (s, 6H, H7), 2.17-1.94 (m, 2H, H6), 1.88-1.67 (m, 4H, H4 + H5), 1.36-1.17 (m, 30H, (H2 + H3 overlap)), 0.86 (t, J = 7.03 Hz, 3H, H1) ppm; 13C NMR (100 MHz, CDCl3, ): 70.77 (d, 2J C-P = 6.70 Hz, (C15)), 70.19 (C14), 64.33 (C13), 51.27 (C12), 31.87 (C11), 29.60-29.50 (C10), 29.42 (C9), 29.38 (C8), 29.29 (C7), 29.20 (C6), 26.28 (C5), 24.01 (d, 2J C-P = 4.29 Hz, (C4)), 22.69 (d,
1

J C-P = 8.99 Hz, (C3)), 16.79 (d, J = 4.78 Hz, (C2)), 14.08 (C1) ppm; 31P NMR (121.45 MHz,

CDCl3, ): 27.04 ppm.
O 5 P O O
8 6 9 3 4 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1

10 2

N
7

1

H

15 2

O 3 P O O

17 4

16

6 5 7

8 9

10 11

12 12

12 12

12 12

12 12

13 1

N
14

13

C

Diethyl (3-(methyl(octadecyl)amino)propyl)phosphonate (31): A solution of N-methyloctadecylamine (0.284 g, 1 mmol), N,N-diisopropylethylamine (0.26 mL, 1.5 mmol, 1.5 eq.), diethyl (3-bromopropyl)phosphonate 12 (0.2 mL, 1.1mol, 1.1eq.) in 10 mL ACN were heated (24 hrs). After completion of the reaction (monitored by TLC) the reaction mixture was evaporated to dryness under reduced pressure. The residue was dissolved in DCM (40 mL) and washed with H2O (5 mL). The organic layer was dry packed onto Celite and purified by (DVCC) pre-eluting with acetone (150 mL) and eluting with 30% IPA/acetone (300 mL). The solvent was removed under reduced pressure to yield 31 as a white waxy solid. Yield: 90% (0.363 g). Mp = 36oC; 1H NMR (400 MHz, CDCl3, ): 3.50-3.40 (m, 4H, H10), 2.09 (t, J = 6.2 Hz, 2H, H9), 2.00 (t, J = 7.8 Hz, 2H, H8), 1.81(s, 3H, H7), 1.25-1.14 (m, 4H, (H5 + H6
233

overlap)), 0.97-0.87 (m, 2H, H4), 0.71-0.60 (m, 34H, (H2 + H3 overlap)), 0.24 (t, J = 6.1 Hz, 3H, H1) ppm; 13C NMR (100 MHz, CDCl3, ): 61.92 (d, 3J C-P = 43.40 Hz, (C17)), 56.86 (C16), 56.60 (d, 2J C-P = 17.22 Hz, (C15)), 40.21 (C14), 31.69 (C13), 29.44-29.36 (C12 overlap), 29.31 (C11), 29.27 (C10), 29.11 (C9), 26.84 (C8), 25.46 (C7), 23.87 (C6), 22.36 (C4), 21.91 (d 2J C-P = 21.91 Hz, (C5)), 18.64 (d, 1J C-P = 4.41 Hz, (C3)), 15.35 (d, 3J C-P = 6.04 Hz, (C2)), 13.09 (C1) ppm; 31P NMR (121.45 MHz, CDCl3, ): 32.34 ppm.
1 7

O 2 P O O

4 3 6

N
5

Diethyl (4-(dimethylamino)butyl)phosphonate (32):153 A mixture of diethyl (4-bromobutyl)phosphonate 14 (5.0 g, 18.3 mmol) with NHMe2 (5.6 M in EtOH, 10 mL, excess) was placed, with a magnetic stirring bar, into a 20 mL glass reaction tube and sealed. The reaction mixture was placed in the µW at 110 °C (5 min). Volatiles were removed on a rotary evaporator and the crude material purified by DCVC (50 g silica, 3.5 cm × 5.5 cm) eluting first with 150 mL (10% MeOH/acetone) collecting 250 mL (10% MeOH/ 10% NH4+OH- / 80% acetone) and evaporated to a yellow oil. Yield: 81% (3.55 g); TLC (20% NH4+OH- /acetone), Rf = 0.50; 1H NMR (400 MHz, CDCl3, ): 4.06-3.92 (m, 4H, H7), 2.85 (t, 2H, J = 7.96 Hz, H6), 2.62 (s, 6H, H5), 1.83-1.53 (m, 6H, (H4 + H3 + H2 overlap)), 1.22 (t, 6H, J = 7.04 Hz, H1) ppm; 13C NMR (100 MHz, CDCl3, ): 61.71 (d, 2JC-P = 6.60 Hz, (C7)), 57.68 (C6), 43.58 (C5), 25.68 (t, 1JC-P = 14.07 Hz, (C2)), 24.13 (C4), 19.90 (d, 2JC-P = 4.60 Hz, (C3)), 16.41 (d, 3JC-P = 6.22 Hz, (C1)) ppm; well with literature NMR values).153
31

P NMR (121.45 MHz, CDCl3, ): 30.94 ppm. (Agrees

234

5 1

O P O O

2 3 4

N

N

N

Diethyl (3-azidopropyl)phosphonate (33):229 To a stirred solution of diethyl (3-bromopropyl)phosphonate 12 (1 mL, 5.2 mmol) in acetone (20 mL) was added NaN3 (0.68, 10.4 mmol, 2 eq.) and the mixture was refluxed for 12 hrs. After cooling to RT, the mixture was filtered through Celite, washing with acetone and evaporated in vacuo to give the title compound as a yellow oil. Yield: 98% (1.13 g); TLC (60% acetone/hexanes), Rf = 0.50; 1H NMR (400 MHz, CDCl3, ): 4.16-4.02 (m, 4H, H5), 3.37 (t, 2H, J = 6.52 Hz, H4), 1.92-1.74 (m, 4H, (H3 + H2 overlap)), 1.31 (t, 2H, J = 7.06 Hz, H1) ppm; 13C NMR (100 MHz, CDCl3, ): 61.64 (d, 2JC-P = 6.59 Hz, (C5)), 51.45 (d, 3JC-P = 16.29 Hz (C4)), 22.86 (d, 1JC-P = 4.98 Hz, (C3)), 22.40 (d, 2JC-P = 143.06 Hz, (C2)), 16.43 (d, 2JC-P = 5.91 Hz, (C1)) ppm; values).229
31

P NMR (121.45 MHz, CDCl3, ): 30.75 ppm. (Agrees well with literature NMR

O O P O O O P O
6 8 4

7

2 5 2

2 2

2 2

2 2

2 2

2 2

2 2

2 1

N

3

9

Tetraisopropyl ((octadecylazanediyl)bis(propane-3,1-diyl))bis(phosphonate) (39): A solution of octadecylamine (1.0 g, 3.7 mmol), N,N-diisopropylethylamine (0.26 mL, 10 mmol, 2.7 eq.), diethyl (3-bromopropyl)phosphonate 12 (2.34, 8.16 mol, 2.2 eq.) were placed in a 20
235

mL vial, sealed and heated at 110oC (3 hrs). After completion of the reaction (monitored by 31P NMR) the reaction was cooled to RT and the orange residue dissolved in DCM (60 mL) and washed with H2O (60 mL). The organic layer was dry packed onto Celite and purified by (DVCC) pre-eluting with 30% acetone/hexanes (150 mL) and eluting with 10% MeOH/acetone (160 mL). The solvent was removed under reduced pressure to yield the title compound as a yellow oil. Note: this compound may be used without further purification in the next reaction. Yield: 96% (2.43 g). 1H NMR (400 MHz, CDCl3, ): 4.70-4.59 (m, 4H, H9), 2.44-2.28 (m, 6H, (H8 + H7 overlap)), 1.71-1.59 (m, 10H, (H6 + H5 + H4 overlap)), 1.42-1.14 (m, 54H, (H3 + H2 overlap)), 0.83(t, J = 5.4 Hz, 3H, H1) ppm; 31P NMR (121.45 MHz, CDCl3, ): 30.09 ppm.

O O P O
7

I
8 6 9 4 2 5 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1

N

3

10

O O P O

N,N-bis(3-(diisopropoxyphosphoryl)propyl)-N-methyloctadecan-1-ammonium iodide (40): To a solution of 39 (4.0 g, 5.8 mmol) in IPA (3 mL) was added MeI (0.45 mL, 7 mmol, 1.2 eq.), in a 20 mL glass reaction tube and sealed. The reaction mixture was heated in the µW at 110 °C (5 min). Volatiles were removed on a rotary evaporator and the crude material purified by DCVC (100 g silica, 4.5 cm × 5.5 cm) pre-eluting first with 200 mL (10% MeOH/acetone) and collecting 300 mL (50% MeOH/ acetone). Yield: 74% (3.55 g); TLC (50% MeOH/ acetone), Rf = 0.30; 1H NMR (400 MHz, CDCl3, ): 4.72-4.59 (m, 4H, H10), 3.80-3.62 (m, 4H, H9), 3.403.32 (m, 4H, H8), 3.28 (s, 3H, H7), 2.11-1.96 (m, 4H, H6), 1.87-1.68 (m, 6H, (H4 + H5
236

overlap)), 1.40-1.15 (m, 54H, (H3 + H2 overlap)), 0.84 (t, J = 6.9 Hz, 3H, H1) ppm; 31P NMR (121.45 MHz, CDCl3, ): 27.20 ppm. 5.3.3 Didealkylation of Phosphonate diesters.
Br O 5 P HO OH
8 4 6 7 2 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1

N

1

H

Br O 2 P HO OH
16 5 15 17 6 4 7 8 9 10 11 12 13 13 13 13 13 13 14 3 1

N

13

C

N,N-dimethyl-N-(3-phosphonopropyl)octadecan-1-ammonium bromide (34):230,231 Inside a flame dried and evacuated 20 mL screw cap vial N-(3-(diethoxyphosphoryl)propyl)N,N-dimethyloctadecan-1-ammonium bromide 26 (0.27 g, 0.46 mmol) was dissolved in anhydrous DCM (5 mL). To the clear stirred solution was added TMSBr (0.25 mL, 1.9 mmol, 4.0 eq.) through a rubber septum via syringe and the reaction was stirred at RT overnight. Completion of the reaction was followed by 31P NMR spectroscopy after which the reaction was quenched with EtOH (10 mL) and stirred for 1 hr followed by addition of H2O (1 mL). Volatiles were removed with a rotary evaporator connected to a high vacuum Schlenk line and the crude product was centrifuged with Et2O (2 × 10 mL) to remove brown coloured impurities isolating 41 as a white solid. Yield: 94% (0.942 g). A small portion of the title compound was recrystallized as clear, long needles from EtOAc/IPA for MS and X-ray analysis. Mp = 118-120 °C; 1H NMR (400 MHz, MeOD, ): 3.38-3.33 (m, 2H, H8), 3.28-3.23 (m, 2H, H7), 3.02 (s, 6H, H6), 2.021.90 (m, 2H, H5), 1.75-1.65 (m, 4H, H4, H3), 1.20 (brs, 30H, H3), 0.82 (t, J = 6.9 Hz, 3H, H1),
237

ppm;

13

C NMR (CDCl3, 100 MHz, ): 64.24 (C17), 63.54 (d, 1JC-P = 16.5 Hz, C16), 49.94

(C15), 31.68 (C14), 29.45-29.37 (C13 overlap), 29.37 (C12), 29.35 (C11), 29.27 (C10), 29.20 (C9), 29.08 (C8), 29.86 (C7), 26.02 (C6), 23.15 (d, 2JC-P = 141.29 Hz, C5), 22.34 (C4), 22.17 (C3), 16.47 (d, 1JC-P = 4.07 Hz, C2), 13.08 (C1) ppm; 31P NMR (121.45 MHz, CDCl3, ): 26.92 ppm; HRMS-DART (m/z): [M+] - Br- calculated for C23H51NO3P, 420.3601; found, 420.3608. (No NMR values reported in the literature).230,231
Br
2 4

HO

O
1

P HO

N
3

N,N,N-trimethyl-3-phosphonopropan-1-ammonium bromide (35): Table 2.4 (Entry xiiii). A mixture of diisopropylyl (3-bromopropyl)phosphonate 28 (0.96g, 2.78 mmol) and HBr (6 M, 1.85 mL, 4 eq.) was placed, with a magnetic stirring bar, into a 5 mL glass reaction tube and sealed. The reaction mixture was heated in the µW at 140 °C (10 min). Volatiles were removed on a rotary evaporator and the crude material was purified by recrystallization from MeOH/IPA (1:1, 20 mL) by slow evaporation of solvent ON and recovered as white crystals. Yield 80% (0.582 g); 1H NMR (400 MHz, CDCl3, ): 3.35-3.29 (m, 2H, H4) 3.04 (s, 9H, H3), 2.03-1.91 (m, 2H, H2), 1.77-1.66 (m, 2H, H1) ppm; 13C NMR (100 MHz, CDCl3, ): 66.24 (dt, 3JC-P = 2.92 Hz, C4), 52.92 (t, 4JC-P = 3.93 Hz, C3), 22.6 (d, 1JC-P = 137.50 Hz, C1), 16.69 (d, 2JC-P = 3.55 Hz, C2) ppm; 31P NMR (121.45 MHz, CDCl3, ): 26.77 ppm.

HO

O
1

Br
2 3

5

P HO

N
4

6

238

3-phosphonopropan-1-pyridin-1-ium bromide (36): This compound was made by a one pot reaction in either ACN/TMSBr or H2O/HBr. (See 13 for procedure, Table 2.4 (Entry xi)). A mixture of 13 (0.5g, 1.74 mmol) and HBr (2 M, 3.1 mL, 4 eq.) was placed, with a magnetic stirring bar, into a 5 mL glass reaction tube and sealed. The reaction mixture was heated in the µW at (150 °C, 10 min). The aqueous phase was neutralized with NH4+OH- (2 mL) in 20 mL H2O and washed with CHCl3 (10 mL) followed by evaporation of the organic phase (100 mL ACN co-evap) to a solid which was was purified by recrystallization from MeOH/IPA (2:1, 30 mL) by slow evaporation of solvent ON and recovered as white crystals. Yield 90% (0.441 g); 1H NMR (400 MHz, CDCl3, ): 8.78 (t, J = 5.52 Hz, 2H, H6), 8.48 (t, J = 7.0 Hz , 1H, H5), 7.99 (t, J = 5.60 Hz , 2H, H4), 4.80-4.60 (m, 2H, H3 overlap w D2O), 2.27-2.14 (m, 2H, H2), 1.77-1.66 (m, 2H, H1) ppm;
13

C NMR (100 MHz,

CDCl3, ) 13C NMR (100 MHz, CDCl3, ): 147.20 (C5), 144.78 (C6), 128.33 (C4), 61.35 (d, 3JCP

= 18.35 Hz, (C3)), 25.04 (d, 2JC-P = 4.38 Hz, (C2)), 23.21(d, 1JC-P = 139.29 Hz, (C1)) ppm; 31P

NMR (121.45 MHz, CDCl3, ): 26.99 ppm. HRMS-DART (m/z): [M+] - Br- calculated for C8H13NO3P, 202.0628; found, 202.0624.

239

O HO P O O HO P O Na

Na I
7 6 5 8 3 2 4 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1

N

1

H

O HO P O O HO P O Na

Na I
14 12 2 5 6 3 7 8 9 10 11 11 11 11 11 11 11 11 12 4 1

N
13

13

C

Sodium iodide (42):

((methyl(octadecyl)ammonio)bis(propane-3,1-diyl))bis(hydrogenphosphonate)

A mixture of 41 (3.288 g, 4.82 mmol) and HBr (2 M, 8.4 mL, 3.5 eq.) were placed, with a magnetic stirring bar, into a 10 mL glass reaction tube and sealed. The reaction mixture was heated in the µW at 150 °C (10 min). Volatiles were removed on a rotary evaporator and the crude material was purified by adding NaOH (2eq. in 10 mL H20) to make the monosodium salt of the bisphosphonic acid. Evaporation of H2O gave the title compound as a white solid. Yield: 90% (3.15 g); 1H NMR (400 MHz, D2O, ): 3.34-3.16 (m, 4H, (H8 + H7 overlap)), 2.97 (s, 3H, H6), 1.97-1.83 (m, 2H, H5), 1.71-1.61 (m, 2H, H4), 1.50-1.40 (C3),1.23 (brs, 30H, H2), 0.83 (t, J = 5.6 Hz, 3H, H1), ppm; 13C NMR (D2O, 100 MHz, ): 62.52 (C15), 61.85 (d, 3J C-P = 19.94 Hz, C14), 47.96 (C13), 32.00 (C12), 30.20-29.85 (C11 overlap), 29.81 (C10), 29.65 (C9), 29.49 (C8), 29.21 (C7), 26.26 (C6), 25.02 (d, 1JC-P = 132.27 Hz, C5), 22.68 (C4), 22.01 (C3), 17.24 (C2), 13.96 (C1) ppm; 31P NMR (121.45 MHz, D2O, ): 21.11 ppm.
240

N
2 3

N

N
1

N

N1,N1-bis(2-(dimethylamino)ethyl)-N2,N2-dimethylethane-1,2-diamine (44):199 This compound was made by a modification of the literature procedure199 by employing

paraformaldehyde and anydrous HCl. ACN (200 mL) was added to a 500 mL RBF containing tris(2-aminoethyl)amine (7.3115 g, 50 mmol) and paraformaldehyde (10 g, 333 mmol, 6.66 eq.) followed by formic acid (17 mL, 295 mmol, 5.9 eq.) at RT, and the mixture was refluxed for 3 hrs. The mixture was then cooled to RT, placed on ice and anydrous HCl (2 N in EtOH/IPA, 100 mL) was added, and a white precipitate was isolated. The residual solid was diluted with MeOH (200 mL), filtered through a Buchner funnel and washed twice with MeOH (2 × 100 mL) to give tris (N,N-dimethyl-2-aminoethyl)amine hydrochloride as a yellow/white solid (12 g, 70%). Next, tris (N,N-dimethyl-2-aminoethyl)- amine hydrochloride (2.0 g, 6.89 mmol) was added slowly to 50 mL of an ethanolic solution containing NaOEt (1.4g, 20.67 mmol), and stirred at RT for 1 hr. The mixture was filtered through Celite, evaporated in vacuo, CHCl3 was added to the residue, and the solution was filtered to remove more of the inorganic precipitate (NaCl). The evaporation of the solvent on a Schlenk line gave the title compound as a brown liquid. Yield: 65% (7.49 g); 1H NMR (400 MHz, CDCl3, ): 3.28-3.19 (m, 6H, H3), 2.98-2.85 (m, 6H, H2), 2.81 (s, 18H, H1) ppm.
13

C NMR (100 MHz, CDCl3, ): 53.89 (C3), 47.24 (C2), 43.16 (C1)

ppm. (Agrees well with literature NMR values).199

241

5.4 General Procedures for the Synthesis of -CH Bisphosphonic Acids QAC Antimicrobials (-CH-BPQA) 5.4.1 Method 1: Bis Addition of Dialkylphosphites to Aldehydes 5.4.1.1 Sequential Addition
1 6

O
10 9 7 8

2

4 3

N O

O O P O OH
5 9

Diethyl (4-(1,3-dioxoisoindolin-2-yl)-1-hydroxybutyl) phosphonate (51): A 25 mL round bottom flask, equipped with a magnetic stir bar and a condenser was charged with the aldehyde 48 (2.28 g, 10.5 mmol), diethylphosphonate (1.52 g, 11.0 mmol, 1.05 eq.), K2CO3 (0.073 g, 0.53 mmol, 0.05 eq.) and ACN (5 mL). The heterogeneous solution was stirred at 60°C for 15 min at which point TLC showed disappearance of the starting aldehyde (60% EtOAc in hexanes, 10 mL). The reaction was cooled to 0°C, filtered and evaporated. The resulting yellow oil solidified under high vacuum (10 min) and was recrystallized from hot EtOAc (5 mL) after cooling for 20 min at 0°C. Yield 69.1% (2.578 g); TLC (60% EtOAc in hexanes), Rf = 0.2; Mp = 91-94°C; 1H NMR (400 MHz, CDCl3, ): 7.83-7.79 (m, 4H, H8), 7.717.64 (m, 4H, H7), 4.18-4.07 (m, 4H, H6), 3.89 (quintet, J = 4.59 Hz, 1H, H5), 3.77-3.66 (m, 2H, H4), 2.05-1.95 (m, 2H, H3), 1.87-1.68 (m, 2H, H2), 1.29 (t, J = 7.08 Hz, 6H, H1) ppm;
13

C

NMR (100 MHz, CDCl3, ): 168.37 (C10), 133.90 (C9), 132.10 (C7), 123.18 (C8), 68.12 (C5), 62.65 (q2, J C-P = 7.3 Hz, C6), 37.52 (C2), 28.43 (d, 1J C-P = 1.45 Hz, C5), 25.02 (C3), 24.96 (C4),

242

16.46 (d, 3J C-P = 5.20 Hz, C1) ppm; 31P NMR (121.45 MHz, CDCl3, ): 24.64 ppm. ESI-TOF (m/z): [M+] calculated for C16H22NO6P, found, 434.1.
O
11 10 8 9

2

5 3

N O

O O 7 P O O

6

O S O
4

1

Example 14 - 1-(diethoxyphosphoryl)-4-(1,3-dioxoisoindolin-2-yl) butyl methanesulfonate (52): To a flame dried and evacuated 50 mL round bottom flask, equipped with a magnetic stir bar was added sequentially NMe3HCl (0.062g, 0.62 mmol, 0.20 eq.), DCM (2 mL), Et3N (0.65 mL, 4.63 mmol, 1.5 eq.) and 51 (1.097 g, 3.09 mmol) and the solution was cooled to 0°C in an ice bath. To the chilled stirred solution was added, dropwise, mesyl chloride (0.25 mL, 3.70 mmol, 1.2 eq.) in anhydrous DCM (2 mL) and the cloudy yellow mixture was stirred for 20 min at RT at which point TLC showed disappearance of the starting amine (10% MeOH in EtOAc, 10 mL). The reaction was diluted with H2O (1 × 10 mL) and extracted with DCM (2 × 5 mL total), the combined organic layers were dried over MgSO4, filtered and evaporated to give a yellow oil. The crude product (1.409 g) containing traces of DCM and excess mesyl chloride by 1H NMR, was placed under high vacuum at 60°C for 1 hr. Yield 93% (1.201 g); TLC (10% MeOH in EtOAc), Rf = 0.5; 1H NMR (400 MHz, CDCl3, ): 7.85-7.81 (m, 2H, H9), 7.73-7.70 (m, 2H, H8), 4.94-4.88 (m, 1H, H7), 4.20-4.15 (m, 4H, H6), 3.77-3.70 (m, 2H, H5), 3.15 (s, 3H, H4), 1.95-1.82 (m, 4H, H2, H3), 1.41-1.25 (m, 6H, H1) ppm;
13

C NMR (100 MHz, CDCl3, ):

168.26 (C11), 133.98 (C10), 132.08 (C9), 123.22 (C8), 74.79 (C7), 63.31 (q,2J C-P = 7.3 Hz, C6),

243

52.56 (C2) , 39.11 (C4), 27.58 (C3), 24.45 (d, 2J C-P = 11.67 Hz C5), 16.45 (2J C-P = 5.20 Hz, C1) ppm; 31P NMR (121.45 MHz, CDCl3, ): 17.63 ppm. 5.4.1.2 Synthesis of Aldehyde Precursors
Br
7 8 4 5 6 2 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1

HO

N

1

H

Br
13 15 4 12 14 5 3 6 7 8 9 10 10 10 10 10 10 10 10 10 2 1

HO

N

13

C

N-(3-hydroxypropyl)-N,N-dimethyloctadecan-1-ammonium (66):232 This compound was prepared by the Menshutkin reaction using Method 5.2.1: 3(dimethylamino)propan-1-ol (0.515 g, 5 mmol) and 1-bromooctadecane (1.667 g, 5 mmol, 1.0 eq.) were reacted at 100oC neat for 1 hr until the mixture solidified. The mixture was then dissolved in MeOH (40 mL) and hot filtered from charcoal. Volatiles were removed on a rotary evaporator and the crude was recrystallized from MeOH/ACN (1:3, 40 mL) by slow evaporation over a few d. as a brittle crystalline solid. A small sample was used to obtain a crystal structure. Yield: 90% (1.962 g). Mp = 93-95°C; 1H NMR (400 MHz, CDCl3, ): 3.74-3.68 (m, 4H, (H8 + H7 overlap)), 3.43-3.37 (m, 2H, H6), 3.27 (s, 6H, H5), 2.07-1.99 (m, 2H, H4), 1.75-1.67 (m, 2H, H3), 1.21 (brs, 30H, H2), 0.84 (t, J = 7.0 Hz, 3H, H1) ppm;
13

C NMR (100 MHz, CDCl3, ):

64.59 (C15), 62.65 (C14), 58.20 (C13), 51.24 (C12), 31.89 (C11), 29.73-29.60 (C10 overlap), 29.51 (C9), 29.45 (C8), 29.33 (C7), 29.24 (C6), 26.33 (C5), 25.98 (C4), 22.82 (C3), 22.66 (C2),

244

14.09 (C1) ppm. HRMS-DART (m/z): [M+] - Br calculated for C23H50NO, 356.3886; found, 356.3891. (Agrees well with literature NMR values).232
Br HO
9 4 5 6 8 7 2 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1

N

1

H

Br HO
14 4 5 13 16 15 6 3 7 8 9 10 11 11 11 11 11 11 11 11 12 2 1

N

13

C

N-(4-hydroxybutyl)-N,N-dimethyloctadecan-1-ammonium bromide (67): This compound was prepared by the Menshutkin reaction using method 5.2.1, 4(dimethylamino)butan-1-ol (0.586 g, 9.8 mmol) and 1-bromooctadecane (1.667 g, 9.8 mmol, 1.0 eq.) were reacted at 110oC neat for 20 min until the mixture solidified The mixture was then dissolved in EtOH (20 mL) and hot filtered from charcoal. Volatiles were removed on a rotary evaporator and the crude was recrystallized from acetone (20 mL) by slow evaporation after 20 min as fine white crystalline needles. Yield: 63% (2.8 g). Mp = 94°C; 1H NMR (400 MHz, MeOD, ): 3.64 (t, J = 6.13 Hz, 2H, H9), 3.39-3.31 (m, 4H, (H7 + H8 overlap)), 3.11 (s, 6H, H6), 1.89-1.80 (m, 4H, (H5 + H4 overlap)), 1.64-1.57 (m, 2H, H3), 1.30 (brs, 30H, H2), 0.91 (t, J = 7.0 Hz, 3H, H1) ppm;
13

C NMR (100 MHz, MeOD, ): 63.99 (C16), 63.70 (C15), 60.43

(C14), 49.86 (C13), 31.69 (C12), 29.42-29.35 (C11 overlap), 29.28 (C10), 29.20 (C9), 29.10 (C8), 28.87 (C7), 28.68 (C6), 26.03 (C5), 22.36 (C4), 22.18 (C3),18.98 (C2), 13.10 (C1) ppm.

245

5.4.2 Method 2: Michael Addition to Diethylvinylphosphonate
1 1 5 2 7 4 6 3

O

O

Br

2-(3-bromopropoxy)tetrahydro-2H-pyran (9):233 To a stirred solution inside a 125 mL round bottom flask containing 3-bromo-1-propanol (6.95 g, 50 mmol, 1 eq.) in DCM (25 mL) was added 3,4-dihydropyran (5.93 mL, 65 mmol, 1.3 eq.). The mixture was stirred overnight at RT at which point TLC showed disappearance of 3-bromo-1propanol (20% EtOAc in hexanes, 10 mL, KMnO4). The reaction was evaporated and the crude material was purified by flash chromatography on silica gel (20 g silica, 1.5 cm i.d) eluting with 10% EtOAc: hexanes (100 mL) to obtain the title compound as a clear oil. Yield: 86.4% (9.637 g); TLC (20% EtOAc in hexanes), Rf = 0.85; 1H NMR (400 MHz, CDCl3, ): 4.59 (t, 1H, J = 3.52 Hz, H7), 3.90-3.81 (m, 2H, H6), 3.55-3.47 (m, 4H, (H4, H5)), 2.16-2.08 (m, 2H, H3), 1.901.64 (m, 2H, H2), 1.57-1.50 (m, 4H, H1) ppm;
13

C NMR (100 MHz, CDCl3, ): 98.90 (C7),

64.88 (C6), 62.26 (C5), 32.90 (C3), 30.59 (d, 2J = 6.04 Hz, C4), 25.41 (C2), 19.48 (C1) ppm. (Agrees well with literature NMR values).233
O P O O O P O O

2 1

3

4

Tetraethyl ethene-1,1-diylbis(phosphonate) (68):234 A 50 mL round bottom flask was charged with paraformaldehyde (6.3 g, 200 mmol, 4.0 eq.) and HNEt2 (5.2 mL, 50 mmol, 1 eq.) in MeOH (125 mL) and the mixture was stirred under reflux until a clear solution was obtained (~ 5 min). Tetraethylmethylene bisphosphonate was added via
246

syringe (12.4 mL, 50 mmol, 1.0 eq.) and the solution was refluxed overnight (24 hrs). The clear solution was concentrated in vacuo and then re-evaporated from TOL (2 × 10 mL) completely removing residual MeOH to give the intermediate methyl ether as a clear oil. The residue was dissolved in TOL (100 mL), treated with p-toluenesulphonic acid (38 mg, 0.02 mmol), and refluxed through a Dean-Stark trap overnight. The orange solution was concentrated in vacuo, dissolved in CHCL3 (50 mL), washed with H2O (2 × 10 mL), dried over MgSO4, and concentrated in vacuo. A portion of the orange oil (6 g) was further distilled under high vacuum. Yield: 90% (5.40 g); TLC (EtOAc), Rf = 0.2; 1H NMR (400 MHz, CDCl3, ): 7.02-6.86 (m, H3, 2H), 4.10-4.05 (m, H2, 8H), 1.34-1.21 (m, H1, 12H) ppm;
13

C NMR (100 MHz, CDCl3, ):

149.04 (m, C4), 133.77-129.71 (m, C3), 62.54 (t, 2JC-P = 2.88 Hz, C2), 16.17 (t, 3JC-P = 3.15 Hz, C1) ppm; values).234 5.4.3 Method 3: C-P Bond Formation
1 8

31

P NMR (121.45 MHz, CDCl3, ): 21.0 ppm. (Agrees well with literature NMR

O O P O O 5 P 4 O O

2 3 7 9 2

O

O

6

Tetraisopropyl (3-((tetrahydro-2H-pyran-2-yl)oxy)propane-1,1-diyl)bis(phosphonate) (77 ):235 To a solution of freshly prepared LDA (n-BuLi (1.6 M in hexane, 4.93 mL, 7.88 mmol) and HN(iPr2) (1.12 mL, 7.97 mmol) in anhydrous THF (10 mL) -78 °C) was added 18 (1.10 g, 3.94 mmol) in THF (5 mL). After 0.5 h, diethyl chlorophosphate (0.84 mL, 4.73 mmol) was added
247

dropwise via syringe, and the mixture stirred for 1 hr at -78 °C and 30 min at RT. The reaction was quenched with NH4Clsat (10 mL) and extracted with EtOAc (1 × 10 mL). The organic layer separated, dried over MgSO4, evaporated in vacuo and the crude product (in a 0.8:0.2 ratio with excess unreacted diethyl chlorophosphate) was loaded onto silica (10 g, EtOAc, 15 mL) and purified by column chromatography on silica gel (50 g) pre-eluting with EtOAc (1 × 50 mL) to remove unextracted diethyl chlorophosphate. The column was eluted with MeOH:EtOAc (20%, 60 mL) to afford the title compound as a light yellow oil. Yield: 74% (0.741 g); TLC (10% MeOH:EtOAc), Rf = 0.30; 1H NMR (400 MHz, CDCl3, ): 4.59-4.55 (m, 1H, H9), 4.22-4.06 (m, 2H, H8), 3.90-3.77 (m, 2H, H7), 3.62-3.42 (m, 2H, H6), 2.66-2.48 (m, 1H, H5), 2.26-2.09 (m, 2H, H4), 1.82-1.61 (m, 2H, H3), 1.58-1.42 (m, 4H, H2), 1.33 (t, J = 7.03 Hz, 12H, H1); 13C NMR (100 MHz, CDCl3, ): 98.57 (C9), 65.13 (C7), 62.63-63.39 (m, C8), 62.19 (C6), 32.81 (t,
1

JC-P = 134.7 Hz, (C6)), 30.59 (C3), 25.40 (C4), 19.46 (C2), 16.34 (t, 3JC-P = 2.81 Hz, (C2)) ppm; P NMR (121.45 MHz, CDCl3, ): 23.77 ppm. (Agrees well with literature NMR values).235

31

5.4.4 Method 4: Alkylation of Methylenebisphosphonate
4 1

O O P O 2
3

5

O O P O

Tetraethyl cyclopentane-1,1-diylbis(phosphonate) (97):236 To a stirred solution (250 mL Schlenk flask, under argon) of tetraethyl methylidene bisphosphonate (7.45 mL, 30 mmol, 1.0 eq.) in DMSO (60 mL) at 0°C was added excess solid NaH (60% dispersion in mineral oil, 2.4 g, 60 mmol, 2.0 eq.) portionwise. The reaction was brought to RT and stirred (30 min), washed with more DMSO (60 mL) and evacuated and
248

backfilled with Ar (2 cycles).When hydrogen gas evolution ceased and the mixture cleared (~ 40 min later), 1,4-dibromobutane (5.37 mL, 45.0 mmol, 1.5 eq.) was added and the resulting yellow orange mixture was stirred overnight at RT. The solution was then cooled to RT, neutralized with NH4+Cl-sat:H2O (1:3, 400 mL) and extracted with EtOAc (1 × 400 mL, 1 × 300 mL). The organic phases were washed with brine (1 × 50 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude product (only one peak by 31P NMR at 28.50 ppm) was loaded onto silica (40 g, 30 mL EtOAc) and purified by column chromatography (100 g) pre-eluting with EtOAc (2 × 60 mL) to remove any unextracted DMSO. The column was eluted with 10% MeOH/acetone (200 mL) to afford the title compound as a light yellow oil. Yield: 78% (10.0 g); TLC (20% MeOH in acetone), Rf = 0.60; 1H NMR (400 MHz, CDCl3, ): 4.18 (t, J = 6.61 Hz, 8H, H4), 2.16 (t, J = 18.17 Hz, 4H, H3), 1.80-1.70 (m, 4H, H2), 1.34 (t, 12H, J = 6.97 Hz, H1) ppm;
13

C NMR (100 MHz, CDCl3, ): 63.00 (t, 2J = 2.81 Hz, (C5, C4 overlap)), 30.96 (t, 3J =
31

4.14 Hz, C3), 26.48 (t, 2J = 4.28 Hz, C2), 15.37 (t, 3J = 2.67 Hz, C1) ppm; MHz, CDCl3, ): 28.40. (Agrees well with literature NMR values).236
10 1

P NMR (121.45

O O P O O 6 P 4 O O

7 8

O
3

9

O

5 2

2

Tetraisopropyl (95):237

(4-((tetrahydro-2H-pyran-2-yl)oxy)butane-1,1-diyl)

bis

(phosphonate)

To a stirred suspension (250 mL Schlenk flask, under Ar) of NaH (60% dispersion in mineral oil, 1.76 g, 60 mmol, 2.0 eq.) in anhydrous THF (100 mL, pre-dried ON over MS) was added
249

dropwise (canula) tetraisopropyl methylidene bisphosphonate (14 mL, 44 mmol, 1.0 eq.) in THF (20 mL) at 0°C. The reaction was brought to RT and stirred (30 min), and evacuated and backfilled with Ar (2 cycles). When hydrogen gas evolution ceased and the mixture cleared, 2(3-bromopropoxy)tetrahydro-2H-pyran (5.976 g, 43 mmol, 0.98 eq.) in THF (20 mL) was added dropwise by canula and the resulting clear mixture was refluxed (72 hrs). The solution was then cooled to RT, neutralized with NH4+Cl-sat:H2O (1:1, 100 mL) and extracted with EtOAc (1×150 mL). The organic phases were washed with brine (1 × 50 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude product (in a 0.62:0.38 ratio with unreacted tetraisopropyl methylidenebisphosphonate) was loaded onto silica (40 g, 10% acetone/hexanes, 30 mL) and purified by column chromatography on silica gel (100 g) pre-eluting with 10% acetone/hexanes (2 × 100 mL) to remove unextracted (3-bromopropoxy)tetrahydro-2H-pyran. The column was eluted with acetone (200 mL) to afford the title compound in a 0.62:0.38 ratio with unreacted tetraisopropyl methylidenebisphosphonate by (31P NMR) as a light yellow oil (14.78 g). Yield 49.5% (9.163 g); TLC (acetone), Rf = 0.50; 1H NMR (400 MHz, CDCl3, ): 4.85-4.65 (m, 4H, H10), 4.59-4.50 (m, 1H, H9), 3.86-3.60 (m, 2H, H8), 3.50-3.20 (m, 2H, H7), 2.27-2.06 (m, 1H, H6), 2.08-1.71 (m, 4H, (H5, H4)), 1.70-1.40 (m, 6H, (H3 + H2)), 1.30 (s, 24H, H1); 13C NMR (100 MHz, CDCl3, ): 98.51 (C9), 70.96 (C10), 66.57 (C8), 62.09 (C5), 38.21 (C6), 30.62 (C7), 29.01 (C3), 25.45 (C4), 23.85 (C1), 19.22 (C2) ppm; 31P NMR (121.45 MHz, CDCl3, ): 21.83 ppm. (Agrees well with literature NMR values).237

7 1

O O P O O 3 P 2 O O

4 6

5

OH

250

Tetraisopropyl (3-hydroxbutane-1,1-diyl)bis(phosphonate) (98):237,238 To a stirred solution of the crude product 95 (10 g, 14.4 mmol) in MeOH (50 mL) was added Amberlite IR-120 (0.5 g). The reaction mixture was heated to 50°C ON, filtered (Celite), and concentrated in vacuo. The crude product containing the unreated tetraispropyl

methylenebisphosphonate (38% by weight, 3.8g, 31P NMR,  = 17.36 ppm) was used directly in the next reaction without purification. Yield: 100% (5.791 g); TLC (15% MeOH/EtOAc), Rf = 0.35; 1H NMR (400 MHz, CDCl3, ): 4.80-4.65 (m, 4H, H7), 3.60 (m, 2H, H6), 3.11 (s, 1H, H5), 2.25-1.70 (m, 5H, (H4 + H3 + H2 overlap)), 1.29 (s, 32H, H1);
13

C NMR (100 MHz,

CDCl3, ): 71.13 (C7), 61.19 (C6), 37.25 (t, 1J = 138.0 Hz, C3), 31.98 (t, 2J = 5.64 Hz, C2), 23.88 (d, 3J = 2.52 Hz, C1), 21.63 (t, 3J = 5.33 Hz, C4) ppm; 31P NMR (121.45 MHz, CDCl3, ): 22.33 ppm. (Agrees well with literature NMR values).237,238

7 1

O O P O O 4 P 2 O O

3 6

O

O S O

5

4,4-bis(diisopropoxyphosphoryl)butyl methanesulfonate (99): To a flame dried and evacuated 125 mL round bottom flask, equipped with a magnetic stir bar was added sequentially NMe3HCl (1.5g, 1.44 mmol, 0.1 eq.), DCM (20 mL), Et3N (17.43 mL, 21.6 mmol, 1.5 eq.) the crude alcohol 98 (5.791 g, 14.4 mmol, 1.0 eq.) and the solution cooled to 0°C (ice bath). To the chilled, stirred solution was added, dropwise, MsCl (1.22 mL, 15.8 mmol, 1.1 eq.) followed by rinsing the addition funnel with anhydrous DCM (5 mL) and the cloudy yellow mixture was stirred for 30 min at RT at which point TLC showed disappearance of the
251

starting alcohol (15% MeOH in EtOAc, 10 mL). The reaction was diluted with H2O (1 × 100 mL) and extracted with DCM (100 mL total), the organic layer was re-washed with brine (1 × 50 mL), dried over MgSO4, filtered and evaporated to give a light yellow oil. The crude product (10.72 g) containing the unreated tetraispropyl methylenebisphosphonate (38% by weight, 3.80 g,
31

P NMR,  = 17.36 ppm) was used directly in the next reaction without purification. Yield

100 % (6.919 g); TLC (15% MeOH/EtOAc), Rf = 0.45; 1H NMR (400 MHz, CDCl3, ): 4.834.60 (m, 4H, H7), 4.24-4.17 (m, 2H, H6), 2.98 (m, 3H, H5), 2.40-2.25 (m, 1H, H4), 2.11-1.86 (m, 4H, (H3 + H2)), 1.46-1.14 (m, 24H, H1) ppm; 13C NMR (100 MHz, CDCl3, ): 71.09 (C7), 69.50 (C6), 37.42 (d, 3J = 2.81 Hz, C4), 36.46 (C5), 28.36 (C3), 24.06 (C1), 22.29 (C2) ppm; 31P NMR (121.45 MHz, CDCl3, ): 20.95 ppm.
6 1

O O P O O 3 P 2 O O

4 5

Cl

Tetraisopropyl (4-chlorobutane-1,1-diyl)bis(phosphonate) (91): To a stirred solution (250 mL Schlenk flask, under argon) of tetraisopropyl

methylidenebisphosphonate (9.0 mL, 25 mmol, 1 eq.) in DMSO (40 mL) at 0°C was added solid NaH (60% dispersion in mineral oil, 1.05 g, 26.4 mmol, 1.05 eq.) portionwise. The reaction was brought to RT and then stirred at 60oC (10 min), washed with additional DMSO (50 mL), evacuated and backfilled with Ar (2 cycles).When hydrogen gas evolution ceased and the mixture cleared (30 min later), 3-bromo-1-chloropropane (2.47 mL, 25.0 mmol, 1 eq.) was added and the resulting yellow mixture was stirred overnight at RT. The solution was then cooled to RT, neutralized with NH4+Cl- (300 mL) and extracted with ethyl acetate (300 mL). The organic
252

phase was washed with brine (1 × 300 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude product (~7.712 g, after high vac, 3 hrs) was loaded onto silica (40 g, 30 mL hexanes) and purified by column chromatography on silica gel (100 g) pre-eluting with hexanes (200 mL), followed by 30% EtOAc/hexanes (100 mL) to remove any unextracted DMSO. The column was eluted with 50% acetone/hexanes (50 mL) to afford the title compound, a colourless oil (1.0 g) while the rest of the crude product was recovered by eluting with acetone (200 mL) as a yellow oil (5.305 g) that was comprised of a mixture of the title compound with unreacted tetraisopropyl methylidenebisphosphonate in a 0.38:0.62 ratio by 31P NMR spectroscopy. Yield: 25.1% (3.02 g); TLC (70% acetone in hexanes), Rf = 0.45; 1H NMR (400 MHz, CDCl3, ): 4.564.40 (m, 4H,H6), 3.10-3.00 (m, 2H, H5), 2.38-2.20 (m, 4H, (H4 + H3 overlap)), 1.99-1.85 (m, 2H, H2), 1.11 (s, 24H, H1) ppm; 13C NMR (100 MHz, CDCl3, ): 78.07 (C5), 71.72 (t, 2J = 3.46 Hz, C6), 24.56 (C3), 22.98 (d, 3J = 22.38 Hz,C1), 16.77 (C4) ppm; CDCl3, ): 24.34 ppm.
6 1

31

P NMR (121.45 MHz,

O O P O O 3 P 2 O O

4 5

Br

Tetraisopropyl (4-bromobutane-1,1-diyl)bis(phosphonate) (87): To a stirred solution of the crude product 99 (3.459 g, 7.2 mmol) in ACN (25 mL) was added LiBr (1.25 g, 14.4 mmol, 2.0 eq.) and the reaction was refluxed (1.5 hrs). The solution was then cooled to RT, quenched with H2O (50 mL), extracted with ethyl acetate (100 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude product containing the unreated
253

tetraispropyl methylenebisphosphonate (38% by weight, 1.9 g, 31P NMR (CDCl3) = 17.36 ppm) was used directly in the next reaction without purification and recovered as an orange oil.Yield: 100 % (3.35 g); TLC (15% MeOH/EtOAc), Rf = 0.45; 1H NMR (400 MHz, CDCl3, ): 4.82-4.62 (m, 4H,H6), 3.41-3.28 (m, 2H, H5), 2.31 (t, J = Hz, 3H, H5), 2.19-1.86 (m, 4H, (H3 + H2 overlap)), 1.29 (s, 24H, H1) ppm; 31P NMR (121.45 MHz, CDCl3, ): 21.36 ppm.
7 1

O O P O O 3 P 2 O O

4 6

N
5

Tetraisopropyl (4-(dimethylamino)butane-1,1-diyl)bis(phosphonate) (96): To a 20 mL glass screw cap vial equipped with a magnetic stir bar was added the crude product 87 (3.459 g, 7.2 mmol), NHMe2 (5.6 M in EtOH, 3.8 mL, excess) and stirred at reflux sealed for 1.5 hrs, at which point the TLC plate showed disappearance of the starting material (1% NH4+OH- in acetone, 10 mL, Rf = 0.95). The reaction was cooled to RT, evaporated, filtered (Celite), washed with EtOAc and loaded onto silica (40 g, 30 mL EtOAc). The title compound was purified by column chromatography on silica gel (100 g) pre-eluting with 10% MeOH/EtOAc (50 mL), and eluted with (10% NH4OH/ACN, 100 mL). The eluted fraction was separated from H2O by coevaporation from ACN, stirring in CHCl3 (10 mL) for 5 min, filtering (Celite) and drying under high vaccum (60 min) and recovered as a yellow oil. Yield: 64% (2.0 g); TLC (1% NH4+OH- in Acetone, 10 mL) or (20% MeOH (6% NaBr): ACN, Rf = 0.40; 1H NMR (400 MHz, CDCl3, ): 4.82-4.65 (m, 4H,H7), 2.29-2.07 (m, 2H, H6), 2.17 (s, 6H, H5), 1.91-1.62 (m, 6H, (H4 + H3 + H2 overlap)), 1.29 (s, 24H, H1) ppm;
254
13

C NMR (100 MHz,

CDCl3, ): 70.87 (q, 2J = Hz, C7), 59.50 (C6), 45.34 (C5), 38.36 (d, 1J = Hz,C3), 27.06 (t, 2J = Hz,C2), 24.19 (C4), 23.90 (t, 3J = Hz,C1) ppm 31P NMR (121.45 MHz, CDCl3, ): 24.34 ppm.
10 3

O O P O O 4 P 3 O O

Br
5 8

N
7 9

6 2

2 2

2 2

2 2

2 2

2 2

2 2

2 2

1

1

H

18 5

O O P O O 14 P 1 O O

Br
3 16

N
17 15

6 7

8 9

10 11

12 12

12 12

12 12

12 12

13 4

2

13

C

N-(4,4-bis(diisopropoxyphosphoryl)butyl)-N,N-dimethyloctadecan-1-ammonium (93): This compound was prepared by the Menshutkin reaction using Method 5.2.1: 87 (2.28 g, 5.57 mmol) and DMOA (1.65 g, 5.57 mmol, 1.0 eq.) in ACN (10 mL) were refluxed for 4 hrs. The mixture was then cooled to RT, poured into 20 mL of Et2O, and placed into a freezer (-20oC) ON. The title compound did not solidify so the crude product was loaded onto silica (40 g, 30 mL acetone) and purified by column chromatography on silica gel (100 g) pre-eluting with acetone (100 mL), and eluted with 20% (6% NaBr in MeOH): ACN (150 mL) to give the title compound as a yellow oil. Yield: 50% (2.12 g); 1H NMR (400 MHz, CDCl3, ): 3.82-3.71 (m, 4H, (H8 + H7 overlap)), 3.56-3.49 (m, 2H, H6), 3.40 (s, 6H, H5), 2.36-2.28 (m, 2H, H4), 1.801.69 (m, 2H, H3), 1.23 (brs, 30H, H2), 0.85 (t, J = 7.0 Hz, 3H, H1) ppm; 13C NMR (100 MHz, CDCl3, ): 65.88 (C15), 61.55 (C14), 52.14 (C13), 41.14 (C12), 31.90 (C11), 29.71-29.62 (C10

255

overlap), 29.46 (C9), 29.34 (C8), 29.18 (C7), 26.15 (C6), 26.14 (C5), 22.75 (C4), 22.66 (C3), 22.66 (C2), 14.10 (C1) ppm.
Br
5 8 4 6 7 2 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1

Br

N

1

H

Br
12 15 4 13 14 5 3 6 7 8 9 10 10 10 10 10 10 10 10 11 2 1

Br

N

13

C

N-(4-hydroxybutyl)-N,N-dimethyloctadecan-1-ammonium bromide (83):239 This compound was prepared by the Menshutkin reaction using Method 5.2.1: 1,3dibromopropane (4.079 mL, 44 mmol, 4 eq.) and DMOA (2.9 g, 9.8 mmol, 1.0 eq.) in ACN:EtOH (6:1, 70 mL) were refluxed for 3 hrs. The mixture was then cooled to RT, poured into 30 mL of Et2O, and placed into a freezer (-20oC) for 10 min to precipitate the title compound as a white solid. Yield: 50% (2.95 g). Mp = 93-95°C; 1H NMR (400 MHz, CDCl3, ): 3.84-3.77 (m, 4H, H8), 3.53-3.44 (m, 2H, H7), 3.36 (s, 6H, H6), 2.33-2.19 (m, 4H, (H5 + H4 overlap)), 1.80-1.71 (m, 2H, H3), 1.23 (brs, 30H, H2), 0.86 (t, J = 7.0 Hz, 3H, H1) ppm;
13

C

NMR (100 MHz, CDCl3, ): 66.47 (C15), 60.90 (C14), 51.29 (C13), 34.54 (C12), 31.92 (C11), 29.95-29.62 (C10 overlap), 29.55 (C9), 29.48 (C8), 29.36 (C7), 29.29 (C6), 26.32 (C5), 22.95 (C4), 22.68 (C3), 20.88 (C2), 14.12 (C1) ppm. (Agrees well with literature NMR values).239

256

I
7 8 4 5 6 2 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1

Cl

N

1

H

I
12 15 4 13 14 5 3 6 7 8 9 10 10 10 10 10 10 10 10 11 2 1

Cl

N

13

C

N-(3-chloropropyl)-N,N-dimethyloctadecan-1-ammonium iodide (102):240 This compound was prepared by the Menshutkin reaction using Method 5.2.1: 3-chloro-1-iodo propane (2.019 g, 9.8 mmol) and DMOA (2.9 g, 9.8 mmol, 1.0 eq.) in ACN (10 mL) were refluxed for 1.5 hrs. The mixture was then cooled to RT, poured into 20 mL of Et2O, and placed into a freezer (-20oC) for 10 min to precipitate the title compound as a white solid. Yield: 69% (3.1 g). Mp = 91°C; 1H NMR (400 MHz, CDCl3, ): 3.82-3.71 (m, 4H, (H8 + H7 overlap)), 3.56-3.49 (m, 2H, H6), 3.40 (s, 6H, H5), 2.36-2.28 (m, 2H, H4), 1.80-1.69 (m, 2H, H3), 1.23 (brs, 30H, H2), 0.85 (t, J = 7.0 Hz, 3H, H1) ppm; 13C NMR (100 MHz, CDCl3, ): 65.88 (C15), 61.55 (C14), 52.14 (C13), 41.14 (C12), 31.90 (C11), 29.71-29.62 (C10 overlap), 29.46 (C9), 29.34 (C8), 29.18 (C7), 26.15 (C6), 26.14 (C5), 22.75 (C4), 22.66 (C3), 22.66 (C2), 14.10 (C1) ppm. (Agrees well with literature NMR values).240 5.5.0 General Procedure for the 3-Component Reaction
O P O O
4 1

O N
2 3

P O O

Tetraethyl dimethylaminomethylenediphosphonate (105):202
257

To a chilled solution of DMF (3.87 mL, 50 mmol) in DCM (75 mL) was added dropwise with stirring a solution of oxalyl chloride (25 mL, 2M in DCM, 50 mmol). Following addition, the mixture was allowed to warm to RT and stirred for 1 hr. P(OEt)3 (18.77 mL, 109.5 mmol, 2.19 eq.) was then added dropwise with stirring. After 1 hr the mixture was concentrated under reduced pressure to a yellow oil. Yield: 75.5% (12.42 g). 1H NMR (400 MHz, CDCl3, ): 4.214.14 (m, 8H, H4), 3.22 (dt, 1H, 1J = 24.98 Hz, 2J = 24.98 Hz, H3), 2.58 (s, 6H, H2), 3.18 (dt, 12H, 1J = 7.07 Hz, 2J = 7.06 Hz, 1H) ppm; 13C NMR (100 MHz, CDCl3, ): 62.70 (t,1J C-P = 3.05 Hz, C3), 62.40 (t,2J C-P = 3.61 Hz, C4), 44.11 (t, 3J C-P = 4.71 Hz, C2), 16.39 (q, 3J C-P = 3.01 Hz, C1) ppm; values).202 5.6.0 General Procedure for the Bis Kabachnik Fields Reaction
31

P NMR (121.45 MHz, CDCl3, ): 19.15 ppm. (Agrees well with literature NMR

1

O
6

O
4

P O

N
3

2 5

Cl

O P O O

Tetraethyl (((3-chloropropyl)azanediyl)bis(methylene))bis(phosphonate) (114): To a 20 mL glass screw cap vial, equipped with a magnetic stir bar was added diethylphosphite (2.86 g, 20.74 mmol, 2.0 eq.). The vial was placed on ice to cool. In a separate beaker, 3aminopropyl-1-chloride hydrochloride (2.0 g, 11.4 mmol) was treated with NaOH (~12 N, 2.0 g in 5 mL) and stirred at 0°C until a yellow oil appeared (~ 5 min). The mixture was then extracted without solvent, adding the upper yellow layer of the free base 3-aminopropyl-1258

chloride to the vial containing diethylphosphite cooled to 0-5 °C (ice bath). To the chilled solution was added formalin, dropwise, via syringe (37%, 2.15 mL, 25.79 mmol, 2.5 eq.) over 10 min maintaining the reaction temp under 10°C. The mixture was then warmed, with stirring, to RT for 10 min, then heated to 100°C for 30 min. Excess formaldehyde and H2O were removed via rotary evaporator and the crude material purified by DCVC (20 g silica, 3.5 cm × 4.5 cm) eluting with 80 mL EtOAc and collecting 50 mL (20% MeOH/EtOAc). Yield: 50% (2.03 g); TLC (10% MeOH in EtOAc), Rf = 0.70; 1H NMR (400 MHz, CDCl3, ): 4.18-4.09 (m, 8H, H6), 3.62 (t, 2H, J = 6.6 Hz, H5), 3.17 (d, 4H, J = 8.6 Hz, H4), 2.97 (t, 2H, J = 6.6 Hz, H3), 2.00 (m, 2H, H2), 1.33 (t, 12H, J = 7.1 Hz, H1); 13C NMR (100 MHz, CDCl3, ): 61.84 (m, C6), 53.93 (t,
3

JC-P = 7.44 Hz, (C5)), 50.18 (dd, 1JC-P = 6.08 Hz, 1JC-P = 6.00 Hz, (C4)), 42.47 (C3), 30.77 (C2),

16.45 (t, 3JC-P = 2.94 Hz, (C1)); 31P NMR (121.45 MHz, CDCl3, ): 24.40 ppm.

1

O
6

O
4

P O

N
3

2 5

Br

O P O O

Tetraethyl (((3-bromopropyl)azanediyl)bis(methylene))bis(phosphonate) (116): To a 20 mL glass screw cap vial, equipped with a magnetic stir bar was added diethylphosphite (2.77 mL, 21.56 mmol, 2.2 eq.) and the vial was placed on ice meanwhile 3-aminopropyl-1bromide hydrobromide (~2.5 g, ~11 mmol) was treated with KOH (6 N, 6 g in 20 mL) and stirred at 0°C until a yellow oil appeared (~5 min). The mixture was then extracted without solvent, collecting the upper yellow layer of the free base aminopropyl-1-bromide (incompletely
259

dry by NMR, 50% H2O present). The amine (1.350 g, 9.78 mmol) was added to the vial containing diethylphosphite and cooled at 0-5 °C (ice bath). To the chilled, stirred solution was added formalin, dropwise (37%, 2.12 mL, 25.43 mmol, 2.6 eq.) over 10 min while maintaining the reaction temp under 10°C, then warming the mixture to RT for 30 min, and finally to 100 °C for 1hr. The reaction was diluted with 0.2N NaOH (~ 300 mg in 40 mL) and extracted with CHCl3 (1 × 30 mL, 1 × 10 mL), the organic layer was separated, washed with brine (1 × 20 mL) and dried over anhydrous MgSO4 filtered and concentrated to afford a yellow oil. The title compound was in poor yield, however analysis by 1H NMR spectroscopy revealed >98% purity and required no further purification. Yield: 20.9 % (0.76 g); TLC (5% MeOH in EtOAc), Rf = 0.48; 1H NMR (400 MHz, CDCl3, ): 4.17-4.07 (m, 8H, H6), 3.47 (t, 2H, J = 6.7 Hz, H5), 3.14 (d, 4H, J = 8.5 Hz, H4), 2.93 (t, 2H, J = 6.6 Hz, H3), 2.00 (q, 2H, J = 6.58 Hz, H2), 1.31 (t, 12H, J = 7.1 Hz, H1);
13

C NMR (100 MHz, CDCl3, ): 61.9 (t, 2JC-P = 3.36 Hz, C6), 55.08 ( C3),
31

49.43 (C4), 31.09 (C5), 30.96 (C2), 16.49 (t, 3JC-P = 2.94 Hz, C1); CDCl3, ): 24.60 ppm.

P NMR (121.45 MHz,

1

O
6

O
4

P O

N
3

2 5

OH

O P O O

Tetraethyl (((3-hydroxypropyl)azanediyl)bis(methylene))bis(phosphonate) (117):241-243 To a 20 mL glass screw cap vial, equipped with a magnetic stir bar was added diethylphosphite (2.86 g, 20.74 mmol, 2.0 eq.) and 3-amino-1-propanol (0.768 g, 10.24 mmol,) and the mixture cooled to 0-5 °C (ice bath). To the chilled solution was added formalin, dropwise, via syringe
260

(37%, 2.15 mL, 25.79 mmol, 2.5 eq.) over 10 min maintaining the reaction temp under 10°C. The mixture was warmed, with stirring, to RT for 30 min, then heated to 100°C for 60 min. Excess formaldehyde and H2O were removed via rotary evaporator and the crude material purified by DCVC (20 g silica, 3.5 cm × 4.5 cm) eluting with 100 mL EtOAc (20% MeOH/EtOAc) to give a light yellow oil after evaporation of solvent. Yield: 50% (2.03 g); TLC (10% MeOH in EtOAc), Rf = 0.50; 1H NMR (400 MHz, CDCl3, ): 4.18-4.09 (m, 8H, H6), 3.62 (t, 2H, J = 6.6 Hz, H5), 3.17 (d, 4H, J = 8.6 Hz, H4), 2.97 (t, 2H, J = 6.6 Hz, H3), 1.61 (m, 2H, H2), 1.32 (t, 12H, J = 7.1 Hz, H1) ppm; 13C NMR (100 MHz, CDCl3, ): 62.06 (t, 2J C-P = 3.61 Hz, C6), 59.04 (C5), 53.44 (t, 3J C-P = 7.46 Hz, C3), 50.66 (dd, 1J C-P = 9.14 Hz, C4), 29.78 (C2), 16.43 (t, 3J C-P = 2.93 Hz, C1) ppm; 31P NMR (121.45 MHz, CDCl3, ): 25.0 ppm. (Agrees well with literature NMR values).241-243
1 6

5

O O P O N 3
2

7

O

O P O O

O S O 4

3-(bis((diethoxyphosphoryl)methyl)amino)propyl methanesulfonate (118): To a flame dried and evacuated 125 mL round bottom flask, equipped with a magnetic stir bar was added sequentially NMe3HCl (1.50 g, 5 mmol, 0.1 eq.), DCM (50 mL), Et3N (17.43 mL, 75 mmol, 1.5 eq.), 117 (18.76 g, 50 mmol, 1.0 eq.) and the solution cooled to 0°C in an ice bath. To the chilled, stirred solution was added, dropwise, mesyl chloride (4.5 mL, 58.1 mmol, 1.16 eq.) followed by rinsing the addition funnel with anhydrous DCM (15 mL) and the cloudy yellow
261

mixture was stirred for 30 min at RT at which point TLC showed disappearance of the starting amine (5% MeOH in EtOAc, 10 mL). The reaction was diluted with H2O (1 × 75 mL) and extracted with DCM (100 mL total), the organic layer was re-washed with H2O (2 × 75 mL), dried over MgSO4, filtered and evaporated to give a light orange oil. The crude material was used without further purification. Yield: 74% (13.39 g); TLC (30% MeOH in EtOAc), Rf = 0.45;
1

H NMR (400 MHz, CDCl3, ): 4.33 (t, 12H, J = 6.44 Hz, 2H, H7), 4.16-4.06 (m, 8H, H6), 3.12

(d, 4H, J = 8.57 Hz, H5), 3.01 (s, 3H, H4), 2.97 (t, 2H, J = 6.57 Hz, H3), 1.94-1.85 (m, 2H, H2), 1.31 (t, 12H, J = 7.05 Hz, H1);
13

C NMR (100 MHz, CDCl3, ): 67.90 (C7), 61.84 (t, 2J C-P =

3.50 Hz, C6), 52.50 (t, 3J C-P = 7.61 Hz, C3) 52.54,49.30 (dd, 1J C-P = 6.57 Hz, C5), 37.07 (C4), 27.21 (C2), 16.39 (t, 3J C-P = 2.81 Hz, C1) ppm; 31P NMR (121.45 MHz, CDCl3, ): 24.50 ppm.
1 6

O
5

O P
4

O
2 7

N O P O O

O

O S O
9 8 3

3-(bis((diethoxyphosphoryl)methyl)amino)propyl 4-methylbenzenesulfonate (119): To a flame dried and evacuated 25 mL round bottom flask, equipped with a magnetic stir bar was added sequentially NMe3HCl (0.045g, 0.24 mmol, 0.24 eq.), DCM (1 mL), Et3N (0.58 mL, 2.5 mmol, 2.5 eq.), 117 (0.375g, 1 mmol) and the solution cooled to 0°C in an ice bath. To the chilled, stirred solution was added, dropwise, TsCl (0.286 mg, 1.5 mmol, 1.5 eq.) in anhydrous DCM (2 mL) and the cloudy yellow mixture was stirred for 1 hr at RT at which point TLC showed disappearance of the starting amine (5% MeOH in EtOAc, 10 mL). The reaction was diluted with H2O (1 × 15 mL) and extracted with DCM (10 mL total), the aqueous layer was re262

extracted with EtOAC (15 mL) and the combined organic layers were dried over MgSO4, filtered and evaporated to give a yellow oil. The crude material was purified by flash chromatography on silica gel (20 g silica, 1.5 cm i.d) with gradient elution: 100% EtOAc (35 mL) then 5% MeOH:EtOAc (90 mL) to obtain the title compound as a yellow oil. Yield: 56.7% (0.300 g); TLC (5% MeOH in EtOAc), Rf = 0.42; 1H NMR (400 MHz, CDCl3, ): 7.76 (d, 2H, J = 8.24 Hz, H9), 7.32 (d, 2H, J = 8.04 Hz, H8), 4.13-4.05 (m, 10H, (H7, H6)), 3.08 (d, 4H, J = 8.40 Hz, H5), 2.83 (t, 2H, J = 6.70 Hz, H4), 2.42 (s, 3H, H3), 1.81 (t, 2H, J = 6.65 Hz, H2), 1.30 (t, 12H, J = 7.08 Hz, H1) ; 13C NMR (100 MHz, CDCl3, ): 44.67 (C11), 133.19 (C10), 129.81 (C8), 127.83 (C9), 68.50 (C7), 61.86 (t, 2J C-P = 3.19 Hz, C6), 52.67 (dd, 1J C-P = 6.02 Hz, C5), 52.67 (C4), 27.22 (C2), 21.57 (C3), 16.46 (t, 3J C-P = 2.78 Hz, C1) ppm; 31P NMR (121.45 MHz, CDCl3, ): 24.56 ppm.

1

O
7

O
6 3 2 5 4

P O

N

N

O P O O

Tetraethyl (((3-(dimethylamino)propyl)azanediyl)bis(methylene)) bis(phosphonate) (113): To a 20 mL glass screw cap vial equipped with a magnetic stir bar containing the bromo amino bisphosphonate (0.954 g, 1.8 mmol) was added NHMe2 (5.6 M in EtOH, 2.5 mL, excess) followed by H2O (0.5 mL) and the clear mixture was stirred at reflux sealed for 1.5 hr, at which point TLC showed disappearance of the starting material (1% NH4+OH- in Acetone, 10 mL, Rf = 0.95). The cooled yellow reaction diluted with H2O (1 × 20 mL, pH was 11) and extracted with CHCl3 (2 × 30 mL), dried over MgSO4, filtered and evaporated to give an orange oil. The title
263

compound was isolated > 98% purity (1H and

31

P NMR) and required no further purification.

Yield 62% (0.446 g); TLC (1% NH4+OH- in Acetone, 10 mL) or (20% MeOH (6% NaBr)): ACN, Rf = 0.47; 1H NMR (400 MHz, CDCl3, ): 4.15-4.06 (m, 8H, H7), 3.11 (d, 4H, J = 8.9 Hz, H6), 2.80 (t, 2H, J = 6.8 Hz, H5), 2.27 (t, 2H, J = 7.5 Hz, H4), 2.18 (s, 6H, H3), 1.61 (p, 2H, J = 7.15 Hz, H2), 1.28 (t, 12H, J = 7.0 Hz, H1) ppm; 13C NMR (100 MHz, CDCl3, ): 61.8 (t, 2JCP

= 3.3 Hz, C7), 57.24 (C4), 55.03 (C5), 50.92 (dd, 1JC-P = 7.1 Hz, C6), 49.36 (dd,1JC-P = 6.7 Hz,

C6), 45.48 (C3), 25.65 (C2), 16.48 (t, 3JC-P = 2.8 Hz, C1) ppm; 31P NMR (121.45 MHz, CDCl3, ): 24.89 ppm. HRMS-DART (m/z): [MH+] calculated for C15H36N2O6P2, 403.2126; found, 403.2135.

1

O
6

O
4

P O

N
3

2 5

I

O P O O

Tetraethyl (((3-iodopropyl)azanediyl)bis(methylene))bis(phosphonate) (120): A mixture of diethyl (4-bromobutyl)phosphonate (1.0 g, 2.21 mmol, 1.0 eq.) and NaI (0.69 g, 4.6 mmol, 2.08 eq.) in acetone (3 mL) were placed, with a magnetic stirring bar, into a 5 mL µW glass reaction tube and sealed. The reaction mixture was heated in the µW at 100 °C (5 min). The yellow solid was transferred to a 100 mL RBF washing with acetone (50 mL). Volatiles were removed on a rotary evaporator and the crude material was diluted with brine (10 mL) and extracted with CHCl3 (1 × 10 mL). The organic layer was separated, dried over anhydrous MgSO4 filtered, concentrated and recovered as a yellow oil without further purification. Yield: 75% (0.80 g); TLC (10% NH4+OH- / acetone), Rf = 0.85; 1H NMR (400 MHz, CDCl3, ): 4.20264

4.09 (m, 8H, H6), 3.24 (t, 2H, J = 7.01 Hz, H5), 3.15 (d, 4H, J = 8.75 Hz, H4), 2.89 (t, 2H, J = 6.6 Hz, H3), 2.03-1.94 (m, 2H, H2), 1.33 (t, 12H, J = 7.03 Hz, H1); CDCl3, ): 24.79 ppm.
31

P NMR (121.45 MHz,

O O P O
6 11 9 5

Br N
10 8 4 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1

3

O P O O

N
7

1

H

O O P O
15 16 18 4

Br N
17 14 3 6 7 8 9 10 11 11 11 11 11 11 11 11 12 5 1

2

N O P 13 O O

13

C

N-(3-(bis((diethoxyphosphoryl)methyl)amino)propyl)-N,N-dimethyloctadecan-1ammonium (121): To a flame dried and evacuated 20 mL screw cap vial, equipped with a magnetic stir bar was added a mixture of bromoaminobisphosphonate (0.20 g, 0.51 mmol) and DMOA (0.143 g, 0.6 mmol, 1.19 eq.) was which was sealed and heated to 100°C on a sand bath. After 1 hr, TLC showed the disappearance of the starting amine (5% MeOH in EtOAc, 10 mL). The mixture was partitioned between hexanes (~ 7 mL) and MeOH/H2O (4:1, 5 mL), the bottom yellow methanolic layer was separated and concentrated (2 × 5 mL ACN to azeotrope excess H2O) to afford a yellow oily solid (0.308 g). The crude material was purified by DCVC (20 g silica, 3.5 cm × 4.5 cm) pre-washed with 60 mL 20% (NaBr 6% in MeOH): ACN then eluting with the
265

same eluent (1st 40 mL removed upper Rf impurity, compound 121 was obtained in the next 7 fractions totaling (95 mL)) as a yellow oil after filtering off NaBr (Celite), washing with CHCl3. Yield: 46.1% (0.162 g). TLC (20% MeOH (NaBr 6%): ACN), Rf = 0.5 ; 1H NMR (400 MHz, CDCl3, ) 4.15-4.08 (m, 8H, H11), 3.72-3.69 (m, 2H, H10), 3.55-3.51 (m, 2H, H9), 3.33 (s, 6H, H8), 3.12-3.08 (m, 4H, H7), 2.99-2.97 (m, 2H, H6), 2.0-1.98 (m, 2H, H5), 1.74-1.71 (m, 2H, H4), 1.24-1.20 (br m, 42H, (H2 + H3 overlap)), 0.88-0.83 (m, 3H, H1) ppm;
13

C NMR (100

MHz, CDCl3, ): 65.19-61.96 (C19-C16 overlap, from HSQC: 65.19 (C18), 62.52 (C17), 61.96 (C16)), 53.64 (C15), 50.86 (C14), 50.5 (d, C13), 31.90 (C12), 29.68-29.60 (C11 overlap), 29.57 (C10), 29.47 (C9), 29.39 (C8), 29.34 (C7), 29.26 (C6) 26.12 (C5), 22.83 (C4), 22.66 (C3), 16.58-16.50 (m, 3JC-P = unresolved, C2), 14.10 (C1) ppm;
31

P NMR (121.45 MHz, CDCl3, )

24.40 ppm. HRMS-DART (m/z): [M+] ­ Br- calculated for C33H73N2O6P2, 655.4937; found, 655.4938.
2 3 4 5 1

N

N N N

N

N

3,3',3''-(1,3,5-triazinane-1,3,5-triyl)tris(N,N-dimethylpropan-1-amine) (123):244-245 To a 125 mL round bottom flask, paraformaldehyde (1.652 g, 55 mmol, 1.1 eq.) was added to a solution of N,N-dimethylpropane-1,3-diamine (6.29 mL, 50 mmol) in TOL (15 mL). The reaction was refluxed using a Dean-Stark trap for 1.5 hrs. TOL was evaporated and a portion of the residue (1.96 g) was partitioned between CHCl3 (15 mL) and H2O (5 mL). The organic layer was separated, dried with MgSO4 and concentrated to give a clear oil. Yield: 66% (1.307 g).
266

TLC (20% MeOH in EtOAc, 10 mL), Rf = 0.05 ; 1H NMR (400 MHz, CDCl3, ): 3.29 (brs, 6H, H5), 2.40 (t, 6H, J = 7.5 Hz, H4), 2.25 (t, 6H, J = 7.5 Hz, H3), 2.18 (s, 18H, H2), 1.59 (p, 6H, J = 7.5 Hz, H1) ppm; 13C NMR (100 MHz, CDCl3, ): 74.65 (C5), 57.83 (C3), 50.78 (C4), 45.54 (C2), 25.88 (C1) ppm. (Agrees well with literature NMR values).244-245
3
2 4 1

OH

5

N N
OH

HO

N

3,3',3''-(1,3,5-triazinane-1,3,5-triyl)tris(propan-1-ol) (122): 40,246 To a 125 mL round bottom flask, formalin (0.813 mL, 10 mmol) was added to a solution of 3amino-1-propanol (0.751 g, 10 mmol) in ACN (10 mL). The reaction was stirred at RT overnight. Evaporation of volatiles followed by DCVC (20 g silica, 3.5 cm × 4.5 cm) eluting with 5% NH4+OH- in acetone (50 mL) then collecting (150 mL), provided pure product as a clear oil. Yield: 92% (0.8 g). TLC (5% NH4+OH- in acetone, 10 mL), Rf = 0.3; 1H NMR (400 MHz, CDCl3, ): 4.37 (s, 6H, H5), 3.84 (t, 6H, J = 7.0 Hz, H4), 3.71 (s, 3H, H3), 2.97 (t, 6H, J = 5.6 Hz, H2), 1.60 (q, 6H, J = 5.40 Hz, H1) ppm; 13C NMR (100 MHz, CDCl3, ): 83.06 (C4), 68.12 (C3), 47.78 (C2), 22.45 (C1) ppm. (Agrees well with literature NMR values).40,246 5.7.0 General Procedure for the Bis Michael Addition of Amines onto Vinylphosphonates
O O P
3 5 1

O

N
2

OH

O
6

4

P

O

O

267

Tetramethyl (((3-hydroxypropyl)azanediyl)bis(ethane-2,1-diyl))bis(phosphonate) (135): To a 25 mL round bottom flask equipped with a magnetic stir bar, was added a stirred solution of the primary amine (0.448 g, 5.9 mmol) in distilled H2O (5 mL) at RT. Two equivalents of diethyl vinylphosphonate (1.637 g, 12.03 mmol, 2.01 eq.) was then added and the reaction stirred at RT ON. The reaction was transferred to a 125 mL round bottom flask along with 30 mL ACN and evaporated to a clear oil (2.14 g, containing ~ 7% starting material by 31P NMR). The crude material was purified by DCVC (20 g silica, 3.5 cm × 4.5 cm) eluting with 30% MeOH:EtOAc (30 mL fractions, 240 mL). Fractions (2-7) containing were filtered (Celite) and evaporated to obtain the title compound as a yellow oil. Yield: 95% (1.968 g); TLC (30% MeOH:EtOAc), Rf = 0.33; 1H NMR (400 MHz, CDCl3, ): 3.73 (d, J = 11.0 Hz, 12H, H6), 3.74-3.70 (m, 2H, H5), 2.82-2.74 (m, 4H, H4), 2.60 (t, 2H, J = 6.0 Hz, H3), 1.98-1.88 (m, 4H, H2), 1.71-1.64 (m, 2 H, Hz, H1) ppm; 13C NMR (100 MHz, CDCl3, ): 61.54 (C5), 52.65 (d, 2JC-P =6.61 Hz, C6), 50.69 (C3), 46.26 (C4), 28.69 (C1), 21.84 (d, 2JC-P =138.47 Hz, C1) ppm. CDCl3, ): 32.66 ppm.
O O P
4 6 2

31

P NMR (121.45 MHz,

O

N
3 1 7

OH

O O

5

P

O

Tetraethyl (((3-hydroxypropyl)azanediyl)bis(ethane-2,1-diyl))bis(phosphonate) (136):247 To a 125 mL round bottom flask equipped with a magnetic stir bar, was added a stirred solution of the primary amine (1.016 g, 13.5 mmol) in distilled H2O (15 mL) at RT. Two equivalents of
268

diethyl vinylphosphonate (4.44 g, 27.0 mmol, 2.00 eq.) was then added and the reaction stirred at RT ON. H2O was co-evaporated from ACN (80 mL) and evaporated to a yellow oil (containing ~ 14% starting material by 31P NMR). The crude material was purified by DCVC (50 g silica, 3.5 cm × 4.5 cm) pre-eluting with acetone (50 mL) and then eluting with 35% EtOH:Acetone (150 mL) to obtain the title compound as a yellow oil. Yield: 50% (2.722 g); TLC (30% EtOH:Acetone), Rf = 0.40; 1H NMR (400 MHz, CDCl3, ): 4.16-4.03 (m, 8H, H7), 3.75-3.67 (m, 3H, H6), 2.83-2.75 (m, 4H, H5), 2.64-2.59 (m, 2H, H4), 1.97-1.86 (m, 4H, H3), 1.68 (q, 2H, J = 5.58 Hz, H2), 1.31 (t, 12 H, J = 7.06 Hz, H1) ppm; 31P NMR (121.45 MHz, CDCl3, ): 30.00 ppm.247

O

O O P
6 5 2

N
3 1 8

N
4

O O

7

P

O

Tetraethyl (((3-(dimethylamino)propyl)azanediyl)bis(ethane-2,1-diyl)) bis (phosphonate) (139): Synthesized from alcohol via mesylate and dimethylamine, see Tetraethyl
1

(((3-

(dimethylamino)propyl)azanediyl)bis(methylene))bis(phosphonate) 113 procedure;

H NMR

(400 MHz, CDCl3, ): 4.11-3.99 (m, 8 H, H8), 2.76-2.69 (m, 4H, H7), 2.40 (t, 2H, J = 7.12 Hz, H6), 2.22 (t, H5, J = 7.14 Hz, H5), 2.16 (s, 6H, H4), 1.91-1.81 (m, 4H, H3), 1.60-1.53 (m, H2, 2H), 1.28 (t, H1, J = 7.04 Hz) ppm; 31P NMR (121.45 MHz, CDCl3, ): 30.57 ppm.

269

O

O O P
8 11 6 9 10 4 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1

N
5 3 12

N Br

O O

7

P

O
1

H

O

O O P
5 15 3 13 14 8 3 9 10 11 11 11 11 11 11 11 11 11 11 12 4 1

N
6 2 7

N Br

O O

7

P

O
13

C

N-(3-(bis(2-(diethoxyphosphoryl)ethyl)amino)propyl)-N,N-dimethyloctadecan-1ammonium bromide (140): To a flame dried and evacuated 20 mL screw cap vial, equipped with a magnetic stir bar was added a mixture of 139 (0.181 g, 0.42 mmol) and bromooctadecane (0.140 g, 0.42 mmol, 1.0 eq.) was sealed and heated to 100°C on a sand batch. After 1 hr, TLC showed the disappearance of the starting amine (5% MeOH in EtOAc, 10 mL). The mixture was drypacked onto silica and the crude material was purified by DCVC (20 g silica, 3.5 cm × 4.5 cm) pre-washed with 2 × 40 mL 20% MeOH (NaBr 6%): ACN then eluting with the same eluent (50 mL), evaporating, redissolving with CHCl3 and filtering off NaBr through a pad of Celite, washing with CHCl3 to provide a yellow wax. Yield: 44% (0.15 g). TLC (20% MeOH (NaBr 6%): ACN), Rf = 0.3; 1H NMR (400 MHz, CDCl3, ) 4.14-4.04 (m, 8H, H12), 3.72-3.67 (m, 2H, H11), 3.47-3.36 (m, 2H, H10), 3.27 (s, 6H, H9), 2.85-2.76 (m, 4H, H8), 2.05-1.09 (m, 4H, (H6 + H5)), 1.75-1.65 (m, 2H,
270

H4), 1.31 (t, J = 7.03 Hz, 6H, H3), 1.23 (brs, 30 H, H2), 0.86 (t, J = 6.94 Hz, 3H, H1) ppm; 13C NMR (100 MHz, CDCl3, ): 67.49 (C15), 61.93 (C14), 61.78 (C13), 31.89 (C12), 29.68 (C11 overlap), 29.63 (C10), 29.49 (C9), 29.42 (C8), 29.33 (C7), 29.26 (C6), 26.29 (C5), 25.60 (C4), 22.66 (C3), 16.48 (d, 3JC-P = 6.03 Hz, C2), 14.08 (C1) ppm; 31P NMR (121.45 MHz, CDCl3, ) 24.40 ppm.

O
7 5 9 4 6

Br
8 2 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1

N H
10

N

1

H

O
14 3 18 17 4 15

Br
16 6 5 7 8 9 10 11 12 12 12 12 12 12 12 13 2 1

N H

N

13

C

N-(3-acetamidopropyl)-N,N-dimethyloctadecan-1-ammonium (153):248 This compound was prepared by the Menshutkin reaction using Method 5.2.1: N-(3(dimethylamino)propyl)acetamide 148 (0.285 g, 1.97 mmol) and 1-bromooctadecane (0.664 g, 1.99 mmol, 1.01 eq.) were reacted at 100oC neat for 4 hrs until the mixture solidified. The mixture was then dissolved in MeOH (10 mL) and hot filtered from charcoal. Volatiles were removed on a rotary evaporator and the crude was recrystallized from acetone (15 mL) by placing the solution on ice (15 min) as a white solid. Yield: 74% (0.720 g). Mp = 93-95°C; 1H NMR (400 MHz, CDCl3, ): 7.98 (t, J = 7.98 Hz, 1H, H10), 3.84-3.78 (m, 2H, H9), 3.39-3.32 (m, 4H, (H7 + H8 overlap)), 3.26 (s, 6H, H5), 2.10-2.00 (m, 2H, H5), 2.04 (s, 3H, H4), 1.75-1.65 (m, 2H, H3), 1.22 (brs, 30H, H2), 0.84 (t, J = 6.79 Hz, 3H, H1) ppm;
13

C NMR (100 MHz,

CDCl3, ): 171.60 (C18), 64.97 (C17), 63.00 (C16), 51.13 (C15), 36.22 (C14), 32.00 (C13),
271

29.80-29.74 (C12 overlap), 29.73 (C11), 29.66 (C10), 29.53 (C9), 29.46 (C8), 29.44 (C7), 29.25 (C6), 26.38 (C5), 23.36 (C4), 22.85 (C3), 22.76 (C2), 14.20 (C1) ppm. (Agrees well with literature NMR values).248
Br
5 7 4 6 8 2 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1

H2N

N

1

H

Br
11 13 4 12 14 5 3 6 7 8 9 9 9 9 9 9 9 9 9 10 2 1

H2N

N

13

C

N-(3-aminopropyl)-N,N-dimethyloctadecan-1-ammonium bromide (144):248 This compound was prepared by dissolving 152 (10.80 g, 14.16 mmol) in EtOH (80 mL) and deprotecting with hydrazine hydrate (5.5 mL, 5 eq.) under reflux 1.5 hrs. The mixture was then cooled to RT, diluted with CHCl3/ACN (1:1, 100 mL) and filtered through Celite. Volatiles were removed in vacuo and the crude product (8.647 g, yellow gum) was again diluted with CHCl3/ACN (1:1, 100 mL) and placed in the freezer (-20oC, 30 min) to further precipitate the pthalylhydrazide impurity (white solid) and filtered through Celite. Volatiles were evaporated and the sample was placed under high vaccum (1 hr) to obtain the title compound as a yellow/white waxy solid. Yield: 87% (5.361 g); 1H NMR (400 MHz, CDCl3, ): 3.75-3.66 (m, 2H, H8), 3.48-3.39 (m, 2H, H7), 3.33 (s, 6H, H6), 2.29-2.82 (m, 2H, H5), 2.01-1.87 (m, 2H, H4), 1.79-1.67 (m, 2H, H3), 1.24 (brs, 30H, H2), 0.86 (t, J = 7.06 Hz, 3H, H1) ppm; 13C NMR (100 MHz, CDCl3, ): 64.15 (C11), 62.27 (C10), 51.02 (C9), 38.28 (C8), 31.55 (C7), 29.40-27.31 (C6 overlpa), 26.32 (C5), 25.84 (C4), 22.54 (C3 ), 22.44(C2), 13.86 (C1) ppm.248

272

Cl
6 7 2 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1

N

4 5

N

N-(2-cyanoethyl)-N,N-dimethyloctadecan-1-ammonium (154): This compound was prepared by the Menshutkin reaction using Method 5.2.1: 3chloropropanenitrile 149 (1.429 g, 18.9 mmol) and DMOA (6.258 g, 18.7 mmol, ~ 1.0 eq.) were reacted at 100oC neat for 5 min until the mixture solidified. To the solid mixture was added MeOH (10 mL) and heating was continued for another 30 min. Volatiles were removed on a rotary evaporator and the crude product was recrystallized from acetone (200 mL) by placing the solution on ice (15 min) recovered a waxy white solid. Yield: 88% (6.0 g). Mp = 54-55°C; 1H NMR (400 MHz, CDCl3, ): 3.72-3.67 (m, 2H, H7), 3.56 (s, 6H, H6), 2.09-1.98 (m, 2H, H5), 1.86-1.76 (m, 2H, H4), 1.42-1.32 (s, 2H, H2), 1.24 (brs, 30H, H2), 0.87 (t, J = 6.68 Hz, 3H, H1) ppm.

O
6 3 9 5 7

Br
8 2 4 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1

O

N H
10

N

1

H

O
14 2 18 16 5 15

Br
17 5 4 6 7 8 9 10 11 12 12 12 12 12 12 13 3 1

O

19

N H

N

13

C

N-(3-((tert-butoxycarbonyl)amino)propyl)-N,N-dimethyloctadecan-1-ammonium (155):249

273

This compound was prepared by the Menshutkin reaction using Method 5.2.1: tert-butyl (3bromopropyl)carbamate 150 (1.421 g, 5.96 mmol) and DMOA (2.4649 g, 7.37 mmol, ~1.23 eq.) were reacted at 100oC neat for 35 min until the mixture solidified. The crude reaction was recrystallized from acetone (20 mL) by placing the solution on ice (10 min) and recovered as an off white waxy solid. The final product was isolated as a mixture with the starting material DMOA in a 0.63:0.37 ratio by 1H NMR and used without further purification. Yield: 70% (2.243 g). Mp = 98-100°C; 1H NMR (400 MHz, CDCl3, ): 5.8 (s, 1H, H10), 3.65-3.56 (m, 2H, H9), 3.44-3.33 (m, 2H, H8), 3.28 (s, 6H, H7), 3.25-3.17 (m, 2H, H6), 2.07-1.95 (m, 2H, H5), 1.741.60 (m, 2H, H4), 1.38 (s, 12H, H3), 1.23 (brs, 30H, H2), 0.83 (t, J = 7.02 Hz, 3H, H1) ppm; 13C NMR (100 MHz, CDCl3, ): 156.92 (C23), 136.77 (C22), 128.49 (C21), 128.07 (C20), 128.0 (C19), 66.52 (C18), 64.50 (C17), 62.33 (C16), 51.07 (C15), 37.88 (C14), 31.90 (C13), 29.8029.74 (C12 overlap), 29.65 (C11), 29.59 (C10), 29.47 (C9), 29.40 (C8), 29.34 (C7), 29.19 (C6), 26.25 (C5), 23.19 (C4), 22.73 (C3), 22.67 (C2), 14.11 (C1) ppm. (Agrees well with literature NMR values).249

O
9 6 7 4 5

Br
8 2 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1

O
11 12 13

N H
10

N

1

H

O
22 18 14 16 4 15

Br
17 5 3 6 7 8 9 10 11 12 12 12 12 12 12 13 2 1

O
19 21 20

23

N H

N

13

C

N-(3-(((benzyloxy)carbonyl)amino)propyl)-N,N-dimethyloctadecan-1-ammonium (156):

274

This compound was prepared by the Menshutkin reaction using Method 5.2.1: benzyl (3bromopropyl)carbamate 151 (0.991 g, 3.64 mmol) and DMOA (1.21 g, 3.62 mmol, ~1.0 eq.) were reacted at 100oC neat for 35 min until the mixture solidified. The mixture was then cooled to RT, poured into 20 mL of Et2O, and placed into a freezer (-20oC) for 60 min to precipitate the title compound as a white waxy solid. Yield: 70% (1.52 g). Mp = 98-100°C; 1H NMR (400 MHz, CDCl3, ): 7.32-7.27 (m, 3H, H11-13), 6.51 (t, J = 6.51 Hz, H10), 5.06 (s, 2H, H9), 3.653.56 (m, 2H, H8), 3.35-3.25 (m, 4H, (H6, H7)), 3.18 (s, 6H, H5), 2.05-1.95 (m, 2H, H4), 1.651.50 (m, 2H, H3), 1.23 (brs, 30H, H2), 0.86 (t, J = 6.69 Hz, 3H, H1) ppm; 13C NMR (100 MHz, CDCl3, ): 156.92 (C23), 136.77 (C22), 128.49 (C21), 128.07 (C20), 128.0 (C19), 66.52 (C18),64.50 (C17), 62.33 (C16), 51.07 (C15), 37.88 (C14), 31.90 (C13), 29.80-29.74 (C12 overlap),29.65 (C11), 29.59 (C10), 29.47 (C9), 29.40 (C8), 29.34 (C7), 29.19 (C6), 26.25 (C5), 23.19 (C4), 22.73 (C3), 22.67 (C2), 14.11 (C1) ppm.
Br
7 8 4 6 2 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1

O N

N
5

O
10 9

1

H

O N
19 16 17 18

Br
12 2 14 15 5 4 6 7 8 9 10 10 10 10 10 10 10 10 11 3 1

N
13

O

13

C

N-(3-(1,3-dioxoisoindolin-2-yl)propyl)-N,N-dimethyloctadecan-1-ammonium bromide (152):

275

This compound was prepared by the Menshutkin reaction using Method 5.2.2: 3bromopropylphthalimide 10 (8.00 g, 29.38 mmol, 1.0 eq.) and DMOA (8.80 g, 29.38 mmol, 1.0 eq.) in ACN (80 mL) were refluxed for 4.2 hrs. The mixture was then cooled to RT, poured into 100 mL of Et2O, and left at RT for 30 min to precipitate the title compound as a white solid. Yield: 84% (14.172 g). Mp = 100-105°C; 1H NMR (400 MHz, CDCl3, ): 7.82-7.76 (m, 2H, H10), 7.72-7.64 (m, 2H, H9), 3.81 (t, J = 6.62 Hz, 2H, H8), 3.76-3.64 (m, 2H, H7), 3.53-3.46 (m, 2H, H6), 3.41 (s, 6H, H5), 2.24-2.13 (m, 2H, H4), 1.75-1.58 (m, 2H, H3), 1.22 (brs, 30H, H2), 0.84 (m, J = 6.8 Hz, 3H, H1) ppm; 13C NMR (100 MHz, CDCl3, ): 168.23 (C19), 134.29 (C18),131.78 (C17), 123.50 (C16), 64.32 (C15), 61.32 (C14), 51.41 (C13), 34.92 (C12), 31.90 (C11), 29.75-29.65 (C10 overlap), 29.58 (C9), 29.47 (C8), 29.34 (C7), 29.21 (C6), 26.22 (C5), 23.80 (C4), 22.66 (C3), 22.48 (C2), 14.10 (C1) ppm. 5.8.0 Preparation of Tris Phosphonic Acid Derivatives
3 1

O O P O

OH 4
2

Diethyl (hydroxymethyl)phosphonate (169):250 Into a Schlenk flask (250 mL flask), equipped with a condenser and a magnetic stirrer, was introduced diethylhydrogenphosphonate HP(O)(OEt)2 (20 g, 144.8 mmol), paraformaldehyde (5.2 g, 1.2 eq.), EtOH (30 mL) and powdered K2CO3 (1 g, 0.05 eq.) and the mixture was refluxed for 60 min. At the end of the reaction, the solution was evaporated and filtered through a short pad of Celite from acetone (50 mL). The solvent was removed under vacuum to obtain the title compound as a clear liquid which may be distilled (bp = 95°C, ~ 5 × 10-2 mbar) but was used
276

without any further purification. Yield: 94% (22.84 g). 1H NMR (400 MHz, CDCl3, ): 4.87 (s, 1H, H4); 4.14 (t, 2J = 5.8 Hz, 4H, H3); 3.57 (d, 2J = 5.9 Hz, 2H, H2); 1.29 (t, 3J = 7.0 Hz, 6H, H1) ppm; 13C NMR (100 MHz, CDCl3, ): 62.45 (d, 1J = 6.7 Hz, C3), 56.90 (d, 1J = 162.6 Hz, C2), 16.35 (d, 1J = 5.6 Hz, C1) ppm; well with literature NMR values).250
4 1

31

P NMR (121.45 MHz, CDCl3, ): 24.72 ppm. (Agrees

O O P O

O
3

2

S O

O

(Diethoxyphosphoryl)methyl methanesulfonate (158):250 To a flame dried and evacuated 125 mL round bottom flask, equipped with a magnetic stir bar was added sequentially NMe3HCl (2.41g, 12.68 mmol, 0.20 eq.), DCM (100 mL), Et3N (13.26 mL, 95.1 mmol, 1.5 eq.) and the alcohol 169 (10.60 g, 63.4 mmol, 1.0 eq.) and the solution was cooled to 0°C in an ice bath. To the chilled stirred solution was added, dropwise, mesyl chloride (~8.5 mL, 69.74 mmol, 1.1 eq.) in anhydrous DCM (2 mL) and the cloudy yellow mixture was stirred for 30 min at RT at which point TLC showed disappearance of the starting alcohol (10% MeOH in EtOAc, 10 mL). The reaction was diluted with H2O (1 × 80 mL) and extracted. The organic layer was washed with brine (60 mL) and dried over MgSO4, filtered and evaporated to give a yellow oil. The crude product was packed onto silica and purified by dry column chromatography (4.5 cm × 5.0 cm frit, 40 g silica) pre-eluting with EtOAC/Hexanes (60%, 150 mL) then eluting with EtOAC/MeOH (25%,200 mL) to afford the title compound as a yellow oil.Yield: 99% (15.50g). 1H NMR (400 MHz, CDCl3, ): 4.36 (d, 2J = 7.9 Hz 4H, H4); 4.204.11 (m, 2H, H3); 3.07 (s, 3H, H2); 1.31 (t, 3J = 7.1 Hz, 6H, H1) ppm;
277
13

C NMR (100 MHz,

CDCl3, ): 63.45 (d, 1J = 6.4 Hz, C3),61.0 (d, 2J = 169.5 Hz, C4), 37.80 (C2),16.35 (d, 1J = 5.7 Hz, C1) ppm; 31P NMR (121.45 MHz, CDCl3, ): 15.65 ppm. (Agrees well with literature NMR values).250
4 1 7 2

O O P O

O
3

8

S O

5 6

O

(Diethoxyphosphoryl)methyl 4-methylbenzenesulfonate (170):251 To a chilled and stirred solution of the alcohol 169 (0.168 g, 1 mmol), NMe3HCl (0.040 g, 0.21 mmol, 0.21 eq.), Et3N (0.21 mL, 1.5 mmol, 1.5 eq.) in ACN (1 mL) inside a flame dried and evacuated 25 mL round bottom flask was added TsCl (0.210 g, 1.1 mmol, 1.1 eq.) in ACN (1 mL) at 0 °C. The clear and cloudy mixture was stirred for 1 hr at RT at which point TLC showed disappearance of the starting amine (5% MeOH in EtOAc , 10 mL). The reaction was diluted with H2O (2 mL) and extracted with EtOAc (2 × 5 mL), the organic layer was washed with brine (2 mL), dried over MgSO4, filtered and evaporated to give a clear oil. The crude material was purified by flash chromatography on silica gel (20 g silica, 1.5 cm i.d) with gradient elution: 100% EtOAc (35 mL) then 5% MeOH:EtOAc (90 mL) to obtain the title compound as a yellow oil. Yield 93% (0.30 g); TLC (5% MeOH in EtOAc), Rf = 0.42; 1H NMR (400 MHz, CDCl3, ): 7.73 (t, J = 8.0 Hz, 4H, H6); 7.29 (t, J = 3.8 Hz, 4H, H5); 4.14-4.02 (m, 6H, (H3 + H4 overlap)); 3.39 (s, 3H, H2); 1.23 (t, J = 7.1 Hz, 6H, H1) ppm; 13C NMR (100 MHz, CDCl3, ): 145.52 (C8), 131.64 (C7), 129.99 (C6), 129.99 (C5), 128.13 (C6), 63.31 (d, 1J = 36.53 Hz, C3),61.28 (d, 2J = 168.91 Hz, C4), 21.60 (C2),16.25 (d, 1J = 5.81 Hz, C1) ppm; (121.45 MHz, CDCl3, ): 15.12 ppm. (Agrees well with literature NMR values).251
278
31

P NMR

HO HO
2 3

O
4

1

HO

N H

5

O

Tert-butyl (1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)carbamate (157):252 To a solution of 2-amino-2-(hydroxymethyl)propane-1,3-diol (tris) 171 (6.057 g; 50 mmol) dissolved in MeOH (180 mL) was added a solution of Boc2O (11.350 g; 52 mmol) in MeOH (40 mL over 30 min and the reaction mixture was stirred at RT overnight. Volatiles were evaporated to dryness, and the title compound recrystallized from EtOAc (100 mL) as white cotton like needles. Yield 94% (10.00 g); 1H NMR (400 MHz, D2O, ): 3.65 (s, 9H, H2); 1.38 (s, 6H, H1) ppm; 13C NMR (100 MHz, DMSO, ): 155.25 (C5), 78.10 (C4), 60.54 (C2), 60.43 (C3), 28.39 (C1) ppm. (Agrees well with literature NMR values).252
HO HO
4 5

O
2 1

HO

N H
7

6 3

N

N-(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)-3-(dimethylamino)propanamide (163): To a solution of N-[tri(hydroxy- methyl)methyl]acrylamide 173 (1.051g, 6 mmol, 1.0 eq.) in H2O (3 mL) was added HNMe2 (2 mL, 5.6 M in EtOH, ~ 2 eq.) at RT and the reaction was stirred for 5 min at which point TLC (EtOAc:MeOH: 1:1, 20 mL) showed consumption of the starting amine. The reaction was separated from H2O by coevaporation from ACN, stirring in CHCl3 (10 mL) for 5 min with decanting followed by drying under high vaccum (60 min) and recovered as a white solid. Yield 100% (1.321 g); TLC (50% MeOH in EtOAc), Rf = 0.05; 1H NMR (400 MHz, D2O, ): 3.76 (s, 6H, H4); 2.67 (t, J = 7.03 Hz, 2H, H3); 2.48 (t, J = 3.46 Hz, 2H, H2); 2.23
279

(s, 6H, H1) ppm;

13

C NMR (100 MHz, CDCl3, ): 175.0 (C6), 62.95 (C5), 60.27 (C4), 54.12

(C3), 43.59 (C1), 33.38 (C2) ppm. HRMS-DART (m/z): [M+] calculated for C9H20N2O4, 221.15013; found, 221.14964. 5.9.0 Preparation of Bis Amines Scaffolds for Multidentate Phosphonic Acid Synthesis
1 5

O
3

O

6

N H

H N
2

O N H
4

O

Di-tert-butyl (azanediylbis(ethane-2,1-diyl))dicarbamate (176):253 To a stirred solution of 1,1'-carbonyldiimidazole (CDI) (12.97 g. 80 mmol, 2 eq.), KOH (0.112 g, 2 mmol) and t-BuOH (7.65 mL, 80 mmol, 2 eq.) in anhydrous TOL (300 mL) preheated to 60oC for 3 hrs was added N-(2-aminoethyl)ethane-1,2-diamine dropwise (4.34 mL, 40 mmol, 1.0 eq.) via a syringe. The reaction was further stirred at 60oC for another 3 hrs and then cooled to RT and rotovaped to remove volatiles. The residue was dissolved in DCM (100 mL) and washed with H2O (3 × 50 mL), dried with MgSO4, evaporated and placed under high vaccum for 4 hrs to give a thick light yellow oil. Yield: 62% (7.51 g). 1H NMR (400 MHz, CDCl3, ): 4.10-3.93 (m, 4H, H6), 3.38-3.29 (m, 2H, H5), 1.91-1.80 (m, 2H, H4), 1.75-1.60 (m, 4H, (H2 + H3)), 1.301.20 (m, 6H, H1) ppm. (Agrees well with literature NMR values).253
HO O
8 1 5 2 6 4

O N H O

O

9

N H
7

N
3

Di-tert-butyl (((3-hydroxypropyl)azanediyl)bis(ethane-2,1-diyl))dicarbamate (177):

280

A solution of the secondary amine 176 (7.511 g, 24.7 mol), N,N-diisopropylethylamine (5.17 mL, 37.13 mmol, 1.2 eq.), 3-bromo-1-propanol 74 (2.46 mL, 27.23 mmol, 1.1eq.) in 100 mL ACN were refluxed (24 hrs). After completion of the reaction (monitored by TLC) the reaction mixture was evaporated to dryness under reduced pressure. The residue was dissolved in DCM (200 mL) and washed with H2O (200 mL) followed by another extraction with DCM (200 mL) and a brine wash (100 mL) of the organic phases. Volatiles were removed under reduced pressure and the yellow liquid was placed under hight vaccum (15 min) to give a yellow thick oil that solidified in the freezer (-20oC). The collected organic fractions were dried over MgSO4 and the solvent was removed under reduced pressure to yield the crude product as a yellow oil. Yield: 81% (6.0 g). 1H NMR (400 MHz, CDCl3, ): 5.06 (s, 2H, H7), 3.70 (t, J = 5.57 Hz, 2H, H6), 3.22-3.15 (m, 4H, H5), 2.61 (t, J = 6.14 Hz, 2H, H4), 2.52 (t, J = 6.02 Hz, 4H, H3), 1.61 (m, 2H, H2), 1.42 (s, 18H, H1) ppm; 13C NMR (100 MHz, CDCl3, ): 156.301 (C8), 79.15 (C7), 61.97 (C6), 53.94 (C3), 52.70C (4), 38.20 (C5), 30.45 (C2), 28.38 (C1) ppm.
NH2
4 2

O
3

1

H2N

N

N H
5

7

O

6

Tert-butyl (2-(bis(2-aminoethyl)amino)ethyl)carbamate (181):254 To a stirred solution of tris(2-aminoethyl)amine (36.5 g, 249 mmol) in dioxane (200 mL) was added Boc2O dropwise (6.91 mL,30 mmol, 0.12 eq. ) over 15 min, followed by rinsing the addition funnel with dioxane (10 mL). The reaction was stirred at RT overnight (~20 hrs) and then dioxane was removed under reduced pressure. The residue was dissolved in H2O (80 mL) and repeatedly extracted with DCM (5 × 100 mL) followed by a brine wash (80 mL). Volatiles
281

were removed under reduced pressure and the yellow liquid was placed under high vaccum (15 min) to give a yellow thick oil that solidified in the freezer (-20oC). Note the NMR spectrum recorded the final product was contamined with dioxane even after high vaccum. Yield: 81% (6.0g). 1H NMR (400 MHz, CDCl3, ): 5.21 (s, 1H, H6), 3.16-3.07 (m, 4H, H4), 2.71 (t, J = 6.15 Hz, 2H, H3), 2.53-2.46 (m, 6H, H2), 1.40 (s, 18H, H1) ppm;
13

C NMR (100 MHz, CDCl3, ):

156.30 (C7), 79.13 (C6), 57.31 (C2), 54.07 C(3), 54.07 (C3), 39.15 (C4), 28.40 (C1) ppm. (Agrees well with literature NMR values).254 5.10 Preparation of Catechol QAC
O
4 10 9 5 7 3 8 6 2 1

O

N H

2-(3,4-dimethoxyphenyl)-N-methylethanamine (185):255 This compound was prepared by the Echweiler clarke reaction using Method 5.2.1: To a refluxing solution of 2-(3,4-dimethoxyphenyl)ethanamine (3.0 g, 16.5 mmol, 1.0 eq.) in MeOH (5 mL) was added by syringe formalin (4.5 mL, 44.8 mmol, 2.7 eq.), formic acid (5.5 mL, 105.05 mmol, 6.3 eq.) and the mixture was left to reflux overnight. MeOH was evaporated in vacuo and the reaction pH was brought to pH = 14 with KOH (5.7 g in 50 mL H2O) at which point a white solid precipitated out on ice and was filtered to afford the crude monomethylated amine as a yellow white solid. This compound was contaminated with the starting material dopamine in ~ 8% by 1H NMR spectroscopy. Yield: 66% (2.30 g); 1H NMR (400 MHz, CDCl3, ): 6.73-6.65 (m, 1H, H5), 6.52 (s, 1H, H6), 6.43 (s, 1H, H7), 3.75 (d, J = 6.5 Hz, 9H, H4), 2.75 (t, J = 5.8 Hz, 2 H, H3), 2.57 (t, J = 6.0 Hz, 2 H, H2), 2.35 (s, 3H, H1) ppm. 13C NMR (100 MHz, CDCl3, ): 147.48 (C9), 147.17 (C10), 126.52 (C8), 125.67 (C7), 111.40 (C6), 109.35
282

(C5), 55.81 (d, J = 4.15 Hz, C4), 52.88 (C1), 45.94 (C2), 28.72 (C3) ppm. (Agrees well with literature NMR values).255
O
3 9 4 6 2 7 5 1

8

O

Br

4-(2-bromoethyl)-1,2-dimethoxybenzene (188):256 To a solution of 2-(3,4-dimethoxyphenyl)ethanol (0.51 g, 2.8 mmol) and CBr4 (1.083, 3.2 mmol, 1.14 eq.) dissolved in DCM (10 mL) was added a solution of PPh3 (0.907g, 3.45 mmol, 1.23 eq.) in DCM (10 mL ) over a 30 min period. The reaction was stirred at RT overnight. The crude product was packed onto silica and purified by dry column chromatography (4.5 cm × 5.0 cm frit, 40 g silica) pre-eluting with hexanes (150 mL) then with 5% EtOAC/Hexanes (100 mL) to remove excess of CBr4 and then eluting with 10% EtOAC/Hexanes (150 mL) to yield the product as a viscous oil, which solidified under high vaccum as a white/yellow solid. TLC (10% EtOAc/hexanes), Rf = 0.3; Yield: 56% (0.64 g). Mp. 57 °C; 1H NMR (400 MHz, CDCl3, ): 6.85-6.70 (m, 3H, (H4 + H5 + H6), 3.87 (d, J = 6.4 Hz, 6H, H3), 3.53 (t, J = 7.6 Hz, 2H, H2), 3.09 (t, J = 7.7 Hz, 2H, H1) ppm. 13C NMR (100 MHz, CDCl3, ): 148.96 (C9), 147.98 (C8), 131.51 (C7), 120.68 (C6), 111.89 (C5), 111.28 (C4), 55.90 (C3), 39.07 (C2), 33.25 (C1) ppm. (Agrees well with literature NMR values).256
O
8 13 14 9 11 7 12 10 4 5

Br
6 2 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1

O

N

N-(3,4-dimethoxyphenethyl)-N,N-dimethyloctadecan-1-ammonium bromide (189):
283

To a stirred solution of 188 (0.540 g, 2.2 mmol), in ACN (5 mL) was added DMOA (0.6640 g, 2.43 mmol, 1.1 eq.), and the mixture was refluxed (3 hrs). The reaction was cooled to RT and placed in the fridge (60 min) until a white precipitate appeared. The solid was filtered and dried to give the title compound as an impure mixture with N,N-dimethyloctadecylamine (white/yellow solid) and was not purified any further. TLC (10% NH4+OH-/acetone), Rf = 0.4; Yield: 56% (0.82 g); 1H NMR (400 MHz, CDCl3, ): 7.12-7.05 (m, 1 H, H11), 6.86-6.77 (m, 2H, (H10, H9)), 3.96 (s, 6H, H9), 3.93-3.86 (m, 2H, H7), 3.57-3.47 (m, 2H, H6), 3.41 (s, 6H, H5), 3.05-2.98 (m, 2H, H4), 1.76-1.59 (m, 2H, H3), 1.24 (brs, 30H, H2), 0.87 (t, J = 7.0 Hz, 3H, H1) ppm. 5.11 Preparation of Organosulfur QAC
O
5 6 9 4 7

Cl
8 2 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1

S

N

1

H

O
13 12 17 16 2 14

Cl
15 5 4 6 7 8 9 10 10 10 10 10 10 10 10 11 3 1

S

N

13

C

N-(3-(acetylthio)propyl)-N,N-dimethyloctadecan-1-ammonium bromide (192): This compound was prepared by the Menshutkin reaction using Method 5.2.1: 3chloropropylthioacetate (7 mL, 53 mmol, 90% from SA) and DMOA (~17 g, 51 mmol, 89% from FLUKA 1.1 eq.) were reacted neat for 24 hrs at 120°C. The hot gummy mixture was dissolved in acetone: Et2O (1:1, 70 mL) and after 5 min at RT the white solid was filtered. A small portion was further centrifuged from Et2O (15 mL), and recrystallized from 6 mL acetone
284

(5 min on ice) to afford the title compound as a white solid. Yield: 70% (16.27 g). Mp = 5455°C; 1H NMR (400 MHz, CDCl3, ): 3.69­3.64 (m, 2H, H9), 3.49-3.44 (m, 2H, H8), 3.40 (s, 6H, H7), 2.36 (s, 3H, H6), 2.09-2.01 (m, 2H, H5), 1.78-1.64 (m, 4H, (H3, H4)), 1.24 (brs, 30H, H2), 0.87 (t, J = 6.9 Hz, 3H, H1) ppm;
13

C NMR (100 MHz, CDCl3, ): 195.71 (C17), 71.17

(C16), 69.07 (C15), 55.36 (C14), 45.78 (C13), 30.71 (C12), 29.69 (C11), 29.71-29.68 (C10), 29.56 (C9), 29.35 (C8), 29.32 (C7), 29.19 (C6), 26.21 (C6), 25.72 (C4), 23.42 (C3), 22.68 (C2), 14.11 (C1) ppm.

5

7 3 4

Cl
6 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1

HS

N

1

H

Cl
4 13 2 12 14 3 2 4 5 6 7 8 9 10 10 10 10 10 10 11 3 1

HS

N

13

C

N-(3-mercaptopropyl)-N,N-dimethyloctadecan-1-ammonium chloride (194):213 To a flame dried and evacuated 20 mL screw cap vial was added N-(3-(acetylthio)propyl)-N,Ndimethyloctadecan-1-ammonium chloride (0.490g, 1 mmol) followed by HBr by pasteur pipette (1 mL, 8.88 M) and 5 mL MeOH. The mixture was purged with nitrogen and placed in a 100 C sand batch for 12 hrs. The mixture was then cooled to RT and concentrated to remove H2O and methanol, re-dissolved in 5 mL MeOH and stirred with activated charcoal for 3 hrs at RT. The mixture was filtered through Celite (washed with 2 × 10 mL MeOH), concentrated and recrystallized from CHCl3/pentanes to afford a white solid. Yield 83% (0.339 g). Mp = 58-60°C;
1

H NMR (400 MHz, CDCl3, ): 3.85-3.41 (m, 2H, H7), 3.75-3.54 (m, 2H, H6), 3.52-3.40 (m,
285

2H, H5), 3.31 (s, 6H, H4), 1.82-1.60 (m, 2H, H3), 1.19 (brs, 30H, H2), 0.82 (t, J = 6.9 Hz, 3H,

H1) ppm; 13C NMR (100 MHz, CDCl3, ): 65.79 (C14), 60.58 (C13), 51.35 (C12), 31.89 (C11), 29.80-29.85 (C10), 29.71 (C9), 29.65 (C8), 29.61 (C7), 29.39 (C6), 29.34 (C5), 26.38 (C4), 22.95 (C3), 22.64 (C2), 14.06 (C1) ppm. HRMS-DART (m/z): [M+] ­ Cl- calculated for C24H52NS, 386.3814; found, 386.3821. (Agrees well with literature NMR values).213
4

Br N
1

S

5

S

N
7

3 6 2

2 2

2 2

2 2

2 2

2 2

2 2

2 2

1

Br

H
Br N
11

S

5

S

N
12 13

2 3

4 6

7 8

9 9

9 9

9 9

9 9

10 3

1

Br
13

C

2,2'-disulfanediylbis N,N-dimethyloctadecan-1-ammonium bromide (198):214 This compound was prepared by first stirring 2,2'-disulfanediylbis(N,N-dimethylethanaminium) HCl (0.896 g, 3.18 mmol) with NaOEt (0.433 g, 6.37 mmol, 2 eq.) in EtOH (10 mL) for 20 min at RT to free base the bisamine. Next the mixture was filtered through Celite and bromooctadecane was added (2.30 g, 6.9 mmol, 2.2 eq.) followed by reflux overnight. The mixture was hot filtered from charcoal. Volatiles were removed on a rotary evaporator and the crude was recrystallized from acetone (60 mL) by slow evaporation overnight at RT as a white solid. Yield: 70% (1.11 g). Mp = 98-100°C; 1H NMR (400 MHz, CDCl3, ): 3.90-3.77 (m, 2H, H7), 3.64-3.44 (m, 4H, (H6, H5)), 3.37 (s, 6H, H4), 1.82-1.62 (m, 2H, H3), 1.23 (brs, 30H, H2), 0.85 (t, J = 6.9 Hz, 3H, H1) ppm;
13

C NMR (100 MHz, CDCl3, ): 64.64 (C13), 62.13 (C12),

51.59 (C11), 31.92 (C10), 29.80-29.70 (C9), 29.67 (C8), 29.58 (C7), 29.42 (C6), 29.36 (C5), 26.35 (C5), 22.96 (C3), 22.67 (C2), 14.10 (C1) ppm. (Agrees well with literature NMR values).214
286

5.12 Preparation of Benzophenone QAC
O 9 6 12 11 7 5 8 4 10 O 3

1 2

Br

4-O-(4-bromobutyl)benzophenone (202):105 A 50 mL round bottom flask was charged with 1,3-dibromopropane (~ 4 mL, 40 mmol, 4 eq.), K2CO3 (2.76 g, 20 mmol, 2 eq.) and ACN (10 mL). A solution of 4-hydroxybenzophenone (1.989 g, 10 mmol) in ACN (4 mL) was prepared and added dropwise to the previous mixture under reflux. The resultant yellow mixture was heated at reflux until a colourless solution was obtained or until TLC showed the disappearance of starting material 4-hydroxybenzophenone (~20 hrs). The excess KBr salt was filtered through Celite and washed with acetone (10 mL). The solution was evaporated under reduced pressure to give the crude product. The crude product was packed onto silica and purified by dry column chromatography (4.5 cm × 5.0 cm frit, 40 g silica) pre-eluting with 5% EtOAC/Hexanes (150 mL) then eluting with 100% acetone (200 mL) to afford 2.7 g of the desired product contaminated with trace of starting material. The resulting yellow oil was recrystallized from hexanes/EtOAc (8:2) to yield clear, colourless crystals. Yield: 90% (2.3 g). TLC (50% acetone/hexanes, KMnO4 stain), Rf = 0.8, Mp = 5253°C. 1H NMR (400 MHz, CDCl3, ): 7.83 (d, 2H, J = 8.7 Hz, H1), 7.77 (d, 2H, J = 8.3 Hz, H7), 7.58 (t, 1H, J = 7.4 Hz, H3), 7.48 (t, 2H, J = 7.7 Hz, H2), 6.98 (d, 2H, J = 8.7 Hz, H8), 4.20 (t, 2H, J = 5.8 Hz, H10), 3.63 (t, 2H, J = 6.3 Hz, H12), 2.37 (q, 2H, J = 6.0 Hz, H11) ppm;
13

C

NMR (100 MHz, CDCl3, ): 195.51 (C5), 162.30 (C9), 138.23 (C4), 132.58 (C3), 131.94 (C7), 130.36 (C6), 129.74 (C1), 128.21 (C2), 114.04 (C8), 65.53 (C10), 32.13 (C12), 29.74 (C11)
287

ppm. HRMS-DART (m/z): [MH+] calculated for C16H15BrO2, 319.0334; found, 319.0329. (Agrees well with literature NMR values).105
O 10 9 12 7 6 8 5 11 O 4 2 1 3 N

(4-(3-(dimethylamino)propoxy)phenyl)(phenyl)methanone (204):257 In a 50 mL round bottom flask, powdered KOH was added (0.8 g, 20 mmol, 2 eq.) to a stirred solution of 4-hydroxybenzophenone (1.98 g, 10 mmol) in ACN (4 mL) and the mixture was brought to reflux for 15 min. Dimethylaminopropionylchloride HCl (1.58 g, 10 mmol) was added to the hot mixture in one portion turning the reaction initially from a yellow colour to a clear colour and after a few seconds, back to yellow. The mixture was refluxed ON. The mixture was cooled to RT, evaporated under reduced pressure, packed onto silica and purified by dry column chromatography (4.5 cm × 5.0 cm frit, 40 g silica) pre-eluting with 100% acetone (100 mL) then eluting with 10% Et3N/acetone (150 mL) to afford of the desired product as a yellow oil. Yield: 50% (1.426 g). TLC (30% MeOH/acetone), Rf = 0.3; 1H NMR (400 MHz, CDCl3, ): 7.77 (d, J = 8.8, 2H, H9), 7.72 (d, J = 7.0, 2H, H8), 7.52 (t, J = 7.4, 1H, H7), 7.43 (t, J = 7.6, 2H, H6), 6.93 (d, J = 8.8, 2H, H5), 4.07 (t, J = 6.4 Hz, 2H, H4), 2.43 (t, J = 7.0 Hz, 2H, H3), 2.23 (s, 6H, H2) 1.97 (m, 2H, H1) ppm;
13

C NMR (100 MHz, CDCl3, ): 195.4 (C12), 162.7 (C11),

138.3 (C7), 132.5 (C9), 131.8 (C10), 129.7 (C6), 128.1 (C8), 114.0 (C5), 66.4 (C4), 56.2 (C3), 45.5 (C2), 27.4 (C1) ppm. (Agrees well with literature NMR values).257

288

O 14 13 16 11 10 12 9 15 O 8 O 12 13 16 14 11 10 9 15 O 8 Cl 3 6 N 7 5 O O Si O 2 3 7 Cl 4 N 5 O O Si O 1

2

6
1

H

1

4
13

C

3-(4-benzoylphenoxy)-N,N-dimethyl-N-(3-(trimethoxysilyl)propyl)propan-1-ammonium chloride (206). This compound was prepared according to Method 5.2.1 employing compound 204 (1.426 g, 5 mmol) and 3-chloropropyltrimethoxysilane 1 (1.7075g, 5.1 mmol, 1.1 eq.) in MeOH (2.5 mL) for 48 hrs. To purify, Et2O (2 × 15 mL) was added directly to the reaction mixture and the mixture was triturated followed by drying under high vaccum to give a yellow oil. Yield: 67% (1.76 g); 1H NMR (400 MHz, CDCl3, ): 7.81 (d, J = 8.74, 2H, H13), 7.74 (d, J = 7.37, 2H, H12), 7.58 (t, J = 7.37, 1H, H11), 7.48 (t, J = 7.77, 2H, H10), 6.87 (d, J = 8.79, 2H, H9), 4.22 (t, J = 5.33 Hz, 2H, H8), 3.93-3.82 (m, 2H, H7), 3.59 (s, 9H, H6), 3.53-3.57 (m, 2H, H5), 3.47 (m, 6H, H4), 2.43-2.28 (m, 2H, H3), 1.95-1.82 (m, 2H, H2), 0.69 (t, J = 7.0 Hz, 2H, H1) ppm; 13C NMR (100 MHz, CDCl3, ): 195.38 (C16), 161.69 (C15), 137.92 (C14), 132.37 (C13), 130.48 (C12), 129.53 (C11), 128.15 (C10), 114.12 (C9), 64.28 (C8), 60.71 (C7), 55.99 (C6), 50.42 (C5), 45.25 (C4), 22.91 (C3), 15.14 (C2), 5.54 (C1) ppm.
O
14 17 12 11 13 15 10 16 9 3 4 8 6

Br N
7 3 5 2 2 2 2 2 2 2 2 2 2 2 2 2 11

O

H

289

O
23 26 24 21 20 22 19 25 18 5 2 17 15

Br N
16 4 6 7 8 9 10 11 12 13 13 13 13 13 14 3 1 13

O

C

N-(4-(4-benzoylphenoxy)butyl)-N,N-dimethylheptadecan-1-ammonium bromide (205):258 This compound was prepared by the Menshutkin reaction using Method 5.2.2: 4-O-(4bromobutyl)benzophenone (0.333 g, 1 mmol) and DMOA (0.238 g,1.0 mmol, 1.0 eq.) in ACN (0.5 mL) were heated at 150 °C (2 min). The title compound was placed on ice for 5 min and precipitated from the reaction vial upon cooling as a white solid. Yield: 65% (0.40 g). Mp = 8487°C; 1H NMR (400 MHz, CDCl3, ): 7.77 (d, J = 3.28, 2H, H14), 7.71 (d, J = 6.94, 2H, H13), 7.55 (t, J = 7.25, 1H, H12), 7.44 (t, J = 7.7, 2H, H11), 6.93 (t, J = 8.82, 2H, H10), 4.15-4.08 (m, 2H, H9), 3.78-3.69 (m, 2H, H8), 3.51-3.43 (m, 2H, H7), 3.38 (s, 6H, H6), 1.99-1.87 (m, 4H, (H6,H5)), 1.78-1.58 (m, 2H, H3), 1.21 (brs, 30H, H2), 0.84 (t, J = 7.07 Hz, 3H, H1) ppm;
13

C

NMR (100 MHz, CDCl3, ): 195.47 (C26), 162.15 (C15), 138.07 (C24), 132.55 (C23), 131.99 (C22), 129.68 (C21), 128.18 (C20), 114.08 (C19), 67.10 (C18), 67.11 (C17), 66.97 (C16), 51.19 (C15), 31.88 (C14), 29.67 (C13), 29.62 (C12), 29.57 (C11), 29.45 (C10), 29.38 (C9), 29.32 (C8), 29.20 (C7), 27.73 (C6), 26.27 (C5), 25.81 (C4), 22.65 (C3), 19.75 (C2), 14.09 (C1) ppm. (Agrees well with literature NMR values).258 5.13 Preparation of Dansyl QAC
1 1

N
2 3 4 5 7

8 9 10 11 16

6

O S O 14 HN 12
13 15

N
16

290

5-(dimethylamino)-N-(3-(dimethylamino)propyl)naphthalene-1-sulfonamide (208):177,259 To a flame dried 500 mL round bottom flask with a reflux condenser connected to an inert atmosphere manifold anhydrous DCM (300 mL) was added followed by dansyl chloride (10.0 g, 37.07 mmol), Et3N (~ 8 mL, 55.61 mmol). While the solution was stirring at RT, 3-(dimethylamino)propylamine (7.0 ml, 55.61 mmol) was added drop wise via syringe resulting in a colour change from orange to lime-green. After stirring for 1 hr, HCl (g) was bubbled through the solution until pH 2 was reached. The resulting mixture was evaporated to dryness, then re-dissolved in saturated brine H2O (100 mL) and basified to pH 11 with 6 N NaOH (15 mL) at 0 °C until white-yellow precipitate was observed. The mixture was refrigerated overnight enhancing further precipitation of product. The precipitate was filtered washing with H2O and the filtrate was extracted with DCM (500 mL) and evaporated to dryness to afford a white solid. Yield: 97% (12.1 g). (Recrystallized using 80% EtOH/H2O). Mp = 122­124°C; TLC (5% NH4+OH-:Acetone), UV-Vis (MeOH, 1 × 10-3 M), Abs max = 516 nm,  = 447 M-1 cm-1. 1H NMR (400 MHz, CDCl3, ): 8.52 (d, 1H, J = 8.5 Hz, H8), 8.31 (d, 1H, J = 8.6 Hz, H5), 8.23 (dd, 1H, 1J = 1.2 Hz, 2J = 7.3 Hz, H10), 7.58 ­ 7.50 (m, 2H, H4, H9), 7.17 (d, 1H, J = 7.5: H3), 2.94 (t, 2H, J = 5.5 Hz, H13), 2.88 (s, 6H, H1), 2.21 (t, 2H, J = 5.5 Hz, H15), 2.12 (s, 6H, H16), 1.58-1.52 (m, 2H, H14) ppm;
13

C NMR (100 MHz, CDCl3, ): 151.90 (C2), 134.77

(C11), 129.98 (C6), 128.89 (C8), 129.71 (C4), 129.65 (C9), 128.07 (C10), 123.17 (C5), 119.03 (C7), 115.00 (C3), 59.58 (C15), 45.42 (C1, C16), 44.54 (C13), 24.61 (C14) ppm. HRMS-DART (m/z): [M+] calculated for C17H26N3O2S1, 336.1736; found, 336.1745. (This compound has also been prepared on a 25 g, 92.6 mmol scale). (Agrees well with literature NMR values).177,259
291

1

1

N
2 3 4 5 7 8 9 10 11

6

O S O 14 12 HN
13 15

Cl

N-(3-chloropropyl)-5-(dimethylamino)naphthalene-1-sulfonamide (209):260 A flame dried 100 mL round bottom flask was charged with DCM (30 mL), Et3N (~ 1.6 mL, 11.1 mmol, 3.0 eq.) and 3-chloropropan-1-aminium chloride (1.0 g, 5.56 mmol, 1.5 eq.). The reaction was stirried at RT until the amine salt dissolved, afterwhich the dansyl chloride (1.0 g, 3.7 mmol) was added in one portion resulting in a colour change from dark yellow to lime-green. After stirring for 30 min the reaction was quenched with H2O (50 mL) and the organic layer was extracted, washed with brine (30 mL), dried with MgSO4 and evaporated to dryness to afford a brown orange solid that was used without any further purification.Yield: 95% (1.15 g). TLC (5% NH4+OH-:Acetone), Rf = 0.85 : 1H NMR (400 MHz, MeOD, ): 8.66-8.58 (m, 1H, H8), 8.33 (d, J = 7.9 Hz, 1H, H5), 8.26 (d, J = 6.4 Hz, 1H, H10), 7.39 (q, 2H, J = 7.57 Hz, 2H, (H4 + H9)), 7.29-7.21 (m, 1H, H3), 3.34-3.28 (m, 2H, H13), 3.11-3.03 (m, 2H, H15), 2.94 (s, 6H, H1), 1.95 (t, J = 6.1 Hz, 2H, H14) ppm; 13C NMR (100 MHz, MeOD, ): 151.9 (C3), 135.5 (C12), 129.8 ­ 127.7 (m, (C5, C7, C9, C10, C11 overlap)), 122.9 (C6), 119.0 (C8), 115.0 (C4), 44.4 (C1, C2), 44.1 (C16), 39.5 (C14), 32.3 (C15) ppm. (Agrees well with literature NMR values).260

292

1

1

N
2 3 4 5 7 8 9 10 11

6

O S O 14 12 HN
13 15

Br

N-(3-bromopropyl)-5-(dimethylamino)naphthalene-1-sulfonamide (210):261 A flame dried 250 mL round bottom flask was charged with DCM (50 mL), Et3N (~ 1.6 mL, 11.1 mmol, 3.0 eq.) and 3-bromopropan-1-aminium bromide (0.9 g, 4.1 mmol, 1.1 eq.). The reaction was stirred at RT to dissolve the amine salt, afterwhich the dansyl chloride (1.0 g, 3.7 mmol) was added in one portion resulting in a colour change from orange to lime-green. After stirring for 40 min the reaction was quenched with H2O (50 mL) and the organic layer was extracted, washed with brine (30 mL), dried with MgSO4 and evaporated to dryness to afford a brown orange solid that was used without any further purification. Yield: 95% (1.30 g). TLC (10% IPA:Acetone), Rf = 0.80 : 1H NMR (400 MHz, MeOD, ): 8.61 (d, J = 8.2 Hz, 1H, H8), 8.32 (d, J = 7.9 Hz, 1H, H5), 8.26 (d, J = 6.4 Hz, 1H, H10), 7.57 (q, 2H, J = 8.4 Hz, 2H, (H4 + H9)), 7.30-7.21 (m, 1H, H3), 3.30 (t, J = 3.3 Hz, 2H, H13), 3.13-3.02 (m, 2H, H15), 2.90 (s, 6H, H1), 1.94 (t, J = 6.2 Hz, 2H, H14) ppm. (Agrees well with literature NMR values).261
1 1

N
2 3 4 5 7 8 9 10 11 16 20 21

6

O S O 14 12 HN
13 15

Br
18 17

N
16

O O P O 19

20

21

293

3-(diethoxyphosphoryl)-N-(3-(5-(dimethylamino)naphthalene-1-sulfonamido)propyl)-N,Ndimethylpropan-1-ammonium bromide (211):177 This compound was prepared according to Method 5.2.1: To a stirred solution of compound 208 (2.057 g, 6.13 mmol, 1.0 eq.) in refluxing ACN (15 mL) was added diethyl(3bromopropyl)phosphonate 12 (~ 2.4 g, 9.2 mmol, 1.5 eq.) via syringe, and the vial was capped and refluxed for 20 hrs. To purify, Et2O (2 × 40 mL) was added directly to the reaction mixture and the mixture was triturated with decanting to remove any unreacted starting material followed by drying under high vaccum and recovered as a yellow solid. Yield: 90% (3.64 g). UV-Vis (MeOH, 1 × 10-3 M), Abs max = 334 nm,  = 505 M-1 cm-1. 1H NMR (400 MHz, CDCl3, ): 8.51 (d, 1H, J = 8.3 Hz, H8), 8.43 (d, 1H, J = 8.6 Hz, H5), 8.20 (dd, 1H, 1J = 1.0 Hz, 2J = 7.3 Hz, H10), 7.71 (s, 1H, H12), 7.59 (t, 1H, J = 8.4 Hz, H9), 7.50 (t, 1H, J = 7.3 Hz, H4), 7.16 (d, 1H, J = 7.4 Hz, H3), 4.11­4.02 (m, 4H, H20), 3.67­3.56 (m, 4H, H15, H17), 3.17 (s, 6H, H16), 3.10­ 2.99 (m, 2H, H13), 2.86 (s, 6H, H1), 2.10-1.95 (m, 4H, H14, H18), 1.89­1.77 (m, 2H, H19), 1.28 (t, 6H, J = 7.1 Hz, H21) ppm;
13

C NMR (100 MHz, CDCl3, ): 151.79 (C2), 134.62 (C11),

130.29 (C4), 129.79 (C6), 129.47 (C8), 129.34 (C9), 128.60 (C10), 123.28 (C5), 119.28 (C7), 115.30 (C3), 62.23­62.16 (overlap, C15, C17, C20), 51.31 (C16), 45.43 (C1), 39.73 (C13), 24.75­22.83 (C14, C18, C19), 16.45 (d, 2J = 6.0 Hz, C21) ppm; 31P NMR (121.45 MHz, CDCl3, ): 29.29 ppm. HRMS-DART (m/z): [M+ - Br-] calculated for C24H41BrN3O5P1S1, 514.2504; found, 514.2519. (Agrees well with literature NMR values).177

294

1

1

N
2 3 4 5 7 8 9 10 11 16 21 21

6

20

O S O 14 12 HN
13 15

Br
18 17

N
16

O O P O 19

21 20 21

3-(diisopropoxyphosphoryl)-N-(3-(5-(dimethylamino)naphthalene-1-sulfonamido)propyl)N,N-dimethylpropan-1-ammonium (212): This compound was prepared according to Method 5.2.1: To a stirred solution of compound 208 (0.5 g, 1.5 mmol) in refluxing ACN (3 mL) was added diisopropyl(3bromopropyl)phosphonate 13 (0.46 g, 1.6 mmol) via syringe, and the vial was capped and refluxed for 7 hrs. To purify, Et2O (2 × 15 mL) was added directly to the reaction mixture and the mixture was triturated with decanting to remove any unreacted starting material followed by drying under high vaccum and recovered as a yellow solid. Yield: 70% (0.653 g). UV-Vis (MeOH, 1 × 10-3 M), Abs max = 340 nm,  = 519 M-1 cm-1. 1H NMR (400 MHz, CDCl3, ): 8.50 (d, 1H, J = 8.3 Hz, H8), 8.43 (d, 1H, J = 8.6 Hz, H5), 8.22 (dd, 1H, 1J = 1.0 Hz, 2J = 7.3 Hz, H10), 7.75 (s, 1H, H12), 7.59 (t, 1H, J = 8.4 Hz, H9), 7.49 (t, 1H, J = 7.3 Hz, H4), 7.15 (d, 1H, J = 7.4 Hz, H3), 4.68­4.56 (m, 2H, H20), 3.66­ 3.49 (m, 4H, H15, H17), 3.16 (s, 6H, H16), 3.09­2.97 (m, 2H, H13), 2.85 (s, 6H, H1), 2.05-1.90 (m, 4H, H14, H18), 1.80­1.69 (m, 2H, H19), 1.26 (t, 12H, J = 7.1 Hz, H21) ppm;
13

C NMR (100 MHz, CDCl3, ): 151.79 (C2), 134.62 (C11), 130.31 (C4), 129.87

(C6), 129.49 (C8), 129.31 (C9), 128.64 (C10), 123.28 (C5), 119.28 (C7), 115.30 (C3), 70.69 (C20), 62.23­62.16 (overlap, C15, C17), 51.19 (C16), 45.42 (C1), 41.80 (C13), 39.60 (C21), 33.76 (C19), 24.08 (C14, C18) ppm;
295
31

P NMR (121.45 MHz, CDCl3, ):

27.32 ppm. HRMS-ESI-TOF (m/z): [M+ - Br-] calculated for C26H45BrN3O5P1S1, 542.2813; found, 542.2815.
1 1

N
2 3 4 5 7 8 9 10 11 16

6

20

O S O 14 12 HN
13 15

Cl
18 17

N
16

O O Si 19 O

3-(5-(dimethylamino)naphthalene-1-sulfonamido)-N,N-dimethyl-N-(3-(trimethoxysilyl) propyl)propan-1-ammonium chloride (213):177 To a flame dried 25 mL round bottom flask with a reflux condenser connected to an inert atmosphere manifold, ACN (20 mL) was added followed by 5-(dimethylamino)-N-(3(dimethylamino)propyl)naphthalene-1-sulfonamide 208 (3.35 g, 10 mmol). While stirring, (3chloropropyl)trimethoxysilane 1 (~ 5 mL, 25 mmol) was added via an inert syringe. The solution was stirred for 48 hrs at 110oC, and the solution turned to yellow-brownish oil. The oil precipitated in cold (1:1) DCM : Et2O mixture, forming two layers; a gummy layer and a white liquid layer. The white liquid layer was separated inside a 10 mL syringe and collected in a second 25 mL round bottom flask; the gummy layer left behind was dissolved using DCM and collected in a 25 mL round bottom flask. Excess DCM was evaporated using rotary evaporator resulting in a light yellow powder. Yield: 72.0% (3.849 g). Mp = 85-87oC. UV-Vis (MeOH, 1 × 10-3 M), Abs max = 340 nm,  = 413 M-1 cm-1. 1H NMR (400 MHz, CDCl3, ): 8.48 (d, 2H, J = 8.6 Hz, H8, H5), 8.37 (s, 1H, H12), 8.19 (d, 1H, J = 7.3 Hz, H10), 7.59 (t, 1H, J = 7.9 Hz, H4), 7.49 (t, 1H, J = 8.2 Hz, H9), 7.13 (d, 1H, J = 7.6 Hz, H3), 3.57-3.52 (m, 2H, H17), 3.49 (s, 9H, H20), 3.27-3.20 (m, 2H, H15), 3.10 (s, 6H, H16), 3.08­3.03 (m, 2H, H13), 2.84 (s, 6H, H1),
296

2.01-1.90 (m, 2H, H14), 1.71­1.60 (m, 2H, H18), 0.54 (t, 2H, J = 7.8 Hz, H19) ppm; 13C NMR (100 MHz, CDCl3, ): 151.70 (C2), 135.06 (C11), 130.18 (C4), 129.75 (C6), 129.58 (C8), 128.93 (C9), 128.53 (C10), 123.35 (C5), 119.45 (C7), 115.14 (C3), 65.62 (C15), 62.27 (C17), 50.79 (C16), 50.68 (C20), 45.40 (C1), 39.81 (C13), 26.00 (C14), 16.16 (C18), 5.35 (C19) ppm;
29

Si NMR (79.4 MHz, CD3OD, ): -68.86 ppm. HRMS-DART (m/z): [M+ - Cl-, - CH3],

calculated for C23H40ClN3O5SSi, 484.2314; found 484.2315. (Agrees well with literature NMR values).177
1 1

N
2 3 4 5 7 8 9 10 11 16

6

O S O 14 12 HN
13 15

Cl
18 17 19

N
16

S

20

21

O

3-(acetylthio)-N-(3-(5-(dimethylamino)naphthalene-1-sulfonamido)propyl)-N,Ndimethylpropan-1-ammonium chloride (214): This compound was prepared according to Method 5.2.1: To a stirred solution of compound 208 (1.0 g, 2.98 mmol) in refluxing EtOH (4 mL) was added 3-chloropropylthioacetate (90%) (0.65 mL, 4.9 mmol, 1.5 eq.) via syringe, and the vial was capped and refluxed for 24 hrs. To purify, Et2O (2x 15 mL) was added directly to the reaction mixture and the mixture was triturated with decanting to remove any unreacted starting material followed by drying under high vaccum recovered a yellow powder. Yield: 63% (1.10 g). Mp = 35-40°C;  = 439 M-1 cm-1. UV-VIS (MeOH, 1 × 10 -3 M), Abs max = 334 nm,  = 439 M-1 cm-1. 1H NMR (400 MHz, CDCl3, ): 8.49 (d, 1H, J = 8.4 Hz, H8), 8.43 (d, 1H, J = 8.5 Hz, H5), 8.18 (d, 1H, J = 7.3 Hz, H10), 7.57 (t, 1H, J = 8.0 Hz, H4), 7.49 (t, 1H, J = 8.2 Hz, H9), 7.15 (d, 1H, J = 7.5 Hz, H3), 3.57-3.48 (m, 2H,
297

H15), 3.40-3.32 (m, 2H, H17), 3.10 (s, 6H, H16), 3.05-2.98 (m, 2H, H13), 2.86 (s, 6H, H1), 2.83-2.77 (m, 2H, H19), 2.28 (s, 3H, H21), 2.03-1.85 (m, 4H, H14, H18) ppm;
13

C NMR (100

MHz, CDCl3, ): 195.80 (C21), 149.79 (C2), 134.73 (C11), 130.34 (C4), 129.67 (C6), 129.43 (C8), 128.32 (C9), 128.71 (C10),124.64 (C5), 123.52 (C7), 115.45 (C3), 62.92 (C15), 62.73 (C17), 55.14 (C16), 45.32 (C1), 42.90 (C13), 30.77 (C21), 25.57 (C19), 23.16 (C18), 23.00 (C14) ppm. HRMS-ESI-TOF (m/z): [M+ - Cl-] calculated for C22H34ClN3O3S2, 452.2036; found, 452.2037.
1 1

N
2 3 4 5 7 8 9 10 11 16 21 22

6

O S O 14 12 HN
13 15

Br
18 17 19

20

O O P O O P O O

N
16

N

3-(bis((diethoxyphosphoryl)methyl)amino)-N-(3-(5-(dimethylamino)naphthalene-1sulfonamido)propyl)-N,N-dimethylpropan-1-ammonium bromide (215): This compound was prepared according to Method 5.2.1: To a stirred solution of compound 208 (0.658 g, 1.35 mmol) in refluxing ACN (3 mL) was added compound 120 (0.658 g, 1.35 mmol), and the vial was capped and refluxed for 7 hrs. To purify, Et2O (2 × 15 mL) was added directly to the reaction mixture and the mixture was triturated with decanting to remove any unreacted starting material followed by drying under high vaccum to give a yellow powder. Yield: 60% (0.626 g). Mp = 35 ­ 36°C, UV-Vis (MeOH, 1 × 10-3 M), Abs max = 340 nm,  = 526 M-1 cm-1. 1H NMR (400 MHz, CDCl3, ): 8.48-8.38 (m, 2H, H8), 8.37-8.29 (m, 1H, H5), 8.19-8.12 (m, 1H, H10), 7.72 (s, 1H, H12), 7.56-7.38 (m, 2H, H4, H9), 7.15 (m, 1H, H2), 4.16-3.97 (m, 8H, H21),
298

3.62-3.25 (m, 4H, H15, H17), 3.05-2.85 (s, 6H, H16), 3.10-2.91 (m, 8H, H19, H20, H13), 2.81 (s, 6H, H1), 1.99-1.75 (m, 4H, H14, H18), 1.25 (t, 12H, J = 7.0 Hz, H22) ppm; 13C NMR (100 MHz, CDCl3, ): 151.85 (C2), 135.16 (C11), 130.18 (C6), 129.76 (C8), 129.47 (C4), 129.12 (C9), 128.38 (C10), 123.34 (C5), 119.34 (C7), 115.19 (C3), 62.74 (C15), 62.24 (t, 2JC-P = 3.5 Hz, C21), 61.84 (C17), 53.78 (C19), 51.65 (C16), 50.49 (C20), 45.38 (C1), 39.61 (C13), 22.79 (C14), 21.22 (C18), 16.51 (d, 2JC-P = 2.5 Hz, C22) ppm; 31P NMR (121.45 MHz, CDCl3, ): 24.42 ppm. HRMS-ESI-TOF (m/z): [MH+ - I-] calculated for C30H55IN4O8P2S1, 693.3210; found, 693.3213.
1 1

N
2 3 4 5 7 8 9 10 11 16 22 21

O
24 22 26

26 27 25 28 27

6

O S O 14 12 HN
13 15

Br
18 17 19

23

N
16

O

20

21

3-(4-benzoylphenoxy)-N-(3-(5-(dimethylamino)naphthalene-1-sulfonamido)propyl)-N,Ndimethylpropan-1-ammonium bromide (216):105 This compound was prepared according to Method 5.2.1: To a stirred solution of compound 208 (0.5 g, 1.5 mmol) in refluxing ACN (4 mL) was added (4-(3bromopropoxy)phenyl)(phenyl)methanone (0.72 g, 2.25 mmol, 1.5 eq.) via syringe, and the vial was capped and refluxed for 24 hrs. To purify, Et2O (2 × 15 mL) was added directly to the reaction mixture and the mixture was triturated with decanting to remove any unreacted starting material followed by drying under high vaccum to a yellow powder. Yield: 93% (0.91 g). Mp = 75-76°C; UV-VIS (MeOH, 1 × 10 335 nm, 1 = 524 M-1 cm-1, Abs max = 288 nm, 2 = 327 M-1 cm-1.
299
1 -3

M), Abs max =

H NMR (400 MHz,

CDCl3, ): 8.49-8.43 (m, 2H, H5, H10), 8.18 (d, 1H, J = 7.3 Hz, H8), 7.76-7.68 (m, 5H, H28, H22, H12, H9), 7.59-7.52 (m, 2H, H27), 7.47-7.42 (m, 3H, H26, H4), 7.07 (d, 1H, J = 7.6 Hz, H3), 6.82 (d, 2H, J = 8.8 Hz, H21), 4.00 (t, 2H, J = 5.4 Hz, H19), 3.73-3.69 (m, 2H, H15), 3.62-3.59 (m, 2H, H17), 3.22 (s, 6H, H16), 3.11-3.03 (m, 2H, H13), 2.81 (s, 6H, H1), 2.29-2.09 (m, 2H, H14), 2.05-1.95 (m, 2H, H18) ppm;
13

C NMR (100 MHz,

CDCl3, ): 195.47 (C24), 161.69 (C20), 151.86 (C2), 137.99 (C11), 134.86 (C25), 132.42 (C6), 132.06 (C28), 130.51 (C23), 130.37 (C8), 129.71 (C22), 129.44 (C26), 129.23 (C4), 129.20 (C9), 128.71 (C10), 128.25 (C27), 123.36 (C5), 119.39 (C7), 115.30 (C3), 114.15 (C21), 65.82 (C17), 64.50 (C15), 62.50 (C19), 51.37 (C16), 45.34 (C1), 39.87 (C13), 22.90 (C18), 15.26 (C14) ppm. HRMS-ESI-TOF (m/z): [M+ - Br-] calculated for C33H40BrN3O4S, 574.2749; found, 574.2734. (Agrees well with literature NMR values).105
1 1

N
2 3 4 5 7 8 9 10 11 16

6

O S O 14 12 HN
13 15

Br
18 17

N
16

O OH P OH 19

3-(5-(dimethylamino)naphthalene-1-sulfonamido)-N,N-dimethyl-N-(3phosphonopropyl)propan-1-ammonium bromide (217): Inside a flame dried and evacuated 20 mL screw cap vial N-(3-(diethoxyphosphoryl)propyl)N,N-dimethyloctadecan-1-ammonium bromide (0.35g, 0.58 mmol) was dissolved in anhydrous DCM (5 mL). To the clear stirred solution was added TMSBr (0.23 mL, 1.76 mmol, 3.0 eq.) through a rubber septum via syringe and the reaction was stirred at RT overnight. Completion of
300

the reaction was followed by 31P NMR spectroscopy after which the reaction was quenched with EtOH (10 mL) and stirred for 1hr followed by addition of H2O (1 mL). Volatiles were removed with a rotary evaporator connected to a high vacuum Schlenk line and the crude product was triturated with Et2O (2 × 10 mL) to remove brown colored impurities. Further purification entailed extraction with NH4+OH-:H2O (1:10, 10 mL) and washing with Et2O (1 × 5 mL). The aqueous fluorescent layer was evaporated from ACN (1 × 50 mL) to give the pure product as beige solid. Yield: 79% (0.25g). Mp = 165-168°C;  = 449 M-1 cm-1. UV-Vis (MeOH, 1 × 10-3 M), Abs max = 342 nm,  = 449 M-1 cm-1. 1H NMR (400 MHz, D2O, ): 8.58 (d, 1H, J = 8.5 Hz, H8), 8.35 (d, 1H, J = 8.5 Hz, H5), 8.23 (d, 1H, J = 7.0 Hz, H10), 7.70­7.58 (m, 2H, H4, H9), 7.31 (d, 1H, J = 7.5 Hz, H3), 3.32 (s, 6H, H16), 3.30-3.22 (m, 2H, H17 overlap), 3.19-3.11 (m, 2H, H15), 2.97 (t, 2H, J = 6.0 Hz, H13), 2.89 (s, 6H, H1), 1.93-1.86 (m, 4H, H14, H18), 1.571.49 (m, 2H, H19) ppm; 13C NMR (100 MHz, D2O, ): 133.80 (C2), 131.15 (C11), 130.15 (C6), 129.76 (C8), 128.99 (C4), 128.61 (C9), 128.40 (C10), 124.54 (C5), 119.81 (C7), 116.59, (C3), 64.32 (d, 3JC-P = 18.8 Hz, C17), 61.33 (C15), 53.99 (C16), 45.08 (C1), 39.04 (C13), 24.77 (d,
1

JC-P = 136.1 Hz, C19), 21.96 (C14), 16.85 (d, 2JC-P = 3.2, C18) ppm; 31P NMR (121.45 MHz,

D2O, ): 20.99 ppm. HRMS-ESI-TOF (m/z): [M+ - Br-] calculated for C20H33BrN3O5P1S1, 458.1873; found, 458.1868.
1 1

N
2 3 4 5 7 8 9 10 11 16

6

O S O 14 12 HN
13 15

Br
18 17 19

20

N
16

H N

22 21

H 25
23

O
21

H
24

301

3-acrylamido-N-(3-(5-(dimethylamino)naphthalene-1-sulfonamido)propyl)-N,Ndimethylpropan-1-ammonium bromide (219): This compound was prepared according to Method 5.2.1: To a stirred solution of compound 210 (1 g, 2.9 mmol, 1.0 eq.) in refluxing ACN (4 mL) was added N-(3-(dimethylamino) propyl)acrylamide (0.5 g, 3.2 mmol, 2.14 eq.) and the vial was capped and refluxed for 24 hrs. To purify, Et2O (2 × 15 mL) was added directly to the reaction mixture and the mixture was triturated with decanting to remove any unreacted starting material followed by drying under high vaccum and recovered as a yellow solid. Yield: 90% (1.16 g). Mp = 34 ­ 36°C; 1H NMR (400 MHz, CDCl3, ): 8.61-8.26 (m, 2H, 4 H, (H8, H5, H12, H20)), 8.31 (d, J = 8.13 Hz, 1H, H10), 7.54 (t, J = 7.3 Hz, 1H, H4), 7.45 (t, J = 7.3 Hz, 1H, H5), 7.09 (d, J = 7.0 Hz, 1H, H3), 6.38 (t, J = 10.3 Hz, 1H, H22), 6.18 (d, J = 16.6 Hz, 1H, H24), 5.50 (d, J = 9.9 Hz, 1H, H25), 3.60-3.12 (m, 6H, (H19, H17, H15)), 2.97 (s, 6H, H16), 2.80 (s, 6H, H1), 2.12-1.69 (m, 4H, (H14, H18)) ppm; 13C NMR (100 MHz, CDCl3, ): 166.5 (C21), 151.9 (C2), 134.9 (C11),131.3 (C6), 130.2 (C22), 129.7 (C8), 129.4 (C4), 129.2 (C9), 128.6 (C10), 126.1 (C23), 123.4 (C5), 119.2 (C7), 115.2 (C3), 66.0 (C17), 62.5 (C15), 51.1 (C16), 45.4 (C1), 39.5 (C13), 36.2 (C19), 22.5 (C14), 15.3 (C18) ppm.
1 1

N
2 3 4 5 7 8 9 10 11 16 22 23 23 21 22

6

O S O 14 12 HN
13 15

Br
18 17

O

N
16

21 20 N 20

19

O

3-(5-(dimethylamino)naphthalene-1-sulfonamido)-N-(3-(1,3-dioxoisoindolin-2-yl)propyl)N,N-dimethylpropan-1-ammonium bromide (220):
302

This compound was prepared according to Method 5.2.1 (500 mL glass bottle): A stirred solution of compound 208 (9.02 g, 26.88 mmol, 1.0 eq.) and 3-bromopropylphthalimide 10 (8.716 g, 32.5 mmol, 1.2 eq.) in EtOH (50 mL) was sealed and refluxed for 16 hrs. To purify, Et2O (1 × 300 mL) was added directly to the reaction mixture and the mixture was triturated with decanting to remove any unreacted starting material followed by another rinse with Et2O:acetone (3:1, 150 mL). The bottle was placed under high vaccum (60 min) to give a light yellow powder. X-ray quality crystals were obtained by recrystalizaiton from boiling EtOH:H2O (4:1, 100 mL), cooled to RT and placed at -20oC (2 hrs) or formed ON at RT in an NMR tube (D2O). Star shaped, colourless crystals were recovered. Yield: 43% (7.0 g). Mp = 123-125°C; 1H NMR (400 MHz, CDCl3, ): 8.44 (d, J = 8.3 Hz, 1H, H8), 8.26 (d, J = 8.6 Hz, 1H, H5), 8.10 (d, J = 6.9 Hz, 1H, H10), 7.86 (t, J = 8.4 Hz, 4H, (H22 + H23)), 7.66-7.56 (m, 2H, (H9, H4)), 7.24-7.20 (d, J = 7.2 Hz, 1H, H3), 3.69-3.51 (m, 2H, H19), 3.37-3.24 (m, 2H, H17), 3.23-3.09 (m, 2H, H15), 2.87 (s, 6H, H16), 2.79 (s, 6H, (H1, (H2 + H14 overlap)), 2.02-1.85 (m, 2H, H14), 1.81-1.66 (m, 2H, H18) ppm;
13

C NMR (100 MHz, CDCl3, ): 168.4 (C20), 151.89 (C2), 134.88 (C23),130.07

(C6), 129.47 (C8), 129.38 (C4), 128.98 (C9), 128.49 (C10), 124.16 (C5), 123.54 (C8), 119.48 (C7), 115.23 (C3), 61.76 (C17), 61.59 (C15), 50.26 (C16), 45.50 (C1), 39.50 (C13), 35.14 (C19), 23.01 (C18), 22.12 (C14) ppm.
1 1

N
2 3 4 5 7 8 9 10 11 16

6

O S O 14 12 HN
13 15

Br
18 17 19

N
16

NH2

303

3-amino-N-(3-(5-(dimethylamino)naphthalene-1-sulfonamido)propyl)-N,N-dimethylpropan -1-ammonium bromide (221): This compound was prepared by dissolving 220 (6.655 g, 11 mmol) in EtOH (50 mL) and deprotecting with hydrazine hydrate (5.0 mL, 44 mmol, 4 eq.) under reflux 2 hrs. The mixture was then cooled to RT, diluted with Et2O (100 mL) and filtered throught Celite. Volatiles were removed in vacuo and the crude product (8.647 g, yellow gum) was again diluted with Et2O (100 mL) and triturated followed by decanting and placed under high vaccum (1 hr) to obtain the title compound as a yellow/white puffy solid. Yield: 99% (5.2 g); Mp = 35-40°C; 1H NMR (400 MHz, D2O, ): 8.17 (d, J = 8.61 Hz, 1H, H8), 8.07 (d, J = 8.68 Hz, 1H, H5), 8.04 (dd, 1J = 0.95 Hz, 2J = 7.35 Hz, 1H, H10), 7.45 (t, J = 7.79 Hz, 1H, H4), 7.36 (t, J = 7.49 Hz, 2H, H9), 7.05 (d, J = 7.05 Hz, 1H, H3), 2.97-2.86 (m, 2H, H13), 2.83-2.57 (m, 2H, H15), 2.63 (t, J = 2.63Hz, 2H, H17), 2.57 (s, 6H, H16), 2.52 (s, 6H, H1), 2.47 (d, J = 2.47 Hz, 2H, H19), 1.66-1.54 (m, 2H, H14), 1.49-1.40 (m, 2H, H18) ppm; 13C NMR (100 MHz, D2O, ): 150.90 (C2), 138.82 (C11), 130.12 (C6), 129.70 (C8), 129.89 (C4), 128.75 (C9), 128.65 (C10), 124.02 (C5), 118.80 (C7), 115.85 (C3), 61.53-61.24 (C15, C17), 50.53 (C16), 44.76 (C1), 39.09 (C13), 33.85 (C19), 22.75 (C18), 22.13 (C14) ppm. DART (m/z): [M+-Br] calculated for C20H33N4O2S, found, 407.3.
1 1

N
2 3 4 5 7 8 9 10 11 16

6

O S O 14 12 HN
13 15

Br
18 17 19

22

N
16

N
20

N
21 22

304

(E)-3-((1-(dimethylamino)ethylidene)amino)-N-(3-(5-(dimethylamino)naphthalene-1sulfonamido)propyl)-N,N-dimethylpropan-1-ammonium bromide (222): To a stirred solution (20 ml ST) of dansylamine 221 (0.5 g, 1.06 mmol) and HNMe2 (1.0 mL of 5.6 M in EtOH, 5.6 mmol) in EtOH (1 mL) was added N,N-dimethylacetamide dimethyl acetal (0.2 g, 1.5 mmol) dropwise via a syringe. The reaction mixture was sealed, wrapped in aluminum foil stirred ON at RT in the dark. Volatile EtOH and Me2NH were evaporated in vacuo followed by placing the vial under high vaccum (50oC, 8 hrs) and recovered as a light orange solid. Yield: 99% (0.57 g). 1H NMR (400 MHz, D2O, ): 8.22 (d, J = 8.2 Hz, 1H, H8), 8.08 (d, J = 8.5 Hz, 1H, H5), 8.01 (d, J = 7.1 Hz, 1H, H10), 7.52-7.38 (m, 2H, (H4 + H9)), 7.12 (d, J = 7.36 Hz, 1H, H3), 2.97-2.70 (m, 6H, (H15 + H17 + H13)), 2.58 (s, 4H, H16), 2.47 (s, 8H, (H1 + H22)), 1.83 (s, 3H, H20), 1.50-1.27 (m, 4H, (H14 + H19)), 1.03 (t, J = 6.97 Hz, 2H, H19) ppm;
13

C NMR

(100 MHz, D2O, ): 174.11 (C21), 150.85 (C2), 134.05 (C11), 130.07 (C7), 129.72 (C9), 128.87 (C10), 128.73 (C5), 128.61 (C3), 124.10 (C6), 118.88 (C8), 115.91 (C4), 61.73 (C18), 61.10 (C15), 57.34 (C16), 50.29 (C22), 44.77 (C1), 39.11 (C13), 35.84 (C20), 22.01 (C18), 21.80 (C14), 16.70 (C19) ppm. ESI-TOF (m/z): [M+] calculated for C24H40N5O2P, found, 435.2
1 1

N
2 3 4 5 7 8 9 10 11 16

25

OH O Br
18 17 16 20 19 23 24

O H N
22

6

O S O 14 12 HN
13 15

N

N
21 22

305

(E)-N1-(1-(dimethylamino)ethylidene)-N3-(3-(5-(dimethylamino)naphthalene-1sulfonamido)propyl)-N3,N3-dimethylpropane-1,3-diammonium bromide hydrogencarbonate (223): This compound was prepared by dissolving 222 in D2O and bubbling CO2 directly into the solution for 60 min. 1H NMR (400 MHz, D2O, ): 8.26 (d, J = 8.56 Hz, 1H, H8), 8.12 (d, J = 8.64 Hz, 1H, H5), 8.01 (d, J = 7.28 Hz, 1H, H10), 7.52 (t, J = 8.24 Hz, 1H, H4), 7.46 (t, J = 8.02 Hz, 1H, H9), 7.15(d, J = 7.68 Hz, 1H, H3), 3.00 (t, J = 6.80 Hz, 2H, H19), 2.93-2.89 (m, 6H, (H15 + H17)), 2.71-2.70 (m, 2H, H13), 2.62 (s, 6H, H1), 2.54 (s, 6H, H22), 1.90 (s, 3H, H20), 1.51-1.44 (m, 4H, (H14 + H18)) ppm; 13C NMR (100 MHz, D2O, ): 174.17 (C21), 151.00 (C2), 133.98 (C11), 130.23 (C6), 129.81 (C8), 128.98 (C4), 128.81 (C9), 128.26 (C10), 124.13 (C5), 118.42 (C7), 115.95 (C3), 61.62 (C17), 61.10 (C16), 50.38 (C16, C22), 44.83 (C1), 38.96 (C13), 35.92 (C19), 22.05 (C20), 21.90 (C14), 21.86 (C18) ppm.
1 1

N
2 3 4 5 7 8 9 10 11 16

6

O S O 14 12 HN
13 15

Br
18 17 19

20

N
16

H N

21

S

S

(3-((3-(5-(dimethylamino)naphthalene-1-sulfonamido)propyl) dimethylammonio) propyl) carbamodithioate (225): To a stirred solution of flourophore 221 (0.5g, 1.05 mmol) in methanolic KOH (5 mL, 65 mg, 1.15 mmol, 1.1 eq.) was added CS2 (0.1 mL, 1.65 mmol, 1.57 eq.) dropwise via a syringe. A precipitate was observed after a few min and the reaction was further stirred for an additional 5
306

min until an oily precipitate formed around the stir bar and stopped stirring. The mixture was then diluted with EtOH (10 mL) and decanted. The yellow sticky solid left behind was again diluted with Et2O (10 mL), triturated followed by decanting and placed under high vaccum (1 hr) to obtain the title compound as a yellow/white powder. This compound was insoluble in CDCl3, D2O and MeOD. Yield: 81% (0.4 g); Mp = 220°C; 1H NMR (400 MHz, DMSO, ): 8.46 (d, J = 8.46 Hz, 1H, H8), 8.27 (d, J = 8.72 Hz, 2H, H5), 8.16-8.03 (m, 2H, (H10 + H12)), 7.69-7.57 (m, 2H, (H4 + H9)), 7.27 (d, J = 7.11 Hz, 1H, H3), 3.26-3.03 (m, 2H, (H15 + H17)), 2.81 (brs, 14H, (H1 + H16 + H20)), 1.85-1.65 (m, 4H, (H14 + H19)), ppm;
13

C NMR (100 MHz, DMSO, ):

216.09 (C21), 152.10 (C2), 136.07 (C11), 130.30 (C6), 129.66 (C8), 129.56 (C4), 129.20 (C9), 128.78 (C10), 124.36 (C5), 119.47 (C7), 115.92 (C3), 62.23 (C17), 61.24 (C15), 50.67 (C16), 45.71 (C1), 22.97 (C19), 22.37 (C14), 19.20 (C18) ppm. ESI-TOF (m/z): [M+] calculated for C21H32N4O2S3, found, 393.2.

307

6.0 Appendix List of Appendix Tables Table A 1. Crystal data and structure refinement for 34. ........................................................... 319 Table A 2. Atomic coordinates and equivalent isotropic displacement parameters for 34. ....... 320 Table A 3. Bond lengths [Å] and angles [°] for 34. ................................................................... 321 Table A 4. Anisotropic displacement parameters for 34. ........................................................... 328 Table A 5. Hydrogen coordinates and isotropic displacement parameters ............................... 329 Table A 6. Hydrogen bonds for 34 ............................................................................................ 331 Table A 7. Crystal data and structure refinement for 66. ........................................................... 331 Table A 8. Atomic coordinates and equivalent isotropic displacement parameters for 66. ..... 332 Table A 9. Bond lengths [Å] and angles [°] for 66. .................................................................. 332 Table A 10. Anisotropic displacement parameters for 66. ......................................................... 340 Table A 11. Hydrogen coordinates and isotropic displacement parameters for 66. .................. 341 Table A 12. Torsion angles [°] for 66. ....................................................................................... 342 Table A 13. Hydrogen bonds for 66 ......................................................................................... 343 Table A 14. Crystal data and structure refinement for 19. ......................................................... 343 Table A 15. Atomic coordinates and equivalent isotropic displacement parameters for 19.. .. 344 Table A 16. Bond lengths [Å] and angles [°] for 19. ................................................................. 345 Table A 17. Anisotropic displacement parameters for 19. ......................................................... 349 Table A 18. Hydrogen coordinates and isotropic displacement parameters for 19. .................. 350 Table A 19. Torsion angles [°] for 19. ....................................................................................... 351 Table A 20. Crystal data and structure refinement for 220. ....................................................... 353 Table A 21. Atomic coordinates and equivalent isotropic displacement parameters for 220. ... 354 Table A 22. Bond lengths and angles [°] for 220. ...................................................................... 355 Table A 23. Anisotropic displacement parameters for 222. ....................................................... 361 Table A 24. Hydrogen coordinates and isotropic displacement parameters for 220. ................ 363 Table A 25. Torsion angles for 220............................................................................................ 364 Table A 26. Hydrogen bonds for 220 ........................................................................................ 366 List of Appendix Figures Figure A 1. 1H NMR spectrum of compound 2 in CDCl3 ......................................................... 368 Figure A 2. 13C NMR spectrum of compound 2 in CDCl3 ........................................................ 369 Figure A 3. COSY 2D NMR spectrum of compound 2 in CDCl3 ............................................. 370 Figure A 4. 1H NMR spectrum of purified 46 in CDCl3............................................................ 371 Figure A 5. 13C NMR spectrum of purified 46 in CDCl3 .......................................................... 372 Figure A 6. COSY 2D NMR spectrum of purified 46 in CDCl3 ............................................... 373 Figure A 7. HSQC 2D NMR spectrum of purified 46 in CDCl3 ............................................... 374 Figure A 8. 1H NMR spectrum of compound 22 in CDCl3 ....................................................... 375 Figure A 9. 13C NMR spectrum of compound 22 in CDCl3 ...................................................... 376
308

Figure A 10. HSQC 2D NMR spectrum of compound 22 in CDCl3 ......................................... 377 Figure A 11. 1H NMR spectrum of compound 1+2 in CDCl3 ................................................... 378 Figure A 12. 13C NMR spectrum of compound 1 in CDCl3 ...................................................... 379 Figure A 13. 1H NMR spectrum of compound 3 in CDCl3 (Table 2.1, entry i)....................... 380 Figure A 14. 13C NMR spectrum of compound 3 in CDCl3 (Table 2.1, entry i)...................... 381 Figure A 15. COSY 2D NMR spectrum of compound 3 in CDCl3 (Table 2.1, entry i) .......... 382 Figure A 16. HSQC 2D NMR spectrum of compound 3 in CDCl3 (Table 2.1, entry i) .......... 383 Figure A 17. 1H stacked NMR spectra of compound 3 in CDCl3 (Table 2.1, entry i-iii) ........ 384 Figure A 18. 1H stacked NMR spectra of compound 3 in CDCl3 (Table 2.1, entry iv-v, viii) 385 Figure A 19. 1H NMR spectrum of compound 3 in CDCl3 (Table 2.2, entry iii) .................... 386 Figure A 20. 13C NMR spectrum of compound 3 in CDCl3 (Table 2.2, entry iii) ................... 387 Figure A 21. 1H NMR spectrum of compound 12 in CDCl3 (Table 2.3, entry iii) .................. 388 Figure A 22. 13C NMR spectrum of compound 12 in CDCl3 (Table 2.3, entry iii) ................. 389 Figure A 23. COSY 2D NMR spectrum of compound 12 in CDCl3 (Table 2.3, entry iii) ...... 390 Figure A 24. HSQC 2D NMR spectrum of compound 12 in CDCl3 (Table 2.3, entry iii) ...... 391 Figure A 25. 31P NMR spectrum of compound 12 in CDCl3 (Table 2.3, entry iii) .................. 392 Figure A 26. 1H NMR spectrum of compound 13 in CDCl3 (Table 2.3, entry vii).................. 393 Figure A 27. 13C NMR spectrum of compound 13 in CDCl3 (Table 2.3, entry vii) ................ 394 Figure A 28. COSY 2D NMR spectrum of compound 13 in CDCl3 (Table 2.3, entry vii) ..... 395 Figure A 29. HSQC 2D NMR spectrum of compound 13 in CDCl3 (Table 2.3, entry vii) ..... 396 Figure A 30. 31P NMR spectrum of compound 13 in CDCl3 (Table 2.3, entry vii) ................. 397 Figure A 31. 1H NMR spectrum of compound 14 in CDCl3 (Table 2.3, entry ix) .................. 398 Figure A 32. 13C NMR spectrum of compound 14 in CDCl3 (Table 2.3, entry ix).................. 399 Figure A 33. COSY 2D NMR spectrum of compound 14 in CDCl3 (Table 2.3, entry ix) ...... 400 Figure A 34. HSQC 2D NMR spectrum of compound 14 in CDCl3 (Table 2.3, entry ix) ...... 401 Figure A 35. 31P NMR spectrum of compound 14 in CDCl3 (Table 2.3, entry ix) .................. 402 Figure A 36. 1H NMR spectrum of compound 16 in CDCl3 (Table 2.3, entry xv) .................. 403 Figure A 37. 13C NMR spectrum of compound 16 in CDCl3 (Table 2.3, entry xv) ................. 404 Figure A 38. COSY 2D NMR spectrum of compound 16 in CDCl3 (Table 2.3, entry xv) ..... 405 Figure A 39. HSQC 2D NMR spectrum of compound 16 in CDCl3 (Table 2.3, entry xv) ..... 406 Figure A 40. 31P NMR spectrum of compound 16 in CDCl3 (Table 4.3, entry xv) ................. 407 Figure A 41. 1H NMR spectrum of compound 17 in CDCl3 (Table 2.3, entry xvi) ................. 408 Figure A 42. 13C NMR spectrum of compound 17 in CDCl3 (Table 2.3, entry xvi)................ 409 Figure A 43. COSY 2D NMR spectrum of compound 17 in CDCl3 (Table 2.3, entry xvi) .... 410 Figure A 44. HSQC 2D NMR spectrum of compound 17 in CDCl3 (Table 2.3, entry xvi) .... 411 Figure A 45. 31P NMR spectrum of compound 17 in CDCl3 (Table 2.3, entry xvi) ................ 412 Figure A 46. 1H NMR spectrum of compound 18 in CDCl3 (Table 2.3, entry xvii)................ 413 Figure A 47. 13C NMR spectrum of compound 18 in CDCl3 (Table 2.3, entry xvii) .............. 414 Figure A 48. COSY 2D NMR spectrum of compound 18 in CDCl3 (Table 2.3, entry xvii) ... 415 Figure A 49. 31P NMR spectrum of compound 18 in CDCl3 (Table 4.3, entry xvii) ............... 416
309

Figure A 50. 1H NMR spectrum of compound 19 in CDCl3 (Table 2.3, entry xviii) .............. 417 Figure A 51. 13C NMR spectrum of compound 19 in CDCl3 (Table 2.3, entry xviii) ............. 418 Figure A 52. COSY 2D NMR spectrum of compound 19 in CDCl3 (Table 2.3, entry xviii) .. 419 Figure A 53. HSQC 2D NMR spectrum of compound 19 in CDCl3 (Table 2.3, entry xviii) .. 420 Figure A 54. 31P NMR spectrum of compound 19 in CDCl3 (Table 2.3, entry xviii) .............. 421 Figure A 55. 1H NMR spectrum of compound 26 in CDCl3 (Table 2.4, entry i) ..................... 422 Figure A 56. 13C NMR spectrum of compound 26 in CDCl3 (Table 2.4, entry i).................... 423 Figure A 57. COSY 2D NMR spectrum of compound 26 in CDCl3 (Table 2.4, entry i) ........ 424 Figure A 58. HSQC 2D NMR spectrum of compound 26 in CDCl3 (Table 2.4, entry i) ........ 425 Figure A 59. 31P NMR spectrum of compound 26 in CDCl3 (Table 2.4, entry i) .................... 426 Figure A 60. 1H NMR spectrum of compound 27 in CDCl3 (Table 4.4, entry iv) ................... 427 Figure A 61. 13C NMR spectrum of compound 27 in CDCl3 (Table 2.4, entry iv).................. 428 Figure A 62. COSY 2D NMR spectrum of compound 27 in CDCl3 (Table 2.4, entry iv) ...... 429 Figure A 63. 31P NMR spectrum of compound 27 in CDCl3 (Table 2.4, entry iv) .................. 430 Figure A 64. 1H NMR spectrum of compound 28 in CDCl3 (Table 2.4, entry vii).................. 431 Figure A 65. 13C NMR spectrum of compound 28 in CDCl3 (Table 2.4, entry vii) ................ 432 Figure A 66. COSY 2D NMR spectrum of compound 28 in CDCl3 (Table 2.4, entry vii) ..... 433 Figure A 67. 31P NMR spectrum of compound 28 in CDCl3 (Table 2.4, entry vii) ................. 434 Figure A 68. 31P NMR spectrum of compound 29 in CDCl3 (Table 2.4, entry viii) ................ 435 Figure A 69. 1H NMR spectrum of compound 30 in CDCl3 (Table 2.4, entry ix) ................... 436 Figure A 70. 13C NMR spectrum of compound 30 in CDCl3 (Table 2.4, entry ix).................. 437 Figure A 71. COSY 2D NMR spectrum of compound 30 in CDCl3 (Table 4.4, entry ix) ...... 438 Figure A 72. HSQC 2D NMR spectrum of compound 30 in CDCl3 (Table 2.4, entry ix) ...... 439 Figure A 73. 31P NMR spectrum of compound 30 in CDCl3 (Table 2.4, entry ix) .................. 440 Figure A 74. 1H NMR spectrum of compound 31 in CDCL3 (Table 2.4, entry x) ................... 441 Figure A 75. 13C NMR spectrum of compound 31 in CDCL3 (Table 2.4, entry x) .................. 442 Figure A 76. COSY 2D NMR spectrum of compound 31 in CDCL3 (Table 2.4, entry x) ...... 443 Figure A 77. HSQC 2D NMR spectrum of compound 31 in CDCL3 (Table 4.4, entry x) ...... 444 Figure A 78. 31P NMR spectrum of compound 31 in CDCL3 (Table 2.4, entry x) .................. 445 Figure A 79. 1H NMR spectrum of compound 32 in CDCl3 (Table 2.4, entry xi) ................... 446 Figure A 80. 13C NMR spectrum of compound 32 in CDCl3 (Table 2.4, entry xi) .................. 447 Figure A 81. HSQC 2D NMR spectrum of compound 32 in CDCl3 (Table 2.4, entry xi)....... 448 Figure A 82. 31P NMR spectrum of compound 32 in CDCl3 (Table 2.4, entry xi) .................. 449 Figure A 83. 1H NMR spectrum of compound 33 in CDCL3 (Table 2.4, entry xii)................. 450 Figure A 84. 13C NMR spectrum of compound 33 in CDCL3 (Table 2.4, entry xii) ............... 451 Figure A 85. COSY 2D NMR spectrum of compound 33 in CDCl3 (Table 2.4, entry xii) ..... 452 Figure A 86. HSQC 2D NMR spectrum of compound 33 in CDCl3 (Table 2.4, entry xii) ..... 453 Figure A 87. 31P NMR spectrum of compound 33 in CDCL3 (Table 2.4, entry xii)................ 454 Figure A 88. 1H NMR spectrum of compound 39 in CDCl3 ..................................................... 455 Figure A 89. COSY 2D NMR spectrum of compound 39 in CDCl3 ......................................... 456
310

Figure A 90. 31P NMR spectrum of compound 39 in CDCl3..................................................... 457 Figure A 91. 1H NMR spectrum of compound 40 in CDCl3 ..................................................... 458 Figure A 92. 31P NMR spectrum of compound 40 in CDCl3 (BEFORE COLUMN) ............... 459 Figure A 93. 31P NMR spectrum of compound 40 in CDCl3 (AFTER COLUMN) .................. 460 Figure A 94. 1H NMR spectrum of compound 34 in MeOD (Table 2.5, entry i) .................... 461 Figure A 95. 13C NMR spectrum of compound 34 in MeOD (Table 2.5, entry i) ................... 462 Figure A 96. 1H NMR spectrum of compound 34 in MeOD (Table 2.5, entry i) .................... 463 Figure A 97. 1H NMR spectrum of compound 34 in MeOD (Table 2.5, entry i) .................... 464 Figure A 98. 31P NMR spectrum of compound 34 in MeOD (Table 2.5, entry i).................... 465 Figure A 99. 1H NMR spectrum of compound 35 in D2O (Table 4.5, entry ix) ...................... 466 Figure A 100. 13C NMR spectrum of compound 35 in D2O (Table 2.5, entry ix) ................... 467 Figure A 101. HSQC spectrum of compound 35 in D2O (Table 2.5, entry xi) ........................ 468 Figure A 102. COSY spectrum of compound 35 in D2O (Table 2.5, entry ix) ........................ 469 Figure A 103. 31P spectrum of compound 35 in D2O (Table 2.5, entry ix).............................. 470 Figure A 104. 1H NMR spectrum of compound 35 in D2O (Table 2.5, entry ix) .................... 471 Figure A 105. 13C NMR spectrum of compound 36 in D2O (Table 2.5, entry x) .................... 472 Figure A 106. 1H NMR spectrum of compound 36 in D2O (Table 2.5, entry x) ..................... 473 Figure A 107. HSQC NMR spectrum of compound 36 in D2O (Table 2.5, entry x) ............... 474 Figure A 108. 31P NMR spectrum of compound 36 in D2O (Table 2.5, entry x)..................... 475 Figure A 109. 1H NMR spectrum of compound 42 in D2O. ...................................................... 476 Figure A 110. 13C NMR spectrum of compound 42 in D2O. ..................................................... 477 Figure A 111. COSY 2D NMR spectrum of compound 42 in D2O. ......................................... 478 Figure A 112. HSQC 2D NMR spectrum of compound 42 in D2O. ......................................... 479 Figure A 113. 31P NMR spectrum of compound 42 in D2O. ..................................................... 480 Figure A 114. 1H NMR spectrum of compound 44 in D2O. ...................................................... 481 Figure A 115. 13C NMR spectrum of compound 44 in D2O. ..................................................... 482 Figure A 116. COSY 2D NMR spectrum of compound 44 in D2O. ......................................... 483 Figure A 117. HSQC 2D NMR spectrum of compound 44 in D2O. ......................................... 484 Figure A 118. 1H NMR spectrum of compound (51) in CDCl3................................................. 485 Figure A 119. 13C NMR spectrum of compound (51) in CDCl3................................................ 486 Figure A 120. COSY 2D NMR spectrum of compound (51) in CDCl3. ................................... 487 Figure A 121. HSQC 2D NMR spectrum of compound (51) in CDCl3. ................................... 488 Figure A 122. 31P NMR spectrum of compound (51) in CDCl3. ............................................... 489 Figure A 123. 1H NMR spectrum of compound (52) in CDCl3................................................. 490 Figure A 124. 13C NMR spectrum of compound (52) in CDCl3................................................ 491 Figure A 125. COSY 2D NMR spectrum of compound (52) in CDCl3. ................................... 492 Figure A 126. 31P NMR spectrum of compound (52) in CDCl3. ............................................... 493 Figure A 127. 1H NMR spectrum of compound (66) in CDCl3................................................. 494 Figure A 128. 13C NMR spectrum of compound (66) in CDCl3................................................ 495 Figure A 129. COSY 2D NMR spectrum of compound (66) in CDCl3. ................................... 496
311

Figure A 130. HSQC 2D NMR spectrum of compound (66) in CDCl3. ................................... 497 Figure A 131. 1H NMR spectrum of compound (67) in MeOD. ............................................... 498 Figure A 132. 13C NMR spectrum of compound (67) in MeOD. .............................................. 499 Figure A 133. COSY 2D NMR spectrum of compound (67) in MeOD. ................................... 500 Figure A 134. HSQC 2D NMR spectrum of compound (67) in MeOD. ................................... 501 Figure A 135. 1H NMR spectrum of compound (9) in CDCl3................................................... 502 Figure A 136. 13C NMR spectrum of compound (9) in CDCl3.................................................. 503 Figure A 137. COSY 2D NMR spectrum of compound (9) in CDCl3. ..................................... 504 Figure A 138. HSQC 2D NMR spectrum of compound (9) in CDCl3. ..................................... 505 Figure A 139. 1H NMR spectrum of compound (68) in CDCl3................................................. 506 Figure A 140. 13C NMR spectrum of compound (68) in CDCl3................................................ 507 Figure A 141. HSQC 2D NMR spectrum of compound (68) in CDCl3. ................................... 508 Figure A 142. 31P NMR spectrum of compound (68) in CDCl3. ............................................... 509 Figure A 143. 1H NMR spectrum of compound (105) in CDCl3. .............................................. 510 Figure A 144. 13C NMR spectrum of compound (105) in CDCl3.............................................. 511 Figure A 145. COSY 2D NMR spectrum of compound (105) in CDCl3. ................................. 512 Figure A 146. HSQC 2D NMR spectrum of compound (105) in CDCl3. ................................. 513 Figure A 147. 31P NMR spectrum of compound (105) in CDCl3. ............................................. 514 Figure A 148. 1H NMR spectrum of compound (77) in CDCl3................................................. 515 Figure A 149. 13C NMR spectrum of compound (77) in CDCl3................................................ 516 Figure A 150. HSQC 2D NMR spectrum of compound (77) in CDCl3. ................................... 517 Figure A 151. 31P NMR spectrum of compound (77) in CDCl3. ............................................... 518 Figure A 152. 1H NMR spectrum of compound (97) in MeOD. ............................................... 519 Figure A 153. 13C NMR spectrum of compound (97) in MeOD. .............................................. 520 Figure A 154. COSY 2D NMR spectrum of compound (97) in MeOD. ................................... 521 Figure A 155. HSQC 2D NMR spectrum of compound (97) in MeOD. ................................... 522 Figure A 156. 31P NMR spectrum of compound (97) in MeOD................................................ 523 Figure A 157. 1H NMR spectrum of compound (95) in CDCl3................................................. 524 Figure A 158. 13C NMR spectrum of compound (95) in CDCl3................................................ 525 Figure A 159. COSY 2D NMR spectrum of compound (95) in CDCl3. ................................... 526 Figure A 160. 31P NMR spectrum of compound (95) in CDCl3. ............................................... 527 Figure A 161. 1H NMR spectrum of compound (98) in CDCl3................................................. 528 Figure A 162. 13C NMR spectrum of compound (98) in CDCl3................................................ 529 Figure A 163. COSY 2D NMR spectrum of compound (98) in CDCl3. ................................... 530 Figure A 164. HSQC 2D NMR spectrum of compound (98) in CDCl3. ................................... 531 Figure A 165. 31P NMR spectrum of compound (98) in CDCl3. ............................................... 532 Figure A 166. 1H NMR spectrum of compound (99) in CDCl3................................................. 533 Figure A 167. 13C NMR spectrum of compound (99) in CDCl3................................................ 534 Figure A 168. COSY 2D NMR spectrum of compound (99) in CDCl3. ................................... 535 Figure A 169. HSQC 2D NMR spectrum of compound (99) in CDCl3. ................................... 536
312

Figure A 170. 31P NMR spectrum of compound (99) in CDCl3. ............................................... 537 Figure A 171. 1H NMR spectrum of compound (91) in MeOD. ............................................... 538 Figure A 172. 13C NMR spectrum of compound (91) in MeOD. .............................................. 539 Figure A 173. COSY 2D NMR spectrum of compound (91) in MeOD. ................................... 540 Figure A 174. HSQC 2D NMR spectrum of compound (91) in MeOD. ................................... 541 Figure A 175. 31P NMR spectrum of compound (91) in MeOD. (CRUDE) ............................. 542 Figure A 176. 31P NMR spectrum of compound (91) in MeOD. (COLUMNED FRACTION) 543 Figure A 177. 1H NMR spectrum of compound (87) in CDCl3................................................. 544 Figure A 178. 31P NMR spectrum of compound (87) in CDCl3. ............................................... 545 Figure A 179. 1H NMR spectrum of compound (87) in CDCl3................................................. 546 Figure A 180. 13C NMR spectrum of compound (87) in CDCl3................................................ 547 Figure A 181. COSY 2D NMR spectrum of compound (96) in CDCl3. ................................... 548 Figure A 182. HSQC 2D NMR spectrum of compound (96) in CDCl3. ................................... 549 Figure A 183. 31P NMR spectrum of compound (96) in CDCl3. ............................................... 550 Figure A 184. 1H NMR spectrum of compound (93) in CDCl3................................................. 551 Figure A 185. COSY 2D NMR spectrum of compound (93) in CDCl3. ................................... 552 Figure A 186. HSQC 2D NMR spectrum of compound (93) in CDCl3. ................................... 553 Figure A 187. 31P NMR spectrum of compound (93) in CDCl3. ............................................... 554 Figure A 188. 1H NMR spectrum of compound (83) in CDCl3................................................. 555 Figure A 189. 13C NMR spectrum of compound (83) in CDCl3................................................ 556 Figure A 190. COSY 2D NMR spectrum of compound (83) in CDCl3. ................................... 557 Figure A 191. HSQC 2D NMR spectrum of compound (83) in CDCl3. ................................... 558 Figure A 192. 1H NMR spectrum of compound (102) in CDCl3............................................... 559 Figure A 193. 13C NMR spectrum of compound (102) in CDCl3.............................................. 560 Figure A 194. COSY 2D NMR spectrum of compound (102) in CDCl3. ................................. 561 Figure A 195. HSQC 2D NMR spectrum of compound (102) in CDCl3. ................................. 562 Figure A 196. 1H NMR spectrum of compound (202) in CDCl3............................................... 563 Figure A 197. 13C NMR spectrum of compound (202) in CDCl3.............................................. 564 Figure A 198. 1H NMR spectrum of compound (204) in CDCl3............................................... 565 Figure A 199. 13C NMR spectrum of compound (204) in CDCl3.............................................. 566 Figure A 200. 1H NMR spectrum of compound (206) in CDCl3............................................... 567 Figure A 201. 13C NMR spectrum of compound (206) in CDCl3.............................................. 568 Figure A 202. 1H NMR spectrum of compound (205) in CDCl3............................................... 569 Figure A 203. 13C NMR spectrum of compound (205) in CDCl3.............................................. 570 Figure A 204. 13C NMR spectrum of compound (114) in CDCl3.............................................. 571 Figure A 205. COSY 2D NMR spectrum of compound (114) in CDCl3. ................................. 572 Figure A 206. HSQC 2D NMR spectrum of compound (114) in CDCl3. ................................. 573 Figure A 207. 31P NMR spectrum of compound (114) in CDCl3. ............................................. 574 Figure A 208. 1H NMR spectrum of compound (116) in CDCl3............................................... 575 Figure A 209. 13C NMR spectrum of compound (116) in CDCl3............................................. 576
313

Figure A 210. COSY 2D NMR spectrum of compound (116) in CDCl3. ................................. 577 Figure A 211. HSQC 2D NMR spectrum of compound (116) in CDCl3. ................................ 578 Figure A 212. 31P NMR spectrum of compound (116) in CDCl3. ............................................ 579 Figure A 213. 1H NMR spectrum of compound (117) in CDCl3.............................................. 580 Figure A 214. 13C NMR spectrum of compound (117) in CDCl3............................................. 581 Figure A 215. COSY 2D NMR spectrum of compound (117) in CDCl3. ................................ 582 Figure A 216. HSQC 2D NMR spectrum of compound (117) in CDCl3. ................................ 583 Figure A 217. 31P NMR spectrum of compound (117) in CDCl3. ............................................ 584 Figure A 218. 1H NMR spectrum of compound (118) in CDCl3.............................................. 585 Figure A 219. 13C NMR spectrum of compound (118) in CDCl3............................................. 586 Figure A 220. COSY 2D NMR spectrum of compound (118) in CDCl3. ................................ 587 Figure A 221. HSQC 2D NMR spectrum of compound (118) in CDCl3. ................................ 588 Figure A 222. 31P NMR spectrum of compound (118) in CDCl3. ............................................ 589 Figure A 223. 1H NMR spectrum of compound (119) in CDCl3.............................................. 590 Figure A 224. 13C NMR spectrum of compound (119) in CDCl3............................................. 591 Figure A 225. COSY 2D NMR spectrum of compound (119) in CDCl3. ................................ 592 Figure A 226. HSQC 2D NMR spectrum of compound (119) in CDCl3. ................................ 593 Figure A 227. 31P NMR spectrum of compound (119) in CDCl3. ............................................ 594 Figure A 228. 1H NMR spectrum of compound (113) in CDCl3.............................................. 595 Figure A 229. 13C NMR spectrum of compound (113) in CDCl3............................................. 596 Figure A 230. COSY 2D NMR spectrum of compound (113) in CDCl3. ................................ 597 Figure A 231. HSQC 2D NMR spectrum of compound (113) in CDCl3. ................................ 598 Figure A 232. 31P NMR spectrum of compound (113) in CDCl3. ............................................ 599 Figure A 233. 1H NMR spectrum of compound (120) in CDCl3.............................................. 600 Figure A 234. 31P NMR spectrum of compound (120) in CDCl3. ............................................ 601 Figure A 235. 1H NMR spectrum of compound (121) in CDCl3.............................................. 602 Figure A 236. 13C NMR spectrum of compound (121) in CDCl3............................................. 603 Figure A 237. COSY 2D NMR spectrum of compound (121) in CDCl3. ................................ 604 Figure A 238. HSQC 2D NMR spectrum of compound (121) in CDCl3. ................................ 605 Figure A 239. 31P NMR spectrum of compound (121) in CDCl3. ............................................ 606 Figure A 240. 1H NMR spectrum of compound (123) in CDCl3.............................................. 607 Figure A 241. 13C NMR spectrum of compound (123) in CDCl3............................................. 608 Figure A 242. HSQC 2D NMR spectrum of compound (123) in CDCl3. ................................ 609 Figure A 243. 1H NMR spectrum of compound (122) in CDCl3.............................................. 610 Figure A 244. 13C NMR spectrum of compound (122) in CDCl3............................................. 611 Figure A 245. COSY 2D NMR spectrum of compound (122) in CDCl3. ................................ 612 Figure A 246. HSQC 2D NMR spectrum of compound (122) in CDCl3. ................................ 613 Figure A 247. 1H NMR spectrum of compound (135) in CDCl3.............................................. 614 Figure A 248. 13C NMR spectrum of compound (135) in CDCl3.............................................. 615 Figure A 249. HSQC 2D NMR spectrum of compound (135) in CDCl3. ................................. 616
314

Figure A 250. 31P NMR spectrum of compound (135) in CDCl3. ............................................. 617 Figure A 251. 1H NMR spectrum of compound (136) in CDCl3............................................... 618 Figure A 252. 31P NMR spectrum of compound (136) in CDCl3. ............................................. 619 Figure A 253. 1H NMR spectrum of compound (131) in CDCl3............................................... 620 Figure A 254. 31P NMR spectrum of compound (131) in CDCl3. ............................................. 621 Figure A 255. 1H NMR spectrum of compound (140) in CDCl3............................................... 622 Figure A 256. 13C NMR spectrum of compound (140) in CDCl3.............................................. 623 Figure A 257. COSY 2D NMR spectrum of compound (140) in CDCl3. ................................. 624 Figure A 258. HSQC 2D NMR spectrum of compound (140) in CDCl3. ................................. 625 Figure A 259. 1H NMR spectrum of compound (153) in CDCl3............................................... 626 Figure A 260. 13C NMR spectrum of compound (153) in CDCl3.............................................. 627 Figure A 261. 13C NMR spectrum of compound (153) in CDCl3.............................................. 628 Figure A 262. 1H NMR spectrum of compound (154) in CDCl3.............................................. 629 Figure A 263. COSY 2D NMR spectrum of compound (154) in CDCl3. ................................ 630 Figure A 264. 1H NMR spectrum of compound (155) in CDCl3.............................................. 631 Figure A 265. COSY 2D NMR spectrum of compound (155) in CDCl3. ................................ 632 Figure A 266. 13H NMR spectrum of compound (155) in CDCl3. ........................................... 633 Figure A 267. 1H NMR spectrum of compound (156) in CDCl3.............................................. 634 Figure A 268. 13C NMR spectrum of compound (156) in CDCl3............................................. 635 Figure A 269. 1H NMR spectrum of compound (152) in CDCl3.............................................. 636 Figure A 270. 13C NMR spectrum of compound (152) in CDCl3............................................. 637 Figure A 271. COSY 2D NMR spectrum of compound (152) in CDCl3. ................................ 638 Figure A 272. HSQC 2D NMR spectrum of compound (152) in CDCl3. ................................ 639 Figure A 273. 1H NMR spectrum of compound (144) from (152) in CDCl3. ......................... 640 Figure A 274. 1H NMR spectrum of compound (144) from (156) in CDCl3. .......................... 641 Figure A 275. 13C NMR spectrum of compound (144) from (152) in CDCl3. ......................... 642 Figure A 276. COSY 2D NMR spectrum of compound (144) from (152) in CDCl3. .............. 643 Figure A 277. HSQC 2D spectrum of compound (144) from (152) in CDCl3 .......................... 644 Figure A 278. 1H NMR spectrum of compound (169) in CDCl3............................................... 645 Figure A 279. 13C NMR spectrum of compound (169) in CDCl3............................................. 646 Figure A 280. COSY 2D NMR spectrum of compound (169) in CDCl3. ................................ 647 Figure A 281. HSQC 2D NMR spectrum of compound (169) in CDCl3. ................................ 648 Figure A 282. 31P NMR spectrum of compound (169) in CDCl3. ............................................ 649 Figure A 283. 1H NMR spectrum of compound (158) in CDCl3............................................... 650 Figure A 284. 13C NMR spectrum of compound (158) in CDCl3.............................................. 651 Figure A 285. COSY 2D NMR spectrum of compound (158) in CDCl3. ................................. 652 Figure A 286. HSQC 2D NMR spectrum of compound (158) in CDCl3. ................................ 653 Figure A 287. 31P NMR spectrum of compound (158) in CDCl3. ............................................. 654 Figure A 288. 1H NMR spectrum of compound (170) in CDCl3............................................... 655 Figure A 289. 13C NMR spectrum of compound (170) in CDCl3............................................. 656
315

Figure A 290. COSY 2D NMR spectrum of compound (170) in CDCl3. ................................ 657 Figure A 291. HSQC 2D NMR spectrum of compound (170) in CDCl3. ................................ 658 Figure A 292. 31P NMR spectrum of compound (170) in CDCl3. ............................................. 659 Figure A 293. 1H NMR spectrum of compound (157) in D2O. ................................................ 660 Figure A 294. 13C NMR spectrum of compound (157) in D2O. ................................................ 661 Figure A 295. 13C NMR spectrum of compound (157) in DMSO-d6. ...................................... 662 Figure A 296. HSQC 2D NMR spectrum of compound (157) in CDCl3. ................................. 663 Figure A 297. 1H NMR spectrum of compound (163) in D2O. ................................................. 664 Figure A 298. 13C NMR spectrum of compound (163) in D2O. ................................................ 665 Figure A 299. COSY 2D NMR spectrum of compound (163) in CDCl3. ................................ 666 Figure A 300. HSQC 2D NMR spectrum of compound (163) in CDCl3. ................................. 667 Figure A 301. 1H NMR spectrum of compound (176) in CDCl3............................................... 668 Figure A 302. COSY 2D NMR spectrum of compound (176) in CDCl3. ................................. 669 Figure A 303. 1H NMR spectrum of compound (177) in CDCl3............................................... 670 Figure A 304. 13C NMR spectrum of compound (177) in CDCl3.............................................. 671 Figure A 305. COSY 2D NMR spectrum of compound (177) in CDCl3. ................................. 672 Figure A 306. HSQC 2D NMR spectrum of compound (177) in CDCl3. ................................. 673 Figure A 307. 1H NMR spectrum of compound (181) in CDCl3............................................... 674 Figure A 308. 13C NMR spectrum of compound (181) in CDCl3.............................................. 675 Figure A 309. COSY 2D NMR spectrum of compound (181) in CDCl3. ................................. 676 Figure A 310. HSQC 2D NMR spectrum of compound (181) in CDCl3. ................................. 677 Figure A 311. 1H NMR spectrum of compound (185) in CDCl3. (CRUDE) ............................ 678 Figure A 312. 13C NMR spectrum of compound (185) in CDCl3.(CRUDE) ............................ 679 Figure A 313. COSY 2D NMR spectrum of compound (185) in CDCl3. ................................. 680 Figure A 314. HSQC 2D NMR spectrum of compound (185) in CDCl3. ................................. 681 Figure A 315. 1H NMR spectrum of compound (188) in CDCl3............................................... 682 Figure A 316. 13C NMR spectrum of compound (188) in CDCl3.............................................. 683 Figure A 317. COSY 2D NMR spectrum of compound (188) in CDCl3. ................................. 684 Figure A 318. HSQC 2D NMR spectrum of compound (188) in CDCl3. ................................. 685 Figure A 319. 1H NMR spectrum of compound (189) in CDCL3.(CRUDE) ............................ 686 Figure A 320. 1H NMR spectrum of compound (192) in CDCl3............................................... 687 Figure A 321. 13C NMR spectrum of compound (192) in CDCl3.............................................. 688 Figure A 322. COSY 2D NMR spectrum of compound (192) in CDCl3. ................................. 689 Figure A 323. 1H NMR spectrum of compound (194) in CDCl3............................................... 690 Figure A 324. 1H NMR spectrum of compound (194) in CDCl3............................................... 691 Figure A 325. COSY 2D NMR spectrum of compound (194) in CDCl3. ................................. 692 Figure A 326. HSQC 2D NMR spectrum of compound (194) in CDCl3. ................................. 693 Figure A 327. 1H NMR spectrum of compound (198) in CDCl3............................................... 694 Figure A 328. 13C NMR spectrum of compound (198) in CDCl3.............................................. 695 Figure A 329. COSY 2D NMR spectrum of compound (198) in CDCl3. ................................. 696
316

Figure A 330. HSQC 2D NMR spectrum of compound (198) in CDCl3. ................................. 697 Figure A 331. 1H NMR spectrum of compound (202) in CDCl3............................................... 698 Figure A 332. 13C NMR spectrum of compound (202) in CDCl3.............................................. 699 Figure A 333. 1H NMR spectrum of compound (204) in CDCl3............................................... 700 Figure A 334. 13C NMR spectrum of compound (204) in CDCl3.............................................. 701 Figure A 335. 1H NMR spectrum of compound (205) in CDCl3............................................... 702 Figure A 336. 13C NMR spectrum of compound (205) in CDCl3.............................................. 703 Figure A 337. 1H NMR spectrum of compound (206) in CDCl3............................................... 704 Figure A 338. 13C NMR spectrum of compound (206) in CDCl3.............................................. 705 Figure A 339. 1H NMR spectrum of compound (208) in CDCl3............................................... 706 Figure A 340. 13C NMR spectrum of compound (208) in CDCl3.............................................. 707 Figure A 341. COSY 2D NMR spectrum of compound (208) in CDCl3. ................................. 708 Figure A 342. HSQC 2D NMR spectrum of compound (208) in CDCl3. ................................. 709 Figure A 343. 1H NMR spectrum of compound (209) in MeOD. ............................................. 710 Figure A 344. 13C NMR spectrum of compound (209) in MeOD. ............................................ 711 Figure A 345. COSY 2D NMR spectrum of compound (209) in MeOD. ................................. 712 Figure A 346. HSQC 2D NMR spectrum of compound (209) in MeOD. ................................. 713 Figure A 347. 1H NMR spectrum of compound (210) in MeOD. ............................................ 714 Figure A 348. COSY 2D NMR spectrum of compound (210) in MeOD. ................................. 715 Figure A 349. 1H NMR spectrum of compound (211) in CDCl3............................................... 716 Figure A 350. 13C NMR spectrum of compound (211) in CDCl3.............................................. 717 Figure A 351. COSY 2D NMR spectrum of compound (211) in CDCl3. ................................. 718 Figure A 352. HSQC 2D NMR spectrum of compound (211) in CDCl3. ................................. 719 Figure A 353. 31P NMR spectrum of compound (211) in CDCl3. ............................................. 720 Figure A 354. 1H NMR spectrum of compound (212) in CDCl3............................................... 721 Figure A 355. 13C NMR spectrum of compound (212) in CDCl3.............................................. 722 Figure A 356. HSQC 2D NMR spectrum of compound (212) in CDCl3. ................................. 723 Figure A 357. 31P NMR spectrum of compound (212) in CDCl3. ............................................. 724 Figure A 358. 1H NMR spectrum of compound (213) in CDCl3............................................... 725 Figure A 359. 13C NMR spectrum of compound (213) in CDCl3.............................................. 726 Figure A 360. COSY 2D NMR spectrum of compound (213) in CDCl3. ................................. 727 Figure A 361. HSQC 2D NMR spectrum of compound (213) in CDCl3. ................................. 728 Figure A 362. 1H NMR spectrum of compound (214) in CDCl3............................................... 729 Figure A 363. 13C NMR spectrum of compound (214) in CDCl3.............................................. 730 Figure A 364. COSY 2D NMR spectrum of compound (214) in CDCl3. ................................. 731 Figure A 365. HSQC 2D NMR spectrum of compound (214) in CDCl3. ................................. 732 Figure A 366. 1H NMR spectrum of compound (215) in CDCl3............................................... 733 Figure A 367. 13C NMR spectrum of compound (215) in CDCl3.............................................. 734 Figure A 368. COSY 2D NMR spectrum of compound (215) in CDCl3. ................................. 735 Figure A 369. HSQC 2D NMR spectrum of compound (215) in CDCl3. ................................ 736
317

Figure A 370. 31P NMR spectrum of compound (215) in CDCl3 ............................................. 737 Figure A 371. 1H NMR spectrum of compound (216) in CDCl3.............................................. 738 Figure A 372. 13C NMR spectrum of compound (216) in CDCl3............................................. 739 Figure A 373. COSY 2D NMR spectrum of compound (216) in CDCl3. ................................ 740 Figure A 374. HSQC 2D NMR spectrum of compound (216) in CDCl3. ................................ 741 Figure A 375. 1H NMR spectrum of compound (217) in D2O. ................................................ 742 Figure A 376. 13C NMR spectrum of compound (217) in D2O. ............................................... 743 Figure A 377. COSY 2D NMR spectrum of compound (217) in D2O. ..................................... 744 Figure A 378. HSQC 2D NMR spectrum of compound (217) in D2O. .................................... 745 Figure A 379. 31P NMR spectrum of compound in (217) D2O................................................. 746 Figure A 380. 1H NMR spectrum of compound (219) in CDCl3............................................... 747 Figure A 381. 13C NMR spectrum of compound (219) in CDCl3.............................................. 748 Figure A 382. COSY 2D NMR spectrum of compound (219) in CDCl3. ................................. 749 Figure A 383. 1H NMR spectrum of compound (220) in DMSO-d6. ....................................... 750 Figure A 384. 13C NMR spectrum of compound (220) in DMSO-d6. ...................................... 751 Figure A 385. HSQC 2D NMR spectrum of compound (220) in DMSO-d6. ........................... 752 Figure A 386. 1H NMR spectrum of compound (221) in D2O. ................................................. 753 Figure A 387. 13C NMR spectrum of compound (221) in D2O. ................................................ 754 Figure A 388. COSY 2D NMR spectrum of compound (221) in D2O. ..................................... 755 Figure A 389. HSQC 2D NMR spectrum of compound (221) in D2O. ..................................... 756 Figure A 390. 1H NMR spectrum of compound (222) in D2O. ................................................. 757 Figure A 391. 13C NMR spectrum of compound (222) in D2O. ................................................ 758 Figure A 392. COSY 2D NMR spectrum of compound (222) in D2O. .................................... 759 Figure A 393. HSQC 2D NMR spectrum of compound (222) in D2O. ..................................... 760 Figure A 394. 1H NMR spectrum of compound (223) in D2O. ................................................. 761 Figure A 395. 13C NMR spectrum of compound (223) in D2O. ................................................ 762 Figure A 396. HSQC 2D NMR spectrum of compound (223) in D2O. ..................................... 763 Figure A 397. 1H NMR spectrum of compound (225) in DMSO-d6. ...................................... 764 Figure A 398. 13C NMR spectrum of compound (225) in DMSO-d6. ...................................... 765 Figure A 399. ESI-TOF spectrum of compound 19................................................................... 766 Figure A 400. ESI-TOF spectrum of compound 26................................................................... 767 Figure A 401. HRMS ESI-TOF spectrum of compound 27. .................................................... 768 Figure A 402. ESI-TOF spectrum of compound 34................................................................... 769 Figure A 403. HRMS ESI-TOF spectrum of compound 36. .................................................... 770 Figure A 404. ESI-TOF spectrum of compound 51.................................................................. 771 Figure A 405. ESI-TOF spectrum of compound 66................................................................... 772 Figure A 406 .DART-HRMS spectrum of compound 113. ....................................................... 773 Figure A 407. ESI-TOF spectrum of compound 121................................................................. 774 Figure A 408. DART spectrum of compound 163..................................................................... 775 Figure A 409. HRMS-DART spectrum of compound 163. ...................................................... 776
318

Figure A 410. ESI-TOF spectrum of compound 194................................................................. 777 Figure A 411. ESI-TOF spectrum of compound 205................................................................. 778 Figure A 412. DART spectrum of compound 208..................................................................... 779 Figure A 413. HRMS-DART spectrum of compound 208. ....................................................... 780 Figure A 414. DART spectrum of compound 211..................................................................... 781 Figure A 415. HRMS-DART spectrum of compound 211. ....................................................... 782 Figure A 416. ESI-TOF spectrum of compound 212................................................................. 783 Figure A 417. HRMS-DART spectrum of compound 213. ....................................................... 784 Figure A 418. HRMS-DART spectrum of compound 213. ....................................................... 785 Figure A 419. ESI-TOF spectrum of compound 217................................................................ 786 Figure A 420. DART spectrum of compound 221..................................................................... 787 Figure A 421. ESI-TOF spectrum of compound 222................................................................. 788 Figure A 422. ESI-TOF spectrum of compound 225................................................................. 789

319

6.1 Appendix 1.1 ­ X-Ray Data Table A 1. Crystal data and structure refinement for 34. Identification code Empirical formula Formula weight Temperature Wavelength Crystal system Space group Unit cell dimensions k1180 C23 H51 Br N O3 P 500.53 150(1) K 0.71073 Å Triclinic P -1 a = 6.5523(5) Å = 87.242(4)°. b = 7.3545(4) Å = 89.564(3)°. c = 28.873(2) Å  = 77.409(4)°. 3 1356.32(16) Å 2 1.226 Mg/m3 1.596 mm-1 540 0.50 x 0.50 x 0.02 mm3 2.83 to 25.00°. -7<=h<=7, -8<=k<=8, -34<=l<=34 12148 4737 [R(int) = 0.1147] 99.1 % Semi-empirical from equivalents 0.992 and 0.706 Full-matrix least-squares on F2 4737 / 0 / 265 1.079 R1 = 0.0767, wR2 = 0.1501 R1 = 0.1429, wR2 = 0.1819 0.500 and -0.610 e.Å-3

Volume Z Density (calculated) Absorption coefficient F(000) Crystal size Theta range for data collection Index ranges Reflections collected Independent reflections Completeness to theta = 25.00° Absorption correction Max. and min. transmission Refinement method Data / restraints / parameters Goodness-of-fit on F2 Final R indices [I>2sigma(I)] R indices (all data) Largest diff. peak and hole

320

Table A 2. Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) for 34. ______________________________________________________________________________ x y z U(eq) ______________________________________________________________________________ Br(1) 6398(1) 3573(1) 6468(1) 56(1) P(1) 6397(3) 7024(2) 4707(1) 40(1) O(1) 7347(7) 4952(6) 4696(2) 44(1) O(2) 4221(7) 7436(6) 4912(2) 45(1) O(3) 6408(7) 7948(6) 4210(2) 49(1) N(1) 9810(8) 8204(7) 6300(2) 37(1) C(1) 8069(10) 8120(8) 5022(2) 38(2) C(2) 8050(11) 7605(9) 5546(2) 39(2) C(3) 9370(10) 8708(8) 5787(2) 38(2) C(4) 7742(10) 8344(9) 6553(2) 36(2) C(5) 7936(10) 8286(9) 7081(2) 40(2) C(6) 5862(11) 8014(9) 7289(2) 42(2) C(7) 5683(11) 8235(9) 7807(2) 42(2) C(8) 3732(11) 7685(9) 8010(2) 42(2) C(9) 3324(11) 8125(9) 8512(2) 44(2) C(10) 1422(11) 7501(9) 8712(2) 44(2) C(11) 907(11) 8011(9) 9210(2) 43(2) C(12) -985(11) 7345(9) 9403(2) 44(2) C(13) -1505(11) 7846(9) 9896(2) 42(2) C(14) -3389(11) 7170(10) 10092(2) 45(2) C(15) -3944(11) 7691(9) 10584(2) 44(2) C(16) -5802(11) 6978(10) 10779(2) 44(2) C(17) -6376(11) 7491(9) 11272(2) 43(2) C(18) -8234(11) 6791(10) 11463(2) 44(2) C(19) -8853(11) 7298(9) 11952(2) 43(2) C(20) -10742(11) 6602(10) 12125(2) 45(2) C(21) -11409(12) 7187(10) 12608(2) 52(2) C(22) 11117(11) 6252(9) 6355(2) 46(2) C(23) 11004(10) 9534(9) 6473(3) 48(2)
321

Table A 3. Bond lengths [Å] and angles [°] for 34. _____________________________________________________ P(1)-O(2) 1.514(5) P(1)-O(1) 1.517(4) P(1)-O(3) 1.559(5) P(1)-C(1) 1.773(7) O(1)-H(1O) 0.8400 O(3)-H(3O) 0.8402 N(1)-C(23) 1.486(8) N(1)-C(22) 1.505(7) N(1)-C(4) 1.522(8) N(1)-C(3) 1.523(8) C(1)-C(2) 1.544(8) C(1)-H(1A) 0.9900 C(1)-H(1B) 0.9900 C(2)-C(3) 1.503(9) C(2)-H(2A) 0.9900 C(2)-H(2B) 0.9900 C(3)-H(3A) 0.9900 C(3)-H(3B) 0.9900 C(4)-C(5) 1.528(9) C(4)-H(4A) 0.9900 C(4)-H(4B) 0.9900 C(5)-C(6) 1.530(9) C(5)-H(5A) 0.9900 C(5)-H(5B) 0.9900 C(6)-C(7) 1.513(9) C(6)-H(6A) 0.9900 C(6)-H(6B) C(7)-C(8) C(7)-H(7A) C(7)-H(7B) C(8)-C(9) C(8)-H(8A) C(8)-H(8B)
322

0.9900 1.527(9) 0.9900 0.9900 1.511(9) 0.9900 0.9900

C(9)-C(10) C(9)-H(9A) C(9)-H(9B) C(10)-C(11) C(10)-H(10A) C(10)-H(10B) C(11)-C(12) C(11)-H(11A) C(11)-H(11B) C(12)-C(13) C(12)-H(12A) C(12)-H(12B) C(13)-C(14) C(13)-H(13A) C(13)-H(13B) C(14)-C(15) C(14)-H(14A) C(14)-H(14B) C(15)-C(16) C(15)-H(15A) C(15)-H(15B) C(16)-C(17) C(16)-H(16A) C(16)-H(16B) C(17)-C(18) C(17)-H(17A) C(17)-H(17B) C(18)-C(19) C(18)-H(18A) C(18)-H(18B) C(19)-C(20) C(19)-H(19A) C(19)-H(19B) C(20)-C(21) C(20)-H(20A)
323

1.520(9) 0.9900 0.9900 1.520(9) 0.9900 0.9900 1.522(9) 0.9900 0.9900 1.504(9) 0.9900 0.9900 1.523(9) 0.9900 0.9900 1.512(9) 0.9900 0.9900 1.522(9) 0.9900 0.9900 1.513(9) 0.9900 0.9900 1.512(9) 0.9900 0.9900 1.507(9) 0.9900 0.9900 1.511(9) 0.9900 0.9900 1.515(9) 0.9900

C(20)-H(20B) C(21)-H(21A) C(21)-H(21B) C(21)-H(21C) C(22)-H(22A) C(22)-H(22B) C(22)-H(22C) C(23)-H(23A) C(23)-H(23B) C(23)-H(23C) O(2)-P(1)-O(1) O(2)-P(1)-O(3) O(1)-P(1)-O(3) O(2)-P(1)-C(1) O(1)-P(1)-C(1) O(3)-P(1)-C(1) P(1)-O(1)-H(1O) P(1)-O(3)-H(3O) C(23)-N(1)-C(22) C(23)-N(1)-C(4) C(22)-N(1)-C(4) C(23)-N(1)-C(3) C(22)-N(1)-C(3) C(4)-N(1)-C(3) C(2)-C(1)-P(1) C(2)-C(1)-H(1A) P(1)-C(1)-H(1A) C(2)-C(1)-H(1B) P(1)-C(1)-H(1B) H(1A)-C(1)-H(1B) C(3)-C(2)-C(1) C(3)-C(2)-H(2A) C(1)-C(2)-H(2A) C(3)-C(2)-H(2B)
324

0.9900 0.9800 0.9800 0.9800 0.9800 0.9800 0.9800 0.9800 0.9800 0.9800 112.9(3) 111.1(3) 109.7(3) 110.2(3) 109.4(3) 103.0(3) 121.5 123.6 109.3(5) 111.5(5) 110.4(5) 107.3(5) 109.4(5) 108.9(5) 111.8(4) 109.2 109.2 109.2 109.2 107.9 108.0(5) 110.1 110.1 110.1

C(1)-C(2)-H(2B) H(2A)-C(2)-H(2B) C(2)-C(3)-N(1) C(2)-C(3)-H(3A) N(1)-C(3)-H(3A) C(2)-C(3)-H(3B) N(1)-C(3)-H(3B) H(3A)-C(3)-H(3B) N(1)-C(4)-C(5) N(1)-C(4)-H(4A) C(5)-C(4)-H(4A) N(1)-C(4)-H(4B) C(5)-C(4)-H(4B) H(4A)-C(4)-H(4B) C(4)-C(5)-C(6) C(4)-C(5)-H(5A) C(6)-C(5)-H(5A) C(4)-C(5)-H(5B) C(6)-C(5)-H(5B) H(5A)-C(5)-H(5B) C(7)-C(6)-C(5) C(7)-C(6)-H(6A) C(5)-C(6)-H(6A) C(7)-C(6)-H(6B) C(5)-C(6)-H(6B) H(6A)-C(6)-H(6B) C(6)-C(7)-C(8) C(6)-C(7)-H(7A) C(8)-C(7)-H(7A) C(6)-C(7)-H(7B) C(8)-C(7)-H(7B) H(7A)-C(7)-H(7B) C(9)-C(8)-C(7) C(9)-C(8)-H(8A) C(7)-C(8)-H(8A)
325

110.1 108.4 116.3(5) 108.2 108.2 108.2 108.2 107.4 114.0(5) 108.8 108.8 108.8 108.8 107.6 108.1(5) 110.1 110.1 110.1 110.1 108.4 114.4(6) 108.7 108.7 108.7 108.7 107.6 112.6(6) 109.1 109.1 109.1 109.1 107.8 114.6(6) 108.6 108.6

C(9)-C(8)-H(8B) C(7)-C(8)-H(8B) H(8A)-C(8)-H(8B) C(8)-C(9)-C(10) C(8)-C(9)-H(9A) C(10)-C(9)-H(9A) C(8)-C(9)-H(9B) C(10)-C(9)-H(9B) H(9A)-C(9)-H(9B) C(9)-C(10)-C(11) C(9)-C(10)-H(10A) C(11)-C(10)-H(10A) C(9)-C(10)-H(10B) C(11)-C(10)-H(10B) H(10A)-C(10)-H(10B) C(10)-C(11)-C(12) C(10)-C(11)-H(11A) C(12)-C(11)-H(11A) C(10)-C(11)-H(11B) C(12)-C(11)-H(11B) H(11A)-C(11)-H(11B) C(13)-C(12)-C(11) C(13)-C(12)-H(12A) C(11)-C(12)-H(12A) C(13)-C(12)-H(12B) C(11)-C(12)-H(12B) H(12A)-C(12)-H(12B) C(12)-C(13)-C(14) C(12)-C(13)-H(13A) C(14)-C(13)-H(13A) C(12)-C(13)-H(13B) C(14)-C(13)-H(13B) H(13A)-C(13)-H(13B) C(15)-C(14)-C(13) C(15)-C(14)-H(14A)
326

108.6 108.6 107.6 113.7(6) 108.8 108.8 108.8 108.8 107.7 114.9(6) 108.5 108.5 108.5 108.5 107.5 113.8(6) 108.8 108.8 108.8 108.8 107.7 114.1(6) 108.7 108.7 108.7 108.7 107.6 114.2(6) 108.7 108.7 108.7 108.7 107.6 114.6(6) 108.6

C(13)-C(14)-H(14A) C(15)-C(14)-H(14B) C(13)-C(14)-H(14B) H(14A)-C(14)-H(14B) C(14)-C(15)-C(16) C(14)-C(15)-H(15A) C(16)-C(15)-H(15A) C(14)-C(15)-H(15B) C(16)-C(15)-H(15B) H(15A)-C(15)-H(15B) C(17)-C(16)-C(15) C(17)-C(16)-H(16A) C(15)-C(16)-H(16A) C(17)-C(16)-H(16B) C(15)-C(16)-H(16B) H(16A)-C(16)-H(16B) C(18)-C(17)-C(16) C(18)-C(17)-H(17A) C(16)-C(17)-H(17A) C(18)-C(17)-H(17B) C(16)-C(17)-H(17B) H(17A)-C(17)-H(17B) C(19)-C(18)-C(17) C(19)-C(18)-H(18A) C(17)-C(18)-H(18A) C(19)-C(18)-H(18B) C(17)-C(18)-H(18B) H(18A)-C(18)-H(18B) C(18)-C(19)-C(20) C(18)-C(19)-H(19A) C(20)-C(19)-H(19A) C(18)-C(19)-H(19B) C(20)-C(19)-H(19B) H(19A)-C(19)-H(19B) C(19)-C(20)-C(21)
327

108.6 108.6 108.6 107.6 114.2(6) 108.7 108.7 108.7 108.7 107.6 114.8(6) 108.6 108.6 108.6 108.6 107.5 114.5(6) 108.6 108.6 108.6 108.6 107.6 115.7(6) 108.4 108.4 108.4 108.4 107.4 113.8(6) 108.8 108.8 108.8 108.8 107.7 113.4(6)

C(19)-C(20)-H(20A) 108.9 C(21)-C(20)-H(20A) 108.9 C(19)-C(20)-H(20B) 108.9 C(21)-C(20)-H(20B) 108.9 H(20A)-C(20)-H(20B) 107.7 C(20)-C(21)-H(21A) 109.5 C(20)-C(21)-H(21B) 109.5 H(21A)-C(21)-H(21B) 109.5 C(20)-C(21)-H(21C) 109.5 H(21A)-C(21)-H(21C) 109.5 H(21B)-C(21)-H(21C) 109.5 N(1)-C(22)-H(22A) 109.5 N(1)-C(22)-H(22B) 109.5 H(22A)-C(22)-H(22B) 109.5 N(1)-C(22)-H(22C) 109.5 H(22A)-C(22)-H(22C) 109.5 H(22B)-C(22)-H(22C) 109.5 N(1)-C(23)-H(23A) 109.5 N(1)-C(23)-H(23B) 109.5 H(23A)-C(23)-H(23B) 109.5 N(1)-C(23)-H(23C) 109.5 H(23A)-C(23)-H(23C) 109.5 H(23B)-C(23)-H(23C) 109.5 _____________________________________________________________ Symmetry transformations used to generate equivalent atoms:

328

Table A 4. Anisotropic displacement parameters (Å2x 103) for 34. The anisotropic displacement factor exponent takes the form: -2p2[ h2 a*2U11 + ... + 2 h k a* b* U12 ] ______________________________________________________________________________ U11 U22 U33 U23 U13 U12 ______________________________________________________________________________ Br(1) 47(1) 43(1) 77(1) -9(1) -14(1) -7(1) P(1) 38(1) 37(1) 44(1) 0(1) 4(1) -9(1) O(1) 39(3) 40(2) 52(3) -4(2) 8(2) -5(2) O(2) 36(3) 39(2) 58(3) -4(2) 10(2) -7(2) O(3) 60(3) 54(3) 39(3) 7(2) -4(2) -25(2) N(1) 36(3) 36(3) 38(4) -3(2) -1(3) -4(2) C(1) 42(4) 38(4) 36(4) -2(3) 4(3) -11(3) C(2) 39(4) 45(4) 32(4) 2(3) 1(3) -12(3) C(3) 41(4) 34(3) 40(4) 2(3) 4(3) -11(3) C(4) 30(4) 42(4) 35(4) -6(3) 6(3) -9(3) C(5) 34(4) 44(4) 42(5) -3(3) 3(3) -9(3) C(6) 45(5) 45(4) 34(4) 0(3) 5(3) -11(3) C(7) 46(5) 47(4) 35(4) -4(3) 6(3) -12(3) C(8) 45(4) 46(4) 38(4) -8(3) 7(3) -17(3) C(9) 50(5) 50(4) 32(4) -2(3) 2(3) -16(3) C(10) 48(5) 51(4) 36(4) -2(3) 6(3) -21(3) C(11) 46(5) 48(4) 39(4) -7(3) 5(3) -18(3) C(12) 46(5) 52(4) 37(4) -8(3) 6(3) -16(3) C(13) 41(4) 55(4) 36(4) -5(3) 5(3) -22(3) C(14) 45(5) 57(4) 39(4) -2(3) 3(3) -25(4) C(15) 47(5) 52(4) 36(4) -1(3) 3(3) -16(3) C(16) 47(5) 53(4) 35(4) 0(3) 4(3) -19(3) C(17) 41(4) 49(4) 42(5) -5(3) 5(3) -16(3) C(18) 46(5) 55(4) 36(4) -8(3) 3(3) -19(3) C(19) 43(4) 46(4) 42(5) -4(3) 7(3) -16(3) C(20) 40(4) 59(4) 39(5) -1(3) 0(3) -15(3) C(21) 52(5) 60(5) 42(5) 0(4) 1(4) -12(4) C(22) 39(4) 46(4) 44(5) -1(3) -2(4) 9(3) C(23) 30(4) 56(4) 58(5) -8(4) 1(4) -14(3) ______________________________________________________________________________
329

Table A 5. Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 10 3) for 34. ______________________________________________________________________________ x y z U(eq) ______________________________________________________________________________ H(1O) H(3O) H(1A) H(1B) H(2A) H(2B) H(3A) H(3B) H(4A) H(4B) H(5A) H(5B) H(6A) H(6B) H(7A) H(7B) H(8A) H(8B) H(9A) H(9B) H(10A) H(10B) H(11A) H(11B) H(12A) H(12B) H(13A) H(13B) H(14A)
330

6719 5700 9514 7617 6600 8622 8671 10726 7109 6779 8245 9089 4706 5683 5646 6937 2504 3869 3127 4569 1656 195 645 2135 -2212 -721 -1777 -275 -4613

4152 7712 7739 9490 7907 6253 10044 8555 7304 9525 9466 7244 8927 6751 9550 7451 8337 6329 9488 7511 6129 8060 9384 7466 7889 5972 9219 7309 7691

4808 3988 4903 4971 5665 5604 5754 5623 6465 6450 7182 7187 7134 7221 7873 7961 7824 7980 8541 8698 8696 8515 9227 9408 9205 9387 9912 10094 9890

66 74 46 46 46 46 46 46 43 43 48 48 50 50 51 51 50 50 52 52 52 52 52 52 53 53 51 51 54

H(14B) -3107 5795 10079 54 H(15A) -4255 9067 10596 53 H(15B) -2712 7191 10785 53 H(16A) -7030 7477 10578 53 H(16B) -5487 5602 10767 53 H(17A) -5152 6983 11475 51 H(17B) -6681 8867 11285 51 H(18A) -9448 7288 11257 53 H(18B) -7919 5415 11451 53 H(19A) -9151 8672 11967 51 H(19B) -7658 6775 12161 51 H(20A) -10424 5223 12123 54 H(20B) -11923 7080 11908 54 H(21A) -12606 6661 12704 77 H(21B) -11806 8551 12610 77 H(21C) -10245 6728 12825 77 H(22A) 12343 6131 6152 69 H(22B) 10284 5361 6269 69 H(22C) 11577 5991 6678 69 H(23A) 12217 9546 6274 71 H(23B) 11479 9146 6791 71 H(23C) 10102 10787 6470 71 ______________________________________________________________________________

331

Table A 6. Hydrogen bonds for 34 [Å and °]. ____________________________________________________________________________ D-H...A d(D-H) d(H...A) d(D...A) <(DHA) ____________________________________________________________________________ O(1)-H(1O)...O(2)#1 0.84 1.62 2.449(6) 171.1 O(3)-H(3O)...Br(1)#1 0.84 2.29 3.102(5) 163.7 ____________________________________________________________________________ Symmetry transformations used to generate equivalent atoms: #1 -x+1,-y+1,-z+1

Table A 7. Crystal data and structure refinement for 66. Identification code Empirical formula Formula weight Temperature Wavelength Crystal system Space group Unit cell dimensions cu_d12327_0m C23 H50 Br N O 436.55 147(2) K 1.54178 Å Triclinic P -1 a = 7.3945(3) Å b = 8.2701(4) Å

a= 87.482(2)°. b= 81.558(2)°.

Volume Z Density (calculated) Absorption coefficient F(000) Crystal size Theta range for data collection Index ranges Reflections collected Independent reflections Completeness to theta = 66.36° Absorption correction
332

c = 22.9009(10) Å g = 65.369(2)°. 3 1259.01(10) Å 2 1.152 Mg/m3 2.284 mm-1 476 0.36 x 0.22 x 0.05 mm3 5.89 to 66.36°. -7<=h<=8, -9<=k<=8, -27<=l<=26 12902 4231 [R(int) = 0.0240] 95.8 % Semi-empirical from equivalents

Max. and min. transmission Refinement method Data / restraints / parameters Goodness-of-fit on F2 Final R indices [I>2sigma(I)] R indices (all data) Largest diff. peak and hole

0.8944 and 0.6183 Full-matrix least-squares on F2 4231 / 0 / 242 1.080 R1 = 0.0354, wR2 = 0.0934 R1 = 0.0360, wR2 = 0.0940 1.438 and -0.602 e.Å-3

Table A 8. Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) for 66. ______________________________________________________________________________ x y z U(eq) ______________________________________________________________________________ Br(1) 3802(1) 3378(1) 911(1) 41(1) O(1) 8589(3) 2020(2) 773(1) 46(1) N(1) 7166(3) 7645(2) 825(1) 25(1) C(1) 8881(4) 2712(3) 1284(1) 41(1) C(2) 7749(4) 4721(3) 1355(1) 32(1) C(3) 8252(3) 5628(3) 806(1) 25(1) C(4) 8091(4) 8338(3) 302(1) 31(1) C(5) 4997(3) 8186(3) 770(1) 35(1) C(6) C(7) C(8) C(9) C(10) C(11) C(12) C(13) C(14) C(15) C(16) C(17) C(18)
333

7301(3) 9429(3) 9506(3) 11601(3) 11856(3) 13958(3) 14259(3) 16358(3) 16653(3) 18749(3) 19033(3) 21121(3) 21393(3)

8457(3) 8037(3) 8391(3) 8136(3) 8220(3) 7976(3) 8008(3) 7773(3) 7797(3) 7567(3) 7591(3) 7367(3) 7395(3)

1388(1) 1490(1) 2134(1) 2228(1) 2873(1) 2951(1) 3595(1) 3674(1) 4317(1) 4400(1) 5044(1) 5131(1) 5777(1)

26(1) 26(1) 27(1) 28(1) 29(1) 29(1) 29(1) 29(1) 29(1) 29(1) 29(1) 30(1) 30(1)

C(19) C(20) C(21) C(22) C(23)

23479(3) 23740(3) 25829(3) 26087(4) 28183(4)

7169(3) 7210(3) 6966(3) 7012(3) 6750(4)

5869(1) 6515(1) 6609(1) 7255(1) 7345(1)

30(1) 31(1) 32(1) 35(1) 43(1)

Table A 9. Bond lengths [Å] and angles [°] for 66. _____________________________________________________ O(1)-C(1) 1.408(3) O(1)-H(1O) 0.82(4) N(1)-C(5) 1.499(3) N(1)-C(4) 1.503(3) N(1)-C(6) 1.513(3) N(1)-C(3) 1.520(3) C(1)-C(2) 1.521(3) C(1)-H(1A) 0.9900 C(1)-H(1B) 0.9900 C(2)-C(3) 1.515(3) C(2)-H(2A) 0.9900 C(2)-H(2B) 0.9900 C(3)-H(3A) 0.9900 C(3)-H(3B) 0.9900 C(4)-H(4A) 0.9800 C(4)-H(4B) 0.9800 C(4)-H(4C) 0.9800 C(5)-H(5A) 0.9800 C(5)-H(5B) 0.9800 C(5)-H(5C) 0.9800 C(6)-C(7) 1.516(3) C(6)-H(6A) 0.9900 C(6)-H(6B) 0.9900 C(7)-C(8) 1.528(3) C(7)-H(7A) 0.9900 C(7)-H(7B) 0.9900
334

C(8)-C(9) C(8)-H(8A) C(8)-H(8B) C(9)-C(10) C(9)-H(9A) C(9)-H(9B) C(10)-C(11) C(10)-H(10A) C(10)-H(10B) C(11)-C(12) C(11)-H(11A) C(11)-H(11B) C(12)-C(13) C(12)-H(12A) C(12)-H(12B) C(13)-C(14) C(13)-H(13A) C(13)-H(13B) C(14)-C(15) C(14)-H(14A) C(14)-H(14B) C(15)-C(16) C(15)-H(15A) C(15)-H(15B) C(16)-C(17) C(16)-H(16A) C(16)-H(16B) C(17)-C(18) C(17)-H(17A) C(17)-H(17B) C(18)-C(19) C(18)-H(18A) C(18)-H(18B) C(19)-C(20) C(19)-H(19A)
335

1.521(3) 0.9900 0.9900 1.524(3) 0.9900 0.9900 1.519(3) 0.9900 0.9900 1.526(3) 0.9900 0.9900 1.519(3) 0.9900 0.9900 1.522(3) 0.9900 0.9900 1.522(3) 0.9900 0.9900 1.521(3) 0.9900 0.9900 1.519(3) 0.9900 0.9900 1.523(3) 0.9900 0.9900 1.520(3) 0.9900 0.9900 1.524(3) 0.9900

C(19)-H(19B) C(20)-C(21) C(20)-H(20A) C(20)-H(20B) C(21)-C(22) C(21)-H(21A) C(21)-H(21B) C(22)-C(23) C(22)-H(22A) C(22)-H(22B) C(23)-H(23A) C(23)-H(23B) C(23)-H(23C) C(1)-O(1)-H(1O) C(5)-N(1)-C(4) C(5)-N(1)-C(6) C(4)-N(1)-C(6) C(5)-N(1)-C(3) C(4)-N(1)-C(3) C(6)-N(1)-C(3) O(1)-C(1)-C(2) O(1)-C(1)-H(1A) C(2)-C(1)-H(1A) O(1)-C(1)-H(1B) C(2)-C(1)-H(1B) H(1A)-C(1)-H(1B) C(3)-C(2)-C(1) C(3)-C(2)-H(2A) C(1)-C(2)-H(2A) C(3)-C(2)-H(2B) C(1)-C(2)-H(2B) H(2A)-C(2)-H(2B) C(2)-C(3)-N(1) C(2)-C(3)-H(3A)
336

0.9900 1.519(3) 0.9900 0.9900 1.522(3) 0.9900 0.9900 1.517(3) 0.9900 0.9900 0.9800 0.9800 0.9800 107(3) 108.15(17) 108.90(16) 109.80(16) 109.48(17) 107.72(15) 112.69(15) 113.7(2) 108.8 108.8 108.8 108.8 107.7 110.38(19) 109.6 109.6 109.6 109.6 108.1 114.73(17) 108.6

N(1)-C(3)-H(3A) C(2)-C(3)-H(3B) N(1)-C(3)-H(3B) H(3A)-C(3)-H(3B) N(1)-C(4)-H(4A) N(1)-C(4)-H(4B) H(4A)-C(4)-H(4B) N(1)-C(4)-H(4C) H(4A)-C(4)-H(4C) H(4B)-C(4)-H(4C) N(1)-C(5)-H(5A) N(1)-C(5)-H(5B) H(5A)-C(5)-H(5B) N(1)-C(5)-H(5C) H(5A)-C(5)-H(5C) H(5B)-C(5)-H(5C) N(1)-C(6)-C(7) N(1)-C(6)-H(6A) C(7)-C(6)-H(6A) N(1)-C(6)-H(6B) C(7)-C(6)-H(6B) H(6A)-C(6)-H(6B) C(6)-C(7)-C(8) C(6)-C(7)-H(7A) C(8)-C(7)-H(7A) C(6)-C(7)-H(7B) C(8)-C(7)-H(7B) H(7A)-C(7)-H(7B) C(9)-C(8)-C(7) C(9)-C(8)-H(8A) C(7)-C(8)-H(8A) C(9)-C(8)-H(8B) C(7)-C(8)-H(8B) H(8A)-C(8)-H(8B) C(8)-C(9)-C(10)
337

108.6 108.6 108.6 107.6 109.5 109.5 109.5 109.5 109.5 109.5 109.5 109.5 109.5 109.5 109.5 109.5 114.18(16) 108.7 108.7 108.7 108.7 107.6 111.27(17) 109.4 109.4 109.4 109.4 108.0 111.58(17) 109.3 109.3 109.3 109.3 108.0 114.25(17)

C(8)-C(9)-H(9A) C(10)-C(9)-H(9A) C(8)-C(9)-H(9B) C(10)-C(9)-H(9B) H(9A)-C(9)-H(9B) C(11)-C(10)-C(9) C(11)-C(10)-H(10A) C(9)-C(10)-H(10A) C(11)-C(10)-H(10B) C(9)-C(10)-H(10B) H(10A)-C(10)-H(10B) C(10)-C(11)-C(12) C(10)-C(11)-H(11A) C(12)-C(11)-H(11A) C(10)-C(11)-H(11B) C(12)-C(11)-H(11B) H(11A)-C(11)-H(11B) C(13)-C(12)-C(11) C(13)-C(12)-H(12A) C(11)-C(12)-H(12A) C(13)-C(12)-H(12B) C(11)-C(12)-H(12B) H(12A)-C(12)-H(12B) C(12)-C(13)-C(14) C(12)-C(13)-H(13A) C(14)-C(13)-H(13A) C(12)-C(13)-H(13B) C(14)-C(13)-H(13B) H(13A)-C(13)-H(13B) C(15)-C(14)-C(13) C(15)-C(14)-H(14A) C(13)-C(14)-H(14A) C(15)-C(14)-H(14B) C(13)-C(14)-H(14B) H(14A)-C(14)-H(14B)
338

108.7 108.7 108.7 108.7 107.6 112.93(17) 109.0 109.0 109.0 109.0 107.8 113.76(17) 108.8 108.8 108.8 108.8 107.7 113.80(17) 108.8 108.8 108.8 108.8 107.7 113.56(17) 108.9 108.9 108.9 108.9 107.7 113.98(18) 108.8 108.8 108.8 108.8 107.7

C(16)-C(15)-C(14) C(16)-C(15)-H(15A) C(14)-C(15)-H(15A) C(16)-C(15)-H(15B) C(14)-C(15)-H(15B) H(15A)-C(15)-H(15B) C(17)-C(16)-C(15) C(17)-C(16)-H(16A) C(15)-C(16)-H(16A) C(17)-C(16)-H(16B) C(15)-C(16)-H(16B) H(16A)-C(16)-H(16B) C(16)-C(17)-C(18) C(16)-C(17)-H(17A) C(18)-C(17)-H(17A) C(16)-C(17)-H(17B) C(18)-C(17)-H(17B) H(17A)-C(17)-H(17B) C(19)-C(18)-C(17) C(19)-C(18)-H(18A) C(17)-C(18)-H(18A) C(19)-C(18)-H(18B) C(17)-C(18)-H(18B) H(18A)-C(18)-H(18B) C(18)-C(19)-C(20) C(18)-C(19)-H(19A) C(20)-C(19)-H(19A) C(18)-C(19)-H(19B) C(20)-C(19)-H(19B) H(19A)-C(19)-H(19B) C(21)-C(20)-C(19) C(21)-C(20)-H(20A) C(19)-C(20)-H(20A) C(21)-C(20)-H(20B) C(19)-C(20)-H(20B)
339

113.69(18) 108.8 108.8 108.8 108.8 107.7 113.99(18) 108.8 108.8 108.8 108.8 107.7 113.69(18) 108.8 108.8 108.8 108.8 107.7 114.13(18) 108.7 108.7 108.7 108.7 107.6 113.93(18) 108.8 108.8 108.8 108.8 107.7 114.07(18) 108.7 108.7 108.7 108.7

H(20A)-C(20)-H(20B) 107.6 C(20)-C(21)-C(22) 114.05(19) C(20)-C(21)-H(21A) 108.7 C(22)-C(21)-H(21A) 108.7 C(20)-C(21)-H(21B) 108.7 C(22)-C(21)-H(21B) 108.7 H(21A)-C(21)-H(21B) 107.6 C(23)-C(22)-C(21) 113.7(2) C(23)-C(22)-H(22A) 108.8 C(21)-C(22)-H(22A) 108.8 C(23)-C(22)-H(22B) 108.8 C(21)-C(22)-H(22B) 108.8 H(22A)-C(22)-H(22B) 107.7 C(22)-C(23)-H(23A) 109.5 C(22)-C(23)-H(23B) 109.5 H(23A)-C(23)-H(23B) 109.5 C(22)-C(23)-H(23C) 109.5 H(23A)-C(23)-H(23C) 109.5 H(23B)-C(23)-H(23C) 109.5 _____________________________________________________________ Symmetry transformations used to generate equivalent atoms:

340

Table A 10. Anisotropic displacement parameters (Å2x 103) for 66. The anisotropic displacement factor exponent takes the form: -2p2[ h2 a*2U11 + ... + 2 h k a* b* U12 ] ______________________________________________________________________________ U11 U22 U33 U23 U13 U12 ______________________________________________________________________________ Br(1) 28(1) 43(1) 48(1) -13(1) -9(1) -9(1) O(1) 38(1) 32(1) 66(1) -10(1) 6(1) -18(1) N(1) 28(1) 23(1) 20(1) 0(1) -3(1) -7(1) C(1) 39(1) 29(1) 56(2) 10(1) -7(1) -16(1) C(2) 36(1) 29(1) 33(1) 3(1) -5(1) -16(1) C(3) 26(1) 20(1) 28(1) -2(1) -3(1) -9(1) C(4) 47(1) 31(1) 19(1) 2(1) -4(1) -18(1) C(5) 27(1) 40(1) 32(1) 1(1) -9(1) -6(1) C(6) 32(1) 22(1) 18(1) -2(1) -4(1) -5(1) C(7) 33(1) 22(1) 20(1) -2(1) -3(1) -9(1) C(8) 34(1) 25(1) 19(1) 0(1) -4(1) -8(1) C(9) 33(1) 27(1) 20(1) -1(1) -4(1) -7(1) C(10) 33(1) 29(1) 21(1) -1(1) -4(1) -9(1) C(11) 33(1) 28(1) 20(1) 0(1) -3(1) -8(1) C(12) 33(1) 30(1) 21(1) -1(1) -4(1) -9(1) C(13) 32(1) 27(1) 23(1) -1(1) -3(1) -7(1) C(14) 32(1) 28(1) 23(1) -2(1) -3(1) -9(1) C(15) 32(1) 26(1) 23(1) -1(1) -3(1) -7(1) C(16) 31(1) 28(1) 25(1) -3(1) -3(1) -8(1) C(17) 31(1) 27(1) 26(1) -1(1) -4(1) -7(1) C(18) 31(1) 27(1) 27(1) -2(1) -3(1) -8(1) C(19) 30(1) 28(1) 29(1) -1(1) -4(1) -7(1) C(20) 31(1) 28(1) 30(1) -4(1) -4(1) -9(1) C(21) 30(1) 28(1) 32(1) -1(1) -5(1) -8(1) C(22) 34(1) 35(1) 34(1) -3(1) -6(1) -12(1) C(23) 39(1) 47(1) 44(1) 0(1) -14(1) -15(1) ______________________________________________________________________________

341

Table A 11. Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 10 3) for 66. ______________________________________________________________________________ x y z U(eq) ______________________________________________________________________________ H(1A) H(1B) H(2A) H(2B) H(3A) H(3B) H(4A) H(4B) H(4C) H(5A) H(5B) H(5C) H(6A) H(6B) H(7A) H(7B) H(8A) H(8B) H(9A) H(9B) H(10A) H(10B) H(11A) H(11B) H(12A) H(12B) H(13A) H(13B) H(14A)
342

10334 8444 6285 8118 7921 9718 7437 7909 9529 4300 4378 4894 6639 6548 9956 10297 8541 9097 11925 12582 10874 11552 14245 14939 13274 13977 16639 17345 15661

2389 2149 5047 5131 5172 5293 9641 7879 7944 9488 7707 7718 8024 9764 8777 6772 9624 7571 9065 6967 9385 7282 8933 6826 9156 7049 8736 6627 8940

1272 1634 1426 1701 462 742 308 -63 318 778 1100 397 1727 1377 1230 1386 2249 2390 2010 2056 3047 3091 2740 2766 3780 3805 3465 3487 4503

49 49 38 38 30 30 47 47 47 53 53 53 32 32 31 31 33 33 34 34 35 35 35 35 35 35 35 35 35

H(14B) H(15A) H(15B) H(16A) H(16B) H(17A) H(17B) H(18A) H(18B) H(19A) H(19B) H(20A) H(20B) H(21A) H(21B) H(22A) H(22B) H(23A) H(23B) H(23C) H(1O)

16374 19742 19029 18036 18756 21400 22119 20395 21109 23768 24478 22750 23437 26134 26819 25108 25771 28269 28465 29169 7360(60)

6832 6424 8533 8733 6624 8333 6224 8539 6431 8128 6021 8363 6259 7916 5812 8172 6070 6718 7736 5625 2390(50)

4524 4214 4194 5230 5250 4925 4946 5961 5983 5661 5687 6696 6724 6400 6430 7433 7465 7769 7168 7156 778(17)

35 35 35 35 35 36 36 36 36 37 37 37 37 38 38 42 42 65 65 65 70(11)

Table A 12. Torsion angles [°] for 66. ________________________________________________________________ O(1)-C(1)-C(2)-C(3) -54.0(3) C(1)-C(2)-C(3)-N(1) 178.88(18) C(5)-N(1)-C(3)-C(2) -72.3(2) C(4)-N(1)-C(3)-C(2) 170.31(18) C(6)-N(1)-C(3)-C(2) 49.0(2) C(5)-N(1)-C(6)-C(7) -178.89(17) C(4)-N(1)-C(6)-C(7) -60.6(2) C(3)-N(1)-C(6)-C(7) 59.4(2) N(1)-C(6)-C(7)-C(8) -162.72(16) C(6)-C(7)-C(8)-C(9) -174.78(17)
343

C(7)-C(8)-C(9)-C(10) -172.08(17) C(8)-C(9)-C(10)-C(11) -179.50(17) C(9)-C(10)-C(11)-C(12) -178.52(18) C(10)-C(11)-C(12)-C(13) -179.76(18) C(11)-C(12)-C(13)-C(14) -179.72(18) C(12)-C(13)-C(14)-C(15) -179.82(18) C(13)-C(14)-C(15)-C(16) -179.94(18) C(14)-C(15)-C(16)-C(17) -179.86(18) C(15)-C(16)-C(17)-C(18) 179.90(18) C(16)-C(17)-C(18)-C(19) 179.89(18) C(17)-C(18)-C(19)-C(20) 179.61(18) C(18)-C(19)-C(20)-C(21) 179.43(18) C(19)-C(20)-C(21)-C(22) 179.86(19) C(20)-C(21)-C(22)-C(23) 179.4(2) ________________________________________________________________ Symmetry transformations used to generate equivalent atoms: Table A 13. Hydrogen bonds for 66 [Å and °]. ____________________________________________________________________________ D-H...A d(D-H) d(H...A) d(D...A) <(DHA) ____________________________________________________________________________ O(1)-H(1O)...Br(1) 0.82(4) 2.39(4) 3.206(2) 173(4) ____________________________________________________________________________ Symmetry transformations used to generate equivalent atoms: Table A 14. Crystal data and structure refinement for 19. Identification code Empirical formula Formula weight Temperature Wavelength Crystal system Space group Unit cell dimensions
344

d12321 C16 H22 N O5 P 339.32 150(2) K 1.54178 Å Monoclinic P 21/n a = 12.9548(6) Å

= 90°.

Volume Z Density (calculated) Absorption coefficient F(000) Crystal size Theta range for data collection Index ranges Reflections collected Independent reflections Completeness to theta = 66.38° Absorption correction Max. and min. transmission Refinement method Data / restraints / parameters Goodness-of-fit on F2 Final R indices [I>2sigma(I)] R indices (all data) Largest diff. peak and hole

b = 8.0163(4) Å c = 16.5747(8) Å 1720.96(14) Å3

= 91.100(2)°.  = 90°.

4 1.310 Mg/m3 1.633 mm-1 720 0.32 x 0.12 x 0.09 mm3 4.29 to 66.38°. -15<=h<=15, -9<=k<=4, -19<=l<=19 11311 2936 [R(int) = 0.0258] 96.8 % Semi-empirical from equivalents 0.7528 and 0.6679 Full-matrix least-squares on F2 2936 / 0 / 210 1.059 R1 = 0.0386, wR2 = 0.0996 R1 = 0.0398, wR2 = 0.1007 0.570 and -0.438 e.Å-3

Table A 15. Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) for 19. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. ______________________________________________________________________________ x y z U(eq) ______________________________________________________________________________ P(1) 5032(1) 2830(1) 1022(1) 25(1) O(1) -396(1) 5618(2) 1055(1) 48(1) O(2) 1813(1) 9911(2) 1635(1) 40(1) O(3) 5702(1) 2250(2) 375(1) 34(1) O(4) 4675(1) 1417(2) 1618(1) 30(1) O(5) 5542(1) 4128(2) 1622(1) 32(1) N(1) 894(1) 7480(2) 1408(1) 30(1)
345

C(1) C(2) C(3) C(4) C(5) C(6) C(7) C(8) C(9) C(10) C(11) C(12) C(13) C(14) C(15) C(16)

-83(1) -626(1) -1613(1) -1919(1) -1250(2) -252(1) 39(1) 1032(1) 1673(2) 2339(1) 3170(1) 3907(1) 4434(2) 5232(2) 6535(1) 7137(2)

7026(2) 8625(2) 8909(2) 10561(2) 11859(2) 11566(2) 9925(2) 9201(2) 6275(3) 5647(2) 4463(2) 3914(2) -244(2) -1432(3) 3712(3) 5228(3)

1120(1) 933(1) 636(1) 534(1) 718(1) 1011(1) 1116(1) 1418(1) 1682(1) 1004(1) 1327(1) 671(1) 1316(1) 1619(2) 1986(1) 2104(2)

31(1) 25(1) 31(1) 32(1) 32(1) 29(1) 24(1) 27(1) 38(1) 29(1) 32(1) 28(1) 36(1) 61(1) 37(1) 74(1)

Table A 16. Bond lengths [Å] and angles [°] for 19. _____________________________________________________ P(1)-O(3) 1.4687(13) P(1)-O(5) 1.5765(13) P(1)-O(4) 1.5782(12) P(1)-C(12) 1.7837(17) O(1)-C(1) 1.204(2) O(2)-C(8) 1.210(2) O(4)-C(13) 1.454(2) O(5)-C(15) 1.450(2) N(1)-C(8) 1.390(2) N(1)-C(1) 1.393(2) N(1)-C(9) 1.463(2) C(1)-C(2) 1.492(2) C(2)-C(3) 1.381(2) C(2)-C(7) 1.381(2) C(3)-C(4) 1.392(3)
346

C(3)-H(3A) C(4)-C(5) C(4)-H(4A) C(5)-C(6) C(5)-H(5A) C(6)-C(7) C(6)-H(6A) C(7)-C(8) C(9)-C(10) C(9)-H(9A) C(9)-H(9B) C(10)-C(11) C(10)-H(10A) C(10)-H(10B) C(11)-C(12) C(11)-H(11A) C(11)-H(11B) C(12)-H(12A) C(12)-H(12B) C(13)-C(14) C(13)-H(13A) C(13)-H(13B) C(14)-H(14A) C(14)-H(14B) C(14)-H(14C) C(15)-C(16) C(15)-H(15A) C(15)-H(15B) C(16)-H(16A) C(16)-H(16B) C(16)-H(16C) O(3)-P(1)-O(5) O(3)-P(1)-O(4) O(5)-P(1)-O(4) O(3)-P(1)-C(12)
347

0.9500 1.384(3) 0.9500 1.392(3) 0.9500 1.379(2) 0.9500 1.489(2) 1.515(2) 0.9900 0.9900 1.524(2) 0.9900 0.9900 1.525(2) 0.9900 0.9900 0.9900 0.9900 1.486(3) 0.9900 0.9900 0.9800 0.9800 0.9800 1.455(3) 0.9900 0.9900 0.9800 0.9800 0.9800 115.03(7) 114.48(7) 101.70(7) 114.03(8)

O(5)-P(1)-C(12) O(4)-P(1)-C(12) C(13)-O(4)-P(1) C(15)-O(5)-P(1) C(8)-N(1)-C(1) C(8)-N(1)-C(9) C(1)-N(1)-C(9) O(1)-C(1)-N(1) O(1)-C(1)-C(2) N(1)-C(1)-C(2) C(3)-C(2)-C(7) C(3)-C(2)-C(1) C(7)-C(2)-C(1) C(2)-C(3)-C(4) C(2)-C(3)-H(3A) C(4)-C(3)-H(3A) C(5)-C(4)-C(3) C(5)-C(4)-H(4A) C(3)-C(4)-H(4A) C(4)-C(5)-C(6) C(4)-C(5)-H(5A) C(6)-C(5)-H(5A) C(7)-C(6)-C(5) C(7)-C(6)-H(6A) C(5)-C(6)-H(6A) C(6)-C(7)-C(2) C(6)-C(7)-C(8) C(2)-C(7)-C(8) O(2)-C(8)-N(1) O(2)-C(8)-C(7) N(1)-C(8)-C(7) N(1)-C(9)-C(10) N(1)-C(9)-H(9A) C(10)-C(9)-H(9A) N(1)-C(9)-H(9B)
348

102.37(8) 107.84(8) 120.34(11) 118.00(11) 112.26(14) 124.31(16) 123.41(16) 125.33(17) 129.12(17) 105.54(15) 121.56(16) 130.18(17) 108.26(15) 117.36(17) 121.3 121.3 120.86(16) 119.6 119.6 121.55(17) 119.2 119.2 117.08(17) 121.5 121.5 121.59(16) 130.32(16) 108.09(15) 125.22(16) 128.94(17) 105.84(15) 112.86(14) 109.0 109.0 109.0

C(10)-C(9)-H(9B) H(9A)-C(9)-H(9B) C(9)-C(10)-C(11) C(9)-C(10)-H(10A) C(11)-C(10)-H(10A) C(9)-C(10)-H(10B) C(11)-C(10)-H(10B) H(10A)-C(10)-H(10B) C(10)-C(11)-C(12) C(10)-C(11)-H(11A) C(12)-C(11)-H(11A) C(10)-C(11)-H(11B) C(12)-C(11)-H(11B) H(11A)-C(11)-H(11B) C(11)-C(12)-P(1) C(11)-C(12)-H(12A) P(1)-C(12)-H(12A) C(11)-C(12)-H(12B) P(1)-C(12)-H(12B) H(12A)-C(12)-H(12B) O(4)-C(13)-C(14) O(4)-C(13)-H(13A) C(14)-C(13)-H(13A) O(4)-C(13)-H(13B) C(14)-C(13)-H(13B) H(13A)-C(13)-H(13B) C(13)-C(14)-H(14A) C(13)-C(14)-H(14B) H(14A)-C(14)-H(14B) C(13)-C(14)-H(14C) H(14A)-C(14)-H(14C) H(14B)-C(14)-H(14C) O(5)-C(15)-C(16) O(5)-C(15)-H(15A) C(16)-C(15)-H(15A)
349

109.0 107.8 110.82(14) 109.5 109.5 109.5 109.5 108.1 112.22(14) 109.2 109.2 109.2 109.2 107.9 115.29(12) 108.5 108.5 108.5 108.5 107.5 109.08(16) 109.9 109.9 109.9 109.9 108.3 109.5 109.5 109.5 109.5 109.5 109.5 109.45(18) 109.8 109.8

O(5)-C(15)-H(15B) 109.8 C(16)-C(15)-H(15B) 109.8 H(15A)-C(15)-H(15B) 108.2 C(15)-C(16)-H(16A) 109.5 C(15)-C(16)-H(16B) 109.5 H(16A)-C(16)-H(16B) 109.5 C(15)-C(16)-H(16C) 109.5 H(16A)-C(16)-H(16C) 109.5 H(16B)-C(16)-H(16C) 109.5 _____________________________________________________________ Symmetry transformations used to generate equivalent atoms: Table A 17. Anisotropic displacement parameters (Å2x 103) for 19. The anisotropic displacement factor exponent takes the form: -2p2[ h2 a*2U11 + ... + 2 h k a* b* U12 ] ______________________________________________________________________________ U11 U22 U33 U23 U13 U12 ______________________________________________________________________________ P(1) 22(1) 23(1) 30(1) 0(1) 1(1) 6(1) O(1) 47(1) 24(1) 71(1) 2(1) 4(1) 4(1) O(2) 25(1) 55(1) 38(1) -3(1) -5(1) 0(1) O(3) 29(1) 36(1) 38(1) 0(1) 7(1) 10(1) O(4) 35(1) 23(1) 33(1) 0(1) 3(1) 4(1) O(5) 26(1) 26(1) 44(1) -3(1) -7(1) 5(1) N(1) 26(1) 33(1) 31(1) 5(1) 2(1) 13(1) C(1) 29(1) 28(1) 36(1) 2(1) 6(1) 8(1) C(2) 23(1) 26(1) 27(1) 0(1) 4(1) 5(1) C(3) 23(1) 36(1) 35(1) -1(1) 1(1) 2(1) C(4) 24(1) 44(1) 30(1) 3(1) 2(1) 13(1) C(5) 36(1) 29(1) 32(1) 4(1) 6(1) 14(1) C(6) 32(1) 26(1) 30(1) -1(1) 5(1) 3(1) C(7) 22(1) 28(1) 22(1) 0(1) 4(1) 4(1) C(8) 24(1) 37(1) 21(1) 0(1) 3(1) 6(1) C(9) 34(1) 46(1) 33(1) 10(1) 4(1) 23(1) C(10) 26(1) 32(1) 28(1) 5(1) 1(1) 10(1) C(11) 27(1) 37(1) 31(1) 8(1) 4(1) 13(1)
350

C(12) 24(1) 33(1) 28(1) 1(1) 0(1) 7(1) C(13) 35(1) 27(1) 46(1) -4(1) 2(1) -4(1) C(14) 67(2) 30(1) 86(2) 1(1) -6(1) 10(1) C(15) 26(1) 48(1) 36(1) -1(1) -5(1) 8(1) C(16) 40(1) 50(2) 132(3) -12(2) -24(2) -3(1) ______________________________________________________________________________

Table A 18. Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 10 3) for 19. ______________________________________________________________________________ x y z U(eq) ______________________________________________________________________________ H(3A) H(4A) H(5A) H(6A) H(9A) H(9B) H(10A) H(10B) H(11A) H(11B) H(12A) H(12B) H(13A) H(13B) H(14A) H(14B) H(14C) H(15A) H(15B) H(16A) H(16B)
351

-2066 -2596 -1477 208 1324 2122 2668 1900 2836 3568 4128 3525 4421 3745 5056 5259 5906 6909 6434 7791 6748

8012 10801 12976 12458 5315 6804 6605 5059 3467 5025 4914 3184 -238 -592 -2563 -1401 -1116 2934 3156 4956 6018

506 336 643 1133 1934 2099 735 600 1559 1764 370 287 718 1501 1438 2210 1409 1632 2512 2380 2432

37 39 39 35 45 45 35 35 38 38 34 34 43 43 91 91 91 44 44 112 112

H(16C)

7278

5731

1578

112

Table A 19. Torsion angles [°] for 19. ________________________________________________________________ O(3)-P(1)-O(4)-C(13) -37.34(15) O(5)-P(1)-O(4)-C(13) -162.02(12) C(12)-P(1)-O(4)-C(13) 90.73(14) O(3)-P(1)-O(5)-C(15) -51.29(15) O(4)-P(1)-O(5)-C(15) 73.03(14) C(12)-P(1)-O(5)-C(15) -175.52(13) C(8)-N(1)-C(1)-O(1) -179.67(18) C(9)-N(1)-C(1)-O(1) -0.8(3) C(8)-N(1)-C(1)-C(2) -0.44(19) C(9)-N(1)-C(1)-C(2) 178.46(15) O(1)-C(1)-C(2)-C(3) -0.4(3) N(1)-C(1)-C(2)-C(3) -179.58(17) O(1)-C(1)-C(2)-C(7) 179.2(2) N(1)-C(1)-C(2)-C(7) -0.04(18) C(7)-C(2)-C(3)-C(4) -0.7(3) C(1)-C(2)-C(3)-C(4) 178.83(17) C(2)-C(3)-C(4)-C(5) 0.6(3) C(3)-C(4)-C(5)-C(6) -0.1(3) C(4)-C(5)-C(6)-C(7) C(5)-C(6)-C(7)-C(2) C(5)-C(6)-C(7)-C(8) C(3)-C(2)-C(7)-C(6) C(1)-C(2)-C(7)-C(6) C(3)-C(2)-C(7)-C(8) C(1)-C(2)-C(7)-C(8) C(1)-N(1)-C(8)-O(2) C(9)-N(1)-C(8)-O(2) C(1)-N(1)-C(8)-C(7) C(9)-N(1)-C(8)-C(7) C(6)-C(7)-C(8)-O(2)
352

-0.5(3) 0.5(2) -179.45(16) 0.1(3) -179.48(15) -179.95(15) 0.46(18) -179.32(16) 1.8(3) 0.71(19) -178.17(14) -0.7(3)

C(2)-C(7)-C(8)-O(2) 179.32(17) C(6)-C(7)-C(8)-N(1) 179.22(17) C(2)-C(7)-C(8)-N(1) -0.71(18) C(8)-N(1)-C(9)-C(10) -93.4(2) C(1)-N(1)-C(9)-C(10) 87.8(2) N(1)-C(9)-C(10)-C(11) 177.22(17) C(9)-C(10)-C(11)-C(12) -175.49(16) C(10)-C(11)-C(12)-P(1) 169.45(13) O(3)-P(1)-C(12)-C(11) 177.35(13) O(5)-P(1)-C(12)-C(11) -57.76(15) O(4)-P(1)-C(12)-C(11) 49.02(16) P(1)-O(4)-C(13)-C(14) 111.31(18) P(1)-O(5)-C(15)-C(16) 146.77(19) ________________________________________________________________ Symmetry transformations used to generate equivalent atoms:

353

Table A 20. Crystal data and structure refinement for 220. Identification code Empirical formula Formula weight Temperature Wavelength Crystal system Space group Unit cell dimensions d1317 C28 H35 Br N4 O4 S 603.57 147(2) K 0.71073 Å Triclinic P -1 a = 8.4368(14) Å = 103.268(4)°. b = 11.2944(19) Å = 93.320(4)°. c = 16.383(3) Å  = 109.880(4)°. 3 1413.1(4) Å 2 1.419 Mg/m3 1.569 mm-1 628 0.48 x 0.22 x 0.18 mm3 1.29 to 27.55°. -10<=h<=10, -10<=k<=14, -21<=l<=19 23597 6441 [R(int) = 0.0272] 99.0 % Semi-empirical from equivalents 0.7456 and 0.6341 Full-matrix least-squares on F2 6441 / 0 / 345 1.063 R1 = 0.0272, wR2 = 0.0728 R1 = 0.0304, wR2 = 0.0744 0.959 and -0.336 e.Å-3

Volume Z Density (calculated) Absorption coefficient F(000) Crystal size Theta range for data collection Index ranges Reflections collected Independent reflections Completeness to theta = 27.55° Absorption correction Max. and min. transmission Refinement method Data / restraints / parameters Goodness-of-fit on F2 Final R indices [I>2sigma(I)] R indices (all data) Largest diff. peak and hole

354

Table A 21. Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) for 220. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. ______________________________________________________________________________ x y z U(eq) ______________________________________________________________________________ Br(1) 2188(1) 3861(1) 3729(1) 27(1) S(1) 3811(1) 6885(1) 2219(1) 20(1) O(1) 2067(1) 6168(1) 1839(1) 30(1) O(2) 4506(2) 8277(1) 2356(1) 28(1) O(3) 8054(2) 1106(1) 4611(1) 34(1) O(4) 7236(2) 800(1) 1778(1) 36(1) N(1) 7134(2) 2839(1) 206(1) 26(1) N(2) 3995(2) 6607(1) 3134(1) 22(1) N(3) 8227(2) 5296(1) 3634(1) 20(1) N(4) 7394(2) 1154(1) 3232(1) 24(1) C(1) 5114(2) 6259(1) 1571(1) 19(1) C(2) 6334(2) 7135(2) 1266(1) 22(1) C(3) 7375(2) 6708(2) 725(1) 25(1) C(4) 7226(2) 5431(2) 524(1) 22(1) C(5) 6030(2) 4511(1) 856(1) 18(1) C(6) 5916(2) 3173(2) 667(1) 21(1) C(7) 4602(2) 2278(2) 916(1) 26(1) C(8) 3426(2) 2666(2) 1376(1) 26(1) C(9) 3556(2) 3942(2) 1604(1) 22(1) C(10) 4877(2) 4903(1) 1358(1) 18(1) C(11) 8873(2) 3366(2) 668(1) 36(1) C(12) 6664(3) 1462(2) -225(1) 33(1) C(13) 5422(2) 7415(2) 3809(1) 27(1) C(14) 7060(2) 7128(2) 3723(1) 26(1) C(15) 6733(2) 5734(2) 3753(1) 22(1) C(16) 8737(2) 5276(2) 2781(1) 36(1) C(17) 9745(2) 6169(2) 4284(1) 28(1) C(18) 7741(2) 3948(2) 3807(1) 28(1) C(19) 6248(2) 2904(2) 3194(1) 35(1) C(20) 5946(2) 1570(2) 3342(1) 31(1)
355

C(21) C(22) C(23) C(24) C(25) C(26) C(27) C(28)

8292(2) 9505(2) 10692(2) 11596(2) 11340(2) 10162(2) 9251(2) 7873(2)

916(2) 363(1) -51(2) -594(2) -696(2) -259(2) 260(2) 753(2)

3876(1) 3470(1) 3816(1) 3260(1) 2402(1) 2060(1) 2613(1) 2444(1)

24(1) 22(1) 26(1) 30(1) 32(1) 29(1) 23(1) 25(1)

Table A 22. Bond lengths [Å] and angles [°] for 220. _____________________________________________________ S(1)-O(1) 1.4354(12) S(1)-O(2) 1.4360(12) S(1)-N(2) 1.6106(14) S(1)-C(1) 1.7763(15) O(3)-C(21) 1.214(2) O(4)-C(28) 1.208(2) N(1)-C(6) 1.411(2) N(1)-C(12) 1.456(2) N(1)-C(11) 1.467(2) N(2)-C(13) 1.462(2) N(2)-H(2N) 0.8800 N(3)-C(16) 1.484(2) N(3)-C(17) 1.499(2) N(3)-C(15) 1.5101(18) N(3)-C(18) 1.534(2) N(4)-C(21) 1.391(2) N(4)-C(28) 1.398(2) N(4)-C(20) 1.457(2) C(1)-C(2) 1.372(2) C(1)-C(10) 1.431(2) C(2)-C(3) 1.404(2) C(2)-H(2A) 0.9500 C(3)-C(4) 1.363(2)
356

C(3)-H(3A) C(4)-C(5) C(4)-H(4A) C(5)-C(10) C(5)-C(6) C(6)-C(7) C(7)-C(8) C(7)-H(7A) C(8)-C(9) C(8)-H(8A) C(9)-C(10) C(9)-H(9A) C(11)-H(11A) C(11)-H(11B) C(11)-H(11C) C(12)-H(12A) C(12)-H(12B) C(12)-H(12C) C(13)-C(14) C(13)-H(13A) C(13)-H(13B) C(14)-C(15) C(14)-H(14A) C(14)-H(14B) C(15)-H(15A) C(15)-H(15B) C(16)-H(16A) C(16)-H(16B) C(16)-H(16C) C(17)-H(17A) C(17)-H(17B) C(17)-H(17C) C(18)-C(19) C(18)-H(18A) C(18)-H(18B)
357

0.9500 1.416(2) 0.9500 1.427(2) 1.439(2) 1.377(2) 1.405(2) 0.9500 1.367(2) 0.9500 1.418(2) 0.9500 0.9800 0.9800 0.9800 0.9800 0.9800 0.9800 1.530(2) 0.9900 0.9900 1.516(2) 0.9900 0.9900 0.9900 0.9900 0.9800 0.9800 0.9800 0.9800 0.9800 0.9800 1.512(2) 0.9900 0.9900

C(19)-C(20) C(19)-H(19A) C(19)-H(19B) C(20)-H(20A) C(20)-H(20B) C(21)-C(22) C(22)-C(27) C(22)-C(23) C(23)-C(24) C(23)-H(23A) C(24)-C(25) C(24)-H(24A) C(25)-C(26) C(25)-H(25A) C(26)-C(27) C(26)-H(26A) C(27)-C(28) O(1)-S(1)-O(2) O(1)-S(1)-N(2) O(2)-S(1)-N(2) O(1)-S(1)-C(1) O(2)-S(1)-C(1) N(2)-S(1)-C(1) C(6)-N(1)-C(12) C(6)-N(1)-C(11) C(12)-N(1)-C(11) C(13)-N(2)-S(1) C(13)-N(2)-H(2N) S(1)-N(2)-H(2N) C(16)-N(3)-C(17) C(16)-N(3)-C(15) C(17)-N(3)-C(15) C(16)-N(3)-C(18) C(17)-N(3)-C(18) C(15)-N(3)-C(18)
358

1.519(2) 0.9900 0.9900 0.9900 0.9900 1.484(2) 1.381(2) 1.385(2) 1.389(2) 0.9500 1.383(3) 0.9500 1.393(2) 0.9500 1.378(2) 0.9500 1.487(2) 119.72(7) 106.44(7) 106.73(7) 107.91(7) 106.14(7) 109.69(7) 116.00(14) 115.17(13) 110.27(14) 123.19(11) 118.4 118.4 108.20(13) 112.47(13) 111.09(12) 111.72(14) 105.45(12) 107.70(11)

C(21)-N(4)-C(28) C(21)-N(4)-C(20) C(28)-N(4)-C(20) C(2)-C(1)-C(10) C(2)-C(1)-S(1) C(10)-C(1)-S(1) C(1)-C(2)-C(3) C(1)-C(2)-H(2A) C(3)-C(2)-H(2A) C(4)-C(3)-C(2) C(4)-C(3)-H(3A) C(2)-C(3)-H(3A) C(3)-C(4)-C(5) C(3)-C(4)-H(4A) C(5)-C(4)-H(4A) C(4)-C(5)-C(10) C(4)-C(5)-C(6) C(10)-C(5)-C(6) C(7)-C(6)-N(1) C(7)-C(6)-C(5) N(1)-C(6)-C(5) C(6)-C(7)-C(8) C(6)-C(7)-H(7A) C(8)-C(7)-H(7A) C(9)-C(8)-C(7) C(9)-C(8)-H(8A) C(7)-C(8)-H(8A) C(8)-C(9)-C(10) C(8)-C(9)-H(9A) C(10)-C(9)-H(9A) C(9)-C(10)-C(5) C(9)-C(10)-C(1) C(5)-C(10)-C(1) N(1)-C(11)-H(11A) N(1)-C(11)-H(11B)
359

111.74(13) 123.86(15) 123.70(14) 121.51(14) 116.72(11) 121.75(11) 120.15(14) 119.9 119.9 120.37(14) 119.8 119.8 120.96(14) 119.5 119.5 119.58(13) 120.87(13) 119.50(13) 123.29(14) 118.87(14) 117.80(13) 120.89(14) 119.6 119.6 121.53(15) 119.2 119.2 119.92(14) 120.0 120.0 119.06(13) 123.77(14) 117.15(13) 109.5 109.5

H(11A)-C(11)-H(11B) N(1)-C(11)-H(11C) H(11A)-C(11)-H(11C) H(11B)-C(11)-H(11C) N(1)-C(12)-H(12A) N(1)-C(12)-H(12B) H(12A)-C(12)-H(12B) N(1)-C(12)-H(12C) H(12A)-C(12)-H(12C) H(12B)-C(12)-H(12C) N(2)-C(13)-C(14) N(2)-C(13)-H(13A) C(14)-C(13)-H(13A) N(2)-C(13)-H(13B) C(14)-C(13)-H(13B) H(13A)-C(13)-H(13B) C(15)-C(14)-C(13) C(15)-C(14)-H(14A) C(13)-C(14)-H(14A) C(15)-C(14)-H(14B) C(13)-C(14)-H(14B) H(14A)-C(14)-H(14B) N(3)-C(15)-C(14) N(3)-C(15)-H(15A) C(14)-C(15)-H(15A) N(3)-C(15)-H(15B) C(14)-C(15)-H(15B) H(15A)-C(15)-H(15B) N(3)-C(16)-H(16A) N(3)-C(16)-H(16B) H(16A)-C(16)-H(16B) N(3)-C(16)-H(16C) H(16A)-C(16)-H(16C) H(16B)-C(16)-H(16C) N(3)-C(17)-H(17A)
360

109.5 109.5 109.5 109.5 109.5 109.5 109.5 109.5 109.5 109.5 115.10(13) 108.5 108.5 108.5 108.5 107.5 109.60(13) 109.8 109.8 109.8 109.8 108.2 115.29(12) 108.5 108.5 108.5 108.5 107.5 109.5 109.5 109.5 109.5 109.5 109.5 109.5

N(3)-C(17)-H(17B) H(17A)-C(17)-H(17B) N(3)-C(17)-H(17C) H(17A)-C(17)-H(17C) H(17B)-C(17)-H(17C) C(19)-C(18)-N(3) C(19)-C(18)-H(18A) N(3)-C(18)-H(18A) C(19)-C(18)-H(18B) N(3)-C(18)-H(18B) H(18A)-C(18)-H(18B) C(18)-C(19)-C(20) C(18)-C(19)-H(19A) C(20)-C(19)-H(19A) C(18)-C(19)-H(19B) C(20)-C(19)-H(19B) H(19A)-C(19)-H(19B) N(4)-C(20)-C(19) N(4)-C(20)-H(20A) C(19)-C(20)-H(20A) N(4)-C(20)-H(20B) C(19)-C(20)-H(20B) H(20A)-C(20)-H(20B) O(3)-C(21)-N(4) O(3)-C(21)-C(22) N(4)-C(21)-C(22) C(27)-C(22)-C(23) C(27)-C(22)-C(21) C(23)-C(22)-C(21) C(22)-C(23)-C(24) C(22)-C(23)-H(23A) C(24)-C(23)-H(23A) C(25)-C(24)-C(23) C(25)-C(24)-H(24A) C(23)-C(24)-H(24A)
361

109.5 109.5 109.5 109.5 109.5 113.79(14) 108.8 108.8 108.8 108.8 107.7 111.13(15) 109.4 109.4 109.4 109.4 108.0 113.48(14) 108.9 108.9 108.9 108.9 107.7 125.03(15) 128.86(15) 106.07(14) 121.48(15) 108.16(13) 130.33(15) 117.00(16) 121.5 121.5 121.38(15) 119.3 119.3

C(24)-C(25)-C(26) 121.31(16) C(24)-C(25)-H(25A) 119.3 C(26)-C(25)-H(25A) 119.3 C(27)-C(26)-C(25) 117.04(16) C(27)-C(26)-H(26A) 121.5 C(25)-C(26)-H(26A) 121.5 C(26)-C(27)-C(22) 121.78(15) C(26)-C(27)-C(28) 129.97(16) C(22)-C(27)-C(28) 108.23(14) O(4)-C(28)-N(4) 124.86(15) O(4)-C(28)-C(27) 129.38(16) N(4)-C(28)-C(27) 105.75(14) _____________________________________________________________ Symmetry transformations used to generate equivalent atoms: Table A 23. Anisotropic displacement parameters (Å2x 103) for 222. The anisotropic displacement factor exponent takes the form: -2p2[ h2 a*2U11 + ... + 2 h k a* b* U12 ] ______________________________________________________________________________ U11 U22 U33 U23 U13 U12 ______________________________________________________________________________ Br(1) 23(1) 28(1) 34(1) 13(1) 13(1) 10(1) S(1) 18(1) 20(1) 27(1) 8(1) 6(1) 10(1) O(1) 18(1) 36(1) 36(1) 11(1) 2(1) 11(1) O(2) 31(1) 21(1) 39(1) 12(1) 13(1) 15(1) O(3) 39(1) 37(1) 27(1) 5(1) 8(1) 16(1) O(4) 38(1) 41(1) 33(1) 14(1) -1(1) 18(1) N(1) 34(1) 22(1) 23(1) 2(1) 11(1) 12(1) N(2) 23(1) 21(1) 24(1) 7(1) 7(1) 9(1) N(3) 15(1) 22(1) 23(1) 5(1) 2(1) 6(1) N(4) 22(1) 19(1) 31(1) 5(1) 2(1) 8(1) C(1) 17(1) 20(1) 20(1) 4(1) 2(1) 8(1) C(2) 23(1) 17(1) 25(1) 5(1) 3(1) 6(1) C(3) 24(1) 22(1) 25(1) 8(1) 9(1) 4(1) C(4) C(5)
362

23(1) 20(1)

23(1) 18(1)

20(1) 15(1)

5(1) 3(1)

7(1) 2(1)

7(1) 5(1)

C(6) 25(1) 20(1) 16(1) 3(1) 3(1) 8(1) C(7) 34(1) 17(1) 25(1) 4(1) 6(1) 8(1) C(8) 27(1) 20(1) 28(1) 8(1) 9(1) 3(1) C(9) 21(1) 21(1) 22(1) 5(1) 6(1) 5(1) C(10) 18(1) 18(1) 16(1) 4(1) 0(1) 5(1) C(11) 29(1) 33(1) 48(1) 7(1) 16(1) 13(1) C(12) 50(1) 25(1) 25(1) 2(1) 13(1) 18(1) C(13) 33(1) 20(1) 27(1) -1(1) 0(1) 13(1) C(14) 23(1) 19(1) 32(1) 6(1) -1(1) 5(1) C(15) 17(1) 20(1) 30(1) 7(1) 5(1) 8(1) C(16) 32(1) 61(1) 20(1) 10(1) 7(1) 23(1) C(17) 20(1) 35(1) 25(1) 6(1) -2(1) 9(1) C(18) 25(1) 26(1) 35(1) 9(1) 4(1) 11(1) C(19) 24(1) 27(1) 52(1) 6(1) -2(1) 12(1) C(20) 19(1) 23(1) 48(1) 6(1) 3(1) 8(1) C(21) 24(1) 17(1) 29(1) 3(1) 1(1) 5(1) C(22) 21(1) 15(1) 28(1) 6(1) 3(1) 4(1) C(23) 25(1) 25(1) 30(1) 10(1) 2(1) 8(1) C(24) 23(1) 27(1) 45(1) 14(1) 6(1) 11(1) C(25) 28(1) 30(1) 40(1) 7(1) 10(1) 14(1) C(26) 29(1) 28(1) 28(1) 6(1) 6(1) 9(1) C(27) 22(1) 17(1) 28(1) 6(1) 1(1) 5(1) C(28) 24(1) 19(1) 31(1) 7(1) 1(1) 7(1) ______________________________________________________________________________

363

Table A 24. Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 10 3) for 220. ______________________________________________________________________________ x y z U(eq) ______________________________________________________________________________ H(2N) H(2A) H(3A) H(4A) H(7A) H(8A) H(9A) H(11A) H(11B) H(11C) H(12A) H(12B) H(12C) H(13A) H(13B) H(14A) H(14B) H(15A) H(15B) H(16A) H(16B) H(16C) H(17A) H(17B) H(17C) H(18A) H(18B) H(19A) H(19B)
364

3199 6476 8188 7936 4489 2520 2763 9169 9671 8941 5499 6727 7451 5064 5676 7446 7968 6379 5768 9041 7786 9722 10124 10670 9434 8740 7460 6473 5211

5936 8033 7313 5155 1386 2027 4185 4290 3279 2880 1121 977 1361 7294 8343 7252 7739 5637 5143 6151 4659 5004 7052 5830 6195 3676 4018 2882 3118

3233 1421 498 156 774 1531 1927 960 267 1085 -529 193 -629 4358 3823 3179 4190 4308 3307 2694 2348 2739 4206 4218 4854 3777 4390 2605 3265

67(8) 27 29 27 31 32 26 54 54 54 50 50 50 32 32 31 31 27 27 54 54 54 42 42 42 33 33 42 42

H(20A) 5683 1591 3925 37 H(20B) 4940 917 2944 37 H(23A) 10880 32 4408 32 H(24A) 12407 -903 3474 36 H(25A) 11979 -1071 2038 39 H(26A) 9995 -316 1472 35 ______________________________________________________________________________

Table A 25. Torsion angles [°] for 220. ________________________________________________________________ O(1)-S(1)-N(2)-C(13) O(2)-S(1)-N(2)-C(13) C(1)-S(1)-N(2)-C(13) O(1)-S(1)-C(1)-C(2) O(2)-S(1)-C(1)-C(2) N(2)-S(1)-C(1)-C(2) O(1)-S(1)-C(1)-C(10) O(2)-S(1)-C(1)-C(10) N(2)-S(1)-C(1)-C(10) C(10)-C(1)-C(2)-C(3) S(1)-C(1)-C(2)-C(3) C(1)-C(2)-C(3)-C(4) C(2)-C(3)-C(4)-C(5) C(3)-C(4)-C(5)-C(10) C(3)-C(4)-C(5)-C(6) C(12)-N(1)-C(6)-C(7) C(11)-N(1)-C(6)-C(7) C(12)-N(1)-C(6)-C(5) C(11)-N(1)-C(6)-C(5) C(4)-C(5)-C(6)-C(7) C(10)-C(5)-C(6)-C(7) C(4)-C(5)-C(6)-N(1) C(10)-C(5)-C(6)-N(1) N(1)-C(6)-C(7)-C(8)
365

-162.99(12) -34.05(13) 80.51(13) 123.02(12) -6.47(14) -121.42(12) -55.43(14) 175.08(12) 60.13(14) 0.7(2) -177.76(12) -2.5(2) -0.2(2) 4.6(2) -177.81(15) 18.4(2) -112.54(18) -159.28(14) 69.78(19) -172.13(15) 5.4(2) 5.6(2) -176.78(13) 179.85(15)

C(5)-C(6)-C(7)-C(8) C(6)-C(7)-C(8)-C(9) C(7)-C(8)-C(9)-C(10) C(8)-C(9)-C(10)-C(5) C(8)-C(9)-C(10)-C(1) C(4)-C(5)-C(10)-C(9) C(6)-C(5)-C(10)-C(9) C(4)-C(5)-C(10)-C(1) C(6)-C(5)-C(10)-C(1) C(2)-C(1)-C(10)-C(9) S(1)-C(1)-C(10)-C(9) C(2)-C(1)-C(10)-C(5) S(1)-C(1)-C(10)-C(5) S(1)-N(2)-C(13)-C(14) N(2)-C(13)-C(14)-C(15) C(16)-N(3)-C(15)-C(14) C(17)-N(3)-C(15)-C(14) C(18)-N(3)-C(15)-C(14) C(13)-C(14)-C(15)-N(3) C(16)-N(3)-C(18)-C(19) C(17)-N(3)-C(18)-C(19) C(15)-N(3)-C(18)-C(19) N(3)-C(18)-C(19)-C(20) C(21)-N(4)-C(20)-C(19) C(28)-N(4)-C(20)-C(19) C(18)-C(19)-C(20)-N(4) C(28)-N(4)-C(21)-O(3) C(20)-N(4)-C(21)-O(3) C(28)-N(4)-C(21)-C(22) C(20)-N(4)-C(21)-C(22) O(3)-C(21)-C(22)-C(27) N(4)-C(21)-C(22)-C(27) O(3)-C(21)-C(22)-C(23) N(4)-C(21)-C(22)-C(23) C(27)-C(22)-C(23)-C(24)
366

-2.5(2) -1.0(3) 1.5(2) 1.5(2) -179.79(15) 172.67(14) -4.9(2) -6.2(2) 176.25(13) -175.17(15) 3.2(2) 3.6(2) -178.03(11) -80.18(16) -61.73(19) -64.16(18) 57.29(18) 172.30(14) 177.27(13) -60.96(18) -178.28(14) 63.03(18) 174.26(14) 117.72(18) -72.7(2) -60.4(2) -175.77(15) -5.1(3) 2.47(17) 173.17(13) 176.46(16) -1.69(17) -1.5(3) -179.65(16) -1.0(2)

C(21)-C(22)-C(23)-C(24) 176.70(15) C(22)-C(23)-C(24)-C(25) 1.0(2) C(23)-C(24)-C(25)-C(26) -0.1(3) C(24)-C(25)-C(26)-C(27) -0.9(3) C(25)-C(26)-C(27)-C(22) 0.9(2) C(25)-C(26)-C(27)-C(28) -177.21(16) C(23)-C(22)-C(27)-C(26) 0.0(2) C(21)-C(22)-C(27)-C(26) -178.13(15) C(23)-C(22)-C(27)-C(28) 178.53(14) C(21)-C(22)-C(27)-C(28) 0.36(17) C(21)-N(4)-C(28)-O(4) 176.72(16) C(20)-N(4)-C(28)-O(4) 6.0(3) C(21)-N(4)-C(28)-C(27) -2.26(17) C(20)-N(4)-C(28)-C(27) -172.97(14) C(26)-C(27)-C(28)-O(4) 0.5(3) C(22)-C(27)-C(28)-O(4) -177.81(17) C(26)-C(27)-C(28)-N(4) 179.43(16) C(22)-C(27)-C(28)-N(4) 1.10(17) ________________________________________________________________ Symmetry transformations used to generate equivalent atoms: Table A 26. Hydrogen bonds for 220 [Å and °]. ____________________________________________________________________________ D-H...A d(D-H) d(H...A) d(D...A) <(DHA) ____________________________________________________________________________ N(2)-H(2N)...Br(1) 0.88 2.54 3.3518(14) 152.9 ____________________________________________________________________________ Symmetry transformations used to generate equivalent atoms:

367

6.2 Appendix 1.2 ­ NMR Spectra

Figure A 1. 1H NMR spectrum of compound 2 in CDCl3
368

Figure A 2. 13C NMR spectrum of compound 2 in CDCl3
369

Figure A 3. COSY 2D NMR spectrum of compound 2 in CDCl3
370

Figure A 4. 1H NMR spectrum of purified 46 in CDCl3
371

Figure A 5. 13C NMR spectrum of purified 46 in CDCl3
372

Figure A 6. COSY 2D NMR spectrum of purified 46 in CDCl3
373

Figure A 7. HSQC 2D NMR spectrum of purified 46 in CDCl3
374

Figure A 8. 1H NMR spectrum of compound 22 in CDCl3
375

Figure A 9. 13C NMR spectrum of compound 22 in CDCl3
376

Figure A 10. HSQC 2D NMR spectrum of compound 22 in CDCl3
377

Figure A 11. 1H NMR spectrum of compound 1+2 in CDCl3
378

Figure A 12. 13C NMR spectrum of compound 1 in CDCl3
379

Figure A 13. 1H NMR spectrum of compound 3 in CDCl3 (Table 2.1, entry i)
380

Figure A 14. 13C NMR spectrum of compound 3 in CDCl3 (Table 2.1, entry i)
381

Figure A 15. COSY 2D NMR spectrum of compound 3 in CDCl3 (Table 2.1, entry i)
382

Figure A 16. HSQC 2D NMR spectrum of compound 3 in CDCl3 (Table 2.1, entry i)
383

Figure A 17. 1H stacked NMR spectra of compound 3 in CDCl3 (Table 2.1, entry i-iii)
384

Figure A 18. 1H stacked NMR spectra of compound 3 in CDCl3 (Table 2.1, entry iv-v, viii)
385

Figure A 19. 1H NMR spectrum of compound 3 in CDCl3 (Table 2.2, entry iii)
386

Figure A 20. 13C NMR spectrum of compound 3 in CDCl3 (Table 2.2, entry iii)
387

Figure A 21. 1H NMR spectrum of compound 12 in CDCl3 (Table 2.3, entry iii)
388

Figure A 22. 13C NMR spectrum of compound 12 in CDCl3 (Table 2.3, entry iii)
389

Figure A 23. COSY 2D NMR spectrum of compound 12 in CDCl3 (Table 2.3, entry iii)
390

Figure A 24. HSQC 2D NMR spectrum of compound 12 in CDCl3 (Table 2.3, entry iii)
391

Figure A 25. 31P NMR spectrum of compound 12 in CDCl3 (Table 2.3, entry iii)
392

Figure A 26. 1H NMR spectrum of compound 13 in CDCl3 (Table 2.3, entry vii)
393

Figure A 27. 13C NMR spectrum of compound 13 in CDCl3 (Table 2.3, entry vii)
394

Figure A 28. COSY 2D NMR spectrum of compound 13 in CDCl3 (Table 2.3, entry vii)
395

Figure A 29. HSQC 2D NMR spectrum of compound 13 in CDCl3 (Table 2.3, entry vii)
396

Figure A 30. 31P NMR spectrum of compound 13 in CDCl3 (Table 2.3, entry vii)
397

Figure A 31. 1H NMR spectrum of compound 14 in CDCl3 (Table 2.3, entry ix)
398

Figure A 32. 13C NMR spectrum of compound 14 in CDCl3 (Table 2.3, entry ix)
399

Figure A 33. COSY 2D NMR spectrum of compound 14 in CDCl3 (Table 2.3, entry ix)
400

Figure A 34. HSQC 2D NMR spectrum of compound 14 in CDCl3 (Table 2.3, entry ix)
401

Figure A 35. 31P NMR spectrum of compound 14 in CDCl3 (Table 2.3, entry ix)

402

Figure A 36. 1H NMR spectrum of compound 16 in CDCl3 (Table 2.3, entry xv)
403

Figure A 37. 13C NMR spectrum of compound 16 in CDCl3 (Table 2.3, entry xv)
404

Figure A 38. COSY 2D NMR spectrum of compound 16 in CDCl3 (Table 2.3, entry xv)

405

Figure A 39. HSQC 2D NMR spectrum of compound 16 in CDCl3 (Table 2.3, entry xv)

406

Figure A 40. 31P NMR spectrum of compound 16 in CDCl3 (Table 4.3, entry xv)
407

Figure A 41. 1H NMR spectrum of compound 17 in CDCl3 (Table 2.3, entry xvi)
408

Figure A 42. 13C NMR spectrum of compound 17 in CDCl3 (Table 2.3, entry xvi)
409

Figure A 43. COSY 2D NMR spectrum of compound 17 in CDCl3 (Table 2.3, entry xvi)

410

Figure A 44. HSQC 2D NMR spectrum of compound 17 in CDCl3 (Table 2.3, entry xvi)
411

Figure A 45. 31P NMR spectrum of compound 17 in CDCl3 (Table 2.3, entry xvi)
412

Figure A 46. 1H NMR spectrum of compound 18 in CDCl3 (Table 2.3, entry xvii)

413

Figure A 47. 13C NMR spectrum of compound 18 in CDCl3 (Table 2.3, entry xvii)

414

Figure A 48. COSY 2D NMR spectrum of compound 18 in CDCl3 (Table 2.3, entry xvii)

415

Figure A 49. 31P NMR spectrum of compound 18 in CDCl3 (Table 4.3, entry xvii)
416

Figure A 50. 1H NMR spectrum of compound 19 in CDCl3 (Table 2.3, entry xviii)
417

Figure A 51. 13C NMR spectrum of compound 19 in CDCl3 (Table 2.3, entry xviii)
418

Figure A 52. COSY 2D NMR spectrum of compound 19 in CDCl3 (Table 2.3, entry xviii)

419

Figure A 53. HSQC 2D NMR spectrum of compound 19 in CDCl3 (Table 2.3, entry xviii)

420

Figure A 54. 31P NMR spectrum of compound 19 in CDCl3 (Table 2.3, entry xviii)
421

Figure A 55. 1H NMR spectrum of compound 26 in CDCl3 (Table 2.4, entry i)
422

Figure A 56. 13C NMR spectrum of compound 26 in CDCl3 (Table 2.4, entry i)
423

Figure A 57. COSY 2D NMR spectrum of compound 26 in CDCl3 (Table 2.4, entry i)
424

Figure A 58. HSQC 2D NMR spectrum of compound 26 in CDCl3 (Table 2.4, entry i)
425

Figure A 59. 31P NMR spectrum of compound 26 in CDCl3 (Table 2.4, entry i)
426

Figure A 60. 1H NMR spectrum of compound 27 in CDCl3 (Table 4.4, entry iv)
427

Figure A 61. 13C NMR spectrum of compound 27 in CDCl3 (Table 2.4, entry iv)
428

Figure A 62. COSY 2D NMR spectrum of compound 27 in CDCl3 (Table 2.4, entry iv)
429

Figure A 63. 31P NMR spectrum of compound 27 in CDCl3 (Table 2.4, entry iv)
430

Figure A 64. 1H NMR spectrum of compound 28 in CDCl3 (Table 2.4, entry vii)
431

Figure A 65. 13C NMR spectrum of compound 28 in CDCl3 (Table 2.4, entry vii)

432

Figure A 66. COSY 2D NMR spectrum of compound 28 in CDCl3 (Table 2.4, entry vii)
433

Figure A 67. 31P NMR spectrum of compound 28 in CDCl3 (Table 2.4, entry vii)
434

Figure A 68. 31P NMR spectrum of compound 29 in CDCl3 (Table 2.4, entry viii)
435

Figure A 69. 1H NMR spectrum of compound 30 in CDCl3 (Table 2.4, entry ix)

436

Figure A 70. 13C NMR spectrum of compound 30 in CDCl3 (Table 2.4, entry ix)
437

Figure A 71. COSY 2D NMR spectrum of compound 30 in CDCl3 (Table 4.4, entry ix)

438

Figure A 72. HSQC 2D NMR spectrum of compound 30 in CDCl3 (Table 2.4, entry ix)
439

Figure A 73. 31P NMR spectrum of compound 30 in CDCl3 (Table 2.4, entry ix)
440

Figure A 74. 1H NMR spectrum of compound 31 in CDCL3 (Table 2.4, entry x)
441

Figure A 75. 13C NMR spectrum of compound 31 in CDCL3 (Table 2.4, entry x)
442

Figure A 76. COSY 2D NMR spectrum of compound 31 in CDCL3 (Table 2.4, entry x)

443

Figure A 77. HSQC 2D NMR spectrum of compound 31 in CDCL3 (Table 4.4, entry x)
444

Figure A 78. 31P NMR spectrum of compound 31 in CDCL3 (Table 2.4, entry x)
445

Figure A 79. 1H NMR spectrum of compound 32 in CDCl3 (Table 2.4, entry xi)
446

Figure A 80. 13C NMR spectrum of compound 32 in CDCl3 (Table 2.4, entry xi)
447

Figure A 81. HSQC 2D NMR spectrum of compound 32 in CDCl3 (Table 2.4, entry xi)

448

Figure A 82. 31P NMR spectrum of compound 32 in CDCl3 (Table 2.4, entry xi)

449

Figure A 83. 1H NMR spectrum of compound 33 in CDCL3 (Table 2.4, entry xii)

450

Figure A 84. 13C NMR spectrum of compound 33 in CDCL3 (Table 2.4, entry xii)
451

Figure A 85. COSY 2D NMR spectrum of compound 33 in CDCl3 (Table 2.4, entry xii)
452

Figure A 86. HSQC 2D NMR spectrum of compound 33 in CDCl3 (Table 2.4, entry xii)
453

Figure A 87. 31P NMR spectrum of compound 33 in CDCL3 (Table 2.4, entry xii)
454

Figure A 88. 1H NMR spectrum of compound 39 in CDCl3
455

Figure A 89. COSY 2D NMR spectrum of compound 39 in CDCl3
456

Figure A 90. 31P NMR spectrum of compound 39 in CDCl3
457

Figure A 91. 1H NMR spectrum of compound 40 in CDCl3
458

Figure A 92. 31P NMR spectrum of compound 40 in CDCl3 (BEFORE COLUMN)

459

Figure A 93. 31P NMR spectrum of compound 40 in CDCl3 (AFTER COLUMN)
460

Figure A 94. 1H NMR spectrum of compound 34 in MeOD (Table 2.5, entry i)
461

Figure A 95. 13C NMR spectrum of compound 34 in MeOD (Table 2.5, entry i)
462

Figure A 96. 1H NMR spectrum of compound 34 in MeOD (Table 2.5, entry i)
463

Figure A 97. 1H NMR spectrum of compound 34 in MeOD (Table 2.5, entry i)
464

Figure A 98. 31P NMR spectrum of compound 34 in MeOD (Table 2.5, entry i)
465

Figure A 99. 1H NMR spectrum of compound 35 in D2O (Table 4.5, entry ix)

466

Figure A 100. 13C NMR spectrum of compound 35 in D2O (Table 2.5, entry ix)
467

Figure A 101. HSQC spectrum of compound 35 in D2O (Table 2.5, entry xi)
468

Figure A 102. COSY spectrum of compound 35 in D2O (Table 2.5, entry ix)
469

Figure A 103. 31P spectrum of compound 35 in D2O (Table 2.5, entry ix)
470

Figure A 104. 1H NMR spectrum of compound 35 in D2O (Table 2.5, entry ix)
471

Figure A 105. 13C NMR spectrum of compound 36 in D2O (Table 2.5, entry x)
472

Figure A 106. 1H NMR spectrum of compound 36 in D2O (Table 2.5, entry x)
473

Figure A 107. HSQC NMR spectrum of compound 36 in D2O (Table 2.5, entry x)
474

Figure A 108. 31P NMR spectrum of compound 36 in D2O (Table 2.5, entry x)
475

Figure A 109. 1H NMR spectrum of compound 42 in D2O.

476

Figure A 110. 13C NMR spectrum of compound 42 in D2O.
477

Figure A 111. COSY 2D NMR spectrum of compound 42 in D2O.

478

Figure A 112. HSQC 2D NMR spectrum of compound 42 in D2O.
479

Figure A 113. 31P NMR spectrum of compound 42 in D2O.
480

Figure A 114. 1H NMR spectrum of compound 44 in D2O.
481

Figure A 115. 13C NMR spectrum of compound 44 in D2O.

482

Figure A 116. COSY 2D NMR spectrum of compound 44 in D2O.
483

Figure A 117. HSQC 2D NMR spectrum of compound 44 in D2O.
484

Figure A 118. 1H NMR spectrum of compound (51) in CDCl3.
485

Figure A 119. 13C NMR spectrum of compound (51) in CDCl3.
486

Figure A 120. COSY 2D NMR spectrum of compound (51) in CDCl3.

487

Figure A 121. HSQC 2D NMR spectrum of compound (51) in CDCl3.
488

Figure A 122. 31P NMR spectrum of compound (51) in CDCl3.
489

Figure A 123. 1H NMR spectrum of compound (52) in CDCl3.
490

Figure A 124. 13C NMR spectrum of compound (52) in CDCl3.
491

Figure A 125. COSY 2D NMR spectrum of compound (52) in CDCl3.
492

Figure A 126. 31P NMR spectrum of compound (52) in CDCl3.
493

Figure A 127. 1H NMR spectrum of compound (66) in CDCl3.
494

Figure A 128. 13C NMR spectrum of compound (66) in CDCl3.
495

Figure A 129. COSY 2D NMR spectrum of compound (66) in CDCl3.
496

Figure A 130. HSQC 2D NMR spectrum of compound (66) in CDCl3.
497

Figure A 131. 1H NMR spectrum of compound (67) in MeOD.
498

Figure A 132. 13C NMR spectrum of compound (67) in MeOD.
499

Figure A 133. COSY 2D NMR spectrum of compound (67) in MeOD.
500

Figure A 134. HSQC 2D NMR spectrum of compound (67) in MeOD.
501

Figure A 135. 1H NMR spectrum of compound (9) in CDCl3.
502

Figure A 136. 13C NMR spectrum of compound (9) in CDCl3.
503

Figure A 137. COSY 2D NMR spectrum of compound (9) in CDCl3.
504

Figure A 138. HSQC 2D NMR spectrum of compound (9) in CDCl3.
505

Figure A 139. 1H NMR spectrum of compound (68) in CDCl3.
506

Figure A 140. 13C NMR spectrum of compound (68) in CDCl3.
507

Figure A 141. HSQC 2D NMR spectrum of compound (68) in CDCl3.
508

Figure A 142. 31P NMR spectrum of compound (68) in CDCl3.
509

Figure A 143. 1H NMR spectrum of compound (105) in CDCl3.
510

Figure A 144. 13C NMR spectrum of compound (105) in CDCl3.
511

Figure A 145. COSY 2D NMR spectrum of compound (105) in CDCl3.
512

Figure A 146. HSQC 2D NMR spectrum of compound (105) in CDCl3.
513

Figure A 147. 31P NMR spectrum of compound (105) in CDCl3.
514

Figure A 148. 1H NMR spectrum of compound (77) in CDCl3.
515

Figure A 149. 13C NMR spectrum of compound (77) in CDCl3.
516

Figure A 150. HSQC 2D NMR spectrum of compound (77) in CDCl3.
517

Figure A 151. 31P NMR spectrum of compound (77) in CDCl3.
518

Figure A 152. 1H NMR spectrum of compound (97) in MeOD.
519

Figure A 153. 13C NMR spectrum of compound (97) in MeOD.
520

Figure A 154. COSY 2D NMR spectrum of compound (97) in MeOD.
521

Figure A 155. HSQC 2D NMR spectrum of compound (97) in MeOD.
522

Figure A 156. 31P NMR spectrum of compound (97) in MeOD.
523

Figure A 157. 1H NMR spectrum of compound (95) in CDCl3.
524

Figure A 158. 13C NMR spectrum of compound (95) in CDCl3.
525

Figure A 159. COSY 2D NMR spectrum of compound (95) in CDCl3.
526

Figure A 160. 31P NMR spectrum of compound (95) in CDCl3.
527

Figure A 161. 1H NMR spectrum of compound (98) in CDCl3.
528

Figure A 162. 13C NMR spectrum of compound (98) in CDCl3.
529

Figure A 163. COSY 2D NMR spectrum of compound (98) in CDCl3.
530

Figure A 164. HSQC 2D NMR spectrum of compound (98) in CDCl3.
531

Figure A 165. 31P NMR spectrum of compound (98) in CDCl3.
532

Figure A 166. 1H NMR spectrum of compound (99) in CDCl3.
533

Figure A 167. 13C NMR spectrum of compound (99) in CDCl3.
534

Figure A 168. COSY 2D NMR spectrum of compound (99) in CDCl3.
535

Figure A 169. HSQC 2D NMR spectrum of compound (99) in CDCl3.
536

Figure A 170. 31P NMR spectrum of compound (99) in CDCl3.
537

Figure A 171. 1H NMR spectrum of compound (91) in MeOD.
538

Figure A 172. 13C NMR spectrum of compound (91) in MeOD.
539

Figure A 173. COSY 2D NMR spectrum of compound (91) in MeOD.
540

Figure A 174. HSQC 2D NMR spectrum of compound (91) in MeOD.
541

Figure A 175. 31P NMR spectrum of compound (91) in MeOD. (CRUDE)
542

Figure A 176. 31P NMR spectrum of compound (91) in MeOD. (COLUMNED FRACTION)
543

Figure A 177. 1H NMR spectrum of compound (87) in CDCl3.
544

Figure A 178. 31P NMR spectrum of compound (87) in CDCl3.
545

Figure A 179. 1H NMR spectrum of compound (87) in CDCl3.
546

Figure A 180. 13C NMR spectrum of compound (87) in CDCl3.
547

Figure A 181. COSY 2D NMR spectrum of compound (96) in CDCl3.
548

Figure A 182. HSQC 2D NMR spectrum of compound (96) in CDCl3.
549

Figure A 183. 31P NMR spectrum of compound (96) in CDCl3.

550

Figure A 184. 1H NMR spectrum of compound (93) in CDCl3.
551

Figure A 185. COSY 2D NMR spectrum of compound (93) in CDCl3.

552

Figure A 186. HSQC 2D NMR spectrum of compound (93) in CDCl3.

553

Figure A 187. 31P NMR spectrum of compound (93) in CDCl3.
554

Figure A 188. 1H NMR spectrum of compound (83) in CDCl3.

555

Figure A 189. 13C NMR spectrum of compound (83) in CDCl3.

556

Figure A 190. COSY 2D NMR spectrum of compound (83) in CDCl3.
557

Figure A 191. HSQC 2D NMR spectrum of compound (83) in CDCl3.
558

Figure A 192. 1H NMR spectrum of compound (102) in CDCl3.
559

Figure A 193. 13C NMR spectrum of compound (102) in CDCl3.
560

Figure A 194. COSY 2D NMR spectrum of compound (102) in CDCl3.
561

Figure A 195. HSQC 2D NMR spectrum of compound (102) in CDCl3.
562

Figure A 196. 1H NMR spectrum of compound (202) in CDCl3.

563

Figure A 197. 13C NMR spectrum of compound (202) in CDCl3.
564

Figure A 198. 1H NMR spectrum of compound (204) in CDCl3.
565

Figure A 199. 13C NMR spectrum of compound (204) in CDCl3.
566

Figure A 200. 1H NMR spectrum of compound (206) in CDCl3.
567

Figure A 201. 13C NMR spectrum of compound (206) in CDCl3.
568

Figure A 202. 1H NMR spectrum of compound (205) in CDCl3.

569

Figure A 203. 13C NMR spectrum of compound (205) in CDCl3.
570

Figure A 204. 13C NMR spectrum of compound (114) in CDCl3.
571

Figure A 205. COSY 2D NMR spectrum of compound (114) in CDCl3.
572

Figure A 206. HSQC 2D NMR spectrum of compound (114) in CDCl3.
573

Figure A 207. 31P NMR spectrum of compound (114) in CDCl3.
574

Figure A 208. 1H NMR spectrum of compound (116) in CDCl3.
575

Figure A 209.
576

13

C NMR spectrum of compound (116) in CDCl3.

Figure A 210. COSY 2D NMR spectrum of compound (116) in CDCl3.
577

Figure A 211. HSQC 2D NMR spectrum of compound (116) in CDCl3.
578

Figure A 212.
579

31

P NMR spectrum of compound (116) in CDCl3.

Figure A 213. 1H NMR spectrum of compound (117) in CDCl3.
580

Figure A 214.
581

13

C NMR spectrum of compound (117) in CDCl3.

Figure A 215. COSY 2D NMR spectrum of compound (117) in CDCl3.
582

Figure A 216. HSQC 2D NMR spectrum of compound (117) in CDCl3.
583

Figure A 217.
584

31

P NMR spectrum of compound (117) in CDCl3.

Figure A 218. 1H NMR spectrum of compound (118) in CDCl3.
585

Figure A 219.
586

13

C NMR spectrum of compound (118) in CDCl3.

Figure A 220. COSY 2D NMR spectrum of compound (118) in CDCl3.
587

Figure A 221. HSQC 2D NMR spectrum of compound (118) in CDCl3.
588

Figure A 222.
589

31

P NMR spectrum of compound (118) in CDCl3.

Figure A 223. 1H NMR spectrum of compound (119) in CDCl3.
590

Figure A 224.
591

13

C NMR spectrum of compound (119) in CDCl3.

Figure A 225. COSY 2D NMR spectrum of compound (119) in CDCl3.
592

Figure A 226. HSQC 2D NMR spectrum of compound (119) in CDCl3.
593

Figure A 227.
594

31

P NMR spectrum of compound (119) in CDCl3.

Figure A 228. 1H NMR spectrum of compound (113) in CDCl3.
595

Figure A 229.
596

13

C NMR spectrum of compound (113) in CDCl3.

Figure A 230. COSY 2D NMR spectrum of compound (113) in CDCl3.
597

Figure A 231. HSQC 2D NMR spectrum of compound (113) in CDCl3.
598

Figure A 232.
599

31

P NMR spectrum of compound (113) in CDCl3.

Figure A 233. 1H NMR spectrum of compound (120) in CDCl3.
600

Figure A 234.
601

31

P NMR spectrum of compound (120) in CDCl3.

Figure A 235. 1H NMR spectrum of compound (121) in CDCl3.
602

Figure A 236.
603

13

C NMR spectrum of compound (121) in CDCl3.

Figure A 237. COSY 2D NMR spectrum of compound (121) in CDCl3.
604

Figure A 238. HSQC 2D NMR spectrum of compound (121) in CDCl3.
605

Figure A 239.
606

31

P NMR spectrum of compound (121) in CDCl3.

Figure A 240. 1H NMR spectrum of compound (123) in CDCl3.
607

Figure A 241.
608

13

C NMR spectrum of compound (123) in CDCl3.

Figure A 242. HSQC 2D NMR spectrum of compound (123) in CDCl3.
609

Figure A 243. 1H NMR spectrum of compound (122) in CDCl3.
610

Figure A 244.
611

13

C NMR spectrum of compound (122) in CDCl3.

Figure A 245. COSY 2D NMR spectrum of compound (122) in CDCl3.
612

Figure A 246. HSQC 2D NMR spectrum of compound (122) in CDCl3.
613

Figure A 247. 1H NMR spectrum of compound (135) in CDCl3.
614

Figure A 248. 13C NMR spectrum of compound (135) in CDCl3.
615

Figure A 249. HSQC 2D NMR spectrum of compound (135) in CDCl3.
616

Figure A 250. 31P NMR spectrum of compound (135) in CDCl3.
617

Figure A 251. 1H NMR spectrum of compound (136) in CDCl3.
618

Figure A 252. 31P NMR spectrum of compound (136) in CDCl3.
619

Figure A 253. 1H NMR spectrum of compound (131) in CDCl3.
620

Figure A 254. 31P NMR spectrum of compound (131) in CDCl3.
621

Figure A 255. 1H NMR spectrum of compound (140) in CDCl3.
622

Figure A 256. 13C NMR spectrum of compound (140) in CDCl3.
623

Figure A 257. COSY 2D NMR spectrum of compound (140) in CDCl3.
624

Figure A 258. HSQC 2D NMR spectrum of compound (140) in CDCl3.
625

Figure A 259. 1H NMR spectrum of compound (153) in CDCl3.
626

Figure A 260. 13C NMR spectrum of compound (153) in CDCl3.
627

Figure A 261. 13C NMR spectrum of compound (153) in CDCl3.
628

Figure A 262. 1H NMR spectrum of compound (154) in CDCl3.
629

Figure A 263. COSY 2D NMR spectrum of compound (154) in CDCl3.
630

Figure A 264. 1H NMR spectrum of compound (155) in CDCl3.
631

Figure A 265. COSY 2D NMR spectrum of compound (155) in CDCl3.
632

Figure A 266.

13

H NMR spectrum of compound (155) in CDCl3.

633

Figure A 267. 1H NMR spectrum of compound (156) in CDCl3.

634

Figure A 268.
635

13

C NMR spectrum of compound (156) in CDCl3.

Figure A 269. 1H NMR spectrum of compound (152) in CDCl3.

636

Figure A 270.

13

C NMR spectrum of compound (152) in CDCl3.

637

Figure A 271. COSY 2D NMR spectrum of compound (152) in CDCl3.

638

Figure A 272. HSQC 2D NMR spectrum of compound (152) in CDCl3.

639

Figure A 273. 1H NMR spectrum of compound (144) from (152) in CDCl3.

640

Figure A 274. 1H NMR spectrum of compound (144) from (156) in CDCl3.

641

Figure A 275.

13

C NMR spectrum of compound (144) from (152) in CDCl3.

642

Figure A 276. COSY 2D NMR spectrum of compound (144) from (152) in CDCl3.

643

Figure A 277. HSQC 2D spectrum of compound (144) from (152) in CDCl3
644

Figure A 278. 1H NMR spectrum of compound (169) in CDCl3.
645

Figure A 279. 13C NMR spectrum of compound (169) in CDCl3.
646

Figure A 280. COSY 2D NMR spectrum of compound (169) in CDCl3.
647

Figure A 281. HSQC 2D NMR spectrum of compound (169) in CDCl3.
648

Figure A 282. 31P NMR spectrum of compound (169) in CDCl3.
649

Figure A 283. 1H NMR spectrum of compound (158) in CDCl3.

650

Figure A 284. 13C NMR spectrum of compound (158) in CDCl3.
651

Figure A 285. COSY 2D NMR spectrum of compound (158) in CDCl3.
652

Figure A 286. HSQC 2D NMR spectrum of compound (158) in CDCl3.
653

Figure A 287. 31P NMR spectrum of compound (158) in CDCl3.
654

Figure A 288. 1H NMR spectrum of compound (170) in CDCl3.
655

Figure A 289. 13C NMR spectrum of compound (170) in CDCl3.
656

Figure A 290. COSY 2D NMR spectrum of compound (170) in CDCl3.
657

Figure A 291. HSQC 2D NMR spectrum of compound (170) in CDCl3.

658

Figure A 292. 31P NMR spectrum of compound (170) in CDCl3.

659

Figure A 293. 1H NMR spectrum of compound (157) in D2O.

660

Figure A 294. 13C NMR spectrum of compound (157) in D2O.
661

Figure A 295. 13C NMR spectrum of compound (157) in DMSO-d6.
662

Figure A 296. HSQC 2D NMR spectrum of compound (157) in CDCl3.

663

Figure A 297. 1H NMR spectrum of compound (163) in D2O.

664

Figure A 298. 13C NMR spectrum of compound (163) in D2O.

665

Figure A 299. COSY 2D NMR spectrum of compound (163) in CDCl3.
666

Figure A 300. HSQC 2D NMR spectrum of compound (163) in CDCl3.
667

Figure A 301. 1H NMR spectrum of compound (176) in CDCl3.
668

Figure A 302. COSY 2D NMR spectrum of compound (176) in CDCl3.
669

Figure A 303. 1H NMR spectrum of compound (177) in CDCl3.
670

Figure A 304. 13C NMR spectrum of compound (177) in CDCl3.
671

Figure A 305. COSY 2D NMR spectrum of compound (177) in CDCl3.
672

Figure A 306. HSQC 2D NMR spectrum of compound (177) in CDCl3.

673

Figure A 307. 1H NMR spectrum of compound (181) in CDCl3.

674

Figure A 308. 13C NMR spectrum of compound (181) in CDCl3.

675

Figure A 309. COSY 2D NMR spectrum of compound (181) in CDCl3.
676

Figure A 310. HSQC 2D NMR spectrum of compound (181) in CDCl3.

677

Figure A 311. 1H NMR spectrum of compound (185) in CDCl3. (CRUDE)
678

Figure A 312. 13C NMR spectrum of compound (185) in CDCl3.(CRUDE)
679

Figure A 313. COSY 2D NMR spectrum of compound (185) in CDCl3.
680

Figure A 314. HSQC 2D NMR spectrum of compound (185) in CDCl3.

681

Figure A 315. 1H NMR spectrum of compound (188) in CDCl3.

682

Figure A 316. 13C NMR spectrum of compound (188) in CDCl3.

683

Figure A 317. COSY 2D NMR spectrum of compound (188) in CDCl3.

684

Figure A 318. HSQC 2D NMR spectrum of compound (188) in CDCl3.
685

Figure A 319. 1H NMR spectrum of compound (189) in CDCL3.(CRUDE)

686

Figure A 320. 1H NMR spectrum of compound (192) in CDCl3.

687

Figure A 321. 13C NMR spectrum of compound (192) in CDCl3.

688

Figure A 322. COSY 2D NMR spectrum of compound (192) in CDCl3.
689

Figure A 323. 1H NMR spectrum of compound (194) in CDCl3.
690

Figure A 324. 1H NMR spectrum of compound (194) in CDCl3.
691

Figure A 325. COSY 2D NMR spectrum of compound (194) in CDCl3.

692

Figure A 326. HSQC 2D NMR spectrum of compound (194) in CDCl3.
693

Figure A 327. 1H NMR spectrum of compound (198) in CDCl3.
694

Figure A 328. 13C NMR spectrum of compound (198) in CDCl3.
695

Figure A 329. COSY 2D NMR spectrum of compound (198) in CDCl3.
696

Figure A 330. HSQC 2D NMR spectrum of compound (198) in CDCl3.
697

Figure A 331. 1H NMR spectrum of compound (202) in CDCl3.
698

Figure A 332. 13C NMR spectrum of compound (202) in CDCl3.
699

Figure A 333. 1H NMR spectrum of compound (204) in CDCl3.
700

Figure A 334. 13C NMR spectrum of compound (204) in CDCl3.

701

Figure A 335. 1H NMR spectrum of compound (205) in CDCl3.
702

Figure A 336. 13C NMR spectrum of compound (205) in CDCl3.
703

Figure A 337. 1H NMR spectrum of compound (206) in CDCl3.
704

Figure A 338. 13C NMR spectrum of compound (206) in CDCl3.
705

Figure A 339. 1H NMR spectrum of compound (208) in CDCl3.
706

Figure A 340. 13C NMR spectrum of compound (208) in CDCl3.
707

Figure A 341. COSY 2D NMR spectrum of compound (208) in CDCl3.
708

Figure A 342. HSQC 2D NMR spectrum of compound (208) in CDCl3.

709

Figure A 343. 1H NMR spectrum of compound (209) in MeOD.

710

Figure A 344. 13C NMR spectrum of compound (209) in MeOD.
711

Figure A 345. COSY 2D NMR spectrum of compound (209) in MeOD.

712

Figure A 346. HSQC 2D NMR spectrum of compound (209) in MeOD.
713

Figure A 347. 1H NMR spectrum of compound (210) in MeOD.
714

Figure A 348. COSY 2D NMR spectrum of compound (210) in MeOD.
715

Figure A 349. 1H NMR spectrum of compound (211) in CDCl3.

716

Figure A 350. 13C NMR spectrum of compound (211) in CDCl3.
717

Figure A 351. COSY 2D NMR spectrum of compound (211) in CDCl3.
718

Figure A 352. HSQC 2D NMR spectrum of compound (211) in CDCl3.
719

Figure A 353. 31P NMR spectrum of compound (211) in CDCl3.

720

Figure A 354. 1H NMR spectrum of compound (212) in CDCl3.

721

Figure A 355. 13C NMR spectrum of compound (212) in CDCl3.
722

Figure A 356. HSQC 2D NMR spectrum of compound (212) in CDCl3.
723

Figure A 357. 31P NMR spectrum of compound (212) in CDCl3.
724

Figure A 358. 1H NMR spectrum of compound (213) in CDCl3.
725

Figure A 359. 13C NMR spectrum of compound (213) in CDCl3.
726

Figure A 360. COSY 2D NMR spectrum of compound (213) in CDCl3.
727

Figure A 361. HSQC 2D NMR spectrum of compound (213) in CDCl3.
728

Figure A 362. 1H NMR spectrum of compound (214) in CDCl3.

729

Figure A 363. 13C NMR spectrum of compound (214) in CDCl3.
730

Figure A 364. COSY 2D NMR spectrum of compound (214) in CDCl3.
731

Figure A 365. HSQC 2D NMR spectrum of compound (214) in CDCl3.
732

Figure A 366. 1H NMR spectrum of compound (215) in CDCl3.
733

Figure A 367. 13C NMR spectrum of compound (215) in CDCl3.
734

Figure A 368. COSY 2D NMR spectrum of compound (215) in CDCl3.
735

Figure A 369. HSQC 2D NMR spectrum of compound (215) in CDCl3.
736

Figure A 370.
737

31

P NMR spectrum of compound (215) in CDCl3

Figure A 371. 1H NMR spectrum of compound (216) in CDCl3.
738

Figure A 372.
739

13

C NMR spectrum of compound (216) in CDCl3.

Figure A 373. COSY 2D NMR spectrum of compound (216) in CDCl3.
740

Figure A 374. HSQC 2D NMR spectrum of compound (216) in CDCl3.
741

Figure A 375. 1H NMR spectrum of compound (217) in D2O.
742

Figure A 376.

13

C NMR spectrum of compound (217) in D2O.

743

Figure A 377. COSY 2D NMR spectrum of compound (217) in D2O.
744

Figure A 378. HSQC 2D NMR spectrum of compound (217) in D2O.
745

Figure A 379.
746

31

P NMR spectrum of compound in (217) D2O.

Figure A 380. 1H NMR spectrum of compound (219) in CDCl3.
747

Figure A 381. 13C NMR spectrum of compound (219) in CDCl3.
748

Figure A 382. COSY 2D NMR spectrum of compound (219) in CDCl3.
749

Figure A 383. 1H NMR spectrum of compound (220) in DMSO-d6.
750

Figure A 384. 13C NMR spectrum of compound (220) in DMSO-d6.
751

Figure A 385. HSQC 2D NMR spectrum of compound (220) in DMSO-d6.
752

Figure A 386. 1H NMR spectrum of compound (221) in D2O.
753

Figure A 387. 13C NMR spectrum of compound (221) in D2O.
754

Figure A 388. COSY 2D NMR spectrum of compound (221) in D2O.
755

Figure A 389. HSQC 2D NMR spectrum of compound (221) in D2O.
756

Figure A 390. 1H NMR spectrum of compound (222) in D2O.
757

Figure A 391. 13C NMR spectrum of compound (222) in D2O.
758

Figure A 392. COSY 2D NMR spectrum of compound (222) in D2O.
759

Figure A 393. HSQC 2D NMR spectrum of compound (222) in D2O.
760

Figure A 394. 1H NMR spectrum of compound (223) in D2O.
761

Figure A 395. 13C NMR spectrum of compound (223) in D2O.
762

Figure A 396. HSQC 2D NMR spectrum of compound (223) in D2O.
763

Figure A 397. 1H NMR spectrum of compound (225) in DMSO-d6.
764

Figure A 398. 13C NMR spectrum of compound (225) in DMSO-d6.
765

6.6 Appendix 1.3 ­ MS Spectra

Figure A 399. ESI-TOF spectrum of compound 19.
766

Figure A 400. ESI-TOF spectrum of compound 26.
767

Figure A 401. HRMS ESI-TOF spectrum of compound 27.
768

Figure A 402. ESI-TOF spectrum of compound 34.
769

Figure A 403. HRMS ESI-TOF spectrum of compound 36.
770

Figure A 404. ESI-TOF spectrum of compound 51.
771

Figure A 405. ESI-TOF spectrum of compound 66.
772

Figure A 406 .DART-HRMS spectrum of compound 113.
773

Figure A 407. ESI-TOF spectrum of compound 121.
774

Figure A 408. DART spectrum of compound 163.
775

Figure A 409. HRMS-DART spectrum of compound 163.
776

Figure A 410. ESI-TOF spectrum of compound 194.
777

Figure A 411. ESI-TOF spectrum of compound 205.
778

Figure A 412. DART spectrum of compound 208.
779

Figure A 413. HRMS-DART spectrum of compound 208.
780

Figure A 414. DART spectrum of compound 211.
781

Figure A 415. HRMS-DART spectrum of compound 211.
782

Figure A 416. ESI-TOF spectrum of compound 212.
783

Figure A 417. HRMS-DART spectrum of compound 213.
784

Figure A 418. HRMS-DART spectrum of compound 213.
785

Figure A 419. ESI-TOF spectrum of compound 217.
786

Figure A 420. DART spectrum of compound 221.
787

Figure A 421. ESI-TOF spectrum of compound 222.
788

Figure A 422. ESI-TOF spectrum of compound 225.
789

7.0 REFERENCES

1. Grass, G., Rensing, C., and Solioz., M. Metallic Copper as an Antimicrobial Surface. Appl Environ. Microbiol., 77, 1541-1547 (2011). 2. Chen-Yu, J. H., Eberhardt, D. M., and Kincade, D. H. Antibacterial and Laundering Properties of AMS and PHMB as Finishing Agents on Fabric for Health Care Workers' Uniforms. Cloth. Text. Res. J., 25, 258-272 (2007). 3. Ferreira, L, and Zumbuehl, A. Non-leaching surfaces capable of killing microorganisms on contact. J. Mater. Chem., 19, 7796-7806 (2009). 4. McFee, R. B. Nosocomial or Hospital-acquired Infections: An Overview. Disease-a-Month 55, 422-438 (2009). 5. World Health Organization. Prevention of hospital-acquired infections. A practical guide. 2nd edition (2002). Retrieved August 10, 2013 from http://www.who.int/csr/resources/publications/whocdscsreph200212.pdf. 6. Klevens, R. M. Edwards, J. R., Richards, C. L., Horan, T. C., Gaynes, R. P., Pollock, D. A., and Cardo, D. M. Estimating Health Care-Associated Infections and Deaths in U.S. Hospitals, 2002. Public Health Rep., 122, 160-166 (2007). 7. Hetrick, E. M., and Schoenfisch, M. H. Reducing implant-related infections: active release strategies. Chem. Soc. Rev., 35, 780-789 (2006). 8. Kramer, A., Schwebke, I., and Kampf, G. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infec. Diseas., 6, 1-8 (2006). 9. Page, K., Wilson, M., and Parkin, I. P. Antimicrobial surfaces and their potential in reducing the role of the inanimate environment in the incidence of hospital-acquired infections. J. Mater. Chem., 19, 3819-3831 (2009). 10. Lichter, J. A., Van Vliet, K. J., and Rubner, M. F. Design of Antibacterial Surfaces and Interfaces: Polyelectrolyte Multilayers as a Multifunctional Platform. Macromolecules, 42, 85738586 (2009). 11. Gao, Y., and Cranston, R. Recent Advances in Antimicrobial Treatments of Textiles. Text. Res. J., 78, 60-72 (2008). 12. Tiller, J. C. Antimicrobial Surfaces. Springer, Berlin / Heidelberg, Adv. Polym. Sci., 240, 193-217 (2011). 13. Siedenbiedel, F., and Tiller, J. C. Antimicrobial Polymers in Solution and on Surfaces: Overview and Functional Principles. Polymers, 4, 46-71 (2012).
790

14. Denyer, S. P. Mechanisms of action of biocides. Inter. Biodeter., 26, 89-100 (1990). 15. Russell, A. D. Introduction of biocides into clinical practice and the impact on antibioticresistant bacteria. J. Appl. Microbiol., 92, 121S-135S (2002). 16. Perkins, J. J. Principles and Methods of Sterilization in Health Sciences (2nd Ed.), 39-42, (1980). 17. Sharma, V. K., Yngard, R. A., and Lin, Y. Silver nanoparticles: Green synthesis and their antimicrobial activities. Adv. Colloid Interface Sci., 145, 83-96 (2009). 18. Kugel, A., Stafslien, S., and Chisholm, B. J. Antimicrobial coatings produced by "tethering" biocides to the coating matrix: A comprehensive review. Prog. in Org. Coat., 72, 222-252 (2011). 19. Klibanov, A. M. Permanently microbicidal materials coatings. J. Mater. Chem., 17, 24792482 (2007). 20. Simoncic, B., and Tomsic, B. Structures of Novel Antimicrobial Agents for Textiles - A Review. Text. Res. J., 80, 1721-1737 (2010). 21. Caillier, L., de Givenchy, E. T., Levy, R., Vandenberghe, Y., Géribaldi, S., and Guittard, F. Synthesis and antimicrobial properties of polymerizable quaternary ammoniums. Eur. J. Med. Chem., 44, 3201-3208 (2009). 22. Fristrup, C. J., Jankova, K., and Hvilsted, S. Surface-initiated atom transfer radical polymerization-a technique to develop biofunctional coatings. Sof. Mater., 5, 4623-4634 (2009). 23. Pahnke, J., and Rühe, J. Attachment of Polymer Films to Aluminium Surfaces by Photochemically Active Monolayers of Phosphonic Acids. Macromol. Rapid. Commun., 25, 1396-1401 (2004). 24. Prucker, O., Naumann, C., Ruhe, J., Knoll, W., and Frank, C. Photochemical attachment of polymer films to solid surfaces via monolayers of benzophenone derivatives, J. Am. Chem. Soc., 121, 8766-8770 (1999). 25. Dhende, V. P., Samanta, S., Jones, D. M., Hardin, I. R., and Locklin, J. One-Step Photochemical Synthesis of Permanent, Nonleaching, Ultrathin Antimicrobial Coatings for Textiles and Plastics. ACS Appl. Mater. Interfaces., 3, 2830-2837 (2011). 26. Li, B., Franking, R., Landis, E. C., Kim, H., and Hamers, R. J. Photochemical Grafting and Patterning of Biomolecular Layers onto TiO2 Thin Films. ACS Appl. Mater. Interfaces., 1, 1013-1022 (2009). 27. Ye, Q., Zhou, F., and Liu, W. Bioinspired catecholic chemistry for surface modification. Chem. Soc. Rev., 40, 4244-4258 (2011).
791

28. Barbey, R., Lavanant, L., Paripovic, D., Schuàwer, N., Sugnaux, C., Tugulu, S., and Klok, H. A. Polymer Brushes via Surface-Initiated Controlled Radical Polymerization: Synthesis, Characterization, Properties, and Applications. Chem. Rev., 109, 5437-5527 (2009). 29. Tew, N. W., and Madkour, A. E. Towards self-sterilizing medical devices: controlling infection. Polym. Inter., 57, 6-10 (2008). 30. Dong, H., Huan, J., Koepsel, R., Ye, P., Russell, A. J., and Matyjaszewski, K. Recyclable Antibacterial Magnetic Nanoparticles Grafted with Quaternized Poly(2-(dimethylamino)ethyl methacrylate) Brushes. Biomacromol., 12, 1305-1311 (2011). 31. Faure, E., Lecomte, P., Lenoir, S., Vreuls, C., Weerdt, Van De., Archambeau, C., Martial, J., Jerome, C., Duwez, A. S., and Detrembleur, C. Sustainable and bio-inspired chemistry for robust antibacterial activity of stainless steel. J. Mater. Chem., 21, 7901-7904 (2011). 32. Huang, J., Murata, H., Koepsel, R. R., Russell, A. J. and Matyjaszewski, K. Antibacterial Polypropylene via Surface-Initiated Atom Transfer Radical Polymerization Biomacromolecules. Biomacromol., 8, 1396-1399 (2007). 33. Sweat, D. P., Kim, M., Yu, X., and Gopalan, P. A Single-Component Inimer Containing Cross-Linkable Ultrathin Polymer Coating for Dense Polymer Brush Growth. Langmuir, 29, 3805-3812 (2013). 34. Yang, Y., Hu, H., Li, Y., Wan, L., and Xu, Z. Membrane surface with antibacterial property by grafting polycation. J. Membr. Sci., 376, 132-141 (2011). 35. Isquith, A. J., and McCollum, C. J. Surface kinetic test method for determining rate of kill by an antimicrobial solid. Appl. Environ. Microbiol., 36, 700-704 (1978). 36. Speier, J. L., and Malek, J. R. Destruction of microorganisms by contact with solid surfaces. J. Colloid Interface Sci., 89, 68-76 (1982). 37. Plueddemann, E. P. and Revis, A. Organosilicon quaternary ammonium antimicrobial compounds. Dow Corning Corporation, US 4866192 A (1988). 38. Isquith, A. J., Abbott, E. A., and Walters, P. A. Surface bonded antimicrobial activity of an organosilicon quaternary ammonium chloride. Appl. Microbiol., 2, 859-863 (1972). 39. Pallavicini, P., Taglietti, A., Dacarro, G., Diaz-Fernandez, Y. A., Galli, M., Grisoli, P., Patrini, M., Santucci De Magistris, G., and Zanoni, R. Self-assembled monolayers of silver nanoparticles firmly grafted on glass surfaces: Low Ag+ release for an efficient antibacterial activity. J. Colloid. Inter. Sci., 350, 110-116 (2010). 40. Guido, K., Rutzinger, D., and Gallauner, T. Synthesis of hexadentate hexahydro 1,3,5triazine based ligands and their copper (I) complexes. Mont. fuer Chem., 133, 1157-1164 (2002).
792

41. Gottesman, R., Shukla, S., Perkas, N., Solovyov, L. A., Nitzan, Y., and Gedanken, A. Sonochemical Coating of Paper by Microbiocidal Silver Nanoparticles. Langmuir, 27, 720-726 (2011). 42. Huang, J., Koepsel, R. R., Murata, H., Wu, W., Lee, S.B., Kowalewski, T., Russell, A. J., Matyjaszewski, K. Nonleaching Antibacterial Glass Surfaces via "Grafting Onto": The Effect of the Number of Quaternary Ammonium Groups on Biocidal Activity. Langmuir, 24, 6785-6795 (2008). 43. Sambhy, V., Peterson, B. R., and Sen, A. Multifunctional Silane Polymers for Persistent Surface Derivatization and Their Antimicrobial Properties. Langmuir, 24, 7549-7558 (2008). 44. Bouloussa, O., Rondelez, F. and Semetey, V. A new, simple approach to confer permanent antimicrobial properties to hydroxylated surfaces by surface functionalization. Chem. Commun., 951-953 (2008). 45. Ohlhausen, H. G., and Ludwig, J. H. Solvent-Free Organosilane Quaternary Ammonium Compositions, Method of Making and Use. Resource Development, LLC. US 20110271873 (2011). 46. Aegis. Microbeguard Technology, (2009). Retrieved May 10, http://www.nwmoldprevention.com/downloads/microbe_guard_technology.pdf. 2011 from

47. Allred, G. D., and Liebeskind, L. S. Water-stabilized organosilane compounds and methods for using the same. Emory University, US 5959014 A (1996). 48. Isquith, A. J., Abbott, E. A., and Walters, P. A. Algicidal activity of a surface-bonded organosilicon quaternary ammonium chloride. Appl. Microbiol., 25, 253-256 (1973). 49. Nakagawa, Y., Hayashi, H., Tawaratani, T., Kourai, H., Horie, T., and Shibasaki, I. Disinfection of Water with Quaternary Ammonium Salts Insolubilized on a Porous Glass Surface. Appl. Environ. Microbiol., 47, 513-518 (1984). 50. Battice, D. R., and Hales, M. G. A New Technology for Producing Stabilized Foams Having Antimicrobial Activity. J. Cell. Plast., 21, 332-337 (1985). 51. Murray, P. R., Niles, A. C., and Heeren, R. L. Microbial inhibition on hospital garments treated with Dow Corning 5700 antimicrobial agent. J. Clin. Microbiol., 26, 1884-1886 (1988). 52. Gottenbos, B., van der Mei, H. C., Klatter, F., Nieuwenhuis, P., and Busscher, H. J. In vitro and in vivo antimicrobial activity of covalently coupled quaternary ammonium silane coatings on silicone rubber. Biomaterials, 23, 1417-1423 (2002). 53. Abo El Ola, S. M., Kotek, R., White, W. C., Reeve, J. A., Hauser, P., and Kim, J. H. Unusual polymerization of 3-(trimethoxysilyl)-propyldimethyloctadecyl ammonium chloride on PET substrates. Polymer, 45, 3215-3225 (2004).
793

54. Nikawa, H., Ishida, K., Hamada, T., Satoda, T., Murayama, T., Takemoto, T., Tamamoto, M., Tajima, H., Shimoe, S., Fujimoto, H., and Makihira, S. Immobilization of Octadecyl Ammonium Chloride on the Surface of Titanium and Its Effect on Microbial Colonization In Vitro. Dent. Mater. J., 24, 570-582 (2005). 55. Osterhof, J. J., Buijssen, K. J., Busscher, H. J., van der Laan, B.F., and van der Mei, H. C. Effects of quaternary ammonium silane coatings on mixed fungal and bacterial biofilms on tracheoesophageal shunt prostheses. Appl. Environ. Microbiol., 72, 3673-3677 (2006). 56. Andresen, M., Stenstad, P., Møretrø, T., Langsrud, S., Syverud, K., Johansson, L.S., and Stenius, P. Nonleaching Antimicrobial Films Prepared from Surface-Modified Microfibrillated Cellulose. Biomacromol., 8, 2149-2155 (2007). 57. Bouloussa, O., Rondelez, F. and Semetey, V. A new, simple approach to confer permanent antimicrobial properties to hydroxylated surfaces by surface functionalization. Chem. Commun., 951-953 (2008). 58. Sambhy, V., Peterson, B. R., and Sen, A. Multifunctional Silane Polymers for Persistent Surface Derivatization and Their Antimicrobial Properties. Langmuir, 24, 7549-7558 (2008). 59. Saif, M. J., Anwar, J. and Munawar, M. A. A Novel Application of Quaternary Ammonium Compounds as Antibacterial Hybrid Coating on Glass Surfaces. Langmuir, 25, 377379 (2009). 60. Köylü, D., Bilecen, K., ahin, E., Duman, G., and Taralp, A. Cotton gauze bearing nondiffusible quaternary ammonium salts and featuringanti-microbial activity: An example of single-use articles tailored to self-sterilize. Faculty of Engineering & Natural Sciences, Materials Science & Engineering Program, Sabanci University, Istanbul online poster (2010). Retrieved September 01, 2013 from http://people.sabanciuniv.edu/taralp/presentations/ACS2003 %20NewOrleansPoster%20Damla.pdf 61. Song, L., and Baney, R. H. Antibacterial evaluation of cotton textile treated by trialkoxysilane compounds with antimicrobial moiety. Text. Res. J., 81, 504-511 (2011). 62. Song, J., Kong, H. and Jang, J. Bacterial adhesion inhibition of the quaternary ammonium functionalized silica nanoparticles. Coll. Surf. B: Biointerfaces 82, 651-656 (2011). 63. Green, J. D., Bickner, S., Carter, P. W., Fulghum, T., Luebke, M., Nordhaus, M. A., and Strathmann, S. Antimicrobial testing for surfaceimmobilized agents with a surface separated live­dead staining method. Biotechnol. Bioeng., 108, 231-236 (2011). 64. Nanci, A., Wuest, J. D., Peru, L., Brunet, P., Sharma,V., Zalzal, S., McKee, M.D. Chemical modification of titanium surfaces for covalent attachment of biological molecules. J. Biomed. Mater. Res., 40, 324-335 (1998).

794

65. Gawalt, E. S., Avaltroni, M. J., Koch, N., and Schwartz, J. Self-Assembly and Bonding of Alkanephosphonic Acids on the Native Oxide Surface of Titanium. Langmuir, 17, 5736-5738 (2001). 66. Jampala, S. N., Sarmadi, M., Somers, E. B., Wong, A. C. L., and Denes, F. S. PlasmaEnhanced Synthesis of Bactericidal Quaternary Ammonium Thin Layers on Stainless Steel and Cellulose Surfaces. Langmuir, 24, 8583-8591 (2008). 67. Adden, N., Gamble, L. J., Castner, D. G., Hoffmann, A., Gross, G., and Menzel, H. Phosphonic Acid Monolayers for Binding of Bioactive Molecules to Titanium Surfaces. Langmuir, 22, 8197-8204 (2006). 68. Raman, A., Dubey, M., Gouzman, I. and Gawalt, E. S. Formation of Self-Assembled Monolayers of Alkylphosphonic Acid on the Native Oxide Surface of SS316L. Langmuir, 22, 6469-6472 (2006). 69. Schwartz, J., Avaltroni, M. J., Danahy, M. P., Silverman, B. M., Hanson, E. L., Schwarzbauer, J. E., Midwood, K. S., and Gawalt, E. S. Cell attachment and spreading on metal implant materials. Mat. Sci. Eng: C 23, 395-400 (2003). 70. Mani, G., Johnson, D. M., Marton, D., Dougherty, V. L., Feldman, M. D., Patel, D., Ayon, A. A., and Agrawal, C. M. Stability of Self-Assembled Monolayers on Titanium and Gold. Langmuir, 24, 6774-6784 (2008). 71. Vericat, C., Vela, M. E., Benitez, G., Carro, P., and Salvarezza, R. C. Self-assembled monolayers of thiols and dithiols on gold: new challenges for a well-known system. Chem. Soc. Rev., 39, 1805-1834 (2010). 72. Gawalt, E. S., Avaltroni, M. J., Koch, N., and Schwartz, J. Self-Assembly and Bonding of Alkanephosphonic Acids on the Native Oxide Surface of Titanium. Langmuir, 17, 5736-5738 (2001). 73. Silverman, B. M., Wieghaus, K. A. and Schwartz, J. Comparative Properties of Siloxane vs Phosphonate Monolayers on A Key Titanium Alloy. Langmuir, 21, 225-228 (2005). 74. Lecollinet, G., Delorme, N., Edely, M., Gibaud, A., Bardeau, J. F., Hindré, F., Boury, F., and Portet, D. Self-Assembled Monolayers of Bisphosphonates: Influence of Side Chain Steric Hindrance. Langmuir, 25, 7828-7835 (2009). 75. Hanson, E. L., Schwartz, J., Nickel, B., Koch, N., and Danisman, M. F. Bonding SelfAssembled, Compact Organophosphonate Monolayers to the Native Oxide Surface of Silicon. J. Am. Chem. Soc., 125, 16074-16080 (2003). 76. Raman, A., Dubey, M., Gouzman, I., and Gawalt, E. S. Formation of Self-Assembled Monolayers of Alkylphosphonic Acid on the Native Oxide Surface of SS316L. Langmuir, 22, 6469-6472 (2006).
795

77. Hoque, E., DeRose, J. A., Bhushan, B., and Mathieu, H. J. Self-Assembled Monolayers on Aluminum and Copper Oxide Surfaces: Surface and Interface Characteristics, Nanotribological Properties, and Chemical Stability, Nano. Sci. Tech., 235-281 (2008). 78. Guerrero, G., Amalric, J., Mutin, P., Sotto, A., and Lavigne, J. Inhibition de l'adhésion bactérienne et prévention de la formation d'un biofilm : utilisation de monocouches autoassemblées organiques sur des surfaces inorganiques. Pathologie Biologie 57, 36-43 (2009). 79. Mutin, P., Amalric, J., Guerrero, G., Ponche, J. P., and Lavigne, J. Surface modification of titanium by Phosphonate monolayers Releasing Bactericidal Species. European Cells and Materials 21, 63 (2011). 80. Mutin, P. H, Guerrero, G., and Amalric, J. P. Preparation of an inorganic substrate having antimicrobial properties. WO 2007080291 (2007). 81. Amalric, J., Mutin, P. H., Guerrero, G., Ponche, A., Sotto, A., and Lavigne, J. P. Phosphonate monolayers functionalized by silver thiolate species as antibacterial nanocoatings on titanium and stainless steel. J. Mater. Chem. 19, 141-149 (2009). 82. Denizot B., Hindre, F. and Portet, D. Geminal bisphosphonates containing at least two quaternary ammonium functions in the backbone for coating of metallic and mineral surfaces for protection against biofilm formation and bacterial contamination. Brevet FR 2878248 (2006). 83. Portet, D., LeCollinet, G., Hindre, F., Bejanin, S., Chappard, D., and Denizot, B. Method of covering self-assembled metal or inorganic monolayer surfaces of gem-bisphosphonic compounds and uses thereof. Surfactis Technologies, Fr., WO2008017721 A3 (2008). 84. Pfaffenroth, C., Winkel, A., Dempwolf, W., Gamble, L.J., Castner, D. G., Stiesch, Meike., and Menzel, H. SelfAssembled Antimicrobial and Biocompatible Copolymer Films on Titanium. Macromol. Biosci., 11, 1515-1525 (2011). 85. Chen, C. and Wickstrom, E. Self-Protecting Bactericidal Titanium Alloy Surface Formed by Covalent Bonding of Daptomycin Bisphosphonates. Bioconjug. Chem., 21, 1978-1986 (2010). 86. Dong, H., Huang, J., Koepsel, R., Ye, P., Russell, A. J., and Matyjaszewski, K. Recyclable Antibacterial Magnetic Nanoparticles Grafted with Quaternized Poly(2(dimethylamino)ethyl methacrylate) Brushes. Biomacromol., 12, 1305-1311 (2011). 87. Kruszewski, K. M., Nistico, L., Longwell, M. J., Hynes, M. J., Maurer, J.A., HallStoodley, L., and Gawalt, E. S. Reducing Staphylococcus aureus biofilm formation on stainless steel 316L using functionalized self-assembled monolayers. Mater. Sci. Eng., C: Mater. Biol. Applic., 33, 2059-2069 (2013).

796

88. Dalsin, J. L., Hu, B. H., Lee, B. P., and Messersmith, P. B. Mussel Adhesive Protein Mimetic Polymers for the Preparation of Nonfouling Surfaces. J. Amer. Chem. Soc., 125, 42534258 (2003). 89. Waite, J. H. Surface chemistry: Mussel Power. Nat. Mater., 7, 8-9 (2008). 90. Wach, J., Bonazzi, S. and Gademann, K. Antimicrobial Surfaces through Natural Product Hybrids. Angew. Chem. Int. Ed., 47, 7123-7126 (2008). 91. Yuan, S., Wan, D., L., Liang, B., Pehkonen, S. O., Ting, Y. P., Neoh, K. G., and Kang, E. T. Lysozyme-Coupled Poly(poly(ethylene glycol) methacrylate)-Stainless Steel Hybrids and Their Antifouling and Antibacterial Surfaces. Langmuir, 27, 2761-2774 (2011). 92. Caro, A. Humblot, V., Meathivier, C., Minier, M., Salmain, M., and Pradier, C. M. Grafting of Lysozyme and/or Poly(ethylene glycol) to Prevent Biofilm Growth on Stainless Steel Surfaces. J. Phys. Chem. B., 113, 2101-2109 (2009). 93. Humblot, V., Yala, J. F., Thebault, P., Boukerma, K., Hequet, A., Berjeaud, J. M., and Pradier, C. M. The Antibacterial Activity of Magainin I Immobilized onto Mixed Thiols SelfAssembled Monolayers. Biomaterials, 30, 3503-3512 (2009). 94. Shalev, T., Gopin, A., Bauer., M., Stark, R., and Rahimipour., S. Non-leaching antimicrobial surfaces through polydopamine bio-inspired coating of quaternary ammonium salts or an ultrashort antimicrobial lipopeptide. J. Mater. Chem., 22, 2026-2032 (2012). 95. Appendini, P., and Hotchkiss, J. H. Review of antimicrobial food packaging. Innov. Food Sci. Emerg. Technol., 3, 113-126 (2002). 96. Muñoz-Bonilla, A., and Fernández-García, M. Polymeric materials with antimicrobial activity. Prog. Poly. Sci., 37, 281-339 (2012). 97. Kenawy, E., Worley, S. D. and Broughton, R. The chemistry and applications of antimicrobial polymers: a state-of-the-art review. Biomacromol., 8, 1359-1384 (2007). 98. Harney, M. B., Pant, R. R., Fulmer, P. A., and Wynne, J. H. Surface Self-Concentrating Amphiphilic Quaternary Ammonium Biocides as Coating Additives. ACS App. Mater. Inter., 1, 39-41 (2009). 99. Foucher, D., and Mocella, A. Private Communication. Ryerson University, Toronto, Ontario (2013). 100. Clarkson, N., and Evans, L. V. Further studies investigating a potential non-leaching biocide using the marine fouling diatom Amphora coffeaeformis. Biofouling, 9, 17-30 (1995). 101. Majumdar, P., Crowley, E., Htet, M., Stafslien, S. J., Daniels, J., VanerWal, L., and Chisholm, B. J. Combinatorial Materials Research Applied to the Development of New Surface
797

Coatings XV: An Investigation of Polysiloxane Anti-Fouling/Fouling-Release Coatings Containing Tethered Quaternary Ammonium Salt Groups. ACS Combinat. Sci., 13, 298-309 (2011). 102. Yagci, M. B. Bolca, S. Heuts, J. P. A. and Ming. W. Self-stratifying antimicrobial polyurethane coatings. Prog. Org. Coat., 72, 305-314 (2011). 103. Stovicek, P. Biocidal compositions based on polymers of dihydroxy quaternary ammonium salts. US 5084096 (1992). 104. Waschinski, C., Zimmermann, J., Salz, U., Hutzler, R., Sadowski, G., and Tiller, J.C. Design of Contact-Active Antimicrobial Acrylate-Based Materials Using Biocidal Macromers. Adv. Mater., 20, 104-108 (2008). 105. Mocella, A. UV Cured Benzophenone Terminated Quaternary Ammonium Antimicrobials for Plastics. 4th Year Undergraduate Thesis. Department of Chemistry and Biology, Ryerson University, Toronto, ON, 1-80 (2012). 106. Yang, Y., Hu, H., Li, Y., Wan, L., and Xu, Z. Membrane surface with antibacterial property by grafting polycation. J. Membr. Sci. 376, 132-141 (2011). 107. Griep-Raming, N., Karger, M., and Menzel, H. Using Benzophenone-Functionalized Phosphonic Acid To Attach Thin Polymer Films to Titanium Surfaces. Langmuir, 20, 1181111814 (2004). 108. Zou, P., Hartleb, W., and Lienkamp, K. It takes walls and knights to defend a castle ­ synthesis of surface coatings from antimicrobial and antibiofouling polymers. J. Mater. Chem. 22, 19579-19589 (2012). 109. Hu, R., Li, G., Jiang, Y., Zhang, Y., Zou, J. J., Wang, L., and Zhang, X. Silver­ Zwitterion Organic­Inorganic Nanocomposite with Antimicrobial and Antiadhesive Capabilities. Langmuir, 29, 3373-3779 (2013). 110. (i) Cheng, G., Xue, H., Zhang, Z., Chen, S., and Jiang, S. A Switchable Biocompatible Polymer Surface with Self-Sterilizing and Nonfouling Capabilities. Angew. Chem. Int. Ed. 47, 8831-8834 (2008). (ii) Cao., Z., Mi, L., Mendiola, J., Ella-Menye, J. R., Zhang, Lei., Xue, Hong., and Jiang, S. Reversibly Switching the Function of a Surface between Attacking and Defending against Bacteria. Angew. Chem. Int. Ed., 51, 2602-2605 (2012). (iii) Yu, Q., Cho, J., Shivapooja, P., Ista, L. K. and López, G. P. Nanopatterned Smart Polymer Surfaces for Controlled Attachment, Killing, and Release of Bacteria. ACS Appl. Mater. Interfaces. XXX, XXX-XXX (2013). 111. Gabriel, G., Maegerlein, J. A., Nelson, C. F., Dabkowski, J. M., Eren, T., Nüsslein, K., and Tew, G. N. Comparison of Facially Amphiphilic versus Segregated Monomers in the Design of Antibacterial Copolymers. Chem. Eur. J. 15, 433-439 (2009).
798

112. Gong, S., Niu, L., Kemp, L. K., Yiu, C. K. Y., Ryou, H., Qi, Y., Blizzard, J. D., Nikonov, S., Brackett, M. G., Messer, R. L. W., Wu, C. D., Mao, J., Brister, L. B., Rueggeberg, F. A., Arola, D. D., Pashley, D. H., and Tay, F. R. Quaternary ammonium silanefunctionalized, methacrylate resin composition with antimicrobial activities and self-repair potential. Acta Biomaterialia, 8, 3270-3282 (2012). 113. Gilbert, P., and Moore, L. E. Cationic antiseptics: diversity of action under a common apithet. J Appl. Microbiol., 99, 703-715 (2005). 114. Jansen, A. C., Boucher, C. E., Coetse, E., Kock, J. L. F., vanWyk, P. W. J., Swart, H. C., and Bragg, R. R. The influence of Didecyldimethylammonium Chloride on the morphology and elemental composition of Staphylococcus aureus as determined by NanoSAM. Sci. Res. Ess., 8, 152-160 (2013). 115. Hegstad, K., Langsrud, S., Lunestad, B. T., Scheie, A. A., Sunde, M. and Yazdankhah, S. P. Does the wide use of quaternary ammonium compounds enhance the selection and spread of antimicrobial resistance and thus threaten our health? Microb. Drug Resist., 16, 91-94 (2010). 116. Schaeufele, P. Advances in Quaternary Ammonium Biocides. J. Amer. Oil. Soc. Chem., 61, 387 (1984). 117. Iannou, C. J., Hanlon, G. W., and Denyer, S. P. Action of disinfectant quaternary ammonium compounds against Staphylococcus aureus. Antimicrob. Agents. Chemother., 51, 296-306 (2007). 118. Thebault, P., Taffin de Givency, E., Levy, R., Vandenberghe, Y., Guittard, F., and Géribaldi, S. Preparation and antimicrobial behaviour of quaternary ammonium thiol derivatives able to be grafted on metal surfaces. Eur.J.Med.Chem., 44, 717-724 (2009). 119. Russell, A. D. Mechanism of antimicrobial action of antiseptics and disinfectants: An increasingly important area of investigation. J.Antimicrob.Chemother., 49, 597-599 (2002). 120. McDonnell, G. A., and Russell D. Antiseptics and Disinfectants: Activity, Action, and Resistance. Clin. Microbiol. Rev., 12, 147-179 (1999). 121. Holdsworth, S.R., and Law, C.J. The major facilitator superfamily transporter MdtM contributes to the intrinsic resistance of Escherichia coli to quaternary ammonium compounds. J Antimicrob. Chemother., 68, 831-839 (2013). 122. Tabata, A., Nagamune, H., Maeda, T., Murakami, K., Miyake, Y., and Kourai, H. Correlation between Resistance of Pseudomonas aeruginosa to Quaternary Ammonium Compounds and Expression of Outer Membrane Protein OprR. Antimicrob. Agents Chemother., 47, 2093-2099 (2003).

799

123. Mangalappalli-Illathu, A. K., and Korber, D. R. Adaptive Resistance and Differential Protein Expression of Salmonella enterica Serovar Enteritidis Biofilms Exposed to Benzalkonium Chloride. Antimicrob. Agents Chemother., 50, 3588-3596 (2006). 124. Nonaka, T., Hua, L., Ogata, T., and Kurihara, S. Synthesis of water-soluble thermosensitive polymers having phosphonium groups from methacryloyloxyethyl trialkyl phosphonium chlorides-N-isopropylacrylamide copolymers and their functions. J. Appl. Polym. Sci., 87, 386-393 (2003). 125. Waschinski, C. J., Barnert, S., Theobald, A., Schubert, R., Kleinschmidt, F., Hoffmann, A., Saalwächter, K., and Tiller, J. C. Insights in the Antibacterial Action of Poly(methyloxazoline)s with a Biocidal End Group and Varying Satellite Groups. Biomacromol., 9, 1764-1771 (2008). 126. Lewis, K., and Klibanov, A. M. Surpassing nature: rational design of sterile-surface materials. Trends Biotechno.,. 23, 343-348 (2005). 127. Tiller, J. C., Liao, C.J., Lewis, K., and Klibanov, A. M. Designing surfaces that kill bacteria on contact. PNAS., 98, 5981-5985 (2001). 128. Park, D., Wang, J., and Klibanov, A. M. One-Step, Painting-Like Coating Procedures To Make Surfaces Highly and Permanently Bactericidal. Biotechnol. Prog., 22, 584-589 (2006). 129. Lewis, K., and Klibanov, A. M. Surpassing nature: rational design of sterile-surface materials. Trends Biotechnol., 23, 343-348. 130. Murata, H., Koepsel, R. R., Matyjaszewski, K., and Russell, A. J. Permanent, nonleaching antibacterial surfaces--2: How high density cationic surfaces kill bacterial cells. Biomaterials, 28, 4870-4879 (2007). 131. Kuegler, R., Bouloussa, O., and Rondelez, F. Evidence of a charge-density threshold for optimum efficiency of biocidal cationic surfaces. Microbiology Reading, 151, 1341-1348 (2005). 132. Bieser, A. M., Thomann, Y., and Tiller, J. C. ContactActive Antimicrobial and Potentially SelfPolishing Coatings Based on Cellulose. Macromol. Biosci., 11, 111-121 (2011).

133. Bieser, A. M., and Tiller, J. C. Mechanistic Considerations on ContactActive Antimicrobial Surfaces with Controlled Functional Group Densities. Macromol. Biosci., 11, 526534 (2011). 134. American Society for Testing and Materials. Minimum Inhibitory Concentration (MIC) Determination. Annual Book of ASTM Standards, 1, 1-10 (2002). 135. Antimicrobial Test laboratories. ISO 22196 Test for Antimicrobial Activity of Plastics. (2013). Retrieved June 10, 2013 from http://www.antimicrobialtestlaboratories.com.

800

136. Green, J. D. Science against microbial pathogens: communicating current research and technological advances. Méndez-Vilas Publishing, FORMATEX Microbiology Series Nº 3, 578585 (2011). 137. Ronan, E. Investigating Microbial Ecology at Solid-Air Interfaces. 4th Year Undergraduate Thesis. Department of Chemistry and Biology, Ryerson University, Toronto, ON, 1-89 (2011). 138. Deng, H. 4th Year Undergraduate Thesis. Department of Chemistry and Biology, Ryerson University, Toronto, ON, 1-78 (2013). 139. Menschutkin, N. Ueber die Einwirkung des Chloracetyls auf phosphorige Saure. Ann. Chem. Pharm., 133, 317-320 (1865). 140. Stanger, K. J., Lee, J. J., and Smith, B. D. Dramatic Acceleration of the Menschutkin Reaction and Distortion of Halide Leaving-Group Order. J. Org. Chem., 72, 9663 - 9668 (2007). 141. Reinheimer, J. D., Harley, J. D., and Meyers, W. W. Solvent Effects in the Menschutkin Reaction. J. Org. Chem., 28, 1575-1579 (1963). 142. Smith, M. March's advanced organic chemistry: reactions, mechanisms, and structure Wiley-Interscience, Hoboken, N.J., 525, (2007). 143. Sommer, H. Z., Lipp, H. I., and Jackson, L. J. Alkylation of amines. General exhaustive alkylation method for the synthesis of quaternary ammonium compounds. J. Org. Chem., 36, 824-828 (1971). 144. Long, B., Nikitin, K., and Fitzmaurice, D. Self-Assembly of a Tripodal Pseudorotaxane on the Surface of a Titanium Dioxide Nanoparticle. J. Am. Chem. Soc,. 125, 5152-5160 (2003). 145. Salvatore, R. Synthesis of secondary amines. Tetrahedron, 57, 7785-7811 (2001). 146. Hayashi, Y., Fujiwara, T., Nagano, Y., and Teramura, K. Preparation of tertiary amines having different substituents from quaternary 2-hydroxyethylammonium salts. Yukagaku, 36, 409-412 (1987). 147. Basu, B., Paul, S., and Nanda, A. K. Highly selective N-Alkylation of amines promoted on silica: an efficient and recyclable surface. Green Chem., 11, 115-1120 (2009). 148. Salvatore, R. N., Nagle, A. S., and Jung, K. W. Cesium Effect: High Chemoselectivity in Direct N-Alkylation of Amines. J. Org. Chem., 67, 647-683 (2002). 149. Ju, Y., and Varma, R. S. Aqueous N-alkylation of amines using alkyl halides: direct generation of tertiary amines under microwave irradiation. Green Chem., 6, 219-221 (2004).

801

150. Ju, Y., and Varma, R. S. An efficient and simple aqueous N-heterocyclization of aniline derivatives: microwave-assisted synthesis of N-aryl azacycloalkanes. Org. Lett., 7, 2409-2411 (2005). 151. Singh, C. B., Kavala, V., Samal, A. K., and Patel B. K. Aqueous-Mediated N-Alkylation of Amines. Eur. J. Org. Chem., 2007, 1369-1377 (2007). 152. Li, J. J., and Corey, E. J. Name Reactions of Functional Group Transformations. John Wiley and Sons, USA, CH2, 86-92 (2007). 153. Baxter, E. W., and Reitz, A. B. Reductive aminations of carbonyl compounds with borohydride and borane reducing agents. Org. React. (Hoboken, NJ, U. S.) 59, 101 (2002). 154. Abdel-Magid, A. F., and Mehrman, S. J. A Review on the Use of Sodium Triacetoxyborohydride in the Reductive Amination of Ketones and Aldehydes. Org. Process Res. Dev., 10, 971-1031 (2006). 155. Abdel-Magid, A. F., and Maryanoff, C. A. Use of sodium triacetoxyborohydride in reductive amination of ketones and aldehydes. ACS Symp. Ser., 641, 201-216 (1996). 156. Lane, C. F. Sodium cyanoborohydride, a highly selective reducing agent for organic functional groups. Synthesis, 135-46 (1975). 157. Bhattacharyya, S. Borohydride reductions in dichloromethane: a convenient, environmentally compatible procedure for the methylation of amines. Synth. Commun., 25, 20612069 (1995). 158. Da Silva, R. A., Estevam, I. H. S., and Bieber, L. W. Reductive methylation of primary and secondary amines and amino acids by aqueous formaldehyde and zinc. Tetrahedron Lett., 48, 7680-7682 (2007). 159. Cope, A. C., Ciganek, E., Fleckenstein, L. J. and Meisinger, M. A. P. Tertiary Amines from Methiodides and Lithium Aluminum Hydride. J. Am. Chem. Soc., 82, 4651-4655 (1960). 160. Hutchins, R. O., Kandasamy, D., Dux, F., Maryanoff, C. A., Rotstein, D., Goldsmith, B., Burgoyne,W., Cistone, F., Dalessandro, J., and Puglis, J. Nucleophilic borohydride: selective reductive displacement of halides, sulfonate esters, tertiary amines, and N,Ndisulfonimides with borohydride reagents in polar aprotic solvents. J. Org. Chem., 43, 2259-67 (1978). 161. Saurabh, S., Fadila, L., Moreau, J. P., Hurvois, J. L., Renaudde Weghe, T., and Hierry, R. Synthesis of Alkaloids of Galipea officinalis by Alkylation of an -Amino Nitrile. Eur. J. Org. Chem., 2008, 4622-4631 (2008).

802

162. Yoshida, Y., Sakakura, Y., Aso, N., Okada, S., and Tanabe, Y. Practical and efficient methods for sulfonylation of alcohols using Ts(Ms)Cl/Et3N and catalytic Me3N-HCl as combined base: promising alternative to traditional pyridine. Tetrahedron, 55, 2183-2192 (1999). 163. Olah, G. A., Gupta, B. G., Malhotra, R., and Narang, S. C. Chlorotrimethylsilane/lithium bromide and hexamethyldisilane/pyridinium bromide perbromide: effective and selective reagents for the conversion of alkyl (cycloalkyl and aralkyl) alcohols into bromides. J. Org. Chem., 45, 1638-1639 (1980). 164. Couture, G., Alaaeddine, A., Boschet, F., and Ameduri, B. Polymeric materials as anionexchange membranes for alkaline fuel cells. Prog. Polym. Sci., 36, 1521-1557 (2011). 165. Cai, J. and Wathey, B. A novel traceless solid phase tertiary amine synthesis based on Merrifield resin. Tetrahedron Lett., 42, 1383-1385 (2001). 166. Grovenstein, E., Chandra, S., Collum, C. E., and Davis, W. E. Carbanions. VIII. Products and mechanisms of reaction of allyl- and cyclopropyltrimethylammonium halides and of allyl chloride, alcohol, and p-tolyl sulfide with sodium in liquid ammonia. J. Am. Chem. Soc., 88, 1275-1289 (1966). 167. Ho, T.S. Dequaternization of ammonium salts by nucleophiles. Synth. Commun., 3, 99-100 (1972). 168. Kametani, T., Kigasawa, K., Hiiragi, M., Wagatsuma, N., and Wakisaka, K. Debenzylation of quaternary ammonium salts with thiophenol. Tet. Lett., 8, 635-638 (1969). 169. Hutchins, R. O., Dux, and F. J. Selective demethylation of quaternary salts with lithium propylmercaptide in hexamethylphosphoramide. J. Org. Chem., 38, 1961-1962 (1973). 170. Ho, T. S. Dealkylation of quaternary ammonium salts with 1,4-diazabicyclo[2.2.2]octane. Synthesis, 12, 702 (1972). 171. Bauera, B., Strathmannb, H., Effenbergerc, F. Anion-exchange membranes with improved alkaline stability. Desalination, 79, 125-144 (1992). 172. Cope, A. C., Mehta, and A. S. Mechanism of the Hofmann elimination reaction: an ylide intermediate in the pyrolysis of a highly branched quaternary hydroxide. J. Amer. Chem. Soc., 85, 1949-1952 (1963). 173. William, E. W., and Manning, J. H. Antimicrobial polyalcohols and their derivatives. CA1129851A1 (1982). 174. Battaglini, G. T. Assay of quaternary ammonium antimicrobial compounds by aqueous potentiometric titration. J. Surfact. Deterg., 5, 117-121 (2002).

803

175. Jansson, S. O., Modin, R., and Schill, G. Two-phase titration of organic ammonium ions with lauryl sulphate and methyl yellow as indicator. Talanta, 21, 905-918 (1974). 176. Bioshield Technologies. Certification of Limits and Analytical Method for Enforcement of Limits for BST Protectant 50. 1-6 (1997). 177. Mistry, K. New Self-assembled Quaternary Ammonium Fluorescent Compounds. 4th Year Undergraduate Thesis. Department of Chemistry and Biology, Ryerson University, Toronto, ON, 1-37 (2011). 178. Taffa, D., Kathiresan, M. and Walder, L. Tuning the Hydrophilic, Hydrophobic, and Ion Exchange Properties of Mesoporous TiO2. Langmuir, 25, 5371-5379 (2009). 179. Vermeulen, L. A., Fateen, R. Z. and Robinson, P. D. Single Crystal Structure Determination of a New Zirconium N-Ethylpyridinium Phosphonate: Zr(O3PCH2CH2NC5H5)(F)3. Inorg. Chem., 41, 2310-2312 (2002). 180. Demmer, C. S., Krogsgaard-Larsen, N., and Bunch, L. Review on Modern Advances of Chemical Methods for the Introduction of a Phosphonic Acid Group. Chem. Rev., 111, 79818006 (2011). 181. Jansa, P., Baszczyski, Procházková, B., Dracínský, M., and Janeba, Z. Microwaveassisted hydrolysis of phosphonate diesters: an efficient protocol for the preparation of phosphonic acids. Green Chem., 14, 2282-2288 (2012). 182. Morita, J. Okamoto, Y., and Sakurai, H. A convenient dealkylation of dialkyl phosphonates by chlorotrimethylsilane in the presence of sodium iodide. Tet. Lett., 19, 25232526 (1978). 183. McKenna, C. The facile dealkylation of phosphonic acid dialkyl esters by bromotrimethylsilane. Tet. Lett., 18, 155-158 (1977). 184. Blackburn, G. M., and Ingleson, D. The dealkylation of phosphate and phosphonate esters by lodotrimethylsilane: a mild and selective procedure. J. Chem. Soc. Perkin Trans., 1, 11501153 (1980). 185. Chowdhury, S., Muni, N. J., Greenwood, N. P., Pepperberg, D. R. and Standaert, R. F. Phosphonic acid analogs of GABA through reductive dealkylation of phosphonic diesters with lithium trialkylborohydrides. Bioorg. Med. Chem. Lett., 17, 3745-3748 (2007). 186. Gauvry, N. M. J. Dealkylation of dialkyl phosphonates with boron tribromide. Synthesis, 4, 553-554 (2001). 187. McKenna, C. E., and Schmidhauser, J. Functional selectivity in phosphonate ester dealkylation with bromotrimethylsilane. J. Chem. Soc. Chem. Commun., 739 (1979).
804

188. Mortier, J., Gridnev, I. D., and Guenot, P. Reactions of Phosphonates with Organohaloboranes: New Route to Molecular Borophosphonates. Organometallics, 19, 42664275 (2000). 189. Mortier, J. Recent developments on the mechanism of the reaction of dialkyl phosphonates with haloboranes and their implications for synthesis. Rec. Res. Develop. Org. Chem., 6, 169-176 (2002). 190. Erickson, J. G. Phosphonoammonium compounds. US 2774786 19561218, General Mills Inc. (1956). 191. Frederick, H. Synthetic detergents. NL 79189 19551015 (1955). 192. Germanaud, L., Brunel, S., Chevalier, Y., and Le Perchec, P. Synthesis of neutral amphiphilic phosphobetaines with variable interionic distances. Bull. Soc. Chimi. Fra., 4, 699704 (1988). 193. Fu, X. K., and Chen, W. S. Synthesis of dimethyldodecylammonioethylphosphonic acid betaine. Xinan Shifan Daxue Xuebao, Ziran Kexueban, 27, 61-63 (2002). 194. Hüttinger, K. J. and Jung, M. F. Kinetik der Synthese von Trialkyl[3(trimethoxysilyl) propyl]ammoniumchloriden und deren antimikrobielle Wirkung als fixierte Biozide. Chem. Ingen. Tech., 61, 258-259 (1989). 195. Majumdar, P., Crowley, E., Htet, M., Stafslien, S. J., Daniels, J., VanderWal, L and Chisholm, B. J. Combinatorial Materials Research Applied to the Development of New Surface Coatings XIII: An Investigation of Polysiloxane Antimicrobial Coatings Containing Tethered Quaternary Ammonium Salt Groups. J. Comb. Chem., 11, 1115-1127 (2009). 196. Zhu, X. Yang, C., Chen, G., Wan, Y. Microwave-assisted synthesis of siloxane quaternary ammonium salts. Zhongshan Daxue Xuebao, Ziran Kexueban, 48, 56-59 (2009). 197. Hüttinger, K. J., and Zeller, D. Chemisch und verfahrenstechnisch optimierte, trägergebundene Desinfektionsmittel für die Wasserentkeimung mit Tiefenfiltern. Chem. Ingen. Tech., 59, 516-517 (1987). 198. Ragulin, V. V. -Haloalkylphosphoryl Compounds: Synthesis and Properties. Russ. J. Gen. Chem., 82, 1928-1937 (2012). 199. Yoshimura, T., Kusano, T., Iwase, H., Shibayama, M., Ogawa, T., and Kurata, H. StarShaped Trimeric Quaternary Ammonium Bromide Surfactants: Adsorption and Aggregation Properties. Langmuir, 28, 9322-9331 (2012). 200. Gourves, J. P., Couthon, H., and Sturtz, G. F. Synthesis of 3,4-dihydro-2H-pyrido[1,2b]isoindol-1-one and 3,4-dihydro-2H-pyrido[1,2-b]pyrrolidin-1-one functionalized at the C(6)
805

position by an intramolecular Horner-Wadsworth-Emmons reaction. Eur. J. Org. Chem., 12, 3489-3493 (1999). 201. Smits, J. P., and Wiemer, D. F. Synthesis and Reactivity of Alkyl-1,1,1-trisphosphonate Esters. J. Org. Chem., 76, 8807-8813 (2011). 202. O'Boyle, N. M., Greene, L. M., Bergin, O., Fichet, J. B., McCabe, T., Lloyd, D. G., Zisterer, D. M., and Meegan, M. J. Synthesis, evaluation and structural studies of antiproliferative tubulin-targeting azetidin-2-ones. Bioorg. Med. Chem., 19, 2306-2325 (2011). 203. Zefirov, N. S., and Matveeva, E. D. Catalytic Kabachnik-Fields reaction: new horizons for old reaction. ARKIVOC Special Issue Reviews and Accounts 1, 1-17 (2008). 204. Keglevich, G., Szekrényi, A., Szöllsy, A., and Drahos, L. Synthesis of Bis(phosphonatomethyl), Bis(phosphinatomethyl), and Bis(phosphinoxidomethyl)amines, as Well as Related Ring Bis(phosphine) Platinum Complexes. Synth. Commun., 41, 2265-2272 (2011). 205. Tibhe, G. D., Reyes-González, M. A., Cativiela, C., and Ordóñez, M. Microwaveassisted High Diastereoselective Synthesis of -Aminophosphonates under Solvent and Catalyst Free-conditions. J. Mex. Chem. Soc., 56, 183-187 (2012). 206. Ishikawa, S., Tajima, M. and Mochizuki, M. Synthesis and properties of bifunctional chloroalkyl nitrosamines with an intercalating moiety. Bioorg. Med. Chem., 12, 3791-3796 (2004). 207. Mutin, P. H., Guerrero, G. and Vioux, A. J. Hybrid materials from organophosphorus coupling molecules. Mater. Chem., 15, 3761-3768 (2005). 208. Matveeva, E., Petrovskii, P. V., and Odinets, I. L. Efficient synthesis of racemic aminophosphonates via aza-Michael reaction in water. Tet. Lett., 49, 6129-6133 (2008). 209. Tiasto, F. Preparation of bisphosphonoamine ligands for the synthesis of technetium nitride complexes for radiodiagnostic imaging. PCT Int Appl. 2007083395 (2007). 210. Wang, J., Liang, Y. L., and Qu, J. Boiling water-catalyzed neutral and selective N-Boc deprotection. Chem. Commun., 5144-5146 (2009). 211. Simonyan, G. S., Arutyunyan, R. S., Beileryan, N. M. and Grigoryan, E. A. Synthesis of New Surface-Active N²-Amino Amides, Agents for Fixation of Dyes on Cotton Fibers, from N-Tri(hydroxymethyl)methyl]acrylamide. Russ. J. Appl .Chem.,76, 258-260 (2003). 212. (i) Borgman, R. J., McPhillips, J. J., and Stitzel, R. E. Synthesis and Pharmacology of Centrally Acting Dopamine Derivatives and Analogs in Relation to Parkinson's Disease. J. Med. Chem., 16, 630-633 (1973). (ii) Louafi, F., Hurvois, J., Chibani, A., and Roisnel, T. Synthesis
806

of Tetrahydroisoquinoline Alkaloids via Anodic Cyanation as the Key Step. J. Org. Chem., 75, 5721-5724 (2010). 213. Haslegrave, J. A., and Sullivan, D. S. Nitrogen and sulfur-containing corrosion inhibitors. Exxon Chemical Patents Inc. (Linden, NJ). United States Patent 4673436 (1987). 214. Asakawa, T., Shimizu, Y., Ozawa, T., Ohta, A., and Miyagishi, S. Aqueous solution properties of disulfide linked gemini and cleaved monomeric thiol surfactants. J. Oleo Sci., 57, 243-249 (2008). 215. Thebault, P., Taffin de Givenchy, E., Levy, R., Vandenberghe,Y., Guittard, F., and Géribaldi, S. Contact-active microbicidal gold surfaces using immobilization of quaternary ammonium thiol derivatives. Eur. J. Med. Chem., 44, 4227-4234 (2009). 215. Harjani, J. R., Liang, C., and Jessop, P. G. A Synthesis of Acetamidines. J. Org. Chem., 76, 1683-1691 (2011). 216. Allen, F. H., Kennard, O., Watson, D. G., Brammer, L. and Orpen, A. G. Tables of Bond Lengths Determined by X-Ray and Neutron Diffraction. J. Chem. Soc. Perkin. Trans., 2, S1­S19 (1897). 217. Andrews, J. M. Determination of minimum inhibitory concentrations. J. Antimicrob. Chemother., 48, 5-16 (2001). 218. Wang, X. Xue, Y., Wang, Y. Preparation and application of organosilicon quaternary ammonium salt composition. Faming Zhuanli Shenqing, CN 102391299, A 20120328 (2012). 219. Li, F., Shishkin, E., Mastro, M. A., Hite, J. K., Eddy, C. R., Edgar, J. H., and Ito, T. Photopolymerization of Self-Assembled Monolayers of Diacetylenic Alkylphosphonic Acids on Group-III Nitride Substrates. Langmuir, 26, 10725-10730 (2010). 220. Baber, A., de Vries, J. G., Orpen, A. G., Pringle, P. G., and von der Luehea, K. Allosteric effects in asymmetric hydrogenation catalysis. Asymmetric induction as a function of the substrate and the backbone flexibility of C1-symmetric diphosphines in rhodium-catalysed hydrogenations. Dalton Trans., 4821-4828 (2006). 221. Viornery, C., Pechy, P., Boegli, M., Aronsson, B. O., Descouts, P., and Gratzel, M. Synthesis of new polyphosphonic acids. Phos. Sul. Silic. Rel. Elem., 177, 231-241 (2002). 223. Villemin, D. Simeon, F. Decreus, H., and Jaffres, P. A. Rapid and efficient Arbuzov reaction under microwave irradiation. Phos. Sul. Silic. Rel. Elem., 133, 209-213 (1998). 224. Jansa, P. Holy, A. Dracinsky, M. Baszczynski, O. Cesnek, M., and Janeba, Z. Efficient and green' microwave-assisted synthesis of haloalkylphosphonates via the Michaelis-Arbuzov reaction. Green Chem., 13, 882-888 (2011).

807

225. Sun, L. J., Cao, J. Q., Ge, C. H., Zhang, X. D., Tong, J. and Ma, Y. C. Synthesis and characterization of alkyl substituted dimethyl phosphonates. Liaoning Daxue Xuebao, Ziran Kexueban, 31, 78-80 (2004). 226. Voigt, M. Klaumunzer, M., Ebel, A., Werner, F., Yang, G., Marczak, R., Spiecker, E., Guldi, D. M., Hirsch, A., and Peukert, W. Surface Functionalization of ZnO Nanorods with C60 Derivatives Carrying Phosphonic Acid Functionalities. J. Phys. Chem. C., 115, 5561-5565 (2011). 227. Hara, T., Durell, S. R., Myers, M. C., and Appella, D. H. Probing the Structural Requirements of Peptoids That Inhibit HDM2-p53 Interactions. J. Am. Chem. Soc., 128, 19952004 (2006). 228. (i) Chevalier, Y., Germanaud, L., Brunel, S., Storet, Y., Berthelon, B., LePerchec, P., and Gallot, B. Zwitterionic amphiphiles: synthesis and physical properties. Comun. Jorn. Com. Esp. Deterg., 18, 231-245 (1987). (ii). Brunet, S., Germanaud, L., Perchec, P., and Sillion, B. Neutral phosphobetaines, their preparation, and their use in petroleum recovery. Fr. Demande, 2572078-A1 (1986). 229. Tucker. S. A, K. and Garrell, R. L. Simple Preparation and Application of TEMPOCoated Fe3O4 Superparamagnetic Nanoparticles for Selective Oxidation of Alcohols. Chem. A Eur. J., 16, 12718-12726 (2010). 230. Conibear, A. C., Lobb, K. A., and Kaye, P. T. 31P NMR kinetic study of the tandem cleavage of phosphonate esters by bromotrimethylsilane. Tetrahedron, 66, 8446-8449 (2010). 231. Martinelli, M. J., and Pollack, S. R. Encyclopedia of Reagent for Organic Synthesis. John Wiley and Sons Ltd, Bromotrimethylsilane, 1-21 (2001). 232. Paleos, C. M., Arkas, M. and Skoulios, A. Mesomorphic character of quaternary ammonium salts affected by secondary hydrogen bonding interactions. Molecular Crystals and Liquid Crystals Science and Technology, Section A: Molecular Crystals and Liquid Crystals, 309, 237-250 (1998). 233. Pinchuk, A. N., Rampy, M. A., Longino, M. A., Skinner, R. W. S., Gross, M. D., Weichert, J. P., and Counsell, R. E. Synthesis and Structure-Activity Relationship Effects on the Tumor Avidity of Radioiodinated Phospholipid Ether Analogues. J. Med. Chem., 49, 21552165 (2006). 234. Simoni, D. Gebbia, N., Invidiata, F. P., Eleopra, M., Marchetti, P., Rondanin, R., Baruchello, R., Provera, S. S., Marchioro, C., Tolomeo, M., Marinelli, L., Limongelli, V., Novellino, E., Kwaasi, A., Dunford, J., Buccheri, S., Caccamo, N., and Dieli, F. Design, Synthesis, and Biological Evaluation of Novel Aminobisphosphonates Possessing an in Vivo Antitumor Activity Through a gammadelta-T Lymphocytes-Mediated Activation Mechanism. J. Med. Chem., 51, 6800-6807 (2008).
808

235. Gourves, J. P., Couthon, H., and Sturtz, G. A new efficient synthesis of aminoalkylidene-1,1-bisphosphonate tetraethyl esters. Phos. Sul. Silic. Rel. Elem., 132, 219-229 (1998). 236. Neidlein, R. E. T. Substituted methylphosphonates as synthons for alicyclic functionalized phosphonates. Monatshefte fuer Chemie., 123, 1037-1043 (1992). 237. Tanaka, K. S., Houghton, T. J., Kang, T., Dietrich, E., Delorme, D., Ferreira, S. S., Caron, L., Viens, F., Arhin, F. F., Sarmiento, I., Lehoux, D., Fadhil, I., Laquerre, K., Liu, J., Ostiguy, V., Poirier, H., Moeck, G., Parr, TR. Jr., and Rafai Far, A. Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis. Bioorg. Med. Chem., 16, 9217-9229 (2008). 238. Delorme, D., Houghton, T., Lafontaine, Y., Tanaka, K., Dietrick, E., Kang, T., and Rafai, F. A. Phosphonated oxazolidinones and uses thereof for the prevention and treatment of bone and joint infections and their preparation. WO 2007138381A2 (2007). 239. Lehn, J. M., Blacker, J., and Jazwinski, J. Preparation of 2,7-diazapyrenium dications for photochemical cleavage of nucleic acids. WO 1987-FR142, Compagnie Oris Industrie, Fr., (1987). 240. Polomoscanik, S. C., Holmes-Farley, S. R., Petersen, J. S., Sacchiero, R. J., and Dhal, P. K. Hydrophobically Modified Poly (Allylamine) Hydrogels Containing Internal Quaternary Ammonium Groups as Cholesterol Lowering Agents: Synthesis, Characterization, and Biological Studies . J. Macromol. Sci., Part A: Pure Appl. Chem., 49, 1011-1021 (2012). 241. Cavero, E., Zablocka, M., Caminade, A., and Majoral, J. P. Design of BisphosphonateTerminated Dendrimers. Eur. J. Org. Chem., 2759-2767 (2010). 242. Chougrani, K., Boutevin, B., David, G., Seabrook, S., and Loubat, C. Acrylate based anticorrosion films using novel bis-phosphonic methacrylates. J. Polym. Sci. Part A: Polym. Chem., 46, 7972-7984 (2008). 243. Chougrani, K., Boutevin, B., David, G., and Boutevin, G. New N,N-aminodiphosphonate-containing methacrylic derivatives, their syntheses and radical copolymerizations with MMA. Eur. Polym. J., 44, 1771-1781 (2008). 244. Gatlin, L. W. Alkylaminoalkyl substituted triazine sulfide scavenger. US 20030089641, Clearwater International (2003). 245. Kauffman, W. J. Synthesis and characterization of N,N',N''-tris(dimethylaminopropyl) hexahydro-s-triazine and isolable intermediates. J. Heterocylic Chem., 12, 409-11 (1975). 246. Jasiski, M., Mlosto, G., Mucha, P., Linden, A., and Heimgartner, H. Synthesis of New Bis-Imidazole Derivatives. Helvetica Chimica Acta., 90, 1765-1780 (2007).
809

247. Hu, N., Johnson, L. M., Pothayee, N., Pothayee, N., Lin, Y., Davis, R. M., and Riffle, J. S. Synthesis of ammonium bisphosphonate monomers and polymers. Polymer, 54, 3188-3197 (2013). 248. Bhattacharya, S., and Snehalatha, K. Synthesis and Esterolytic Chemistry of Some (Dialkylamino)pyridine-Functionalized Micellar Aggregates. Evidence of Catalytic Turnover. Langmuir, 11, 4653-4660 (1995). 249. Haldar, J., Venkateswarlu, Y., and Padma, A. Cationic antibacterial vancomycin derivatives and compositions. WO 2013072838 A1 (2013). 250. Romeo, R., Carnovale, C., Giofre, Salvatore V., Romeo, G., Macchi, B., Frezza, C., Marino-Merlo, F., Pistara, V., and Chiacchio, U. Truncated phosphonated C-1'-branched N,Onucleosides: A new class of antiviral agents. Bioorg. Med. Chem., 20, 3652-3657 (2012). 251. Hunter, C. A., Misuraca, M. C. and Turega, S. M. Dissection of Complex Molecular Recognition Interfaces. J. Amer. Chem. Soc., 133, 582-594 (2011). 252. Kaplanek, R., Briza, T., Havlik, M., Martasek, P., and Kral, V. Three-fold polyfluoro alkylated amines and isocyanates based on [tris(hydroxymethyl)amino]methane (TRIS). J. Fluor. Chem., 128, 179-183 (2007). 253. Rannard, S. P., and Davis, N. J. The Selective Reaction of Primary Amines with Carbonyl Imidazole Containing Compounds: Selective Amide and Carbamate Synthesis. Org. Lett., 2, 2117-2120 (2000). 254. Acton, A. L., and Fante, C. Janus PEG-Based Dendrimers for Use in Combination Therapy: Controlled Multi-Drug Loading and Sequential Release. Biomacromol., 14, 564-574 (2013). 255. Babu, D. A., Manohar, C. S., and Visweswaran, V. Synthesis, characterization and antimicrobial activity studies of 2-[{2-(3,4-dimethoxyphenyl) ethyl} methylamino]sulphonylnaphthalenes. Asian J. Chem., 20, 1411-1419 (2008). 256. Shahane, S., Saurabh, S., Fadila, L., Moreau, J., Hurvois, J. P., Renaudde, J-L., and Thierry Roisnel, T. Synthesis of alkaloids of Galipea officinalis by alkylation of an -amino nitrile. Eur. J. Org. Chem., 27, 4622-4631 (2008). 257. Top, S., Kaloun, E. B., Vessières, A., Laïos, I., Leclercq, G., and Jaouen, G. The first titanocenyl dichloride moiety vectorised by a selective estrogen receptor modulator (SERM). Synthesis and preliminary biochemical behaviour. J. Organomet. Chem., 643-644, 350-356 (2002). 258. Saettone C., Alderigi, B., Giannaccini, C., Anslemi, M., Rossetti, M., and Scotton, R. Substantivity of sunscreens-prepatation and evaluation of some quaternary ammonium benzophenone derivatives. Int. J. Cosm. Sci., 10, 99-109 (1988).
810

259. Wang, X. and Schneider, H. Binding of dansylamide derivatives to nucleotides and nucleic acids. J. Chem. Soc. Perkin Trans., 2, 1323-1328 (1998). 260. Jacobsen, D. W. Preparation of cryptofluorescent analogs of cobalamin coenzymes. Methods Enzymol., 67, 12-19 (1980). 261. Simonin, J., Vernekar, S. K. V., Thompson, A. T., Hothersall, J. D., Connolly, C. N., Lummis, S. R. L., and Lochner, M. High-affinity fluorescent ligands for the 5-HT3 receptor. Bioorg. Med. Chem. Lett., 22, 1151-1155 (2012).

811


